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Abstract 
Insect innate immune responses include prophenoloxidase activation and antimicrobial 
peptide production. These responses involve extracellular serine proteinase cascades that are 
regulated by serpins. This work involved the study of serine proteinase 16 (HP16) and serpin-3 
from hemolymph of the tobacco hornworm, Manduca sexta. 
HP16 has an amino-terminal domain with no similarity to any characterized protein and a 
carboxyl-terminal S1 family serine proteinase domain. HP16 levels in plasma were highest 
during the wandering, prepupal, and pupal stages. HP16 mRNA levels in fat body were highest 
at the wandering stage. Injection of bacteria into fifth instar larvae stimulated HP16 expression. 
To further characterize and investigate the biological function of HP16, recombinant proteins for 
proHP16, two HP16 mutants, the amino-terminal domain (NT16), and three NT16 mutants were 
purified. Recombinant HP16 was cleaved at the predicted activation site during expression, and 
its amino-terminal and catalytic domains remained connected by a disulfide bond. ProHP16 in 
plasma was apparently activated in the presence of the microbial elicitor, zymosan. Recombinant 
HP16 formed a complex with serpin-1Z, indicating that it was catalytically active, but no other 
natural or artificial substrates were identified. Analysis of NT16 and NT16 mutants led to the 
discovery that multiple disulfide bond arrangements were formed in the recombinant amino-
terminal domain of HP16. This work furthered the understanding of HP16 and laid a foundation 
for subsequent experiments involving the proteolytic activity, regulation, and biological function 
of HP16. 
Active serine proteinases in insect hemolymph are often regulated by serpins. 
Immunoaffinity chromatography was used to identify plasma proteinases that are inhibited by 
serpin-3. Four serpin-3-proteinase complexes purified from plasma were identified by 
immunoblot analysis as serpin-3 complexes with HP8, PAP-1, PAP-2, and PAP-3. MALDI-
TOF/TOF or ESI-MS/MS analysis after separation by 1D- or 2D-PAGE confirmed serpin-3 
complex formation with HP8, PAP-1, and PAP-3. ProHP8 in plasma was activated by exposure 
to the β-1,3-glucan curdlan and inhibited by serpin-3. Purified recombinant serpin-3 and active 
HP8-Xa formed an SDS-stable complex in vitro. Identification of serpin-3-proteinase complexes 
 in plasma provides insight into proteinase targets of serpin-3 and extends the understanding of 
serpin/proteinase function in the immune response of M. sexta. 
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Abstract 
Insect innate immune responses include prophenoloxidase activation and antimicrobial 
peptide production. These responses involve extracellular serine proteinase cascades that are 
regulated by serpins. This work involved the study of serine proteinase 16 (HP16) and serpin-3 
from hemolymph of the tobacco hornworm, Manduca sexta. 
HP16 has an amino-terminal domain with no similarity to any characterized protein and a 
carboxyl-terminal S1 family serine proteinase domain. HP16 levels in plasma were highest 
during the wandering, prepupal, and pupal stages. HP16 mRNA levels in fat body were highest 
at the wandering stage. Injection of bacteria into fifth instar larvae stimulated HP16 expression. 
To further characterize and investigate the biological function of HP16, recombinant proteins for 
proHP16, two HP16 mutants, the amino-terminal domain (NT16), and three NT16 mutants were 
purified. Recombinant HP16 was cleaved at the predicted activation site during expression, and 
its amino-terminal and catalytic domains remained connected by a disulfide bond. ProHP16 in 
plasma was apparently activated in the presence of the microbial elicitor, zymosan. Recombinant 
HP16 formed a complex with serpin-1Z, indicating that it was catalytically active, but no other 
natural or artificial substrates were identified. Analysis of NT16 and NT16 mutants led to the 
discovery that multiple disulfide bond arrangements were formed in the recombinant amino-
terminal domain of HP16. This work furthered the understanding of HP16 and laid a foundation 
for subsequent experiments involving the proteolytic activity, regulation, and biological function 
of HP16. 
Active serine proteinases in insect hemolymph are often regulated by serpins. 
Immunoaffinity chromatography was used to identify plasma proteinases that are inhibited by 
serpin-3. Four serpin-3-proteinase complexes purified from plasma were identified by 
immunoblot analysis as serpin-3 complexes with HP8, PAP-1, PAP-2, and PAP-3. MALDI-
TOF/TOF or ESI-MS/MS analysis after separation by 1D- or 2D-PAGE confirmed serpin-3 
complex formation with HP8, PAP-1, and PAP-3. ProHP8 in plasma was activated by exposure 
to the β-1,3-glucan curdlan and inhibited by serpin-3. Purified recombinant serpin-3 and active 
HP8-Xa formed an SDS-stable complex in vitro. Identification of serpin-3-proteinase complexes 
 in plasma provides insight into proteinase targets of serpin-3 and extends the understanding of 
serpin/proteinase function in the immune response of M. sexta. 
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CHAPTER 1 - LITERATURE REVIEW 
Introduction 
Manduca sexta, commonly known as the tobacco hornworm, belongs to the insect order 
Lepidoptera and the family Sphingidae. As a holometabolous insect, M. sexta undergoes 
complete metamorphosis, which means that each life stage is dramatically different from the 
other. After 3-5 days, blue-green eggs hatch into larvae (= feeding stage). Larvae undergo larval 
to larval molts in which the old cuticle is shed to allow for an increase in size with each molt. 
After the 5
th
 instar, feeding larvae enter the non-feeding wandering stage. During this stage, 
larvae wander around, looking for a place in the soil to pupate. Under non-diapause conditions, 
adults will emerge from the pupal case in nineteen to twenty-three days. Adults disperse by 
flight, feed on nectar, and reproduce (Dunn, 1990). After successful mating, the female lays her 
eggs on the underside of foliage to start the life cycle again. 
This insect is often used as a model organism in biochemical studies involving innate 
immunity due to its large size, hemolymph volume, relatively short life cycle, and ability to be 
reared year-round on artificial diet (Dunn, 1990; Kanost et al., 2004). Individual 5
th
 instar 
caterpillars can contain 1-2 mL of hemolymph and 10
6
 hemocytes, which make M. sexta an ideal 
candidate for studies involving hemocytes and hemolymph proteins (Kanost et al., 2004). Using 
M. sexta to advance the understanding of mechanisms behind innate immunity can enhance our 
understanding of immune systems in other insects. This, in turn, may lead to the development of 
new pest control measures as well as improvement in the health of beneficial insects. 
Furthermore, since there are some similarities in the innate immune systems of insects and 
mammals, discoveries in insect immunity could help us better understand the human immune 
response and evolution of innate immunity. 
Immunity in Insects 
Invertebrates, like all organisms, can experience invasion by bacteria, fungi, or other 
pathogens. The first line of defense for an insect is a physical barrier in the form of a hard 
exoskeleton, the peritrophic matrix of the midgut, and tracheae lined with cuticle (Dunn, 1990; 
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Lavine and Strand, 2002; Iwanaga and Lee, 2005; Jiravanichpaisal et al., 2006). If the invaders 
survive and pass through these barriers into the hemocoel, the insects must rely on their innate 
immune systems as they lack adaptive immunity. Innate immunity can be divided into two 
categories: cellular and humoral responses. Cellular responses are mediated by hemocytes and 
include phagocytosis, encapsulation, and nodulation (Lavine and Strand, 2002; Jiravanichpaisal 
et al., 2006; Marmaras and Lampropoulou, 2009). Humoral responses include the production of 
antimicrobial peptides, prophenoloxidase activation that leads to melanization, and production of 
reactive intermediate oxygen or nitrogen species (Lavine and Strand, 2002; Jiravanichpaisal et 
al., 2006; Marmaras and Lampropoulou, 2009; Cerenius et al., 2010).  
Hemolymph 
Many immune responses begin when foreign invaders enter the insect’s hemocoel, or 
body cavity. Insects have an open circulatory system in which hemolymph, or insect blood, fills 
the hemocoel, is pumped around the hemocoel by the dorsal vessel, and surrounds organs and 
tissues (Wyatt and Pan, 1978; Chapman, 1998; Uvell and Engström, 2007). Hemolymph is 
comprised of a fluid, called plasma, and blood cells, called hemocytes. Within the plasma are 
inorganic ions, such as sodium, potassium, calcium, and magnesium (Wyatt, 1961; Wyatt and 
Pan, 1978; Chapman, 1998; Klowden, 2002), high levels of free amino acids (Wyatt, 1961; 
Wyatt and Pan, 1978; Chapman, 1998; Klowden, 2002), products of nitrogen metabolism, such 
as uric acid, ammonia, urea, and allantoin (Wyatt, 1961; Chapman, 1998), organic acids like 
citrate, malate, and succinate (Wyatt, 1961), lipids (Wyatt, 1961), and carbohydrates, especially 
trehalose (Wyatt, 1961; Chapman, 1998). Plasma also contains hexamerins (Willott et al., 1989; 
Kanost et al., 1990; Burmester, 1999; Burmester, 2002), lipid transport proteins (Wyatt and Pan, 
1978; Kanost et al., 1990; Ryan and Van der Horst, 2000; Smolenaars et al., 2007; Van der Horst 
et al., 2009), pattern recognition proteins, enzymes, proteinases, proteinase inhibitors, 
antimicrobial peptides, hormones, and chromoproteins (Kanost et al., 1990).  
Hemocytes and cellular immune responses in lepidopterans with an emphasis on 
Manduca sexta 
Hemocytes, or insect blood cells, are important mediators of immune responses. 
Common types of insect hemocytes include prohemocytes, plasmatocytes, granular cells, 
oenocytoids, and spherule cells (Lavine and Strand, 2002; Jiravanichpaisal et al., 2006; Strand, 
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2008). Prohemocytes account for a small portion (<1%) of all hemocytes and are thought to be 
equivalent to stem cells (Lavine and Strand, 2002; Jiravanichpaisal et al., 2006; Strand, 2008). 
However, these cells have not been found in M. sexta (Beetz et al., 2004). Non-adherent 
oenocytoids synthesize and release prophenoloxidase. The role of spherule cells is poorly 
defined (Jiang et al., 2010). In lepidopterans, plasmatocytes and granular cells have the ability to 
adhere to foreign invaders and are key players in phagocytosis, nodulation, and encapsulation. 
(Lavine and Strand, 2002; Kanost and Nardi, 2008; Strand, 2008; Jiang et al., 2010). In 2004 
(Dean et al.), hyper-spreading plasmatocyte-like hemocytes were found in M. sexta. These 
hemocytes were very thin, could spread up to 120 µm on glass, and appeared as “fried egg” or 
speckled type. The hyper-spreading cells attached to bacteria and initiated hemocyte aggregation 
followed by nodule formation. Wounding did not stimulate the presence of these cells, but 
infection by Beauveria bassiana or Photorhabdus luminescens did. Interestingly, these 
hemocytes are present only before pathogen proliferation. Once pathogen growth begins, the 
number of these hyper-spreading cells plummets to zero (Dean et al., 2004). Two years later, 
Nardi et al. (2006) identified a subpopulation of plasmatocytes that exhibited characteristics 
similar to the hyper-spreading plasmatocyte-like hemocytes described by Dean et al. (2004). 
Monoclonal antibodies specific to β1-intergin (MS13), neuroglian (3B11), or an unknown 
antigen on granular cells (MS2) were used to distinguish hemocyte types. All plasmatocytes 
were detected by MS13 and a small proportion was also detected by 3B11, which indicated that 
there were two distinct populations of circulating plasmatocytes (neuroglian-negative and 
neuroglian-positive). Neuroglian-positive, but not neuroglian-negative plasmatocytes serve as 
initiators of hemocyte aggregation and effective adhesion of neuroglian-positive plasmatocytes 
to foreign materials depends on the presence of granular cells or some unidentified factor 
produced by the granular cells (Nardi et al., 2006).  
Phagocytosis is a process that removes small particles, such as bacteria, yeast, or 
apoptotic cells, from an insect (Jiravanichpaisal et al., 2006; Stuart and Ezekowitz, 2008; 
Marmaras and Lampropoulou, 2009). The phagocytic process involves recognition of non-self, 
binding of particle to phagocytic cell, signal transduction, activation of pseudopodium formation, 
ingestion of particle, formation of phagosome, fusion of phagosome and lysosome to form 
phagolysosome, and destruction of particle (Gillespie et al., 1997; Stuart and Ezekowitz, 2005; 
Jiravanichpaisal et al., 2006). Plasmatocytes appear to be the main phagocytic cells in 
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Drosophila while both plasmatocytes and granular cells play a role in lepidopterans (Lavine and 
Strand, 2002; Jiravanichpaisal et al., 2006).  
Large numbers of foreign invaders can be removed from an insect by another cellular 
response called nodulation. Nodulation is the entrapment of foreign invaders by hemocyte 
aggregates (Gillespie et al., 1997; Jiravanichpaisal et al., 2006).  Encapsulation is similar to 
nodulation, but is the process by which large invaders such as nematodes and parasitoids are 
removed. Encapsulation of latex beads by M. sexta revealed that plasmatocytes adhere directly to 
the beads followed by layers containing both plasmatocytes and granular cells until capsule 
formation is complete (Wiegand et al., 2000). In contrast, encapsulation by Pseudoplusia 
includens starts with granular cells, is followed by plasmatocytes, and ends with a layer of 
granular cells (Pech and Strand, 1996), which suggests that the process of capsule formation is 
not the same for all insects. Nodulation and encapsulation are usually accompanied by 
melanization and once the capsule is formed, the invader is destined to die. Factors involved in 
death are thought to include asphyxiation, production of toxic compounds from the 
prophenoloxidase pathway, production of reactive oxygen or nitrogen species, and the 
production of antimicrobial peptides (Jiravanichpaisal et al., 2006; Marmaras and 
Lampropoulou, 2009). 
Work completed in the early 1980s characterized the fate of pathogenic and non-
pathogenic bacteria injected into M. sexta (Dunn and Drake, 1983; Horohov and Dunn, 1983). 
Escherichia coli, a non-pathogenic bacterium, injected into M. sexta larvae did not cause insect 
mortality and a reduction in viable bacteria was observed in the insect after approximately 30 
min (Dunn and Drake, 1983). Mortality caused by Pseudomonas aeruginosa ranged from 25-
100% depending on the strain and dose used. The fate of viable E. coli or P. aeruginosa injected 
into immunized larvae revealed an initial reduction in the number of viable bacteria that was 
followed by a period of no change in bacterial concentration and elimination of the bacteria from 
the insect or host death. From these observations, it was hypothesized that the immune response 
began with nodulation at the injection site, was followed by phagocytosis, and ended with 
bacterial clearance due to bactericidal factors (Dunn and Drake, 1983). Horohov and Dunn 
(1983) examined this hypothesis in more detail and defined three stages (nodulation, 
phagocytosis, and antibacterial reactions) of immune response. Nodulation was characterized by 
a reduction in circulating bacteria and the presence of melanized nodules in dissected larvae. In 
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stage two, or phagocytosis, there was no evidence of nodule formation, many granular cells were 
present, and signs of intracellular digestion were observed (Horohov and Dunn, 1983). 
Hemocyte numbers vary between insects, but in some lepidopterans the hemocyte 
number per larva can be on the order of 10
4
 to10
6
 hemocytes; however, this number is not 
constant (Jiang et al., 2010). In M. sexta, the number and type of circulating hemocytes changed 
throughout development (Beetz et al., 2004, Beetz et al., 2008; Eleftherianos et al., 2008). Total 
hemocyte numbers increased during the 4
th
 larval instar, peaked before molting to 5
th
 instar 
larvae, and decreased during the 5
th
 instar and pupal stages (Beetz et al., 2008). At the same time, 
changes in hemocyte type were observed. Granular cells dominated the hemocyte population 
early in the 5
th
 larval instar while plasmatocytes were the dominant cell type in pupae. 
Oenocytoids and spherule cells disappeared during the wandering stage. Gender differences, 
although not statistically significant, were also observed. In general, females had higher 
hemocyte numbers than males, and plasmatocytes represented the majority of hemocytes from 
the beginning of the 5
th
 larval instar until the onset of the wandering stage in females (Beetz et 
al., 2008). Differences in gender suggest that females are more immunocompetent than males 
with overall fitness being defined by the investment of energy in different activities. In 2008, 
Eleftherianos et al., found that hemocyte number decreases throughout the development of the 5
th
 
instar and was accompanied by a decrease in phenoloxidase activity, lower levels of 
phagocytosis, and less melanotic nodule formation, which indicate that the immune function in 
older larvae is reduced compared to young larvae. As a result, injection of P. luminescens 
resulted in higher levels of bacterial growth, increased bacterial colonization of the gut, and 
increased mortality (Eleftherianos et al., 2008). Such results suggest that developmental stage 
can have a dramatic impact on the stimulation of immune responses. 
Mediators of hemocyte immune responses 
An important step in nodulation and encapsulation is the adhesion of hemocytes to the 
foreign invader. Hemocyte adhesion molecules, such as integrins, tetraspanins, and neuroglian, 
mediate the attachment of hemocytes (Jiang, 2008; Kanost and Nardi, 2008; Jiang et al, 2010). 
Integrins are heterodimeric proteins that are found on the surface of hemocytes, and are 
composed of α and β subunits (Burke, 1999; Takada et al., 2007; Zhuang et al., 2008). In M. 
sexta, one integrin heterodimer has been identified (α1β1) and is referred to as hemocyte-specific 
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integrin (Levin et al., 2005; Zhuang et al., 2007b). Two additional α subunits have been found, 
and RNAi knockdown of each subunit abolished encapsulation, which supports the role of 
integrins in this cellular response (Levin et al., 2005; Zhuang et al., 2008). Another type of 
protein found on the surface of hemocytes is tetraspanin, an integral membrane protein that plays 
a role in cell adhesion. Tetraspanin D76 interacts with hemocyte-specific integrin during 
encapsulation of foreign invaders by M. sexta (Zhuang et al., 2007b). The monoclonal antibody, 
MS13 (specific to β1-integrin), or dsRNA for β1-integrin disrupted the binding of the large 
extracellular loop from D76 to the integrin, and subsequently, cell adhesion. Injection of mAb 
1G2, an antibody specific for D76, into larvae decreased the encapsulation of latex beads 
(Zhuang et al., 2007b). These results were similar to those obtained by injecting an antibody 
specific to β1-integrin or dsRNA for β1-integrin (Levin et al., 2005). Neuroglian can be found on 
the surface of granular cells and a subpopulation of plasmatocytes, and is characterized by 
having six immunoglobulin domains. Binding of neuroglian to integrins is accomplished through 
the immunoglobulin domains and can be disrupted by the addition of an antibody specific to 
these domains (Zhuang et al., 2007a). Furthermore, encapsulation is disrupted when M. sexta 
larvae are treated with dsRNA for neuroglian (Zhuang et al., 2007a).  
In addition to hemocyte adhesion molecules, a number of proteins have been identified as 
mediators of cellular responses. Hemolin and hemocyte aggregation inhibitor protein (HAIP) 
have been found to negatively regulate hemocyte adhesiveness in M. sexta (Ladendorff and 
Kanost, 1991; Kanost et al., 1994). Cytokines from the ENF family, such as plasmatocyte 
spreading peptide (PSP), stimulate the spreading and adhesion of plasmatocytes and reduce 
bleeding (Clark et al., 1997; Wang et al., 1999; Kanost et al., 2004). Knockdown of PSP 
decreases hemocyte aggregation in M. sexta larvae injected with E. coli and nodulation in larvae 
injected with E. coli or P. luminescens (Eleftherianos et al., 2009). Lacunin, a ligand for peanut 
agglutinin lectin, and hemocytin are all molecules produced and released by granular cells. 
Lacunin and a glycoprotein detected by peanut agglutinin bind to granular cells and 
plasmatocytes, possibly through interactions with integrins and neuroglian (Nardi et al., 2005). 
Eicosanoids are regulators of some insect hemocyte responses (Shrestha and Kim, 2008; 
Shrestha and Kim, 2009; Stanley et al., 2009). Seven eicosanoids including six prostaglandins 
and one leukotriene were able to induce phagocytosis and nodulation after Spodoptera exigua 
larvae were treated with an eicosanoid biosynthesis inhibitor and subjected to immune challenge 
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(Shrestha and Kim, 2009). Prostaglandins, but not leukotriene stimulate the rupture of 
oenocytoids and release of prophenoloxidase (Shrestha and Kim, 2008; Shrestha and Kim, 
2009). Release of prophenoloxidase increased phenoloxidase activity and was negatively 
correlated to intact oenocytoid density (Shrestha and Kim, 2008). 
Pattern Recognition Proteins 
Response to infection starts with the recognition of fungi, microbial cells, or cell surface 
components, such as peptidoglycan, lipopolysaccharide, β-1,3-glucan, or lipoteichoic acid by 
pattern recognition proteins in hemolymph. In the past, pattern recognition proteins have been 
cloned and/or purified from a number of insects, including several lepidopterans. Peptidoglycan 
recognition protein (PGRP) was purified and cDNA cloned from Bombyx mori (Yoshida et al., 
1996), cloned from Trichoplusia ni (Kang et al., 1998), and isolated and cDNA cloned from 
Manduca sexta (Yu et al., 2002; Sumathipala and Jiang, 2010). B. mori (Ochiai and Ashida, 
1988), M. sexta (Ma and Kanost, 2001; Jiang et al., 2004), and Plodia interpunctella (Fabrick et 
al., 2003; Fabrick et al., 2004) contain at least one β-1,3-glucan recognition protein (βGRP) that 
recognizes β-1,3-glucan and lipopolysaccharide. Gram-negative binding protein (GNBP) is 
similar to βGRP and has been purified from B. mori (Lee et al., 1996) and Drosophila 
melanogaster (Lemaitre and Hoffman, 2007). Four C-type lectins, referred to as immulectins, 
have been purified and characterized from M. sexta (Yu et al., 1999; Yu and Kanost, 2000; Yu et 
al., 2005; Yu et al., 2006). Hemolin was isolated from Hyalophora cecropia (Sun et al., 1990) 
and M. sexta (Ladendorff and Kanost, 1990; Ladendorff and Kanost, 1991). Subsequent 
discussion will focus on pattern recognition proteins found in M. sexta. 
Hemolin 
Hemolin is a 48 kDa glycoprotein belonging to the immunoglobulin supefamily found in 
M. sexta (Ladendorff and Kanost, 1990; Ladendorff and Kanost, 1991). Four immunoglobulin-
like domains are found within hemolin and arrange in such a way that the three-dimensional 
structure resembles a horseshoe (Su et al., 1998). Hemolin concentration in hemolymph and 
hemolin mRNA levels in fat body increased upon bacterial challenge, which indicated a possible 
role in immune reactions (Ladendorff and Kanost, 1990; Ladendorff and Kanost, 1991). 
Experiments have shown that hemolin associated with hemocytes and blocked hemocyte 
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aggregation (Ladendorff and Kanost, 1991). Hemolin is present at low levels in hemolymph of 
naïve larvae until larvae enter the wandering stage. At this time, hemolymph concentration 
increased and continued to increase to higher levels in pupae and adults. In addition, expression 
of hemolin mRNA increased in the fat body and midgut of wandering stage larvae (Yu and 
Kanost, 1999). Hemolin bound to bacteria (Ladendorff and Kanost, 1991) and more specifically, 
to lipopolysaccharide from gram-negative bacteria and lipoteichoic acid from gram-positive 
bacteria (Yu and Kanost, 2002). RNAi knockdown of hemolin resulted in decreased numbers of 
hemocytes and increased numbers of bacteria in larvae challenged with E. coli. Decreased 
phagocytosis, nodulation, and hemocyte aggregation were also observed in RNAi treated insects 
(Eleftherianos et al., 2007). Similar to RNAi knockdown of hemolin, the presence of 
recombinant CcV1 (endosymbiont bracovirus of Cotesia congregata) decreased hemocyte 
aggregation by hemolin. Binding of hemolin to lipopolysaccharide was also reduced in the 
presence of CcV1 (Labropoulou et al., 2008). These results indicate that hemolin may function 
as a pattern recognition protein or as a modulator of cell-cell interactions during infection. 
Peptidoglycan recognition proteins  
Peptidoglycan is a component of gram-positive and gram-negative bacterial cell walls. 
Polymers of peptidoglycan consist of linear glycan strands containing alternating N-
acetylglucosamine and N-acetylmuramic acid residues linked in a β-1,4 manner and are cross-
linked by short peptide chains (Vollmer et al., 2008). For gram-negative bacteria and Bacillus 
species a meso-diaminopimelic acid (DAP) group is in the third position of the peptide chain 
while a lysine is present in gram-positive bacteria. Peptidoglycan is recognized by proteins 
referred to as peptidoglycan recognition proteins (PGRPs). 
PGRP is a 19 kDa protein that is constitutively expressed in fat body; however, upon 
bacterial challenge, the levels of PGRP mRNA increase (Yu et al., 2002). Two cDNA clones for 
PGRP were identified by substractive hydridization, but only differed in the amino acid sequence 
of the predicted signal peptide (Zhu et al., 2003a). Sumathipala and Jiang (2010) showed that 
recombinant PGRP-1 binds to soluble peptidoglycan from E. coli, but not peptidoglycan from 
Staphylococcus aureus. PGRP-1 bound to insoluble peptidoglycan from Micrococcus luteus, 
Bacillus megaterium, and Bacillus subtilis, but no binding was observed with insoluble 
peptidoglycan from S. aureus (Sumathipala and Jiang, 2010). Phenoloxidase activity increased in 
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a dose dependent manner when recombinant PGRP-1 was added to naïve plasma. Futhermore, 
samples containing PGRP-1, naïve plasma, and elicitor produced higher levels of PO activity 
when compared to samples with only naïve plasma and elicitor. These results indicate that 
PGRP-1 is involved in the proPO activation pathway of M. sexta (Sumathipala and Jiang, 2010).  
β-1,3-glucan recognition proteins  
An important component of fungal cell walls is β-1,3-glucan. Pattern recognition proteins 
that bind to β-1,3-glucan are called β-1,3-glucan recognition proteins. Two βGRPs from M. sexta 
have been isolated and characterized (Ma and Kanost, 2000; Jiang et al., 2004). Like other 
βGRPs, they bind β-1,3-glucan and contain a C-terminal glucanase-like domain. βGRP-1 is 
constitutively expressed in fat body, but not integument or hemocytes (Ma and Kanost, 2000). 
βGRP-1 bound and agglutinated cells from Saccharomyces cerevisiae, Micrococcus 
lysodeikticus (=luteus), and E. coli. The presence of βGRP-1, laminarin, and naïve plasma 
stimulated proPO activation. Unlike βGRP-1, βGRP-2 is present only in wandering, non-feeding 
larvae (Jiang et al., 2004). Transcripts of βGRP-2 are not present in fat body from naïve larvae, 
but levels increase in larvae challenged by yeast or bacteria. Yeast and bacterial cells are 
agglutinated by βGRP-2. βGRP-2 binds to laminarin and lipoteichoic acid, but not 
lipopolysaccharide. Addition of βGRP-2 to induced hemolymph incubated with laminarin 
dramatically increases PO activity, whereas incubation with lipoteichoic acid or 
lipopolysaccharide did not stimulate proPO activation (Jiang et al., 2004). 
Microbe binding protein: A new member of the β-1,3-glucanase-related protein 
superfamily 
Pyrosequencing analysis of expressed sequences tags (ESTs) for hemolymph proteins in 
M. sexta revealed 218 previously unknown sequences coding for defense molecules (Zou et al., 
2008). Of these new cDNA sequences, six encoded polypeptides similar to the gram-negative 
binding protein (GNBP) from Bombyx mori (Lee et al., 1996). The complete sequence, minus the 
first nucleotide, of microbe binding protein (MBP) was obtained by screening plaques of an 
induced fat body cDNA library and searching EST databases (Wang et al., 2011). MBP is an 
inducible 51 kDa protein with five potential glycosylation sites and six cysteine residues. The 
sequence of MBP is 61% identical to B. mori GNBP and 34-36% identical to M. sexta βGRP-1 
and -2. To study the binding properties and potential function of MBP, recombinant protein was 
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produced using a baculovirus system. Purified MBP bound to intact bacteria and fungi as well as 
to specific insoluble and soluble cell surface components (insoluble: β-1,3-glucan, DAP-type 
peptidoglycan from Bacillus subtilis and Escherichia coli, and Lys-type peptidoglycan from 
Staphylococcus aureus; soluble: lipopolysaccharide, lipoteichoic acid, E. coli DAP-type 
peptidoglycan, S. aureus Lys-type peptidoglycan, and laminarin) (Wang et al., 2011). When 
MBP was mixed with naïve or induced plasma in the absence of elicitor, a concentration-
dependent increase in activation of proPO was observed. Following this experiment, 
recombinant MBP was mixed with various elicitors to investigate if the addition of MBP could 
enhance proPO activation. Plasma alone or plasma plus MBP produced low levels of PO activity. 
PO activity was detected in mixtures containing plasma plus elicitor, but higher levels of PO 
activity were observed if plasma was incubated with MBP and elicitor. Statistically significant 
increases in PO activity were observed when the elicitor was DAP-type peptidoglycan from E. 
coli, B. subtilis, or Bacillus megaterium, Lys-type peptidoglycan from Micrococcus luteus, and 
lipoteichoic acid (Wang et al., 2011). Binding to a variety of microbial cells and cell surface 
components suggest that MBP serves as a pattern recognition protein during infection, and the 
ability of MBP to enhance proPO activation indicates that this protein works in concert with 
other defense molecules to stimulate the activation of proPO.  
Immulectins  
M. sexta contains at least four C-type lectins, named immulectins 1-4 (IML 1-4) (Yu et 
al., 1999; Yu and Kanost, 2000; Yu et al., 2005; Yu et al., 2006). Immulectins contain two 
carbohydrate recognition domains that may or may not bind the same type of carbohydrate (Yu 
and Kanost, 2008). IMLs 1-4 can agglutinate gram-negative bacteria (E. coli), gram-positive 
bacteria (S. aureus), and yeast (S. cerevisiae) (Yu et al., 1999; Yu et al., 2005; Yu et al., 2006). 
IML-2 can also agglutinate erythrocytes from horse, human, and sheep (Yu and Kanost, 2000). 
In all cases, agglutination is calcium and IML concentration dependent. mRNA levels in fat body 
of all four IMLs are upregulated after injection of bacteria (Yu et al., 1999; Yu and Kanost, 
2000; Yu et al., 2005; Yu et al., 2006). IML-1 binds lipopolysaccharide from E. coli and sugars, 
including mannose, glucose, and galactose; however, IML-1 does not bind laminarin (Yu et al., 
1999). Immobilized lipopolysaccharide from E. coli, bacterial lipid A, lipoteichoic acid, 
peptidoglycan, fungal mannan, β-1,3-glucan are bound by IML-2 (Yu and Kanost, 2000; Yu and 
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Ma, 2006). IML-3 and IML-4 bind lipopolysaccharide, lipoteichoic acid, and laminarin (Yu et 
al., 2005; Yu et al., 2006). IML-1 and IML-2 bind lipopolysaccharide to stimulate proPO 
activation in plasma (Yu et al., 1999; Yu and Kanost, 2000). Encapsulation by hemocytes is 
enhanced by IML-1, IML-2, IML-3, or IML-4, but only IML-2 and IML-4 enhance melanization 
of immulectin coated beads (Yu and Kanost, 2004; Ling and Yu, 2006; Yu et al., 2005). The 
ability of immulectins to bind bacteria and cell surface components, stimulate proPO activation, 
and enhance encapsulation by hemocytes indicates that immulectins play an important role as 
pattern recognition proteins in response to infection. 
Prophenoloxidase Pathway 
One important component of innate immunity is the prophenoloxidase (proPO or PPO) 
activation pathway. Prophenoloxidase activation can be triggered by foreign invaders or by 
mechanical injury (Cerenius and Söderhäll, 2004). Activation of proPO in response to infection 
starts with the recognition of microbial cells or cell surface components by pattern recognition 
proteins in hemolymph followed by stimulation of a serine proteinase cascade that terminates in 
the activation of proPO (proPO) to phenoloxidase (PO). Phenoloxidase is a copper-containing 
enzyme found in insect hemolymph that is important for melanization and wound healing. PO is 
synthesized as an inactive zymogen in oenocytoids, and is released into the hemolymph upon 
oenocytoid rupture (Kanost and Gorman, 2008; Shrestha and Kim, 2008). Active PO is involved 
in the production of cytotoxic compounds, production of melanin, and encapsulation of foreign 
invaders (Cerenius et al., 2008; Kanost and Gorman, 2008). Chemically speaking, PO is an 
essential component in the conversion of monophenols to o-diphenols by hydroxylation and o-
diphenols to quinones by oxidation.  
Activation of prophenoloxidase 
Active PO is generated by specific proteolysis of proPO or by the presence of certain 
alcohols, organic compounds, detergents, or phospholipids. Prophenoloxidase purified from 
Drosophila melanogaster pupae was found to be activated by various alcohols and organic 
compounds (Asada et al., 1993). Highest proPO activation was observed with the addition of 2-
propanol (Asada et al., 1993; Asada, 1998). Purified M. sexta proPO can be activated in the 
presence of the cationic detergent, cetylpyridinium chloride (CPC), but anionic or non-ionic 
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detergents did not activate proPO (Hall et al., 1995). Kinetic constants to characterize the 
binding and activation of proPO by CPC were determined using purified proPO from the 
blowfly, Sarcophaga bullata (Xie et al., 2007). Phospholipids have also been shown to activate 
proPO (Sugumaran and Nellaiappan, 1991; Bidla et al., 2009). In 1991, Sugumaran and 
Nellaiappan found that proPO from the lobster, Homarus americanas, could be activated by 
some anionic (sodium dodecyl sulfate) and cationic (CPC) detergents, fatty acids (linoleate, 
oleate, and palmitate), and phospholipids. Of all potential activators tested, the addition of 
lysolecithin resulted in the highest levels of proPO activation. More recently, Bidla et al. (2009) 
found that the addition of inner membrane phospholipids (phosphatidylserine and 
phosphatidylinositol), but not outer membrane phospholipids (phosphatidylcholine and 
phosphatidylethanolamine) to hemolymph from D. melanogaster stimulated PO activity. Results 
of the prior two studies suggest that the release of phospholipids from damaged cells could 
stimulate the activation of proPO after an insect has been injured. 
proPO activation in Manduca sexta 
M. sexta contains two proPO polypeptides, proPO-p1 (Jiang et al., 1997) and proPO-p2 
(Hall et al., 1995). Each polypeptide is ~80 kDa. Crystal structure analysis of proPO confirmed 
that the protein is composed of two polypeptides, which form a heterodimer. ProPO-p1 and 
proPO-p2 consist of four domains; pro-region, domain 1, domain 2, and domain 3 (Li et al., 
2009). In terms of secondary structure, domains 1 and 2 are dominated by α-helices, while 
domain 3 contains a seven-stranded, antiparallel β-sheet. The proteolytic cleavage site, Arg 51 is 
located within the α-helical pro-region, but is bordered by a two-stranded, parallel β-sheet. Each 
subunit contains a type 3 di-nuclear copper center in the active site found in domain 2, and each 
copper atom coordinates three His residues (Li et al., 2009). The amino acid sequence of M. 
sexta proPO-p1 is 78% identical to Bombyx mori proPO-p1 and 50% identical to M. sexta 
proPO-p2 while M. sexta proPO-p2 is 77% identical to B. mori proPO-p2 and 49% identical to 
B. mori proPO-p1 (Jiang et al., 1997). In addition, the proPO sequence is homologous to 
arthropod hemocyanins, which are oxygen-transport proteins, and insect hexamerin storage 
proteins. Synthesis of proPO occurs only in oenocytoids (Jiang et al., 1997), does not contain a 
signal peptide, and is released into the hemolymph when the oenocytoids rupture. 
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Prophenoloxidase freely circulates in the hemolymph as an inactive protein, but can become 
active in response to immune challenge.  
Three prophenoloxidase-activating proteinases (PAPs 1-3) were discovered, and are 
involved in the activation of M. sexta proPO (Jiang et al., 1998; Jiang et al., 2003a, Jiang et al., 
2003b). All PAPs are synthesized as zymogens and must be activated by proteolytic cleavage. 
PAP-1 is a 44 kDa protein that was isolated from a cuticular extract. This protein contains a 
signal peptide and one amino-terminal clip domain. Proteolytic activation of proPAP-1 occurs 
between Arg-127 and Ile-128 (Jiang et al., 1998). PAP-2 and PAP-3 were isolated from M. sexta 
hemolymph and contain two amino-terminal clip domains (Jiang et al., 2003a; Jiang et al., 
2003b). PAP-2 undergoes proteolytic cleavage at Lys-153 (Jiang et al., 2003a) while PAP-3 is 
cleaved at Lys-146 (Jiang et al., 2003b). Active PAPs cleave proPO at Arg-51 to form PO, but 
little PO activity is generated. To increase levels of PO activity, serine proteinase homologs 
(SPHs) must be present, along with PAPs and proPO (Jiang et al., 1998; Jiang et al., 2003a; Jiang 
et al., 2003b; Gupta et al., 2005). SPHs contain an amino-terminal clip domain like several 
known serine proteinases, but the active site Ser has been replaced with Gly. SPH-1 and SPH-2 
levels are stimulated by immune challenge, interact with immulectin-2, and enhance proPO 
activation (Yu et al., 2003).  
Inhibition of the phenoloxidase pathway 
Compounds produced by active PO can be detrimental to the health of an insect as some 
of them are cytotoxic. Therefore, it is of the utmost importance for proPO activation and PO 
activity to be regulated. One way that PO is regulated is by the synthesis of a protein zymogen 
that must be activated by proteolytic cleavage (Cerenius and Söderhäll, 2004) in response to a 
foreign invader. Proteinase inhibitors also play an important role in preventing unnecessary 
activation of proPO.  
In the early 1990s, a competitive inhibitor of PO activity was discovered in the 
hemolymph of Musca domestica and named phenoloxidase inhibitor, or POI (Tsukamoto et al., 
1992; Daquinag et al., 1995). POI is a peptide with a mass of 4.2 kDa. Sequence analysis 
revealed that POI is rich in cysteine and lysine residues, and contains a tyrosine residue (residue 
32) that has been hydroxylated to 3,4-dihydroxyphenylalanine (DOPA). Such a modification 
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may play a role in binding to PO (Daquinag et al., 1995), but experimental evidence of this 
interaction is lacking. 
Based on homology to M. domestica POI, a PO inhibitor from Anopheles gambiae was 
cloned and characterized (Shi et al., 2006). The protein had a molecular weight of 33.8 kDa and 
contained five cysteine knot motifs. POI was expressed in all developmental stages tested and 
further analysis revealed that the highest mRNA levels were in the adult fat body. Wounding or 
injection with Sephadex beads resulted in an increase of POI mRNA, but mRNA levels 
decreased after a blood meal. RNA interference (RNAi) was successfully used to knockdown 
POI transcript levels. RNAi treated mosquitoes had more melanization around the wound site 
than non-RNAi treated mosquitoes; however, melanization of Sephadex beads was not affected 
by RNAi treatment. These results suggest that POI plays a role in regulating the activity of PO. 
Sequence analysis identified similarity to two ESTs for a M. sexta POI. Recombinant POI 
production for one of the EST sequences was successful, but the POI could only inhibit PO at 
high concentrations (Lu and Jiang, 2007). Thus, the relevance of this M. sexta POI as a PO 
inhibitor is still in question. In the same study, a low molecular weight compound was isolated 
and exhibited strong inhibition of PO and mushroom tyrosinase. 
Epidermal growth factor-like 1.0 (Egf1.0) is a protein that is similar to small serine 
proteinase inhibitors (smapin family), and is encoded by the Microplitis demolitor bracovirus 
(MdBV) (Beck and Strand, 2007). Recombinant Egf1.0 added to hemolymph from M. sexta 
decreased PO activity in a dose-dependent manner. Amino acid sequence alignment of Egf1.0 
with several small serine proteinase inhibitors predicted P1-P1’ residues to be Arg-Phe, which 
happens to be the P1-P1’ site of most insect proPOs. The authors hypothesized that Egf1.0 may 
interact with prophenoloxidase-activating proteinases to inhibit melanization (Beck and Strand, 
2007). Addition of Egf1.0 to PAP-3 impaired the ability of PAP-3 to cleave an artificial 
substrate, indicating that Egf1.0 is an effective inhibitor of PAP-3. To further verify the results, 
the authors used an Egf1.0 mutant in which the P1 Arg was changed to an Ala. This mutant was 
not able to block PAP-3 amidase activity. Finally, if PO was already activated, the addition of 
Egf1.0 could not inhibit PO activity. This further suggests that Egf1.0 inhibits proPO activation. 
Egf1.0 also inhibits the activity of M. sexta PAP-1, the processing of proPAP-1 and proPAP-3, 
and the processing of proPO and serine proteinase homologs 1 and 2 (SPH1-2) (Lu et al., 2008). 
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Blocking of proPO activation by M. demolitor allows for successful host parasitization and 
prevents the death of the wasp’s offspring by the host immune system.  
Venom from the endoparasitoid, Leptopilina boulardi, inhibits the PO pathway in 
Drosophila yakuba larvae (Colinet et al., 2009). The venom contains a 46 kDa serine proteinase 
inhibitor (serpin family), LbSPNy, which blocks PO activation. Hemolymph injected with 
venom or recombinant LbSPNy exhibited little or no melanization when compared to 
hemolymph injected with bovine serum albumin. Analysis of LbSPNy predicted that the P1 
residue was Arg, which suggests that LbSPNy targets proteinases with trypsin-like specificity. 
Sequence alignment of the reactive center loop from LbSPNy and several known serpins 
revealed that the P3-P1’ residues of LbSPNy matched those of M. sexta serpin-6, a known 
inhibitor of PAP-3 (Wang and Jiang, 2004). Therefore, LbSPNy may inhibit proteinases required 
for proPO activation. Results from this study led authors to hypothesize that LbSPNy inhibits 
steps prior to proPO activation and not PO activity directly (Colinet et al., 2009). 
In the late 1990s, a melanization preventing factor (MPF) was discovered on Sephadex 
carboxymethyl (CM) beads injected into and recovered from Anopheles gambiae strain 4a rr 
(non-melanizing strain). When these beads were transferred into strain L3-5 (melanizing strain), 
no melanization was observed, and treatment of beads with protease K abolished MPF activity 
indicating the MPF was a protein (Paskewitz and Riehle, 1998). Proteins bound to CM beads 
recovered from 4a rr mosquitoes were subjected to electrophoresis followed by silver staining. 
Amino-terminal sequencing revealed the presence of lysozyme c-1 (Lys c-1) and cytochrome C 
(Li and Paskewitz, 2006). Knockdown of Lys c-1 in 4a rr mosquitoes resulted in decreased MPF 
activity and increased melanization of CM beads transferred to the melanizing strain G3 while 
purified Lys c-1 from An. gambiae cell line 4a3B inhibited dopachrome formation by 
phenoloxidase. How these results translate to the melanization of malarial parasites or pathogens 
is not clear, but the authors hypothesized that lysozyme may prevent melanization under certain 
conditions (Li and Paskewitz, 2006). Injection of dsLYSC-1 into one day old An. gambiae G3 
females followed by injection of M. luteus did not impact mosquito survival as the bacteria were 
rapidly melanized. However, the opposite impact was observed with injection of E. coli 
indicating that the role of lysozyme in an immune response may depend on the invading 
pathogen (Kajla et al., 2010). In vitro experiments suggest that lysozyme (0.25 µg/µL) inhibits 
proPO activation in naïve plasma (2 µL) from M. sexta, but not in plasma pre-activated by 
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laminarin (Rao et al., 2010). Purified M. sexta lysozyme in combination with naïve plasma 
contained proPO, but not PO. Conversely, when bovine serum albumin was added to naïve 
plasma, both proPO and PO were detected. Moreover, the addition of lysozyme appeared to 
stimulate the degradation of proSPH-2 and proPAP-1, two key components in the PO cascade. 
Pattern recognition proteins, such as immulectin-2 and -3 were not degraded by the addition of 
lysozyme. These results suggest that lysozyme inhibits the PO pathway by preventing the 
conversion of proPO to PO (Rao et al., 2010). The biological relevance of lysozyme as an 
inhibitor of proPO activation in M. sexta remains unknown, and in vivo experiments must be 
completed.  
Inhibition of phenoloxidase-induced melanin synthesis 
Active PO catalyzes several reactions that lead to the formation of melanin. Excessive 
melanin production can be detrimental to an organism and must be regulated. A novel 
melanization-inhibiting protein (MIP) was isolated from hemolymph of the beetle, Tenebrio 
molitor (Zhao et al., 2005). Recombinant MIP (rMIP) added to crude hemolymph in the presence 
of dopamine, calcium, and β-1,3-glucan inhibited melanin synthesis in a dose-dependent manner. 
However, PO and amidase activity were not impacted by the presence of rMIP, which indicates 
that MIP does not inhibit proPO activation. Knockdown of mip using dsRNA for MIP resulted in 
increased melanin synthesis when compared to larvae injected with dsRNA for green fluorescent 
protein, further confirming that MIP is a regulator of melanin synthesis (Zhao et al., 2005). A 
functionally similar protein to Tenebrio MIP was isolated from the crayfish, Pacifastacus 
leniusculus (Söderhäll et al., 2009). Unlike Tenebrio MIP, Pl-MIP contains a fibrinogen-like 
domain and an Asp-rich region that may be important calcium binding. Recombinant Pl-MIP 
inhibited PO activity in a dose-dependent manner when added to a mixture containing hemocyte 
lysate supernatant, lipopolysaccharide-peptidoglycan or β-1,3-glucan, and L-DOPA as substrate. 
However, if hemolymph was pre-activated, the addition of recombinant Pl-MIP did not inhibit 
PO activity. Deletion of the Asp residues decreased the ability of Pl-MIP to inhibit PO activity, 
indicating that this region is important for protein function. Plasma was depleted of MIP protein 
by the addition of Pl-MIP antibodies and added to a culture of granular cells. After incubation, 
the cells were melanized and melanized particles were found throughout the dish. Control plasma 
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containing Pl-MIP exhibited little or no melanization. These results indicate that Pl-MIP 
regulates proPO activation and subsequent melanin synthesis (Söderhäll et al., 2009). 
Toll Pathway 
In the 1980s, the Toll pathway was first identified in the dorsal-ventral patterning of 
Drosophila melanogaster embryos (Anderson et al., 1985; Imler and Hoffmann, 2001). Since 
then, research has been conducted to identify the serine proteinases that are involved in a 
proteolytic cascade that ends with the activation of the cytokine, spätzle, which binds to a 
receptor called Toll. The initiation of this pathway has not been well characterized, but it has 
been suggested that a product produced by pipe serves as the necessary signal to determine 
dorsal-ventral polarity (Anderson, 1998; Sen et al., 1998; LeMosy et al., 2001). Within the 
oocyte, pipe is located in ventral follicle cells and encodes an enzyme that is similar to heparin 
sulfate 2-O-sulfotransferase (Sen et al., 1998). Once initiated, the cascade takes place in the 
perivitelline space (Morisato and Anderson, 1995) and involves four serine proteinases; nudel, 
gastrulation defective, snake, and easter (LeMosy and Hashimoto, 2000; Dissing et al., 2001; 
LeMosy et al., 2001; Rose et al., 2003). Nudel activation is poorly understood, but appears to be 
independent of gastrulation defective, snake, and easter (LeMosy et al., 1998). After activation, 
nudel has been speculated to play a role in the cleavage of gastrulation defective (Rose et al., 
2003; Kanost and Clarke, 2005). However, it has also been suggested that gastrulation defective 
undergoes autoactivation when in contact with the zymogen of snake (Dissing et al., 2001). In 
the same study, it was shown that snake can cleave gastrulation defective in different locations to 
function as a feedback mechanism. Gastrulation defective cleaves snake, a clip domain serine 
proteinase. In turn, snake cleaves another clip domain serine proteinase, easter (LeMosy et al., 
2001; Rose et al., 2003). Finally, easter, whose activity is regulated by serpin-27A (Ligoxygakis 
et al., 2003), activates spätzle. Spätzle binds and activates Toll at the plasma membrane. 
Activation of Toll leads to a signal transduction pathway that involves Myd88, Tube, Pelle, 
Cactus, and a member of the Rel family of transcription factors, Dorsal (Belvin and Anderson, 
1996; Imler and Hoffmann, 2001). 
Insects have multiple strategies to combat the presence of foreign pathogens including 
bacteria and fungi. One of these strategies is the rapid synthesis of antimicrobial peptides in the 
fat body with subsequent secretion into the hemolymph. Production of antimicrobial peptides in 
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response to gram-positive bacteria or fungi occurs after the activation of the Toll pathway. The 
first documented case of the involvement of the Toll pathway in immune responses came in 
1996, when Lemaitre et al., showed that spätzle, Toll, tube, pelle, and cactus controlled the 
antifungal response in D. melanogaster adults. Interestingly, mutations in snake or easter, had no 
impact on antifungal response, indicating that different genes/proteinases may be involved in the 
Toll pathway for immune response (Lemaitre et al., 1996). In Drosophila, antimicrobial peptides 
include drosomycin and metchnikowin in response to fungi (Fehlbaum et al., 1994; Lemaitre and 
Hoffmann, 2007), attacin, diptericin, drosocin, defensin, and cecropin A1. Diptericin, attacin, 
drosocin, and cecropin A1 are mostly in response to gram-negative bacteria while defensin acts 
in response to infection by gram-positive bacteria (Hoffmann, 2003; Lemaitre and Hoffman, 
2007). However, attacin and cecropin A1 were found to be active against some fungi as well 
(Lemaitre and Hoffman, 2007).  
In Drosophila, induction of the Toll pathway in response to fungi starts with the 
recognition of fungal cell wall components (i.e. β-1,3-glucan) by gram-negative binding proteins, 
which are similar to βGRPs. Members of this family contain an amino-terminal domain that 
binds to β-1,3-glucan and a carboxyl-terminal domain that is similar to a β-glucanase. However, 
the C-terminal domain is not active due to the lack of a key residue that confers glucanase-like 
activity. Specifically, GNBP3 is involved in the recognition of fungal cell wall components and 
activation of the Toll pathway (Gottar et al., 2006). Furthermore, the amino-terminal domain of 
GNBP3 binds to long chains, but not short chains of β-1,3-glucans (Mishima et al., 2009). After 
recognition, a serine proteinase cascade is set in motion. Persephone was the first proteinase 
found to be involved in the response to fungi (Ligoxygakis et al., 2002). Activity of persephone 
is thought to be regulated by the serine proteinase inhibitor, necrotic (Levashina et al., 1999; 
Robertson et al., 2003). Another proteinase found in this cascade is spätzle-processing enzyme 
(SPE) (Jang et al., 2006). SPE activates spätzle, which in turn binds to Toll. After binding to 
Toll, an intracellular signal transduction cascade is initiated that results in the nuclear uptake of 
Dorsal-related immunity factor (DIF) and production of drosomycin. Additionally, the activation 
of the Toll pathway via persephone can occur in response to the secreted fungal virulence factor, 
PR1, a protease (Gottar et al., 2006). 
Initiation of the Toll pathway in Drosophila in the presence of gram-positive bacteria 
requires peptidoglycan recognition proteins (PGRPs). Lys-type peptidoglycan found in gram-
 19 
positive bacteria can be recognized by PGRP-SA or PGRP-SD (Michel et al., 2001; Bischoff et 
al., 2004). Moreover, PGRP-SA forms a complex with GNBP1 to activate a serine proteinase 
cascade that leads to the activation of Toll (Gobert et al., 2003; Pili-Floury et al., 2004). 
Characterization of complex formation between PGRP-SA and GNBP1 is still unclear, but it is 
thought that GNBP1 hydrolyzes Lys-type peptidoglycan into smaller fragments (muropeptides) 
to provide a processed form of peptidoglycan to PGRP-SA. PGRP-SA binds to these smaller 
peptidoglycan fragments while physically interacting with GNBP1 to stimulate downstream 
signaling (Wang et al., 2006). In addition, the presence of PGRP-SD appears to enhance the 
ability of GNBP1 to bind to peptidoglycan which in turn enhances the interaction between 
PGRP-SA and GNBP1 (Wang et al., 2008). After recognition, it has been suggested that a 
modular serine protease, lacking a clip domain, links the PGRP-SA/GNBP1 complex to the 
remainder of the serine proteinase cascade that leads to the production of antimicrobial peptides 
(Buchon et al., 2009). Downstream of modular serine protease are the clip domain containing 
proteinases Grass, Spirit (Kambris et al., 2006; El Chamy et al., 2008) and SPE (Jang et al., 
2006). Once activated, SPE cleaves and activates pro-spätzle (Jang et al., 2006). As with the 
response to fungal infection, activated spätzle will bind Toll, which initiates an intracellular 
signal transduction pathway that leads to the production of antimicrobial peptides. 
In addition to Drosophila, Toll-like receptors have been found in other insect species in 
five different orders which include Orthoptera, Hymenoptera, Coleoptera, Lepidoptera, and 
Diptera (Ao et al., 2008). Within the past several years, the extracellular activation of the Toll 
pathway of Tenebrio molitor and the proteinases involved have been well-characterized (Kim et 
al., 2008; Roh et al., 2009; Jiang et al., 2009). Similar to Drosophila, T. molitor recognizes Lys-
type peptidoglycan from gram-positive bacteria via a PGRP-SA and GNBP1 complex (Park et 
al., 2007). Following recognition is a serine proteinase cascade that involves modular serine 
protease, SPE-activating enzyme (SAE), and spätzle-activating enzyme (SPE). The proteinases 
SAE and SPE both contain a clip domain. Activation of SPE is followed by the cleavage of pro-
spätzle to spätzle and binding of spätzle to Toll (Kim et al., 2008). Binding to Toll stimulates an 
intracellular signal transduction pathway that results in the production of two antimicrobial 
peptides, tenecin 1 and tenecin 2 (Roh et al., 2009). Interestingly, activation of the Toll pathway 
in response to fungal infection utilizes the same three proteinases as determined for the response 
to gram-positive bacteria. The difference occurs at the step of recognition. Here, GNBP3 
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recognizes β-1,3-glucan located on the fungal cell wall (Roh et al., 2009). The serine proteinases 
involved in this pathway, and therefore, the production of antimicrobial peptides in response to 
infection are regulated by serine proteinase inhibitors. Modular serine protease activity is 
inhibited by SPN40 while SAE was inhibited by SPN55 and SPE by SPN48 (Jiang et al., 2009). 
Understanding the role of the Toll pathway in the immune response of lepidopteran 
insects has been slow. In 2008, a Toll receptor cDNA was cloned from Manduca sexta (Ao et 
al.). Expression analysis revealed that MsToll was found in the hemocytes, fat body, epidermis, 
midgut, and Malpighian tubules. Furthermore, upon immune challenge with E. coli, mRNA 
levels were up-regulated in hemocytes, but not fat body (Ao et al., 2008). Injection of B. mori 
spätzle-1 stimulates the transcription of antimicrobial peptides in both Bombyx and M. sexta. 
Additionally, when pro-BmSpz1 and Micrococcus luteus were incubated with plasma from M. 
sexta larvae, processing of pro-BmSpz1 was observed (Wang et al., 2007). Recently, pro-spätzle-
1 was isolated from M. sexta and characterized (An et al., 2010). Pro-spätzle-1 mRNA levels in 
hemocytes increased by 20-fold when larvae had been injected by E. coli or M. luteus. As 
discussed below, recombinant pro-spätzle-1 is cleaved and activated by hemolymph proteinase 8. 
When active spätzle was injected in larvae, mRNA levels of several antimicrobial peptides 
increased (An et al., 2010). The results from these three studies clearly indicate that a Toll 
pathway in response to immune challenge functions in lepidopteran insects. 
Antimicrobial Peptides and Proteins 
Antimicrobial peptides and proteins (AMPs) are synthesized in response to bacterial 
challenge, and are secreted into the hemolymph. AMPs are highly expressed by the fat body, but 
can also be produced in hemocytes, pericardial cells, Malpighian tubules, and midgut (Gillespie 
et al., 1997). AMPs are expressed in extra-embryonic tissues in eggs of M. sexta in response to 
bacterial challenge (Gorman et al., 2004) and in epidermal cells of B. mori in response to 
wounding or infection of the cuticle (Brey et al., 1993; Lee and Brey, 1995). AMPs have been 
isolated, cloned, and biochemically characterized in various insects; however, the following 
discussion will be focused on those found in lepidopteran insects, with emphasis on M. sexta. 
AMPs found in M. sexta include lysozyme (Mulnix and Dunn, 1994; López-Zavala et al., 2004), 
cecropins (Dickinson et al., 1988; Zhu et al., 2003a), attacins (Kanost et al., 1990; Zhu et al., 
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2003a), lebocins (Zhu et al., 2003a; Rayaprolu et al., 2010), moricin (Zhu et al., 2003a; Dai et 
al., 2008), and gloverin (Zhu et al., 2003a). 
 Lysozyme is a ubiquitous protein that degrades peptidoglycan in bacterial cell walls by 
hydrolyzing β-1,4-glycosidic linkages between N-acetylmuramic acid and N-acetylglucosamine. 
This ~ 14 kDa protein has been identified in a number of lepidopteran species, including 
Galleria mellonella (Powning and Davidson, 1973; Mak et al., 2010), Hyalophora cecropia 
(Hultmark et al., 1980), M. sexta (Mulnix and Dunn, 1994), B. mori (Croizier and Croizier, 1978; 
Lee and Brey, 1995), Samia cynthia ricini (Fujimoto et al., 2001), Antheraea mylitta (Jain et al., 
2001), Spodoptera exigua (Bae and Kim, 2003), Pseudoplusia includens (Lavine et al., 2005), 
Trichoplusia ni (Freitak et al., 2007), Helicoverpa armigera (Zhang et al., 2009), and Spodoptera 
frugiperda (Chapelle et al., 2009). Complete amino acid and nucleotide sequences from an 
invertebrate were obtained from analysis of H. cecropia lysozyme (Engström et al., 1985). 
Comparison of cecropia lysozyme to other lysozymes revealed that the protein contains eight 
conserved Cys residues for the stabilization of the protein by disulfide bonds and two amino 
acids that contain carboxylic acid side chains required for catalytic activity (Engström et al., 
1985). Lysozyme from M. sexta shares 78.3% and 80% identity to the amino acid sequences of 
H. cecropia and B. mori, respectively (Mulnix and Dunn, 1994; López-Zavala et al., 2004). 
Circular dichroism revealed the secondary structure of M. sexta lysozyme to be 57% α-helix, 
2.5% β-sheet, 20% loops and turns, and 20.5% random coil (López-Zavala et al., 2004). 
Lysozyme mRNA levels increase in the presence of injected gram-positive bacteria (Lee and 
Brey, 1995), lipopolysaccharide and a phorbol ester, phorbol 12-myristate 13-acetate (Sun et al., 
1991), and injected peptidoglycan fragments (Mulnix and Dunn, 1994). Highest mRNA levels 
were in fat body. Lysozyme activity in M. sexta was increased by the injection of gram-negative 
and gram-positive bacteria with different cell surface components and pathogenicity to M. sexta, 
with highest activity in hemolymph from larvae injected with Escherichia coli 0111:B4 (Kanost 
et al., 1988). Induction of lysozyme activity was also observed with injected particles (India ink 
and latex particles), polysaccharides (zymosan, glucan, and mannan), bacterial components 
(lipopolysaccharide and Lipid A), and purified M. luteus cell walls. The most significant increase 
in lysozyme activity was observed with injected M. luteus cell walls (Kanost et al., 1988). 
Peptidoglycan is a major component of M. luteus cell walls. Injection of soluble peptidoglycan or 
peptidoglycan fragments generated by digestion with hen egg white lysozyme were good 
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inducers of lysozyme activity, indicating that peptidoglycan plays a role in stimulating the 
production of antimicrobial peptides in the immune response of M. sexta. In addition to killing 
bacteria, lysozyme appears to regulate proPO activation in M. sexta (Rao et al., 2010). 
Cecropins were first isolated and purified from immunized pupae of H. cecropia 
(Hultmark et al., 1980). They are ~4 kDa basic proteins (Jiang et al., 2010) that have lytic 
activity against gram-negative and gram-positive bacteria (Steiner et al., 1981; Hultmark et al., 
1982). Three cecropin D-like peptides were isolated and characterized from M. sexta larvae 
(Dickinson et al., 1988). Cecropin mRNA was expressed in several tissues, including midgut, 
malpighian tubules, salivary gland, muscle, pericardial cell complex, epidermis with cuticle, 
hemocytes, and fat body. Highest mRNA levels were detected in fat body (Dickinson et al., 
1988). Subtractive suppression hybridization identified one EST from the fat body of M. sexta 
that showed similarity to preprocecropin D from H. cecropia (Zhu et al., 2003a; Gorman et al., 
2004), which was different from the cecropins discovered by Dickinson et al. (1988). 
Another group of inducible, antibacterial peptides, called attacins, was isolated from H. 
cecropia (Hultmark et al., 1983). Attacins are ~20 kDa, glycine-rich, and can be categorized as 
basic or acidic depending on their amino acid composition. These proteins are effective killers of 
gram-negative bacteria such as E. coli, Acinetobacter calcoaceticus, and Pseudomonas 
maltophilia, but not gram-positive bacteria (Hultmark et al., 1983). Attacin acts by increasing the 
permeability of the outer membrane (Engström et al., 1984) and disrupting outer membrane 
protein synthesis in E. coli (Carlsson et al., 1991). Ten ESTs found in the fat body of M. sexta 
were similar to attacin (Zhu et al., 2003a). Of the ten ESTs, five showed identity to the amino-
terminus of acidic attacin. Further comparison revealed that M. sexta contains at least four genes 
that encode sequences for attacin (Zhu et al., 2003a). Injection of M. sexta larvae with 
lipopolysaccharide or peptidoglycan from E. coli, lipoteichoic acid or peptidoglycan from B. 
subtilis, and lipoteichoic acid or peptidoglycan from S. aureus significantly increased the 
expression of attacin in fat body and hemocytes compared to saline-injected larvae (Rao and Yu, 
2010). Expression also increased in a dose-dependent manner, and the degree of increase 
depended on the bacterial component being tested and the bacterial source of the component.  
Gloverin, like attacin, is a glycine-rich protein. This inducible, antibacterial protein is 
~13.8 kDa and was first isolated from Hyalophora gloveri pupae (Axén et al., 1997). Gloverin 
effectively inhibits the growth of E. coli, a gram-negative bacterium, by using a similar 
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mechanism as attacin. After interacting with lipopolysaccharide, gloverin inhibits the synthesis 
of outer membrane components, which increases the permeability of the outer membrane. 
Gloverin is heat-stable at 100°C for at least 10 min; however, antibacterial activity is lost when 
magnesium or free lipopolysaccharide is present (Axén et al., 1997). Studies involving gloverin 
have also been conducted in Trichoplusia ni (Lundström et al., 2002) and B. mori (Kawaoka et 
al., 2008). Six ESTs corresponding to the gloverin precursor in T. ni were identified in M. sexta 
(Zhu et al., 2003a). 
A proline-rich inducible, antimicrobial peptide, called lebocin, was originally isolated 
from B. mori (Hara and Yamakawa, 1995b; Chowdhury et al., 1995; Furukawa et al., 1997) and 
later from T. ni (Liu et al., 2000) and Pseudoplusia includens (Lavine et al., 2005). Mature 
lebocin is ~3.5 kDa and O-glycosylated on threonine residues (Hara and Yamakawa, 1995b; Liu 
et al., 2000). Synthetic peptides, which lack O-glycosylation, exhibited little or no antibacterial 
activity when compared to wild-type lebocin, suggesting that this modification is essential for 
peptide function (Hara and Yamakawa, 1995b). Lebocin appears to target bacterial membranes 
and increases the permeability of liposomes at low ionic strength (Hara and Yamakawa, 1995b). 
Seven M. sexta ESTs corresponding to lebocin were identified. Five were similar to lebocin 4 
precursor of B. mori and two were similar to lebocin-like protein from T. ni, indicating that at 
least two genes encoding for lebocin are present (Zhu et al., 2003a). Recently, 17 lebocin-like 
cDNA clones were isolated and sequenced from M. sexta (Rayaprolu et al., 2010). Three RXXR 
motifs, which can be recognized by an intracellular processing enzyme to generate five peptides, 
were found during sequence analysis of the pro-segment. Four of the possible peptides were 
chemically synthesized, purified, and tested for antibacterial activity. Peptide 1 (Q
1
-R
22
) 
inhibited growth of both gram-positive and gram-negative bacteria whereas peptide 3 (S
67
-R
101
) 
showed low activity against E. coli, and peptides 2 (E
23
-R
66
) and 4 (S
102
-R
128
) were inactive 
(Rayaprolu et al., 2010). Peptides 1, 2, and 3 were found in larval hemolymph, which supports 
the hypothesis that post-translational processing of pro-lebocin to active lebocin is important for 
function (Rayaprolu et al., 2010). 
Originally isolated from B. mori, moricin is a 42-amino acid residue protein that is highly 
basic and predicted to have an amino-terminal α-helix (Hara and Yamakawa, 1995a). Moricin 
has also been found in M. sexta (Zhu et al., 2003a), Spodoptera litura (Oizumi et al., 2005), 
Galleria mellonella (Brown et al., 2008; Brown et al., 2009), and Helicoverpa armigera (Wang 
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et al., 2010). Injection with bacteria increases moricin mRNA levels in fat body and hemocytes 
(Furukawa et al., 1999; Dai et al., 2008), and expression can be stimulated by lipopolysaccharide 
and lipid A from E. coli (Furukawa et al., 1999; Rao and Yu, 2010). Increases in expression have 
also been observed in M. sexta larvae injected with lipoteichoic acid and peptidoglycan (Rao and 
Yu, 2010). Moricin has a broad spectrum of activity as it can prevent the growth of gram-
positive and gram-negative bacteria (Hara and Yamakawa, 1995a; Oizumi et al., 2005; Brown et 
al., 2008), fungi (Brown et al., 2008), and yeast (Brown et al., 2008). The solution structure of B. 
mori (Hemmi et al., 2002), S. litura (Oizumi et al., 2005), and M. sexta (Dai et al., 2008) moricin 
revealed an eight-turn α-helix that almost spans the full length of the protein, and is speculated to 
play a role in protein function (Hara and Yamakawa, 1995a; Hemmi et al., 2002). To kill 
invading bacteria, moricin is hypothesized to target the bacterial membrane and increase 
membrane permeability (Hara and Yamakawa, 1995a). 
Hemolymph Proteinases Found in Manduca sexta 
Hemolymph of the caterpillar, M. sexta, contains at least twenty-seven serine proteinases 
(Jiang et al., 1999; Jiang et al., 2005; Wang et al., 2006). Hemolymph proteinases (HPs) are 
synthesized as zymogens and are activated by specific proteolytic cleavage. Once activated, 
some of these proteinases may function in aspects of innate immune responses, including the 
activation of cytokine precursors and prophenoloxidase (Kanost et al., 2001). 
Expression analysis of these hemolymph proteinases revealed that transcripts are present 
in hemocytes (HPs 13, 15, and 18), fat body (HPs 12, 20-22), or both tissues (HPs 1-7, 9-11, 14, 
16, 19) (Jiang et al., 2005; Wang et al., 2006). HP12 mRNA was also found in the tracheae and 
integument of day 3, fifth instar larvae and in the midgut of day 3 wandering larvae, suggesting 
that it may function in the protection against pathogen invasion (Wang et al., 2006). HP17 was 
not present in hemocytes or fat body from naïve larvae, but was detected after immune challenge 
(Jiang et al., 2005), whereas HP24 transcripts were not found in hemocytes or fat body of naïve 
or immune-challenged larvae (Wang et al., 2006). Additionally, the expression of many HPs (2, 
5, 7, 9, 10, 13-17, 19-21) can be stimulated when an insect has been immune challenged, 
indicating a possible role in the innate immune response of the insect. mRNA levels for HPs 3, 4, 
11 decreased after immune challenge in both hemocytes and fat body (Jiang et al., 2005). 
Transcripts for HP6 and HP8 were constitutively expressed in hemocytes and fat body, and 
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transcript levels did not increase after larvae were injected with E. coli, M. luteus, or curdlan 
from Alcaligenes faecalis (An et al., 2009). 
Of the known hemolymph proteinases, sixteen contain at least one amino-terminal clip 
domain (Jiang et al., 1999; Jiang et al., 2005; Wang et al., 2006). A clip domain is composed of 
37-55 amino acid residues with three disulfide bonds. Although the function of the clip 
domain(s) is unknown, it is thought that they may play a role in proteinase regulation. The 
amino-terminal clip domain is attached to the carboxyl-terminal serine proteinase domain by a 
linker region that ranges in length from 23 to 101 amino acid residues (Jiang and Kanost, 2000). 
Activation of these proteinases occurs via proteolytic cleavage between the clip and serine 
proteinase domains. After cleavage, the two domains remain connected through a disulfide bond 
(Jiang and Kanost, 2000; Kanost et al., 2001). 
Since the discovery of these proteinases, the task has been to investigate their function 
within the insect. Through the production of recombinant proteinases, the role of seven 
proteinases has been elucidated (Ji et al., 2004; Gorman et al., 2007; Wang and Jiang, 2007; An 
et al., 2009; An et al., 2010). In response to peptidoglycan from gram-positive bacteria or fungi 
plus β-1,3-glucan recognition protein (βGRP-2), HP14 autoactivates (Ji et al., 2004) to start the 
prophenoloxidase activation pathway. HP14, which exhibits chymotrypsin-like specificity, 
cleaves proHP21. Activation of proHP21 has been observed by proteolysis between Leu and Ile, 
the predicted activation site (Wang and Jiang, 2007), and at a site different from the expected 
activation site (Gorman et al., 2007). Active HP21 proteolytically cleaves prophenoloxidase-
activating proteinase-2 (PAP-2; Wang and Jiang, 2007) or PAP-3 (Gorman et al., 2007). Finally, 
PAP-2 or PAP-3, in the presence of cleaved serine proteinase homologs (SPHs), activates 
prophenoloxidase (Gorman et al., 2007; Wang and Jiang, 2007). Active phenoloxidase catalyzes 
oxidation of catechols to quinones. Further reactions involving the quinones result in the 
formation of melanin. 
In another study, An et al. (2009), found a role for HP6 in the activation of 
prophenoloxidase and activation of cytokine-like proteins. HP6 contains one amino-terminal clip 
domain and is most similar to Drosophila Persephone (Jiang et al., 2005; An et al., 2009). When 
bacteria or fungi are present, HP6 is cleaved and activated by an unknown proteinase (An et al., 
2009). Next, HP6 activates proPAP-1 (An et al., 2009). Finally, in the presence of SPHs, PAP-1 
activates proPO and leads to melanin synthesis. In addition, HP6 can cleave and activate another 
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serine proteinase, HP8 (An et al., 2009). HP8 also contains one amino-terminal clip domain and 
is the most similar to Drosophila Easter, Drosophila spätzle-processing enzyme (SPE), and 
Tenebrio SPE (An et al., 2009). The latter group of enzymes has been implicated in the 
activation of the cytokine precursor, prospätzle, in the Toll pathway. Injection of larvae with 
active HP6 or HP8 induced the expression of several antimicrobial peptides and proteins, 
including attacin, cecropin, gloverin, moricin, and lysozyme (An et al., 2009). These results 
suggest that HP8, when activated by HP6 plays a role in the activation of a Toll-like pathway. In 
a subsequent study, recombinant HP8 was shown to cleave recombinant M. sexta prospätzle and 
release active spätzle C108 (An et al., 2010). Spätzle C108 corresponds to the C-terminal 108 
residue domain of prospätzle and is a disulfide-linked homodimer. When spätzle C108 was 
injected into larvae, expression levels of moricin, attacin-1, cecropin-6, and hemolin increased 
when compared to injection of buffer or prospätzle (An et al., 2010). Results from these two 
studies (An et al., 2009; An et al., 2010) provide evidence supporting the hypothesis that HP6 
and HP8 are involved in the activation of a Toll-like pathway in M. sexta that leads to the 
production of antimicrobial peptides. 
Serpins and Serpin Mode of Action 
Serpins belong to a superfamily of proteins that inhibit serine proteinases through a 
suicide inhibition mechanism. However, not all serpins inhibit serine proteinases and not all 
serpins are inhibitory. Noninhibitory serpins have been shown to function as chaperones in rats 
(Clarke et al., 1991) and hormone transporters in humans (Hammond et al., 1987). Inhibitory 
serpins have been found in higher animals, plants, insects and other arthropods, nematodes, 
viruses, green algae, unicellular eukaryotes, prokaryotes, and fungi (Potempa et al., 1994; Irving 
et al., 2000; Irving et al., 2002; Riahi et al., 2004; Roberts et al., 2004; Steenbakkers et al., 2008). 
In humans, such inhibitors play a crucial role in the maintenance of homeostasis, and when 
present in plasma, target proteinases that are involved in phagocytosis, coagulation, complement 
activation, and fibrinolysis (Potempa et al., 1994).  
In 2004, Riahi et al., identified the first serpin from a unicellular eukaryote, Entamoeba 
histolytica. The serpin (Ehserp) from this gastrointestinal protozoan parasite is located in the 
cytoplasm of resting cells, lacks a signal peptide, and is released when the trophozoites come 
into contact with mammalian cells. When tested for inhibitory activity against serine proteinases, 
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recombinant Ehserp showed no activity. However, when the secretion product of activated 
trophozoites was tested, human cathepsin G was inhibited. Further analysis of the interaction 
between the secretion product and cathepsin G identified a stable complex between Ehserp and 
cathepsin G. These results suggest that the presence of Ehserp may help the parasite survive by 
evading the host defense system (Riahi et al., 2004; Roberts et al., 2004). 
The function of serpins in plants remains unclear, but it is hypothesized that they may 
play a role in the regulation of proteolysis that is important for plant growth, development, 
response to stress, defense against insects and pathogens, and protection of seed storage proteins 
from exogenous proteinases (Roberts et al., 2003; Roberts and Hejgaard, 2008). Studies 
involving wheat, barley, rye, oats, pumpkin, apple, and Arabidopisis have shown that plant 
serpins can inhibit chymotrypsin serine proteinases from mammals in vitro (Rosenkrands et al., 
1994; Roberts and Hejgaard, 2008); however, plants do not contain chymotrypsin proteinases. 
Recombinant Arabidopisis serpin1 can inhibit trypsin and the cysteine proteinase, metacaspase 9 
(Vercammen et al., 2006). Inhibition of metacaspase 9 suggests that this serpin may be involved 
in the regulation of programmed cell death. 
Serpins consist of a single chain of 350-400 amino acid residues and share a highly 
conserved structure composed of β-sheets and α-helices (Silverman et al., 2001). Between β-
sheets A and C, is a flexible region termed the reactive center loop (RCL) that contains the P1 
residue. It is the sequence of the RCL that determines serpin specificity. Inhibition of the target 
proteinase begins with the formation of a noncovalent complex between the serpin and the serine 
proteinase. However, once the proteinase cleaves the serpin at the P1 residue of the RCL, a 
covalent ester linkage is formed and the serpin is cleaved. Once cleaved, the serpin undergoes a 
dramatic conformational change. The RCL is inserted into β-sheet A, causing a 70Å 
translocation and active site distortion of the proteinase (Schulze et al., 1994; Wright, 1996; 
Silverman et al., 2001).  
Serine Proteinase Inhibitors in Arthropods 
Serine proteinase inhibitors found in arthropods can be classified into several different 
families which include Kazal, Kunitz, α-macroglobulins, and serpins (Kanost, 1999). Inhibitors 
in hemolymph may function to inhibit proteinases from bacteria and fungi as well as regulating 
endogenous proteinases involved in coagulation, prophenoloxidase activation, and cytokine 
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activation. In crayfish, a member of the Kazal family has been shown to inhibit chymotrypsin 
and subtilisin (Johansson et al., 1994). Members of the Kunitz family inhibit proteinases present 
in the horseshoe crab, B. mori (Sasaki, 1984), M. sexta (Ramesh et al., 1988), and Sarcophaga 
bullata (Papayannopoulos and Biemann, 1992). Serpins have been found in crayfish (Liang and 
Söderhäll, 1995; Liang et al., 1997), insects (Sasaki, 1984; Kanost et al., 1989; Stark et al., 1998; 
Cherqui et al., 2001; de Gregorio et al., 2002; Zou et al., 2006; Zou et al., 2007; Zou et al., 
2009), horseshoe crabs (Miura et al., 1994; Miura et al., 1995; Agarwala et al., 1996), shrimp 
(Liu et al., 2009; Homvises et al., 2010), and ticks (Mulenga et al., 2003; Mulenga et al., 2007; 
Mulenga et al., 2009). 
Serpins in Manduca sexta 
At present, seven serpins have been found in M. sexta (Kanost, 2007). Of the known 
serpins, serpin-1 is unique because the gene that encodes for its production undergoes alternative 
splicing of exon 9 to produce 12 isoforms that exhibit different reactive center loops and, 
therefore, different proteinase specificity (Kanost et al., 1989; Jiang et al., 1994; Jiang et al., 
1996; Jiang and Kanost, 1997). For example, serpin-1A has an Arg at the P1 site and was able to 
inhibit trypsin and plasmin while serpin-1B (Ala at P1) inhibited porcine pancreatic elastase. 
Serpin-1H, 1K, and 1Z all have a Tyr at the P1 site which allowed them to inhibit bovine 
pancreatic α-chymotrypsin and human cathepsin G. Serpin-1I (Leu at P1 site) inhibited elastase 
and chymotrypsin (Jiang and Kanost, 1997). In addition, serpin-1I has been shown to inhibit the 
activity of HP14 (Wang and Jiang, 2006) while serpin-1J inhibits PAP-2&3 (Jiang et al., 2003b). 
With a variety of techniques, stable complexes have been identified between HP8 and serpin-1A, 
1E, and 1J (Ragan et al., 2010; An et al., 2011). Serpin-1J was the most efficient of these 
isoforms as an inhibitor of HP8 (An et al., 2011). SDS-PAGE and MALDI-TOF/TOF analysis of 
serpin-1 immunoaffinity purified from lipopolysaccharide-treated plasma revealed a complex 
between serpin-1K and midgut chymotrypsin and between HP1 and an unidentified serpin-1 
isoform (Ragan et al., 2010). Expression of the serpin-1 gene is constitutive in both the fat body 
and hemocytes. Serpin-1 mRNA is abundant in feeding 4
th
 and 5
th
 instar larvae, but decreased 
quickly at the time of molting. Expression was negatively regulated by 20-hydroxyecdysone, a 
steroid hormone that triggers molting. No mRNA was detected by northern blot in pupae and 
adults (Kanost et al., 1995). 
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Serpin-2 is expressed in granular hemocytes, lacks a signal peptide, and expression is up-
regulated upon bacterial challenge (Gan et al., 2001). Recombinant serpin-2 inhibited human 
cathepsin G (chymotrypsin/elastase-like specificity), but not bovine trypsin or chymotrypsin, 
porcine pancreatic elastase, porcine plasmin, human neutrophil elastase, or the cysteine 
proteinase papain.  However, the biological function of this serpin in the insect is unknown (Gan 
et al., 2001).  
Serpin-3 is a 435 amino acid residue protein that includes a 45-50 residue amino-terminal 
extension that is not observed in the other serpins and a secretion signal peptide. It is expressed 
in fat body, and its expression is up-regulated in the presence of bacteria (Zhu et al., 2003b). 
Functionally, serpin-3 abolishes the activation of proPO by inhibiting all three PAPs (Zhu et al., 
2003b). 
Serpins-4 and 5 are constitutively expressed in the fat body and hemocytes of larvae. 
Upon immune challenge, the expression levels of these serpins dramatically increase. 
Recombinant serpins-4 and -5 are poor inhibitors of PAPs. However, they inhibit the activation 
of the proPO pathway (Tong and Kanost, 2005). Since the PAPs are the final proteinases in the 
proPO activation pathway, this suggests that these serpins inhibit proteinases that occur upstream 
in the serine proteinase cascade. This is the case, as serpin-4 inhibits HP-1, HP-6, and HP-21 
while serpin-5 inhibits, HP-1 and HP-6 (Tong et al., 2005; An and Kanost, 2010). 
Serpin-6, like serpins-1, 4, and 5, is constitutively expressed in the fat body and 
hemocytes. Similarly, expression levels increase upon immune challenge (Zou and Jiang, 2005). 
Serpin-6 plays a role in the inhibition of the proPO pathway by inhibiting PAP-3, but not PAP-1 
or PAP-2 (Wang and Jiang, 2004; Zou and Jiang, 2005). In addition, serpin-6 was shown to form 
a complex with HP8 (Zou and Jiang, 2005). 
Goals of Current Research 
My first project focused on hemolymph proteinase 16. HP16 is one of at least twenty-
seven proteinaseses found in the hemolymph of M. sexta (Jiang et al., 1999; Jiang et al., 2005; 
Wang et al., 2006). These proteinases are synthesized as zymogens and are activated by specific 
proteolytic cleavage. Once activated, some of these proteinases may function in aspects of innate 
immune responses (Kanost et al., 2001). Since the discovery of these proteinases, the task has 
been to investigate their function within the insect. Thus, the goal of this project was to further 
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characterize HP16 and investigate its function in the innate immune response. To address this 
goal, I completed experiments to answer the following questions: 
(1) Do HP16 protein levels in plasma and HP16 mRNA levels in fat body fluctuate 
during larval to pupal development? 
(2) Are HP16 protein and HP16 mRNA expression levels stimulated by the injection of 
bacteria? 
(3) Expression and purification of recombinant HP16 are necessary to elucidate the 
function of HP16; how can this be accomplished? 
(4) Is HP16 activated upon exposure of plasma to microbial elicitors? 
(5) What, if any, serpin-1 isoforms form a covalent complex with active HP16? 
 
In my second project, work focused on the identification of serine proteinases in plasma 
that are inhibited by serpin-3. Original studies to identify endogenous proteinase targets of 
serpin-3 (Zhu et al., 2003b) were completed prior to obtaining sequences of many hemolymph 
proteinases (Jiang et al., 2005; Wang et al., 2006). I hypothesized that additional proteinases are 
also proteinase targets of serpin-3. To test this hypothesis, I performed experiments to investigate 
the following questions: 
(1) Does exposure of plasma to bacteria stimulate the activation of plasma proteinases 
and the formation of serpin-proteinase complexes? 
(2) What plasma proteins does serpin-3 inhibit? 
(3) Can active hemolymph proteinase 8 (HP8) in plasma form a complex with serpin-3? 
(4) Is a complex formed between purified, active HP8 and recombinant serpin-3? 
 
My expection is that results from these two projects will provide a better understanding 
of hemolymph proteinase pathways involved in the innate immune response of M. sexta and their 
regulation. I also expect that findings from this work will lay a foundation for subsequent 
experiments involving the proteolytic activity, regulation, and biological function of HP16 as 
well as for experiments investigating the inhibitory activity of serpins against candidate 
proteinases. 
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CHAPTER 2 - INVOLVEMENT OF HEMOLYMPH 
PROTEINASE 16 IN THE INNATE IMMUNE RESPONSE OF 
MANDUCA SEXTA 
Introduction 
Extracellular serine proteinase cascade pathways are involved in innate immune 
responses of vertebrates and invertebrates, and promote rapid, non-specific responses to infection 
and wounding (Krem and Di Cera, 2002; Kanost and Clarke, 2005; Cerenius et al., 2010). 
Vertebrates utilize proteinase-driven pathways in blood coagulation, fibrinolysis, and 
complement activation (Salvesen, 2004; Sim and Tsiftsoglou, 2004; Dunkelberger and Song, 
2010). After active proteinases perform their functions, they are inactivated by members of the 
serpin superfamily of serine proteinase inhibitors or by α2-macroglobulin to prevent damage to 
the organism (Silverman et al., 2001; Gettins, 2002). Serine proteinase cascades are also 
activated in arthropod hemolymph and have a role in coagulation, melanization, and production 
of antimicrobial peptides (Kanost and Clarke, 2005; Iwanaga and Lee, 2005; Cerenius et al., 
2010). 
Hemolymph of the caterpillar, M. sexta, contains at least twenty-seven serine proteinases, 
including sixteen that possess at least one amino-terminal clip domain (Jiang et al., 1999; Jiang 
et al., 2005; Wang et al., 2006). A clip domain is composed of 37-55 amino acid residues with 
three disulfide bonds. Although the function of the clip domain(s) is unknown, it is thought that 
they may play a role in proteinase regulation. The amino-terminal clip domain is attached to the 
carboxyl-terminal serine proteinase domain by a linker region that ranges in length from 23 to 
101 amino acid residues (Jiang and Kanost, 2000). Hemolymph proteinases (HPs) are 
synthesized as zymogens and are activated by specific proteolytic cleavage. Once activated, 
some of these proteinases may function in aspects of innate immune responses, including the 
activation of cytokine precursors and prophenoloxidase (Kanost et al., 2001). Since the discovery 
of these proteinases, the task has been to investigate their function within the insect.  
The function of seven hemolymph proteinases from M. sexta has been elucidated through 
the use of recombinant proteinases (Ji et al., 2004; Gorman et al., 2007; Wang and Jiang, 2007; 
An et al., 2009; An et al., 2010). In response to bacterial peptidoglycan or fungal β-1,3-glucan 
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and β-1,3-glucan recognition protein (βGRP-2), HP14 autoactivates (Ji et al., 2004) to start the 
prophenoloxidase activation pathway. HP14 then activates proHP21 (Gorman et al., 2007; Wang 
and Jiang, 2007). Finally, HP21 proteolytically cleaves prophenoloxidase-activating proteinase-2 
(PAP-2; Wang and Jiang, 2007) or PAP-3 (Gorman et al., 2007), which activates 
prophenoloxidase in the presence of cleaved serine proteinase homologs (SPHs) (Gorman et al., 
2007; Wang and Jiang, 2007). Active phenoloxidase catalyzes oxidation of catechols to quinones 
that are involved melanin production, encapsulation of foreign invaders, and wound healing 
(Cerenius et al., 2008; Kanost and Gorman, 2008). 
 HP6 plays a role in the activation of prophenoloxidase and activation of cytokine-like 
proteins. When bacteria or fungi are present, HP6 is cleaved and activated by an unknown 
proteinase (An et al., 2009). Next, HP6 activates proPAP-1 (An et al., 2009). Finally, in the 
presence of SPHs, PAP-1 activates proPO and leads to melanin synthesis. In addition, HP6 can 
cleave and activate another serine proteinase, HP8 (An et al., 2009). Injection of larvae with 
active HP6 or HP8 induced the expression of several antimicrobial peptides and proteins (An et 
al., 2009), which suggested a role in the activation of a Toll-like pathway. Recently, recombinant 
HP8 was shown to cleave recombinant M. sexta prospätzle and release active spätzle C108, the 
putative Toll ligand (An et al., 2010). Injection of spätzle C108, a disulfide-linked homodimer of 
the C-terminal 108 residue domain of prospätzle, into larvae increased expression levels of 
moricin, attacin-1, cecropin-6, and hemolin when compared to injection of buffer or prospätzle 
(An et al., 2010). These results further support the hypothesis that HP6 and HP8 are involved in 
the activation of a Toll-like pathway in M. sexta that leads to the production of antimicrobial 
peptides (An et al., 2009; An et al., 2010). 
Hemolymph proteinase 16 (HP16), the focus of this chapter, was identified in M. sexta by 
screening induced hemocyte and fat body cDNA libraries (Jiang et al., 2005). HP16 is a 47 kDa 
protein that has a carboxyl-terminal S1 family serine proteinase domain with predicted 
chymotrypsin/elastase-like specificity. HP16 lacks a clip domain, but contains an amino-terminal 
170 residue region that has no significant match to any characterized protein in the current 
databases, whereas the catalytic domain is most similar to Drosophila gastrulation defective, a 
proteinase that functions in embryonic development. Northern blot analysis revealed that HP16 
mRNA is present at basal levels in naïve hemocytes and fat body. Both HP16 protein levels in 
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plasma and mRNA levels in hemocytes and fat body increased dramatically after injection of 
bacteria, which indicated a possible role in innate immune responses (Jiang et al., 2005).  
In this chapter, I investigated the expression of HP16 at the protein and mRNA levels 
during development and in response to bacterial injection. I developed methods to express and 
purify recombinant HP16, HP16 mutants, NT16 (amino-terminal residues 1-165), and NT16 
mutants to further characterize HP16 and to investigate its potential function in innate immune 
responses. Experiments were also conducted to deterimine if proHP16 in plasma could be 
activated in the presence of microbial elicitors and if any serpin-1 isoforms formed a complex 
with activated HP16-Xa (a mutant activated by bovine factor Xa) in vitro. Findings from this 
work further the understanding of HP16 and lay a foundation for future experiments involving 
the proteolytic activity, regulation, and biological function of HP16. 
Materials and Methods 
Insects 
Manduca sexta eggs were originally obtained from Carolina Biological Supply and used 
to establish a laboratory colony. The colony has been maintained by feeding larvae on an 
artificial diet as previously described by Dunn and Drake (1983). 
Collection of hemolymph 
Hemolymph was collected from naïve larvae, prepupae, and pupae (day 0-day 5 fifth 
instar, day 1-day 3 wandering larvae, prepupa, and day 0 pupa). In addition, hemolymph was 
collected 24 h after injection of day 2 fifth instar larvae injected with 0.85% NaCl (saline), 10
8
 
cells E. coli, or 500 µg M. luteus. Larvae were chilled on ice for at least 20 min. The larval 
posterior horn or the pupal proboscis was clipped to release the hemolymph into individual 
microcentrifuge tubes. An equal volume of anti-coagulant saline (4 mM sodium chloride, 40 mM 
potassium chloride, 8 mM EDTA, 9.5 mM citric acid, 27 mM sodium citrate, 5% sucrose, 0.1 % 
polyvinylpyrollidone, and 1.7 mM PIPES,  pH 6.5) containing diethyldithiocarbamic acid (final 
concentration of 2.25 mg/mL) was added to the hemolymph to prevent coagulation and to inhibit 
prophenoloxidase. Hemocytes were removed from the hemolymph by centrifugation at 8000-
13000 × g for 6-12 min at 4°C depending on developmental stage. The supernatant, or plasma, 
was removed from the hemocytes, placed into a new microcentrifuge tube, and stored at -80°C.  
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Isolation of total RNA 
Fat body (50-100 mg) of naïve day 2 and day 4 fifth instar larvae, day 1 and day 2 
wandering larvae, prepupae, and day 3 fifth instar larvae that were injected (24 h prior to 
collection) with 0.85% saline, 10
8
 cells E. coli, or 500 µg M. luteus was collected for total RNA 
extraction (n =3 for each developmental stage or treatment). Hemolymph from each larva was 
collected prior to fat body collection. Total RNA was extracted using the Tri Reagent (Sigma). 
Fat body samples were homogenized using a Pellet Pestle Motor containing a plastic pestle 
(Kontes) in 1 mL of Tri Reagent. Homogenates were centrifuged at 12,000 × g for 10 min at 
4°C. The resulting supernatants were transferred to an RNase-free 1.5 mL microfuge tube 
(Ambion) and allowed to stand for 5 min at room temperature (RT). Chloroform (200 µL) was 
added to each tube, vigorously shook and vortexed (~15 s), and allowed to stand for 3 min at RT. 
Following centrifugation at 12,000 × g for 15 min at 4°C, the aqueous layer containing RNA was 
transferred to an RNase-free 1.5 mL microfuge tube. After addition of 500 µL of isopropanol to 
each tube, the mixture stood at RT for 10 min and was centrifuged at 12,000 × g for 10 min at 
4°C to pellet the RNA. Supernatants were discarded, and 1 mL of 75% ethanol was used to wash 
the pellet by vortexing. Pellets were centrifuged at 12,000 × g for 5 min at 4°C. Ethanol was 
carefully removed from the pellet. After the pellet was air dried, 40 µL of Nuclease-free water 
was added to each tube to dissolve the pellet. Samples were centrifuged at 12,000 × g for 30 min 
at 4°C to remove glycogen. Supernatants were removed, placed in a new RNase-free tube, and 
kept at -80°C until use for making cDNA. 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Before cDNA synthesis, total RNA samples were treated with Deoxyribonuclease I 
Amplification Grade (DNase I; Invitrogen: 18068-015). RNA (1 µg) was added to 1 µL of 10X 
DNase I reaction buffer, 1 µL DNase I, and Nuclease-free water (Ambion) to bring the total 
reaction volume to 10 µL. Tubes were incubated at RT for 15 min. Inactivation of DNase I was 
accomplished by adding 1 µL of 25 mM EDTA and heating for 10 min at 65°C. 
First-strand cDNA synthesis for each RNA sample was completed using SuperScript III 
First-Strand Synthesis System for RT-PCR (Invitrogen). Reaction mixtures were prepared on ice 
in autoclaved 0.2 mL PCR tubes. Each tube contained 8 µL RNA, 1 µL 50 µM oligo(DT)20 
primer, and 1 µL 10 mM dNTP mix. Samples were mixed, incubated at 65°C for 5 min, and 
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chilled on ice for at least 1 min. Components added, in order, to each tube included 2 µL 10X RT 
buffer, 4 µL of 25 mM MgCl2, 2 µL of 0.1 M DTT, 1 µL RNaseOUT (40 U/µL), and 1 µL 
SuperScript III RT (200 U/µL). Using a PTC-100 Peltier Thermal Cycler (Bio-Rad), mixtures 
were incubated for 50 min at 50°C, followed by 5 min at 85°C (termination). Reactions were 
chilled on ice for 2 min and briefly centrifuged. RNase H (1 µl) was added to each tube, gently 
mixed, and incubated for 20 min at 37°C. Samples were stored at -20°C. 
 HP16 was amplified from fat body cDNA using a forward primer (HP16 F: 5’-CCC 
GCT GAA GAA AAC CAA TA-3’) and a reverse primer (HP16 R: 5’-ACG AAT TTG GCT 
CAT CAA GG-3’). The thermal cycling conditions were 29 cycles of 94°C for 30 s, 53°C for 30 
s, 72°C for 30 s followed by incubation at 72°C for 5 min. M. sexta ribosomal protein S3 (rpS3) 
was used as an internal control and amplified using the same set of fat body cDNA. Primers used 
for rpS3 were 501 (5’-GCC GTT CTT GCC CTC TT-3’) and 504 (5’-CGC GAG TTG ACT 
TCG GT-3’). Thermal cycling conditions were the same as those used for amplification of HP16 
with the exception of the number of cycles and annealing temperature. Twenty (Figure 2-2B: 
larval development) or twenty-three (Figure 2-3B: bacterial injection) cycles were completed for 
rpS3 amplification with an annealing temperature of 55°C. The PCR products were separated by 
electrophoresis on a 1.0% agarose gel containing ethidium bromide. 
Quantitative real-time PCR 
Quantitative real-time PCR was used to determine HP16 and rpS3 mRNA levels using 
cDNA synthesized from total RNA. Primers used for rpS3 were rpS3-F (5’-CTG GCT GAG 
GAT GGC TAC TC-3’) and rpS3-R (5’-TTT CTC AGC GTA CAG CTC CA-3’) and primers 
for HP16 were HP16RT-F (5’-TGA GGA CAT AGC GTT AGT AAG AC-3’) and HP16RT-R 
(5’-GCC GAC GAC AGT TCC ATA C-3’). Each 25 µL reaction contained 12.5 µL of 2X 
SYBR buffer mix (Bio-Rad), 1 µL of forward primer (5 pmol/µL), 1 µL of reverse primer (5 
pmol/µL), and 10.5 µL of diluted cDNA (1/10 dilution). Thermal cycling conditions were 95°C 
for 5 min and 40 cycles of 95°C for 30 s, 53°C for 30 s, and 72°C for 40 s. Amplification was 
monitored on an iCycler (Bio-Rad) by means of SYBR-Green (Bio-Rad). Threshold values were 
individually calculated for each target gene (Ct). Using the formula ΔCt = Cttreated-Ctcontrol, 
transcript abundance values were calculated. For samples analyzed from naïve larvae, an average 
Ct value for day 2 5
th
 instar larvae was used as the control while an average Ct value for saline 
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injected larvae was used as the control for injected larvae. Expression levels of HP16 relative to 
the transcript levels for rpS3 were calculated with the formula ΔΔCt = ΔCtHP16- ΔCtrpS3. Fold 
change is equal to 2
- ΔΔCt
. 
SDS-PAGE and immunoblotting 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using a 10% SDS-
PAGE gel or NuPAGE 4-12% Bis-Tris gels (Invitrogen). Proteins were treated with sample 
loading buffer containing SDS and β-mercaptoethanol; however, in some cases, sample loading 
buffer without β-mercaptoethanol was used. Samples were heated at 95°C for 5 min and briefly 
centrifuged. Electrophoretic separations were carried out in an XCell SureLock
TM
 
Electrophoresis Cell (Invitrogen; Novex Mini-Cell) at a constant voltage of 200 V. Gels were 
stained for 30-60 min in 0.2% (w/v) Coomassie Blue R-250 in 50% (v/v) methanol and 12% 
(v/v) acetic acid, followed by destaining with 30% (v/v) methanol and 10% (v/v) acetic acid. 
Alternatively, when expected protein concentrations were low, gels were silver stained using the 
SilverXpress® Silver Staining Kit (Invitrogen). Gels were placed in a gel drying solution (20% 
(v/v) ethanol, 5% (v/v) glycerol) for 30 min and dried between two cellophane membranes (14 × 
14 cm; Fisher). 
For immunoblotting, proteins were transferred from SDS-PAGE gels to 0.22 or 0.45 µm 
nitrocellulose membranes using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). Membranes 
were blocked for 1 h with 3% dry milk dissolved in TTBS (0.05% Tween 20 in Tris-buffered 
saline, 25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl), washed for 5 min with TTBS, 
and incubated for 2 h with an appropriate primary antiserum diluted 1:2000 (unless otherwise 
specified) in 3% dry milk in TTBS (5 µL antiserum: 10 mL 3% dry milk in TTBS). After three, 5 
min washes with TTBS, membranes were incubated for 1 h with a secondary antibody (Goat 
Anti-Rabbit IgG (H+L)-alkaline phosphatase conjugate; Bio-Rad) diluted 1:3000 in 3% dry milk 
in TTBS (4 µL antibody: 12 mL 3% dry milk in TTBS). Membranes were washed twice with 
TTBS and once with TBS (25 mM Tris-HCl, 137 mM NaCl, 2.7 mM KCl, pH 7.4), followed by 
development using an Alkaline Phosphatase Conjugate Substrate Kit (Bio-Rad). 
DNA sequencing 
Sequences for plasmid verification were obtained on an Applied Biosystems 3730 DNA 
Analyzer at the DNA Sequencing and Genotyping Facility located in the Department of Plant 
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Pathology at Kansas State University in Manhattan, KS. Nucleotide sequences were manually 
aligned using CAP3 (http://pbil.univ-lyon1.fr/cap3.php) and consensus nucleotide sequences 
were translated using the ExPASy Translate Tool (http://expasy.org/tools/dna.html). Both 
nucleotide and amino acid sequences were aligned with the template sequence to ensure that 
undesired changes were not introduced during PCR using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
Mutagenesis and recombinant protein expression 
Expression of HP16 and HP16 mutants 
The entire coding region for HP16, including signal peptide, was amplified from a cDNA 
clone (obtained from Haobo Jiang, Oklahoma State University) by PCR using a forward primer 
(5’-AAG CGG CCG CAT GAA GTT TCT AAT TC-3’) in which a NotI site (underlined) was 
introduced and a reverse primer (5’-GCA AGC TTT TAC AAA TGC CTA GAG ACC-3’) in 
which a HindIII site (underlined) was introduced. A HP16 fragment generated by digestion of 
the PCR product by NotI and HindIII was gel purified using the QIAquick Gel Extraction Kit 
(Qiagen) and ligated into the same restriction sites in pFastBac1 (Invitrogen). The resulting 
HP16-pFastBac1 plasmid, after sequence verification, was used as template to generate two 
HP16 mutants according to the instructions of QuikChange multisite-directed mutagenesis kit 
(Stratagene). Using a mutagenic oligonucleotide primer (5’-AAA CGT CAA GTA TTG ATT 
GAG GGC CGG ATC GTG AAC GGA CAG CCT-3’), residues of the predicted activation site 
of proHP16 were changed from HTGL to IEGR. This mutant was named HP16-Xa. Another 
mutant of HP16 (HP16 S-A) was produced by changing the codon for the active site Ser
382
 
(AGT) to Ala (GCT) by using a mutagenic oligonucleotide primer (5’- GCC TGT AAT GGT 
GAC GCT GGT GGT GGC TTC ATG ATC TTC G-3’). After DNA sequence verification, each 
recombinant plasmid (HP16-pFastBac1, HP16-Xa-pFastBac1, HP16 S-A-pFastBac1) was used 
to transform Max Efficiency DH10Bac E. coli cells (Invitrogen), which contain a bacmid and a 
helper plasmid. Each recombinant bacmid obtained by transposition of the donor plasmid into 
the bacmid was isolated with a High Purity Plasmid Purification System (Marligen Biosciences, 
Inc.). Insertion of HP16 cDNA in the recombinant bacmid was confirmed by PCR using the M13 
forward (-20) primer (5’-GTA AAA CGA CGG CCA G-3’) and the M13 reverse primer (5’-
CAG GAA ACA GCT ATG AC-3’) from Invitrogen. 
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Spodoptera frugiperda Sf-9 cells at a density of 9 × 10
5
 cells/mL were seeded in 2 mL of 
Sf-900 II serum-free medium (SFM) containing 50 units/mL penicillin and 50 µg/mL 
streptomycin in a 6-well plate. The transfection of cells with recombinant bacmid DNA was 
mediated by cationic liposomes using the CellFECTIN reagent and followed the Bac-to-Bac 
Baculovirus Expression System manual (Invitrogen). After incubation at 27°C for 5 h, the 
transfection mixture was removed from the cells and replaced by Sf-900 II SFM plus antibiotics. 
Recombinant baculovirus was collected after the cells were incubated at 27°C for 96 h. The 
initial recombinant baculovirus (P1 virus) for each construct was amplified twice to obtain the P3 
virus. Titer of each P3 virus was determined by performing a plaque assay in 35 mm 6-well 
plates as described by the manufacturer’s manual (Invitrogen). The titers were as follows: 1.8 × 
10
8
 plaque forming units/mL (pfu/mL) for wild-type HP16, 3.1 × 10
8
 pfu/mL for HP16-Xa, and 
1.1 × 10
8
 pfu/mL for HP16 S-A. Long-term storage of the virus was at -80°C in the presence of 
2% fetal bovine serum (Atlanta Biological). Virus to be used immediately for expression was 
protected from light and stored at 4°C. Expression of wild-type HP16, HP16-Xa, and HP16 S-A 
was performed by infecting 2 × 10
6
 cells/mL of Sf-9 cells in 2 liters (400 mL medium/1 L flask) 
of Sf-900 II SFM with the recombinant baculovirus at a multiplicity of infection of 3, 4, or 2, 
respectively. Cells were incubated at 28°C with shaking at 150 rpm. The culture was harvested 
48 h post-infection, and cells were removed by centrifugation at 500 × g for 10 min at 4°C. 
Media removed from the cells was centrifuged again using the same conditions.  
Purification of recombinant wild-type HP16, HP16-Xa, and HP16 S-A  
Cell-free media, achieved by centrifugation, was split into four 1 L flasks (~500 
mL/flask) and mixed with concanavalin A-Sepharose 4B (GE Healthcare) that had been 
equilibrated in ConA binding buffer (20 mM Tris-HCl, 0.5 M NaCl, pH 7.5) and proteinase 
inhibitors (10 mM E-64 to a final concentration of 10 µM and 0.5 M p-aminobenzamidine to a 
final concentration of 0.5 mM). After shaking at 150 rpm for 8 h at 4°C, the slurry was applied to 
a 2.5 × 10 cm column and allowed to drain. The column was washed four times with 35 mL of 
ConA binding buffer at 4°C. Once the A280 reading was below 0.06, 35 mL ConA elution buffer 
(ConA binding buffer with 0.5 M methyl-α-D-mannopyranoside) was added to elute bound 
proteins. The column was rotated overnight at 4°C. After collection of the first elution fraction, a 
fresh 35 mL of ConA elution buffer was added to the column and rotated for an additional 4 h at 
4°C. The second elution fraction (35 mL) was collected and followed by four, 10 mL elutions 
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with ConA elution buffer. The eluted fractions were analyzed by SDS-PAGE and 
immunoblotting. 
Fractions containing HP16 were pooled and dialyzed against Q-Sepharose start buffer (20 
mM Tris, 5 mM NaCl, pH 8.4 and 0.5 M p-aminobenzamidine to a final concentration of 0.5 
mM) (3.5 liters for at least 8 h at 4°C, two times). The dialyzed sample was applied to a Q-
Sepharose
TM
 Fast Flow column (GE Healthcare; 1 × 10 cm) equilibrated with Q-Sepharose start 
buffer (no p-aminobenzamidine) at 1 mL/min. The column was washed with Q-Sepharose start 
buffer at 1 mL/min until the A280 reading was less than 0.025. Proteins bound to the column were 
eluted with a 60 mL linear gradient of 5-1000 mM NaCl in 20 mM Tris-HCl, pH 8.4 at 1 
mL/min. Fractions of 1 mL each were collected and analyzed by SDS-PAGE and 
immunoblotting. 
Q-Sepharose fractions containing HP16 were pooled and prepared for hydrophobic 
interaction chromatography (HIC). An Econo-Pac Methyl HIC Cartridge (Bio-Rad 732-0053) 
was prepared for use as described in the manufacturer’s manual using a low salt buffer (20 mM 
Tris-HCl, pH 8.4) and a high salt buffer (20 mM Tris-HCl, 1.5 M ammonium sulfate, pH 8.4). 
Ammonium sulfate (final concentration = 1.5 M) was dissolved in 3 mL of pooled HP16 Q-
Sepharose fractions, and the resulting solution was centrifuged at 12,000 × g for 30 min at 4°C to 
remove any precipitate. The precipitate was resuspended in 1 mL of 20 mM Tris-HCl, pH 8.4 
and stored at 4°C while the supernatant was loaded onto the HIC column at 0.7 mL/min. The 
column was washed with the high salt buffer for 7 min at 0.7 mL/min. Proteins bound to the 
column were eluted with a 30 mL linear gradient of 1.5 M to 0 M ammonium sulfate in 20 mM 
Tris-HCl, pH 8.4 at 0.7 mL/min. Fractions of 0.7 mL each were collected and analyzed by SDS-
PAGE, followed by silver staining and immunoblotting.  
HIC fractions containing HP16 were pooled and used for further purification by gel 
permeation chromatography. Partially purified HP16 (4 mL) was loaded at 1 mL/min onto a 
Sephacryl-S100 High Resolution (GE Healthcare) 1.5 × 100 cm column equilibrated with gel 
filtration buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.4). Proteins were eluted from the column 
with the gel filtration buffer at 1 mL/min. The first eleven fractions were collected at 4 mL/tube 
as this was determined to be the void volume by running blue dextran (Sigma) through the 
column. After the void volume, 2 mL fractions were collected. Selected fractions were analyzed 
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by SDS-PAGE and immunoblotting. Fractions containing the most HP16 and the least 
contaminating proteins were pooled and stored at -80°C. 
Purification of the two HP16 mutant proteins, HP16-Xa and HP16 S-A, utilized the same 
purification scheme as wild-type HP16 with some modification. First, for both HP16-Xa and 
HP16 S-A, the proteinase inhibitors, E-64 and p-aminobenzamidine, were not added at any step 
of purification. Second, changes in procedure occurred during the use of HIC. The change for 
HP16 S-A was minor as 3.5 mL of pooled Q-Sepharose fractions were applied to the column 
instead of 3 mL. In addition, Coomassie Blue staining was used to detect proteins eluted from the 
HIC column instead of silver staining. For HP16-Xa, the high salt buffer contained 2.4 M 
ammonium sulfate instead of 1.5 M ammonium sulfate. Moreover, proteins bound to the column 
were eluted with a 24 mL (instead of 30 mL) linear gradient of 2.4 M to 0 M ammonium sulfate 
in 20 mM Tris-HCl, pH 8.4 (instead of 1.5 M to 0 M ammonium sulfate in 20 mM Tris-HCl). 
Since the highest levels of HP16-Xa were found in the resuspended precipitate, this solution (3 
mL) was used for further purification by gel permeation chromatography. Fractions containing 
the most HP16-Xa or HP16 S-A were pooled and stored at -80°C. 
Expression and purification of recombinant serpin-1Z 
Manduca sexta serpin-1Z was expressed in Escherichia coli strain XL1-Blue using the 
H6pQE-60 expression vector, which encodes an amino-terminal 6 x histidine tag (Jiang and 
Kanost, 1997). A single colony harboring the recombinant plasmid was inoculated into 50 mL of 
sterile LB containing 50 µL of 50 mg/mL ampicillin in a 250 mL flask and incubated overnight 
at 37°C with shaking at 300 rpm. Fifteen milliliters of the overnight culture was transferred to 
two, 2 L flasks containing 500 mL LB and ampicillin (0.5 mL of 50 mg/mL). Flasks were 
incubated at 37°C with shaking at 300 rpm until OD600 was 0.5 to 0.6. Cultures were kept at 
37°C, and expression of serpin-1Z was induced by adding 1 M isopropyl-β-D-thiogalactoside 
(IPTG) to a final concentration of 1 mM. After 4 h, the bacteria were harvested by centrifugation 
at 4000 × g for 20 min at 4°C. Pellets were frozen at -80°C overnight and resuspended in cold 
lysis buffer (300 mM NaCl, 10 mM imidazole in 0.5 M sodium phosphate buffer, pH 8.0) at 4 
mL lysis buffer/g cells. Proteinase inhibitor cocktail for His-tagged proteins (Sigma P8849) was 
also added at 50 µL inhibitor/g cells. Samples were transferred to 50 mL polypropylene 
centrifuge tubes (Fisher Scientific) and placed in an ice-water bath. Cells were sonicated for 8 × 
10 seconds with a 10 second rest between bursts using a Sonic Dismembrator Model 100 (Fisher 
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Scientific) that was set on level 8. After sonication, the lysate was centrifuged at 10,000 × g for 
30 min at 4°C.  
The soluble serpin-1Z was first purified by nickel-affinity chromatography (Ni
2+
-NTA). 
Clear lysate was incubated with Ni
2+
-NTA agarose (Qiagen) at 1 mL agarose for every 4 mL 
clear lysate in a 50 mL polypropylene centrifuge tube with rotation for 1 h at 4°C. This mixture 
was poured into a 1.5 cm diameter column. The column was washed twice with wash buffer (300 
mM NaCl, 20 mM imidazole in 0.5 M sodium phosphate buffer, pH 8.0) at a volume equal to 
that of the clear lysate. Recombinant serpin-1Z was eluted 4 times with 5 mL of elution buffer 
(300 mM NaCl, 250 mM imidazole in 0.5 M sodium phosphate buffer, pH 8.0). Fractions were 
analyzed by SDS-PAGE under reducing conditions and immunoblotting. To further purify 
serpin-1Z, fractions containing serpin-1Z were pooled and dialyzed against dialysis buffer (20 
mM Tris-HCl, pH 8.0). Serpin-1Z (1.7 mL) was added to a Slide-A-Lyzer 3.5 K Dialysis 
Cassette (Thermo Scientific) and dialyzed in 600 mL dialysis buffer (twice, for at least 8 h) at 
4°C. The dialyzed sample (2 mL) was applied to an equilibrated Q-Sepharose
TM
 Fast Flow 
column (1 × 10 cm) at 1 mL/min. Dialysis buffer (25 mL total) was used to wash the column 
until A280 readings were near zero. Proteins bound to the column were eluted with a 60 mL linear 
gradient of 0-500 mM NaCl in 20 mM Tris-HCl, pH 8.0 at 1 mL/min. Fractions of 1 mL each 
were collected and analyzed by SDS-PAGE under reducing conditions and immunoblotting. 
Fractions containing serpin-1Z were pooled and stored at 4°C. 
Expression and purification of the amino-terminal region of HP16 (NT16) and NT16 mutants 
in E. coli 
The HP16 DNA sequence encoding amino-terminal residues (1-165) was amplified by 
PCR using a forward primer (5'-CCA TGG CCC AAA AGT TAT CTG ATG GT-3') in which an 
NcoI site was introduced (underlined) and a reverse primer (5'-GCG GCC GCC TAT TGA CGT 
TTG CCA CA-3'; reverse complement) in which a NotI site (underlined) and stop codon 
(italicized) were introduced. The PCR product was recovered after purification by agarose 
electrophoresis using the QIAquick Gel Extraction Kit (Qiagen). Recovered DNA was cloned 
into pCR4-TOPO vector following manufacturer’s instructions (Invitrogen), and resulting NT16-
pCR4 plasmid DNA was digested by NcoI and NotI to verify that NT16 was inserted. After 
sequence verification, NT16-pCR4 and the expression vector, pProExHTb (Life Technologies), 
were digested by NcoI and NotI. Digestion products of the expected size for NT16 (~500 bp) and 
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pProExHTb (~4.7 kb) were excised from a 1% agarose gel and gel purified using the QIAquick 
Gel Extraction Kit (Qiagen). NT16 and pProExHTb were ligated with T4 DNA ligase (New 
England BioLabs) at 16°C. After ~17 h, the T4 DNA ligase was heat-inactivated at 65°C for 20 
min. The ligation product was used to transform Max Efficiency DH5α competent E. coli cells 
(Invitrogen). Plasmid DNA was isolated from an overnight culture of a single colony in 3 mL of 
LB with 100 µg/mL ampicillin. The presence of the NT16 DNA insert was checked by 
restriction digestion using NcoI and NotI.  
The NT16-pProExHTb plasmid was used as template to generate three NT16 mutants 
according to the instructions of QuikChange multisite-directed mutagenesis kit (Stratagene). 
Using a mutagenic oligonucleotide primer (5’-GCT GCA TGT GAG GCC CTC CGA GGG 
AGA TAT TAC C-3’), one Cys20 residue (TGC) was changed to Ser (TCC) (Figure 2-9A, 
labeled 20). This mutant was named NT16 C20S. Another mutant of NT16 (NT16 C124S) was 
produced by introducing a mutation to change the second Cys
124
 residue (TGT) to Ser (TCT) 
(Figure 2-9A, labeled 124) by using a mutagenic oligonucleotide primer (5’-GCC ATA CCT 
GAA GAG TTT GGT TAT AAA TAC TAT AGA ATA TTC TAA AAA TGC AAC AAC TGG 
ATA CTT AGA CAG ATT AAT TCA AGG G-3’). The final mutant, NT16 C161S was 
generated by mutating the third Cys
161
 residue (TGT) to Ser (TCT) (Figure 2-9A, labeled 161) 
using a mutagenic oligonucleotide primer (5’-GCA GCG AAA GTA GTC GAT ACG ACT TCT 
GGC AAA CGT C-3’). After DNA sequence verification, each recombinant plasmid (NT16 
C20S, NT16 C124S, or NT16 C161S) was used to transform Max Efficiency DH5α competent 
E. coli cells (Invitrogen). Plasmid DNA was isolated from an overnight culture of a single colony 
in 10 mL of LB with 100 µg/mL ampicillin and sent for sequencing. Sequences of the wild-type 
and mutant NT16 constructs were verified using two primers: M13puCR (5’-AGC GGA TAA 
CAA TTT CAC ACA GG-3’) and pProExRev (5’-TCA CTT CTG AGT TCG GCA TC-3’). 
For expression of recombinant NT16 and NT16 mutants, a single colony harboring the 
recombinant plasmid (NT16-pProExHTb, NT16 C20S, NT16 C124S, or NT16 C161S), was 
inoculated into 40 mL of LB containing 40 µL of 50 mg/mL ampicillin in a 250 mL flask and 
incubated overnight at 37°C with shaking at 275 rpm. Two and a half milliliters of the overnight 
culture were transferred to individual 500 mL flasks containing 100 mL LB and ampicillin (100 
µL of 50 mg/mL). Flasks were incubated at 37°C with shaking at 300 rpm until OD600 was 0.5 to 
0.6. Cultures were cooled to 16°C with shaking at 150 rpm for 10 min before the addition of 
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IPTG to a final concentration of 1 mM. Expression was induced by IPTG for 18 h. The bacteria 
were harvested by centrifugation at 4000 × g for 20 min at 4°C. Pellets were frozen at -80°C 
overnight and resuspended in 10 mL of cold lysis buffer (300 mM NaCl, 10 mM imidazole in 0.5 
M sodium phosphate buffer, pH 8.0). Pellets were then treated as described under the section 
titled “Expression and purification of recombinant serpin-1Z” with some modification. Cells 
were sonicated for 10 × 10 seconds with a 10 second rest between bursts using a sonicator 
connected to a Sonic Dismembrator Model 100 (Fisher Scientific) that was set on level 8.  
The soluble fraction of recombinant NT16 and NT16 mutants was purified by nickel-
affinity chromatography (Ni
2+
-NTA) as described for the purification of recombinant serpin-1Z 
with modification. After the clear lysate (9.4-9.6 mL) was incubated with Ni
2+
-NTA agarose 
(Qiagen), the mixture was poured into a 1 cm diameter column, followed by washing. 
Recombinant NT16 was eluted 4 times with 2.5 mL of elution buffer (300 mM NaCl, 250 mM 
imidazole in 0.5 M sodium phosphate buffer, pH 8.0). Fractions were analyzed by SDS-PAGE 
under reducing and non-reducing conditions and immunoblotting. The first elution fraction for 
purified NT16 and each NT16 mutant was dialyzed against dialysis buffer (20 mM Tris-HCl, 5 
mM NaCl, pH 8.0). Each protein (~1.5 mL) was added to a 0.5-3 mL Slide-A-Lyzer 3.5 K 
Dialysis Cassette (Thermo Scientific) and dialyzed in 1000 mL dialysis buffer (twice, for at least 
6 h) at 4°C.  
Protein concentration assay 
Protein concentrations were determined with the Coomassie Plus
TM
 Protein Assay 
Reagent (Pierce) using bovine serum albumin (Pierce) as the standard. Alternatively, some 
samples of purified protein were analyzed by SDS-PAGE together with several bovine serum 
albumin samples of known amounts to account for the presence of contaminating proteins. This 
was followed by Coomassie Blue staining and determination of protein concentration by 
matching to standard bands of similar intensity. 
Determination of amino-terminal sequences 
To determine amino-terminal sequences, proteins were transferred to a 0.2 µm 
polyvinylidene difluoride membrane (PVDF; Millipore). The PVDF membrane was washed in 
100% methanol for 30 s followed by deionized water for 1 min. Filter paper, fiber pads, PVDF 
membranes, and gel were soaked in transfer buffer (10 mM CAPS in 10% methanol, pH 11.0) 
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for 5 min. The transfer cassette was prepared and placed in the blot module (Bio-Rad). A frozen 
cooling unit was then added to the module and the module was filled with transfer buffer. With 
stirring, proteins were transferred at 75 V for 1 h, then 60 V for 40 min, and finally, 50 V for 20 
min. Membranes were washed three times in deionized water for 5 min each and stained with 
0.025% Coomassie Brilliant Blue R-250 in 40% methanol for 5 min. After destaining with 50% 
methanol for 10 min, the membranes were washed three times in deionized water for 7 min each. 
Desired bands were excised from the PVDF membrane and subjected to Edman degradation 
sequencing at the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale 
University. 
Activation of HP16-Xa by bovine factor Xa 
Purified recombinant HP16-Xa (100 ng) was incubated with different amounts (50, 100, 
200, 300, 400, or 500 ng) of bovine factor Xa (New England Biolabs) in buffer (20 mM Tris-
HCl, 150 mM NaCl, pH 8.4) plus CaCl2 (final concentration = 2 mM) and bovine serum albumin 
(1000 ng). Reaction mixtures were incubated at 37°C for 1 h. Cleavage of HP16-Xa was detected 
by SDS-PAGE followed by immunoblot analysis using antiserum against HP16 as the primary 
antibody.  
Activity of HP16 using synthetic peptide colorimetric substrates 
Amidase activity assays were carried out using the following chromogenic peptides: N-
succinyl-Gly-Gly-Phe-p-nitroanilide (GGFpNa; Sigma S1899), N-succinyl-L-Phe-p-nitroanilide 
(FpNa; Sigma S2628), N-succinyl-Ala-Ala-Ala-p-nitroanilide (AAApNa; Sigma S4760), N-
methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (AAPVpNa; Sigma M4765), L-Leu-p-
nitroanilide (LpNA; Sigma L9125), Ala-Ala-Val-Ala-p-nitroanilide (AAVApNa; Sigma A9273), 
N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (AAPFpNa; Sigma S7388), and acetyl-Ile-Glu-Ala-
Arg-p-nitroanilide (IEARpNA; Kansas State University Microchemical Core Laboratory). 
ProHP16-Xa (100 ng or 1000 ng) was activated by treatment with bovine factor Xa (500 ng) in 
buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.4) plus CaCl2 (final concentration = 2 mM) for 1h 
at 37°C. Equal volumes of activated HP16-Xa or factor Xa in buffer were applied to wells of a 
96-well plate and mixed with 200 µL of 50 µM or 100 µM chromogenic substrate in 0.1 M Tris-
HCl, 0.1 M NaCl, 5 mM CaCl2, pH 8.0. Absorbance at 405 nm was measured continuously for 
30 min in a PowerWave XS plate reader (BioTek). One unit of activity was defined as a change 
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in A405 of 0.001/min. Amidase activity of HP16-Xa was defined as the activity of HP16-Xa in 
the presence of factor Xa minus the activity of factor Xa alone. 
Estimation of HP16 concentration in plasma 
Hemolymph was collected from naïve day 3 fifth instar (n = 3) or from day 3 fifth instar 
(n = 3) larvae 24 h after injection of M. luteus as described in the section titled “Collection of 
hemolymph” with some modification. Only diethyldithiocarbamic acid was added to prevent 
melanization, and hemocytes were removed by centrifugation at 8000 × g for 9 min at 4°C. 
Plasma samples (2 µL) were mixed with water (1 µL), 2X SDS sample buffer (3 µL), and 1X 
SDS sample buffer (1 µL) followed by heating at 95°C for 5 min. The prepared plasma samples 
were analyzed by SDS-PAGE together with several HP16-Xa samples of known quantity 
followed by immunoblot analysis using an HP16 specific antibody. Net pixel intensities 
determined for each HP16-Xa band using Kodak Digital Science 1D software were used to 
construct a standard curve (net pixel intensity vs. quantity of HP16-Xa). A line of best fit was 
determined and used to calculate the concentration of HP16 in naïve and induced plasma. 
Activation of proHP16 in naïve plasma incubated with zymosan 
Hemolymph from naïve day 3, fifth instar larvae was collected into individual 
microcentrifuge tubes and centrifuged at 13,100 × g for 12 min at 4°C to remove hemocytes. 
Cell-free plasma (30 µL) was incubated with 0.4 mg (400 µg) of zymosan A from 
Saccharomyces cerevisiae (Sigma). Day 3, fifth instar plasma only and zymosan A + 30 µL 20 
mM Tris-HCl, 150 mM NaCl, pH 8.0 were included as controls. All samples were incubated at 
room temperature for 1 hr. Incubation was followed by centrifugation at 13,000 × g for 1 min. 
Supernatant was removed from the pellet and kept for analysis (= unbound). Pellets were washed 
two times using 300 µL of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0. Each wash was followed by 
centrifugation at 13,000 × g for 1 min and removal of the buffer. Bound proteins were eluted 
with 30 µL of 2X SDS sample buffer containing β-mercaptoethanol at 95°C for 5 min. 
Supernatants, bound protein samples, and control samples were subjected to SDS-PAGE and 
immunoblot analysis using HP16 antiserum  as the primary antibody. 
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Results 
HP16 protein and mRNA levels during development 
Immunoblot analysis of larval plasma using an antibody to recombinant HP16 detected a 
specific band of expected size for proHP16 (~51 kDa). ProHP16 protein levels increased during 
the larval to pupal transition (Figure 2-2A). Highest expression was observed at the wandering 
(W1-W3), prepupal (PP), and pupal stages. To investigate if the observed fluctuations in 
proHP16 protein level correlated with changes in HP16 mRNA level, total RNA samples were 
collected from fat body of selected developmental stages and analyzed by quantitative RT-PCR 
(Figure 2-2B). HP16 mRNA levels in W2 larvae were significantly greater than D2, D4, and PP. 
HP16 protein and gene expression in immune challenged larvae 
To learn more about HP16 protein expression in plasma and regulation of the HP16 gene 
upon bacterial infection, larvae were injected with 0.85% NaCl (saline), 10
8
 cells E. coli, or 500 
µg M. luteus. Plasma samples from injected larvae were separated by SDS-PAGE followed by 
immunoblot analysis (Figure 2-3A). A specific band corresponding to proHP16 (~51 kDa) was 
more intense in larvae that had been injected with E. coli or M. luteus. HP16 concentration in 
plasma from control (= naïve) larvae was 1.4 µg/mL ± 0.1 µg/mL and increased to 4.9 µg/mL ± 
2.3 µg/mL when larvae were injected with M. luteus 24 h prior to hemolymph collection (Figure 
2-3C). HP16 concentrations between control and injected larvae were not significantly different 
(p = 0.0651). HP16 mRNA levels in fat body samples from larvae injected with M. luteus and E. 
coli were significantly greater (8-10 fold) than those from saline-injected insects (Figure 2-3B). 
Purification of recombinant HP16 and HP16 mutants 
HP16 and two site-directed mutants of HP16 were expressed as recombinant proteins to 
investigate functions of HP16. Figure 2-4 is a schematic representation of wild-type HP16 and 
HP16 mutants that were expressed and purified. To obtain a form of HP16 that could be 
artificially activated, I mutated the predicted activation site of HP16 from HTGL to IEGR, a 
sequence preferred for cleavage by bovine factor Xa. This mutant was named HP16-Xa. I also 
prepared a mutation that changed the catalytic Ser residue of wild-type HP16 to Ala to produce 
an inactive form of HP16 (named HP16 S-A). All of the recombinant proteins were secreted into 
the Sf9 cell culture medium utilizing their own secretion signal peptides. Wild-type HP16, 
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HP16-Xa, and HP16 S-A in the cell culture supernatant bound to concanavalin A-Sepharose 4B, 
indicating that they are glycoproteins. Proteins eluted from the concanavalin A column were 
further purified by anion exchange chromatography using a Q-Sepharose
TM
 Fast Flow column 
followed by hydrophobic interaction chromatography (HIC) with an Econo-Pac Methyl HIC 
Cartridge (wild-type HP16 and HP16 S-A) or ammonium sulfate precipitation (HP16-Xa) and 
gel permeation chromatography on a Sephacryl-S100 High Resolution column. Analysis by 
SDS-PAGE and immunoblot detection indicated that wild-type HP16, HP16-Xa, and HP16 S-A 
were of reasonable purity (Figure 2-5, panels A-C). Wild-type HP16 appeared to be partially 
cleaved during expression and purification, as two bands corresponding to the predicted size of 
the catalytic domain (~28.5 kDa) and the amino-terminal domain (~20.4 kDa) were detected. 
When these two bands were subjected to Edman degradation, the five amino acid residues at the 
amino-terminus of the 28.5 kDa band were determined to be IVNGQ (Figure 2-1), confirming 
that wild-type HP16 was cleaved at its putative activation site during expression. However, 
residues of the 20.4 kDa band, predicted to be the amino-terminal fragment, could not be 
determined. The sequence of the amino-terminus may be blocked by the formation of 
pyroglutamate (expected sequence of QKLSD). HP16-Xa and HP16 S-A had an apparent mass 
of 51 kDa. This mass is slightly larger than the mass of 47 kDa calculated from the amino acid 
sequence of proHP16 deduced from the cloned cDNA sequence, which is consistent with a 
conclusion that the proteins are glycosylated. From a starting culture volume of 2 liters, 0.008 
mg of wild-type HP16, 0.67 mg of HP16-Xa, and 0.16 mg of HP16 S-A were purified. 
HP16 contains an interdomain disulfide bond 
An alignment between HP16 and bovine chymotrysinogen (NP_001098924) showed the 
presence of three conserved pairs of predicted disulfide bonds in the catalytic domain and the 
potential for a disulfide bond between the amino-terminal and catalytic domains of HP16 (Figure 
2-1). To test if the amino-terminal and catalytic domains of HP16 remain connected by a 
disulfide bond after proteolytic activation, purified wild-type HP16 was mixed in sample buffer 
with or without β-mercaptoethanol and analyzed by SDS-PAGE and immunoblotting (Figure 2-
6). In the absence of reducing agent, a single band co-migrated with the zymogen (~51 kDa), but 
under reducing conditions, three bands corresponding to HP16 zymogen (~51 kDa), HP16 
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catalytic domain (~28.5 kDa), and HP16 amino-terminal domain (~20.4 kDa) were detected. 
This result suggests that the two domains of HP16 are connected by a disulfide bond. 
Cleavage of HP16-Xa by bovine factor Xa 
In order to use HP16-Xa to investigate the function of HP16 in immune responses, the 
ability of bovine factor Xa to cleave the recombinant protein was determined. Immunoblot 
analysis revealed that increased cleavage of HP16-Xa correlated with bovine factor Xa amount 
(Figure 2-7). Bovine serum albumin added to the reaction mixture slightly improved cleavage 
efficiency. To determine if HP16-Xa was activated after cleavage by bovine factor Xa and to 
identify a suitable colorimetric substrate for detecting activity of HP16-Xa, several chromogenic 
peptides were tested. Chromogenic peptides with aromatic (Phe, Tyr, Trp) or hydrophobic (Ala, 
Val, Gly, Leu) residues were used, because HP16 is predicted to have chymotrypsin/elastase like 
specificity. Activated HP16-Xa had no detectable activity for any substrate tried, including the 
substrate (acetyl-Ile-Glu-Ala-Arg-p-nitroanilide) for trypsin-like proteinases. Positive controls 
using trypsin, chymotrypsin, and elastase confirmed that the assay was working correctly. These 
results suggest one of two things: (1) substrates tested were not suitable for activated HP16-Xa 
or (2) proHP16-Xa cleaved by bovine factor Xa is not an active proteinase.  
Complex formation between HP16 and serpin-1Z 
Inhibition of a proteinase by a serpin is characterized by cleavage of the serpin, resulting 
in the formation of an SDS-stable serpin-proteinase complex. To detect proteolytic activity of 
HP16, we investigated whether it could form a complex with M. sexta serpin-1Z. The P1 residue 
at the predicted scissile bond in the RCL of serpin-1Z is Tyr and makes it a potential inhibitor of 
HP16, as HP16 is predicted to have chymotrypsin/elastase-like specificity. When serpin-1Z was 
mixed with active HP16-Xa, the 28.5 kDa catalytic domain decreased in intensity, and a new 
immunoreactive band at ~70 kDa was observed with antibodies to HP16 or serpin-1, consistent 
with the expected size of a serpin-proteinase complex (Figure 2-8A). This serpin/proteinase 
complex band was absent in lanes lacking activated HP16-Xa (Figure 2-8A). As a control to 
confirm that HP16 must be in a catalytically active form to react with serpin-1Z to form an SDS- 
stable complex and that the ~70 kDa band was not a complex of serpin-1Z with bovine factor 
Xa, the same experiment was carried out with the catalytically inactive recombinant HP16 S-A 
protein and serpin-1Z (Figure 2-8B). Recombinant HP16 S-A incubated with bovine factor Xa 
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and mixed with serpin-1Z did not result in the detection of a serpin-proteinase complex. These 
results indicate that HP16-Xa was activated by bovine factor Xa and could cleave serpin-1Z to 
form a serpin-proteinase complex. 
Purification of wild-type NT16 and NT16 mutants 
HP16 contains an amino-terminal 170 residue region that has no significant match to any 
characterized protein in the current databases. To characterize this region and investigate its 
potential function, a recombinant protein containing the amino-terminal 165 residues of HP16, 
named NT16 (Figure 2-4D), and three NT16 mutants, each lacking one Cys residue (C20S, 
C124S, and C161S), were expressed in E. coli. In SDS-PAGE under reducing conditions, a 
single band of expected size (21.4 kDa) was observed for wild-type NT16 and each NT16 mutant 
(Figure 2-9B). However, when analyzed using non-reducing conditions, a band at 42 kDa was 
also present, indicating that wild-type NT16 and NT16 mutants can exist as both a monomer and 
disulfide-linked dimer (Figure 2-9B). Moreover, there were multiple bands around 20 kDa for 
each form, which may represent different disulfide bond arrangements between the three Cys 
residues. In wild-type NT16 (monomer form), three possible disulfide bonds (Cys20-Cys124; 
Cys20-Cys161; Cys124-Cys161) could be formed (Figure 2-9A). Upon mutation of a Cys 
residue, that number goes down to one. Wild-type NT16 had four bands (a, b, c, d) around the 
expected size for a monomer (21.4 kDa). When Cys
20
 was mutated, bands a, b, and c, but not d 
were present. Bands a, b, and d (not c) were detected after the mutation of Cys
124
, whereas bands 
b and d (not a/c) were observed after the mutation of Cys
161
. These results suggest that the Cys 
residues of recombinant NT16 are able to form multiple disulfide pairs. Band c disappeared in 
both C124S and C161S samples, indicating that these Cys residues may form a disulfide bond. 
Cys20 may form a disulfide bond with either Cys124 or Cys161 as band d was detected in 
samples 3 and 4, but not sample 2.  
Lack of evidence for autoactivation of HP16 
To test the hypothesis that HP16 possesses the ability to undergo autoactivation, active 
HP16-Xa was incubated with the catalytically inactive mutant, proHP16 S-A. If active HP16-Xa 
can cleave HP16 at the predicted activation site, the amount of proHP16 S-A should decrease, 
and the amount of the catalytic and amino-terminal domains of HP16 should increase. However, 
no difference in the amount of proHP16 S-A (~51 kDa) or the catalytic (~28.5 kDa) and amino-
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terminal (~20.4 kDa) domains of HP16 was observed after incubation with active HP16-Xa for 
4, 6, or 8 h (Figure 2-10A-C). These results suggest that active HP16 does not cleave proHP16 
under the conditions tested. 
Activation of HP16 in plasma by treatment with zymosan 
To determine if proHP16 activation in plasma could be stimulated by a microbial elicitor, 
plasma was incubated with zymosan. After removal of zymosan by centrifugation, the 
supernatant and plasma proteins in the zymosan pellet were subjected to SDS-PAGE followed by 
immunoblot analysis using an antibody specific to HP16 (Figure 2-11). For plasma alone or 
supernatant, the HP16 antibody only recognized a band corresponding to the size of proHP16 
zymogen (~51 kDa). However, in the pellet fraction, several immunoreactive bands were 
detected, including bands at 75-86 kDa, a size consistent with that predicted for serpin-proteinase 
complexes. Bands at ~21 kDa may be the amino-terminal domain of HP16 (expected size = 20.4 
kDa). The catalytic domain of HP16 (~28.5 kDa) was not detected in the bound fraction. This 
may indicate that HP16 was activated in plasma treated with zymosan and rapidly formed a 
serpin-HP16 complex, which remained associated with zymosan. No HP16 signal was detected 
in the control supernatant or bound fraction, indicating that observed bands for HP16 in the pellet 
fraction after incubation of plasma with zymosan were due HP16 in plasma, not components of 
zymosan. 
Discussion 
Since the identification of numerous serine proteinases in the hemolymph of Manduca 
sexta, one goal has been to elucidate their function in response to infection by bacteria, fungi, or 
other pathogens. At present, only a handful of these proteinases have been studied functionally. 
HP14, HP21, and PAPs 2&3 form a cascade for prophenoloxidase activation (Jiang et al., 2003a; 
Jiang et al., 2003b; Ji et al., 2004; Wang and Jiang, 2004; Gorman et al., 2007; Wang and Jiang, 
2007). HP6 and PAP-1 are involved in activation of prophenoloxidase, whereas HP6 and HP8 
are in a pathway resulting in the production of antimicrobial peptides (Jiang et al., 1998; An et 
al., 2009; An et al., 2010).  
Before I could begin to investigate the role of HP16 in innate immune responses, I 
produced recombinant wild-type HP16 and two HP16 mutants (HP16-Xa and HP16 S-A) in 
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insect cells and NT16 and three NT16 mutants in E. coli. I used a baculovirus expression system 
and Spodoptera frugiperda Sf-9 cells to produce wild-type HP16 and two HP16 mutants under 
the control of the polyhedrin promoter. Wild-type HP16, HP16-Xa, and HP16 S-A were all 
successfully expressed using this system. 
Expression and purification of wild-type HP16 
Wild-type HP16 appeared to be activated during expression, as two bands corresponding 
to the expected sizes of the catalytic and amino-terminal domains of HP16 were detected by 
HP16 antibody (Figure 2-5A). Amino-terminal sequencing by Edman degradation confirmed that 
HP16 had been cleaved at the predicted activation site and that the band at ~28.5 kDa was the 
catalytic domain of HP16. Phylogenetic analysis showed that the catalytic domain of HP16 is the 
most similar to Drosophila gastrulation defective, but also clusters with HP14, HP19, and HP20 
from M. sexta and factor C from horseshoe crab (Jiang et al., 2005). HP19 and HP20 have not 
been studied, but the remaining proteinases have all been shown to autoactivate. Therefore, I 
hypothesized that HP16 might undergo autoactivation to function in a proteolytic cascade 
involved in the innate immune response of M. sexta. 
Several proteinases, including HP14, Factor C, Factor G, and gastrulation defective, 
found in arthropods serve as the initiating proteinase in an extracellular proteinase cascade in 
response to infection and possess the ability to autoactivate. HP14 stimulates a pathway leading 
to the activation of prophenoloxidase. This protein consists of five low-density lipoprotein 
receptor class A domains, a Sushi domain, a cysteine-rich region (Wonton), and C-terminal 
serine proteinase domain (Ji et al., 2004). HP14 autoactivates in the presence of peptidoglycan 
(Ji et al., 2004) or β-1,3-glucan and βGRP2 (Wang and Jiang, 2006). Like HP14, factor C from 
the horseshoe crab, which is involved in blood coagulation, is composed of a complex domain 
structure. Factor C contains five Sushi domains, an epidermal growth factor-like domain, a 
lectin-like domain, a cysteine-rich domain, a proline-rich domain, and a C-terminal serine 
proteinase domain (Muta et al., 1991). Autoactivation of factor C occurs upon interaction with 
lipopolysaccharide (Nakamura et al., 1986; Nakamura et al., 1988a), lipid A analogs (Nakamura 
et al., 1988b), and acidic phospholipids (Nakamura et al., 1988b). Active factor C activates factor 
B followed by the activation of clotting enzyme. Clotting enzyme stimulates the conversion of 
coagulogen to coagulin. Factor G is another proteinase from the horseshoe crab that undergoes 
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autoactivation in response to β-1,3-glucan to stimulate blood coagulation (Muta et al., 1995). 
Unlike factor C, factor G is a heterodimer consisting of two noncovalently linked subunits. 
Subunit α is composed of an amino-terminal bacterial β-1,3-glucanase-like sequence followed by 
three tandom repeat structures found in xylanase A and two tandom repeats found in xylanase Z. 
The serine proteinase domain is found on subunit β (Muta et al., 1995; Iwanaga et al., 1998). 
Gastrulation defective is crucial to dorsal-ventral patterning in Drosophila. Gastrulation 
defective contains a ~23 kDa amino-terminal region without any known specialized domains 
(e.g. Sushi, lectin-like, Cys/Pro-rich) and a C-terminal serine proteinase domain (~34 kDa). 
Autoactivation of gastrulation defective takes place in the presence of snake zymogen, which is 
the next proteinase in the cascade (Dissing et al., 2001). 
Autoactivating proteinases are also found in the mammalian complement system 
(classical and lectin pathways). Such proteinases include C1r, mannose-binding lectin (MBL)-
associated serine proteinase (MASP)-1, and MASP-2. Each proteinase is composed of five 
noncatalytic domains followed by one serine proteinase domain. Noncatalytic domains include 
two C1r/C1s/sea urchin Uegf/bone morphogenic protein (CUB) domains, one epidermal growth 
factor-like (EGF) domain, and two complement control protein (CCP) modules (Sim and Laich, 
2000). The two CUB domains and the EGF-like domain function to facilitate the interaction 
between the proteinases and the recognition molecules, whereas the CCP modules function to 
stabilize the serine proteinase domain structure and are involved in the autoactivation of C1r, 
MASP-1, and MASP-2. In the classical pathway, C1r undergoes autoactivation in the presence of 
a recognition molecule, C1q (Kardos et al., 2001; Kardos et al., 2008). Active C1r activates C1s, 
which in turn, cleaves C2 and C4 (Gál et al., 2007). For the lectin pathway, mannose-binding 
lectin is the recognition molecule that binds to carbohydrates on the pathogen surface. MASP-1 
and MASP-2 are proteinases that interact with mannose-binding lectin and undergo 
autoactivation (Vorup-Jensen et al., 2000; Ambrus et al., 2003; Gál et al., 2005). Active MASP-2 
cleaves C2 and C4 to generate the C3 convertase, C4bC2b, and prothrombin to generate 
thrombin (Ambrus et al., 2003; Gál et al., 2005; Gál et al., 2009) while active MASP-1 cleaves 
C2, C3, fibrinogen, and protease activated receptor 4 (Hajela et al., 2002; Ambrus et al., 2003; 
Gál et al., 2009). 
To determine if HP16 could undergo autoactivation like the proteinases mentioned above, 
I conducted an experiment in which I incubated active HP16-Xa with the noncatalytically active 
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mutant, HP16 S-A. If autoactivation was taking place, I expected an increase in the amount of 
HP16 catalytic and amino-terminal domains and a decrease in HP16 zymogen in samples 
containing active HP16-Xa and HP16 S-A when compared to active HP16-Xa alone. However, 
active HP16-Xa did not cleave proHP16 S-A, indicating that HP16 does not autoactivate (Figure 
2-10). When plasma was incubated with zymosan A (yeast cell walls), proHP16 was apparently 
converted to active HP16. Two observations support this idea: (1) HP16 zymogen disappeared 
and (2) potential serpin-HP16 complexes formed (Figure 2-11). This result can be interpreted in 
two ways. First, it is possible that zymosan stimulates activation of an unidentified proteinase 
that cleaves proHP16. Second, an interaction between zymosan and proHP16 may occur that 
allows HP16 to autoactivate. The latter would be consistent with the autoactivation of HP14, 
factors C and G, C1r, MASP-1, and MASP-2. At this point, it is unclear how proHP16 is 
activated and more experiments are necessary to develop a better understanding of this process. 
Fluctuations in HP16 protein and HP16 mRNA levels during larval to pupal 
development 
I found that both HP16 protein level in hemolymph and HP16 mRNA level in fat body 
increased thoughout the feeding stage (5
th
 instar), peaked on day 2 of the wandering stage (non-
feeding), and decreased as larvae entered the prepupal and pupal stages (Figure 2-2). This pattern 
of protein and mRNA expression matches well with changes in the ecdysteroid titer that controls 
metamorphosis (Figure 2-12). The first ecdysteroid peak triggers a behavioral change from 
feeding larvae to non-feeding, wandering larvae, whereas the second ecdysteroid peak triggers 
molting. This led to the hypothesis that HP16 may have a role in metamorphosis and that the 
expression of HP16 may be regulated by ecdysteroids. However, this hypothesis was not 
investigated in the current work. During the larval to pupal transition, the insect undergoes tissue 
rearrangement, and HP16 may play a role in this process by hydrolyzing components of the 
extracellular matrix. Futhermore, since HP16 is similar to gastrulation defective from 
Drosophila, it is feasible to speculate that HP16 may be involved in a serine proteinase cascade 
that leads to the activation of a cytokine, such as spätzle, to aid the insect in development.  
Alternatively, HP16 may be involved in the immune response of the insect to protect developing 
larvae or pupae from infection by foreign invaders throughout metamorphosis.  
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It is well established that molting and metamorphosis are controlled by juvenile hormone 
and ecdysteroids. Juvenile hormone controls the nature of the molt while ecdysteroids, such as 
ecdysone and 20-hydroxyecdysone, direct the molting process (Riddiford, 1993; Riddiford et al., 
2003; Riddiford, 2008). During molting and metamorphorsis, it is common to observe increases 
or decreases in protein synthesis and mRNA expression that are likely to be regulated by changes 
in ecdysteroid and juvenile hormone titers. When such changes are observed, experiments may 
be completed to test the effect of juvenile hormone and 20-hydroxyecdysone on gene expression.  
Kanost et al. (1995) determined the effect of 20-hydroxyecdysone on M. sexta serpin-1 
protein synthesis and gene expression to explain the decrease in serpin-1 mRNA levels at the 
larval-larval molt and the onset of the wandering stage. Addition of 20-hydroxyecdysone to 
cultured fat body led to decreased serpin-1 protein synthesis and mRNA expression. Ligation of 
larvae eliminated the decrease in mRNA expression, and injection of 20-hydroxyecdysone into 
ligated larvae exhibited a decrease in serpin-1 mRNA expression that was reminiscent of 
unligated larvae at the wandering stage, indicating that 20-hydroxyecdysone negatively regulates 
serpin-1 gene expression (Kanost et al., 1995). Decreases in M. sexta prophenoloxidase 
activating proteinase-1 mRNA expression during development were detected by RT-PCR and 
correlated with peaks in ecdysteroid levels in late fifth instar larvae and late wandering stage 
larvae (Zou et al., 2005). The addition of 20-hydroxyecdysone to cultured fat body led to 
decreased prophenoloxidase-activating proteinase-1 mRNA expression, suggesting negative 
regulation of expression by this ecdysteroid (Zou et al., 2005). Prophenoloxidase from Anopheles 
gambiae is another immune related gene that is regulated by 20-hydroxyecdysone (Ahmed et al., 
1999; Müller et al., 1999). Transcript levels for five out of the six prophenoloxidase genes (1-4, 
6) increased in an A. gambiae cell line exposed to 20-hydroxyecdysone, while transcript level of 
prophenoloxidase gene-5 was down-regulated (Ahmed et al., 1999; Müller et al., 1999).  
Activation of HP16-Xa by bovine factor Xa produces an active proteinase 
One strategy to obtain an active proteinase that can be used to study biological function is 
to introduce a mutation at the activation site of the proteinase that can be artificially activated by 
bovine factor Xa. For HP16, I mutated the residues HTGL to IEGR. Purified recombinant HP16-
Xa was incubated with different amounts of bovine factor Xa followed by immunoblot analysis 
using HP16 antibody. I found that all amounts of bovine factor Xa cleaved HP16-Xa, but 500 ng 
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of bovine factor Xa led to the most complete cleavage, as HP16 zymogen (~51 kDa) disappeared 
and two bands corresponding to the catalytic and amino-terminal domains increased in intensity 
(Figure 2-7). The need for such a large amount of bovine factor Xa indicates that cleavage of 
HP16-Xa was not very efficient. Other factor Xa mutant proteinases were efficiently cleaved 
with 40 ng or 50 ng of factor Xa (An et al., 2009; An et al., 2010). When using 500 ng of bovine 
factor Xa in a reaction mixture, it is important to include a factor Xa only control since bovine 
factor Xa has the ability to non-specifically cleave proteinases. Including this control assures that 
observed proteinase activity is due to the proteinase and not bovine factor Xa. 
To confirm that HP16-Xa incubated with bovine factor Xa was an active proteinase, I 
mixed active HP16-Xa with several serpin-1 isoforms. Based on the prediction that HP16 has 
chymotrypsin/elastase-like specificity, I selected serpin-1 isoforms with aromatic or small 
hydrophobic residues at the predicted P1 residue for analysis (serpin-1B, -1C, -1F, -1G, -1H, -1I, 
-1K, and -1Z). Only serpin-1Z (P1 residue = Tyr) showed a potential interaction with active 
HP16-Xa and was selected for further purification and analysis. In samples containing active 
HP16-Xa and serpin-1Z, serpin-1 and HP16 antibodies recognized a higher molecular weight 
band (~70 kDa) consistent with the expected size of a serpin-1-HP16 complex. No band was 
detected in samples containing bovine factor Xa and serpin-1Z indicating that the complex did 
not include factor Xa. Moreover, when HP16 S-A (a catalytically inactive HP16 protein) was 
mixed with serpin-1Z, no complex formation was observed with either antibody. These results 
confirm that HP16-Xa was an active proteinase and cleaved serpin-1Z in the RCL. The 
biological relevance of serpin-1Z as an inhibitor of HP16 was not examined in the current study, 
but warrents further investigation. 
Bacteria induce increased HP16 protein levels in plasma and mRNA levels in fat body 
Consistent with Northern blot results (Jiang et al., 2005), the injection of bacteria (M. 
luteus or E. coli) into larvae increased HP16 protein and mRNA levels when compared to larvae 
injected with saline (Figure 2-3A/B). HP16 concentration in plasma from control (= naïve) larvae 
was determined to be 1.4 µg/mL ± 0.1 µg/mL and increased to 4.9 µg/mL ± 2.3 µg/mL when 
larvae were injected with M. luteus 24 h prior to plasma collection (Figure 2-3C).  
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Analysis of NT16 and NT16 mutants 
The amino-terminal 170 residue region of HP16 is unique and has no significant match to 
any characterized protein in the current databases although a homologous sequence is present in 
ESTs from some other lepidopteran species. With the goal of further characterizing this region, I 
purified recombinant NT16 (residues 1-165) and three NT16 mutants. This region contains three 
Cys residues, one of which may form an interdomain disulfide bond. I attempted to determine 
the Cys-Cys linkage pattern by disulfide mapping, but was not successful. Success was limited 
by the matrix conditions available for use with MALDI mass spectrometry. 
I produced recombinant NT16 and three NT16 mutants by performing site-directed 
mutagenesis to change each Cys residue to Ser. Under reducing conditions, all four NT16 
proteins ran as a single band at the expected size (~21.4 kDa). When the same samples were 
subjected to non-reducing conditions, each protein showed multiple monomer and dimer forms, 
indicating that different disulfide bond arrangements were possible and that the different 
arrangements observed depended on which Cys residue was mutated. Disulfide bonds are 
stabilizers of protein structure, and it is reasonable to hypothesize that one of more of the 
introduced mutations could result in the loss of proper protein folding, providing that this portion 
of HP16 is structured.  
Challenges in working with serine proteinases 
Proteinases can be difficult to study because of inherent instability during purification, 
sensitivity to assay conditions (e.g. temperature, pH, ionic strength, and presence of detergents), 
stability during storage, susceptibility to degradation by other proteinases, and the inability to 
identify a proper substrate to investigate proteinase activity (Beynon and Bond, 1989). One of 
the first challenges that can be faced is finding the best expression system and purification 
scheme for the serine proteinase of interest. This process can take from a few months to over a 
year. There are many choices, and the process usually begins by using a system that has been 
used by others in the lab. Based on success with other hemolymph proteinases, I first tried wild-
type HP16 expression using the Drosophila S2 cell system. Recombinant wild-type HP16 was 
produced by this system; however, the molecular weight was much higher than the expected size 
(51 kDa; data not shown). This suggests that wild-type HP16 may have been activated during 
expression and reacted with a serpin made by the Drosophila S2 cells. Since recombinant HP16 
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was not of expected size, a baculovirus expression system was the next system tried. Trying 
multiple expression systems is not uncommon, which suggests that not all proteinases behave in 
the same way and what worked for one proteinase may not work for another (Beynon and Bond, 
1989). Optimization of the expression system is followed by determination of the purification 
scheme to be used. Deciding what purification steps to use entails a considerable amount of trial 
and error. Each step exploits a different characteristic of the proteinase (e.g. glycosylation, 
charge, hydrophobicity, size, and N- or C-terminal tags) to be purified. The inherent instability of 
proteinases is a challenge during purification. Additionally, the amount of proteinase zymogen 
secreted from an expression in an insect cell line is often low.  
After successful purification of a proteinase, the next challenge that may be encountered 
is proteinase stability during storage. Wild-type HP16 was not stable during storage at -80°C. In 
addition, HP16-Xa tended to form insoluble aggregates during storage. 
Working with proteinases is hard and they do not always behave the way you expect 
them to. To alleviate some of the challenges that I mentioned above, it is important to have a 
plan of what experiments are to be conducted before expressing and purifying a proteinase. Once 
the proteinase is purified, experiments should be rapidly done while the preparation is active.  
Future Directions 
I believe that the work presented in this chapter furthered the understanding of HP16 and 
helped lay a foundation for future experiments involving the proteolytic activity, regulation, and 
biological function. The following questions should be investigated in the future. 
(1) Is HP16 involved in prophenoloxidase activation or production of antimicrobial 
peptides? 
(2) Is HP16 activated by another hemolymph proteinase? 
(3) What is the substrate(s) of HP16? 
(4) What serpin(s) regulates HP16 activity? 
(5) What is the function of the amino-terminal domain of HP16? 
(6) Is HP16 expression regulated by ecdysteroids? 
(7) Does HP16 have a role in metamorphosis? 
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Figures 
 
Figure 2-1. Amino acid sequence of Manduca sexta hemolymph proteinase 16 (AAV91013). 
The amino-terminal signal peptide is italicized. The putative activation site is marked by a solid 
arrow. Residues of the catalytic triad are identified by * located above the one-letter amino acid 
code. The paired letters (a-a, b-b, c-c) indicate predicted disulfide bonds in the catalytic domain 
(based on alignment with bovine chymotrysinogen). Cysteines that may be involved in an 
interdomain disulfide bond are marked with # in the catalytic domain and ? in the amino-
terminal domain. The underlined sequence, IVNGQ, was identified by Edman degradation to be 
the amino-terminus of the catalytic domain of HP16 in a sample of recombinant HP16. Residues 
in blue were inserted into the expression vector, pProExHTb, for expression and purification of 
NT16 in Escherichia coli. 
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Figure 2-2. Fluctuations in HP16 protein levels in plasma correlate with changes in HP16 
mRNA levels in fat body during larval development. 
A) Plasma samples from naïve Manduca sexta larvae (0.2 µL) were treated with sample buffer 
containing β-mercaptoethanol and separated by SDS-PAGE (4-12% Bis-Tris gel) followed by 
immunoblotting with HP16 antibody. D0-D4 = day 0-day 4 5
th
 instar larvae (feeding), W1-W3 = 
day 1-day 3 wandering larvae (non-feeding), PP = prepupa. An arrow indicates the position of 
proHP16. 
B) Fat body samples were collected from day 2 and day 4 5
th
 instar larvae, day 1 and day 2 
wandering larvae, and prepupae. RNA samples were prepared from each insect, and relative 
mRNA levels for HP16 were determined by quantitative RT-PCR. Bars represent the mean fold 
change and standard deviation (n = 3). Data were analyzed using a one-way ANOVA followed 
by the Newman-Keuls Multiple Comparison Test. Means with the same letter are not 
significantly different (p > 0.05).  
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Figure 2-3. Immune stimulation elicits HP16 protein expression in plasma and HP16 
mRNA levels in fat body. 
A) Fifth-instar day 2 larvae were injected with 0.85% NaCl (saline), 10
8
 cells of E. coli, or 500 
µg M. luteus. Hemolymph and fat body were collected 24 h post-injection. Plasma (6 µL) was 
mixed with sample buffer containing β-mercaptoethanol and separated by SDS-PAGE (10%) 
followed by immunoblotting with HP16 antibody.  
B) RNA was extracted from insects described in (A), and HP16 mRNA levels were determined 
by quantitative RT-RCR. Bars represent mean fold change and standard deviation for each 
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treatment (n = 3). Data were analyzed using a one-way ANOVA followed by the Newman-Keuls 
Multiple Comparison Test. Means with the same letter are not significantly different (p > 0.05).  
C) HP16 concentration in hemolymph of control (= naïve) and injected (= M. luteus) larvae. Bars 
represent mean HP16 concentration and standard deviation for each treatment (n = 3). Data were 
analyzed using an unpaired t-test with a two-tailed p-value. As indicated by the same letter, mean 
HP16 concentrations were not significantly different (p = 0.0651). 
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Figure 2-4. Schematic representation of wild-type HP16 and HP16 mutants.  
For proHP16-Xa, the predicted activation site of proHP16 was changed from HTGL to IEGR by 
site-directed mutagenesis. IEGR is the cleavage site for bovine factor Xa. An inactive proteinase, 
proHP16 S-A, was produced by mutating the active site Ser to Ala. NT16 contains residues 1-
165 of the amino-terminal domain of HP16 and a 6 x histidine tag. 
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Figure 2-5. SDS-PAGE and immunoblot analysis of recombinant wild-type HP16 and 
HP16 mutants. 
A) Wild-type HP16 was expressed as a recombinant protein in Spodoptera frugiperda Sf-9 cells, 
using a baculovirus vector. Protein secreted into the media was enriched by ConA sepharose 
(lane 1), followed by Q sepharose chromatography (lane 2), hydrophobic interaction 
chromatography (lane 3), and gel permeation chromatography with Sephacryl S100 (lane 4). 
Protein samples (10 µL) were treated with sample buffer containing β-mercaptoethanol and 
separated by SDS-PAGE (4-12% Bis-Tris gel) followed by Coomassie or silver staining (left) or 
immunoblotting with HP16 antibody (right). HP16 zymogen bands are marked by an arrow 
while the catalytic domain is marked by a square and the amino-terminal domain by a circle.  
B) A mutant (named HP16-Xa) at the putative activation site of HP16 with residues HTGL 
changed to IEAR by site directed mutagenesis was expressed and purified as a recombinant 
protein from Sf-9 cells. For each purification step, 400 ng (left) or 200 ng (right) of total protein 
was mixed with sample buffer containing β-mercaptoethanol and separated by SDS-PAGE (4-
12% Bis-Tris gel) followed by Coomassie staining (left) or immunoblotting with HP16 antibody 
(right). Media post-dialysis (lane 1), after ConA sepharose and dialysis (lane 2), after Q 
sepharose (lane 3), after ammonium sulfate precipitation (lane 4), after gel permeation 
chromatography (lane 5).  
C) HP16 S-A is a mutant in which the active site serine was changed to alanine by site directed 
mutagenesis. Recombinant protein was obtained by expression and purification from Sf-9 cells. 
200 ng of total protein was mixed with sample buffer containing β-mercaptoethanol and 
separated by SDS-PAGE (4-12% Bis-Tris gel) for analysis by silver staining (left) or 
immunoblotting (right). Media post-dialysis (lane 1), after ConA sepharose and dialysis (lane 2), 
after Q sepharose (lane 3), after hydrophobic interaction chromatography (lane 4), after gel 
permeation chromatography (lane 5).  
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Figure 2-6. A disulfide bond connects the catalytic and amino-terminal domains of purified 
recombinant HP16. 
Partially purified wild-type HP16 (ConA Sepharose and Q-Sepharose only; ~20 ng) samples 
were mixed with 2 µL of 6X SDS-sample buffer with or without β-mercaptoethanol and 
separated by SDS-PAGE (4-12% Bis-Tris gel) followed by immunoblot analysis with HP16 
antibody. HP16 zymogen is marked by * while the catalytic domain is marked by an arrow with 
a square head and the amino-terminal domain by an arrow with a circle head. In absence of 
reducing agent, HP16 is marked by a solid arrow. 
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Figure 2-7. Cleavage of HP16-Xa by bovine factor Xa. 
After incubation of recombinant HP16-Xa (100 ng) with different amounts of bovine factor Xa 
in the presence of bovine serum albumin (1000 ng), the mixtures were separated by SDS-PAGE 
(4-12% Bis-Tris gel) followed by immunoblot analysis with HP16 antibody.  
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Figure 2-8. Active HP16-Xa, but not recombinant HP16 S-A, forms a covalent complex 
with serpin-1Z. 
(A) proHP16-Xa or (B) HP16 S-A (100 ng = 2 pmol) was incubated with bovine factor Xa (500 
ng) and BSA (1000 ng) for 1 h at 37°C. Recombinant serpin-1Z (880 ng = 20.2 pmol) was added 
to the activated mixture and incubated for 10 min at room temperature. Mixtures were subjected 
to SDS-PAGE under reducing conditions followed by immunoblot analysis with serpin-1 and 
HP16 antibodies. 
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Figure 2-9. Amino acid sequence of NT16 and immunoblot analysis of recombinant wild-
type NT16 and NT16 mutants. 
(A) Full-length sequence of wild-type NT16. Cysteine residues mutated to serine are underlined 
and numbered 1-3. 
(B) Protein samples (10 µL) were mixed with sample buffer with or without β-mercaptoethanol 
and separated by SDS-PAGE (4-12% Bis-Tris gel) followed by immunoblotting with HP16 
antibody. A single band, marked with a star, is the expected size (~21.4 kDa) of NT16. Labeled 
bands (a-d) detected under non-reducing conditions may represent different disulfide bond 
arrangements that occur upon mutation of each Cys residue. Multiple bands marked by # 
represent potential dimer formation for each recombinant protein. Wild-type NT16 (lane 1), 
NT16 C20S (lane 2), NT16 C124S (lane 3), NT16 C161S (lane 4). 
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Figure 2-10. Lack of evidence for autoactivation of HP16. 
Purified recombinant HP16-Xa (100 ng) or HP16 S-A (200 ng) were either incubated alone or in 
the presence of  100 ng bovine factor Xa (New England Biolabs) in buffer (20 mM Tris-HCl, 
150 mM NaCl, pH 8.4) plus CaCl2 (final concentration = 2 mM) and Tween-20 (final 
concentration = 0.002%) for 2 h at 25°C. Mixtures containing HP16-Xa and bovine factor Xa 
were mixed with recombinant HP16 S-A (200 ng) and incubated at 25°C for an additional 2, 4, 
or 6 h (= 4, 6, or 8 h total). Samples were subjected to SDS-PAGE (4-12% Bis-Tris gel) under 
reducing conditions followed by immunoblot analysis using antiserum against HP16 as the 
primary antibody. 
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Figure 2-11. Activation of proHP16 in plasma incubated with zymosan. 
Plasma from day three, fifth instar larvae (30 µL) was incubated alone or with 0.4 mg of 
zymosan A from Saccharomyces cerevisiae for 1 h at 25°C. As a control, zymosan A was 
incubated in 30 µL of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0. After centrifugation and 
washing, supernatant (S) and bound (B) samples were subjected to SDS-PAGE under reducing 
conditions followed by immunoblot analysis using HP16 antibody. To speculate what bands 1-9 
might be, a standard curve (log molecular weight vs. distance) was constructed. Using point-to-
point analysis, a line of best fit was determined and used to calculate the molecular weight of 
each band. Putative identification of bands: Band 1 = unknown, Bands 2-4 = serpin-HP16 
complexes, Bands 5-6 = cleaved serpin-HP16 complexes, Band 7 = proHP16, Band 8-9 = amino-
terminal domain of HP16. 
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Figure 2-12. Ecdysteroid titer changes during larval to pupal transition in M. sexta. 
Stages represented are day 0-day 4 5
th
 larval instar (0-4), day 1- day 3 wandering larvae (5-7), 
prepupa (PP), and pupa. Increase in ecdysteroid level around day 4, 5
th
 instar triggers a 
behavioral change from feeding larvae to non-feeding, wandering larvae. The increase observed 
around day 7 triggers molting. Ecdysteroid titer data adapted from Bollenbacher et al., 1981. 
Photos courtesy of Drs. Emily Ragan, Neal Dittmer, and Adam Sparks. 
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CHAPTER 3 - IDENTIFICATION OF COMPLEXES OF SERPIN-
3 WITH PROTEINASES IN PLASMA FROM MANDUCA SEXTA 
Introduction 
Humoral immune responses in insects include the production of antimicrobial peptides, 
prophenoloxidase activation that leads to melanization, and production of reactive intermediate 
oxygen or nitrogen species (Lavine and Strand, 2002; Jiravanichpaisal et al., 2006; Marmaras 
and Lampropoulou, 2009; Cerenius et al., 2010). Synthesis of antimicrobial peptides by the Toll 
pathway and activation of prophenoloxidase are stimulated in response to foreign invaders (e.g. 
bacteria, fungi, and other pathogens). Once a foreign invader is recognized, extracellular serine 
proteinase cascades are put into motion to remove the invader from the insect’s system (Kanost 
and Clarke, 2005; Cerenius et al., 2010). Because active proteinases can be detrimental to the 
host, precise regulation is critical. One regulatory mechanism is the production of proteinases as 
zymogens. Zymogens remain inactive until activated by proteolytic cleavage by another 
proteinase. Another regulatory mechanism is the inhibition of proteinases by proteinase 
inhibitors. 
Serine proteinase inhibitors, or serpins, belong to a superfamily of proteins that inhibit 
serine proteinases through a suicide inhibition mechanism. Serpins consist of a single chain of 
350-400 amino acid residues and share a highly conserved structure composed of β-sheets and α-
helices (Silverman et al., 2001). Between β-sheets A and C, is a flexible region termed the 
reactive center loop (RCL) that contains the P1 residue. It is the sequence of the RCL that 
determines serpin specificity. Inhibition of the target proteinase begins with the formation of a 
noncovalent complex between the serpin and the serine proteinase. However, once the proteinase 
cleaves the serpin at the P1 residue of the RCL, a covalent ester linkage is formed. Once cleaved, 
the serpin undergoes a dramatic conformational change. The RCL is inserted into β-sheet A, 
causing a 70Å translocation and active site distortion of the proteinase (Schulze et al., 1994; 
Wright, 1996; Silverman et al., 2001). 
Serpins have a role in regulating prophenoloxidase activation in Aedes aegypti (Zou et 
al., 2010), Anopheles gambiae (Abraham et al., 2005; Michel et al., 2006; An et al., 2010a), 
Tenebrio molitor (Jiang et al., 2009; Park et al., 2011), Drosophila melanogaster (Ligoxygakis et 
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al., 2002; De Gregorio et al., 2002; Scherfer et al., 2008; Tang et al., 2008), and Manduca sexta 
(Jiang et al., 2003; Zhu et al., 2003b; Wang and Jiang, 2004; Tong and Kanost, 2005; Tong et al., 
2005; Zou and Jiang, 2005; Wang and Jiang, 2006; An and Kanost, 2010). Regulation of the Toll 
pathway by serpins has also been observed in Ae. aegypti (Shin et al., 2006), T. molitor (Jiang et 
al., 2009; Park et al., 2011), D. melanogaster (Levashina et al., 1999; Ahmad et al., 2009), and 
M. sexta (Zou and Jiang, 2005; An and Kanost, 2010; An et al., 2011). 
At present, seven serpins have been found in M. sexta (Kanost, 2007), but the 
endogenous proteinase targets for only some of the serpins have been identified. Of the twelve 
serpin-1 isoforms (Jiang et al., 1994; Jiang and Kanost, 1997), proteinase targets for only serpin-
1I and serpin-1J have been determined. Serpin-1I inhibits prophenoloxidase activation, and 
recombinant serpin-1I can form a complex with purified hemolymph proteinase 14 (Wang and 
Jiang, 2006). Serpin-1J can form a complex with prophenoloxidase-activating proteinase-3 
(Jiang et al., 2003). Serpin-1J also inhibits hemolymph proteinase 8 to regulate the expression of 
antimicrobial peptides (An et al., 2011). Serpin-3 inhibits prophenoloxidase-activating proteinase 
activity to block prophenoloxidase activation (Zhu et al., 2003b). Serpin-4 and serpin-5 regulate 
prophenoloxidase activation at steps prior to the prophenoloxidase-activating proteinases. 
Serpin-4 inhibits hemolymph proteinase 21, whereas serpin-5 inhibits hemolymph proteinase 6 
(Tong and Kanost, 2005; Tong et al., 2005). Hemolymph proteinase 6 also stimulates the 
activation of the Toll pathway, and antimicrobial expression is regulated by serpin-5 (An and 
Kanost, 2010). Serpin-6 inhibits prophenoloxidase-activating proteinase-3 to regulate 
prophenoloxidase activation (Wang and Jiang, 2004; Zou and Jiang, 2005) and can form a 
complex with hemolymph proteinase 8 (Zou and Jiang, 2005). 
Previous studies to identify the PAPs as proteinase targets of serpin-3 (Zhu et al., 2003b) 
were completed prior to obtaining sequences of many hemolymph proteinases (Jiang et al., 2005; 
Wang et al., 2006). It is reasonable to hypothesize that additional proteinases are also 
endogenous targets of serpin-3. 
In this study, a serpin-3 immunoaffinity column was used to purify serpin-3-proteinase 
complexes from M. sexta plasma. Proteinase components identified by immunoblot analysis and 
analysis of tryptic peptides by mass spectrometry indicated that a serpin-3-HP8 complex was 
present in plasma. Inhibitory activity of serpin-3 for HP8 was investigated by using purified 
recombinant proteins. Identification of serpin-3-proteinase complexes in plasma provides insight 
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into some of the proteinase targets of serpin-3 and extends the understanding of the functions of 
serpins and proteinases in the immune response of M. sexta and other insects. 
Materials and Methods 
Insects 
Manduca sexta eggs were originally obtained from Carolina Biological Supply and used 
to establish a laboratory colony. The colony has been maintained by feeding larvae on an 
artificial diet as previously described by Dunn and Drake (1983). 
Preparation of plasma samples from bacteria injected larvae 
Hemolymph was collected from thirty-three day 3 fifth instar larvae 24 h after injection 
with 100 µg Micrococcus luteus (injected as day 2 fifth instar larvae) into two 50 mL 
polypropylene centrifuge tubes containing diethyldithiocarbamic acid (final concentration of 
2.25 mg/mL) to prevent melanization. Each tube contained ~15 mL of pooled hemolymph (tube 
1: 18 larvae and tube 2: 15 larvae). Hemocytes were removed by centrifugation at 9000 × g for 
15 min at 4°C. Aliquots (700 µL) of each pooled sample were saved and stored at -80°C. The 
remainder of each pooled sample was mixed together and used for immunoaffinity purification 
as described later. 
Preparation of plasma from naïve larvae 
Day 2 fifth instar larvae were chilled on ice for at least 20 min. Hemolymph was 
collected into individual microcentrifuge tubes by clipping the dorsal horn with scissors. 
Hemocytes were removed by centrifugation at 8000 × g for 7.5 min at 4°C. The samples were 
screened for endogenous phenoloxidase activity as described by Tong and Kanost (2005) with 
some modification. Plasma (4 µL) from each larva was incubated with Nuclease-free water (2 
µL; Ambion) or M. luteus (2 µL of a 1 µg/µL stock) for 10 min at room temperature. Samples 
were transferred to a 96-well plate, and 200 µL of 2 mM dopamine in 50 mM sodium phosphate 
buffer, pH 6.5 were added to each well as substrate. Absorbance at 470 nm was monitored for 15 
min with a read every 30 sec in a BioTek Power Wave XS plate reader. One unit of PO activity 
was defined as a change in A470 of 0.001/min. Plasma samples that exhibited low phenoloxidase 
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activity that could be increased significantly after addition of bacteria were pooled and stored at -
80°C. 
Expression and purification of recombinant hemolymph proteinase 8 mutant (HP8-Xa)  
A HP8-Xa stable cell line prepared by Dr. Chunju An in 2007 and stored in liquid 
nitrogen was used to initiate a cell culture for the expression and purification of HP8-Xa, a 
mutant of HP8 that can be activated by bovine factor Xa (An et al., 2009; An et al., 2010b; An et 
al., 2011).  Six flasks (225 cm
2
) containing Schneider’s Drosophila media (Invitrogen) plus heat-
inactivated fetal bovine serum (Atlanta Biologicals; final concentration = 10%) were seeded with 
1.8 × 10
6
 cells/mL in 60 mL. After cells were incubated for 3 h at 28°C, HP8-Xa expression was 
induced by the addition of 500 mM copper sulfate (final concentration = 500 µM). Media (365 
mL) was collected 48 h after induction by centrifugation at 500 × g for 10 min at 4°C. HP8-Xa 
was secreted into the medium under the control of its own signal peptide and purified by 
sequential chromatography steps including Affi-gel Blue Gel (150-300 µm; Bio-Rad 153-7301), 
Concanavalin A Sepharose 4B (GE Healthcare) affinity, Q-Sepharose
TM
 Fast Flow (GE 
Healthcare) anion exchange, and Sephacryl-S100 High Resolution (GE Healthcare) gel 
permeation as described by An et al. (2009; 2010b) with some modification. 
Cell-free media collected as described above was placed in a 1 L flask along with 
phenylmethylsulfonyl fluoride, a proteinase inhibitor (Sigma P-7626; final concentration = 1 
mM). Approximately 22 mL of Affi-gel Blue gel beads pre-equilibrated in 20 mM Tris-HCl, pH 
7.5 were added to the flask and incubated at 4°C with shaking (150 rpm) for 13 h. Supernatant, 
containing proHP8-Xa, was removed from the beads in two ways. First, the beads were allowed 
to settle on ice for 30 min and most of the supernatant was removed by pipette and placed in a 1 
L flask. Second, the slurry was applied to a 2.5 × 10 cm column and allowed to drain. The 
resulting flow through was added to the 1 L flask containing most of the supernatant. 
Concanavalin A-Sepharose 4B (GE Healthcare) that had been equilibrated in ConA 
binding buffer (20 mM Tris-HCl, 0.5 M NaCl, pH 7.5) and phenylmethylsulfonyl fluoride (final 
concentration = 1 mM) were added to the 1 L flask containing the supernatant from Affi-gel Blue 
gel affinity. After shaking at 150 rpm for 8 h at 4°C, the slurry was applied to a 2.5 × 10 cm 
column and allowed to drain. The column was washed four times with 35 mL of ConA binding 
buffer at 4°C. Once the A280 reading was below 0.06, 35 mL ConA elution buffer (ConA binding 
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buffer and 0.5 M methyl-α-D-mannopyranoside) was added to elute bound proteins. The column 
was rotated overnight at 4°C. After collection of the first elution fraction, a fresh 35 mL of ConA 
elution buffer was added to the column and rotated for an additional 5 h at 4°C. The second 35 
mL elution fraction was collected and followed by four, 10 mL elutions with ConA elution 
buffer. Immunoblotting using an antibody specific to HP8 (OSU 3) was used to analyze the 
eluted fractions. 
Fractions containing HP8-Xa were pooled and dialyzed against Q-Sepharose start buffer 
(20 mM Tris, 20 mM NaCl, pH 8.0; 3.5 L for at least 6 h at 4°C, two times). The dialyzed 
sample was applied to a Q-Sepharose
TM
 Fast Flow column (GE Healthcare; 1 x 10 cm) 
equilibrated with Q-Sepharose start buffer at 1 mL/min. The column was washed with Q-
Sepharose start buffer at 1 mL/min until the A280 reading was less than 0.025. Proteins bound to 
the column were eluted with a 50 mL linear gradient of 20-700 mM NaCl in 20 mM Tris-HCl, 
pH 8.0 at 1 mL/min. Fractions of 1 mL each were collected and analyzed by immunoblotting.  
Q-Sepharose fractions containing HP8-Xa were pooled and used for further purification 
by gel permeation chromatography. Partially purified HP8-Xa (4 mL) was loaded at 1 mL/min 
onto a Sephacryl-S100 High Resolution (GE Healthcare) 1.5 × 100 cm column equilibrated with 
gel filtration buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Proteins were eluted from the 
column with the gel filtration buffer at 1 mL/min. The first eleven fractions were collected at 4 
mL/tube as this was determined to be the void volume by running blue dextran (Sigma) through 
the column. After the void volume, 2 mL fractions were collected. Selected fractions were 
analyzed by SDS-PAGE and immunoblotting. Fractions containing the most HP8-Xa and the 
least contaminating proteins were pooled and stored at -80°C.  
Expression and purification of recombinant serpin-3  
Manduca sexta serpin-3 was expressed in Escherichia coli BL21 DE3 cells using the 
pET28a expression vector, which encodes an amino-terminal 6 x histidine tag. A single colony 
harboring the recombinant plasmid was inoculated into 50 mL of sterile LB containing 50 µL of 
50 mg/mL kanamycin in a 250 mL flask and incubated overnight at 37°C with shaking at 250 
rpm. Ten milliliters of the overnight culture were transferred to four, 2 L flasks containing 500 
mL LB and kanamycin (0.5 mL of 50 mg/mL). Flasks were incubated at 37°C with shaking at 
250 rpm until OD600 was 0.8 to 1.0. Cultures were transferred to a 20°C incubator with shaking 
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at 150 rpm and expression of serpin-3 was induced by adding 1 M isopropyl-β-D-thiogalactoside 
(IPTG) to a final concentration of 1 mM for 10 h. After storage at 4°C overnight, the bacteria 
were harvested by centrifugation at 4000 × g for 20 min at 4°C. Pellets were resuspended in cold 
lysis buffer (300 mM NaCl, 10 mM imidazole in 0.5 M sodium phosphate buffer, pH 8.0) at 4 
mL lysis buffer/g cells (48 mL total). Proteinase inhibitor cocktail for His-tagged proteins 
(Sigma P8849) was also added at 50 µL inhibitor/g cells (600 µL total). Samples were 
transferred to a 50 mL polypropylene centrifuge tubes (Fisher Scientific) and placed in an ice-
water bath. Cells were sonicated for 10 × 30 seconds with a 1 min rest between bursts using a 
Vibra Cell Sonics and Materials Sonicator that was set on level 5 and 50% duty cycle. After 
sonication, the lysed cell sample was centrifuged at 10,000 × g for 30 min at 4°C.  
The soluble serpin-3 was first purified by nickel-affinity chromatography (Ni
2+
-NTA). 
Clear lysate (~46 mL) was incubated with Ni
2+
-NTA agarose (Qiagen) at 1 mL agarose for every 
4 mL clear lysate in two 50 mL polypropylene centrifuge tubes with rotation for 1 h at 4°C. This 
mixture was poured into a 1.5 cm diameter column. The column was washed twice with 46 mL 
of wash buffer (300 mM NaCl, 20 mM imidazole in 0.5 M sodium phosphate buffer, pH 8.0). 
Recombinant serpin-3 was eluted 4 times with 5 mL of elution buffer (300 mM NaCl, 250 mM 
imidazole in 0.5 M sodium phosphate buffer, pH 8.0). Fractions were analyzed by SDS-PAGE 
under reducing conditions and Coomassie Blue staining. To further purify serpin-3, fractions 
containing relatively pure recombinant serpin-3 were pooled and dialyzed against dialysis buffer 
(20 mM Tris-HCl, pH 8.0). Serpin-3 was added to two 3-12 mL Slide-A-Lyzer 3.5 K Dialysis 
Cassettes (~8 mL/cassette; Thermo Scientific) and dialyzed in 2 L dialysis buffer (twice, for at 
least 6 h) at 4°C. The dialyzed sample (~23 mL) was applied to an equilibrated Q-Sepharose
TM
 
Fast Flow column (1 × 10 cm) at 1 mL/min. Dialysis buffer (25 mL total) was used to wash the 
column until A280 readings were near zero. Proteins bound to the column were eluted with a 60 
mL linear gradient of 0-500 mM NaCl in 20 mM Tris-HCl, pH 8.0 at 1 mL/min. Fractions of 1 
mL each were collected and analyzed by SDS-PAGE under reducing conditions and Coomassie 
Blue staining. Fractions containing serpin-3 were pooled and stored at 4°C. 
SDS-PAGE and immunoblotting 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using NuPAGE 4-
12% Bis-Tris gels (Invitrogen). Proteins were treated with sample loading buffer containing SDS 
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and β-mercaptoethanol. Samples were heated at 95°C for 5 min and briefly centrifuged. Gels 
were run in an XCell SureLock
TM
 Electrophoresis Cell (Invitrogen; Novex Mini-Cell) at a 
constant voltage of 200 V. Gels were stained for 30-60 min in 0.2% (w/v) Coomassie Blue R-
250 in 50% (v/v) methanol and 12% (v/v) acetic acid, followed by destaining with 30% (v/v) 
methanol and 10% (v/v) acetic acid. Alternatively, when expected protein concentrations were 
low, gels were stained using the SilverXpress® Silver Staining Kit (Invitrogen). Gels were 
placed in a gel drying solution (20% (v/v) ethanol, 5% (v/v) glycerol) for 30 min and dried 
between two cellophane membranes (14 × 14 cm; Fisher). 
For immunoblotting, proteins were transferred from SDS-PAGE gels to 0.45 µm 
nitrocellulose membranes using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). Membranes 
were blocked for 1 h with 3% dry milk dissolved in TTBS (1X Tris-buffered saline plus 0.05% 
Tween-20), washed for 5 min with TTBS, and incubated for 2 h with an appropriate primary 
antiserum diluted 1:2000 (unless otherwise specified) in 3% dry milk in TTBS (5 µL 
antiserum:10 mL 3% dry milk in TTBS). After three, 5 min washes with TTBS, membranes were 
incubated for 1 h with a secondary antibody (Goat Anti-Rabbit IgG (H+L)-alkaline phosphatase 
conjugate; Bio-Rad) diluted 1:3000 in 3% dry milk in TTBS (4 µL antibody: 12 mL 3% dry milk 
in TTBS). Membranes were washed twice with TTBS and once with TBS (25 mM Tris-HCl, 137 
mM NaCl, 2.7 mM KCl, pH 7.4), followed by development using an Alkaline Phosphatase 
Conjugate Substrate Kit (Bio-Rad). Primary antisera to M. sexta serpin-1I (Jiang and Kanost, 
1997; Ragan et al., 2010), serpin-3 (Zhu et al., 2003b), serpin-4 (Tong and Kanost, 2005), serpin-
5 (Tong and Kanost, 2005), serpin-6 (Zou and Jiang, 2005), hemolymph proteinase 8 (Jiang et 
al., 2005), and prophenoloxidase-activating proteinases 1-3 (Wang et al., 2001; Ji et al., 2003, 
Jiang et al., 2003) were previously prepared. 
Protein concentration assay 
Protein concentrations were determined with the Coomassie Plus
TM
 Protein Assay 
Reagent (Pierce) using bovine serum albumin (Pierce) as the standard. Alternatively, some 
samples of purified protein were analyzed by SDS-PAGE together with several bovine serum 
albumin samples of known amounts to account for the presence of contaminating proteins. This 
was followed by Coomassie Blue staining and determination of protein concentration by 
comparison of band intensity with the standards. 
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Immunoaffinity purification of serpin-proteinase complexes from induced plasma 
Serpin-3 (KSU 114) or HP8 (OSU 3) antibodies were coupled to Protein-A Sepharose 
CL-4B (Sigma P3391) according to Harlow and Lane (1988) with some modification. Protein-A 
Sepharose CL-4B beads (0.5 g) were hydrated in ~6 mL of 1X phosphate buffered saline (PBS) 
for 2 h at room temperature and then at 4°C overnight. Beads were resuspended and aliquoted (3 
mL) into two 15 mL polypropylene centrifuge tubes (Fisher Scientific). After centrifugation at 
1000 × g for 2 min, the pre-swollen beads were washed three times with PBS (10 mL/wash). 
About 1 mL of beads was resuspended in 3 mL of PBS and mixed by rotation with 2 mL of 
serpin-3 or HP8 antiserum by rotation for 2 h at room temperature. Then, the serpin-3 or HP8 
antibody beads were washed three times with PBS (10 mL/wash) and twice with 0.2 M sodium 
borate, pH 9.0 (10 mL/wash). After resuspension in 10 mL of 0.2 M sodium borate, pH 9.0 
buffer, solid dimethylpimelimidate (Sigma D388) was added to a final concentration of 20 mM 
and rotated for 4 h at room temperature. Beads were centrifuged for 2 min at 1000 x g, washed 
once with 0.2 M ethanolamine-HCl, pH 8.0 (10 mL), resupended in 10 mL 0.2 M ethanolamine-
HCl, pH 8.0, and rotated overnight at 4°C. Centrifugation of the beads at 1000 × g for 2 min at 
room temperature was followed by washing the beads once with PBS (10 mL) and resuspension 
of the beads in 10 mL of PBS. Beads were stored at 4°C overnight. Serpin-3 or HP8 antibody 
beads were poured into a 1 cm glass column and washed five times with 5 mL of 100 mM 
glycine-HCl (pH 2.5) plus 10% ethylene glycol (25 mL total) to remove any uncoupled antibody. 
Antibody-coupled beads were equilibrated with 50 mL of PBS, resuspended in 2.5 mL of PBS, 
and stored at 4°C until use. 
Serpin-proteinase complexes were purified from hemolymph according to Tong et al. 
(2005), with some modification. Hemolymph (30 mL) was collected into two 50 mL 
polypropylene centrifuge tubes (15 mL/tube) from day 3 fifth instar larvae 24 h after injection 
with 100 µg Micrococcus luteus (injected as day 2 fifth instar larvae). Tubes contained 
diethyldithiocarbamic acid (final concentration of 2.25 mg/mL) to prevent melanization. 
Hemocytes were removed by centrifugation at 9000 × g for 15 min at 4°C. The resulting plasma 
was mixed with phenylthiourea to 1 mM and M. luteus to stimulate proteinase activation to a 
final concentration of 1 µg/µL for 30 min at room temperature with rocking. 
Phenylmethylsulfonyl fluoride (Sigma P-7626; final concentration = 4 mM) and protease 
inhibitor cocktail (Sigma P8849; 1 mL to 30 mL plasma) were then added to the plasma mixture 
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and incubated for 10 min at room temperature with rocking. The plasma mixture was centrifuged 
at 5000 × g for 15 min at 4°C to remove debris. The supernatant was added to 1 mL of antibody-
coupled beads in 2.5 mL of PBS and rotated horizontally at 4°C overnight. The plasma plus 
antibody-coupled bead mixture was applied to a 1 cm glass column. Beads were washed with 20 
mL of 1 M NaCl followed by 10 mL of 10 mM sodium phosphate buffer, pH 6.5. Bound proteins 
were eluted with twenty 1 mL aliquots of 100 mM glycine-HCl (pH 2.5), 10% ethylene glycol. 
Elution fractions were collected into 1.5 microcentrifuge tubes and neutralized with 100 µL of 1 
M sodium phosphate buffer, pH 8.0. The fractions were analyzed by SDS-PAGE followed by 
Coomassie Blue staining and immunoblot analysis. 
As a control, Protein-A Sepharose CL-4B (Sigma P3391) beads without antibody-
coupling were prepared. Protein-A Sepharose CL-4B beads (0.5 g) were hydrated in ~6 mL of 
1X phosphate buffered saline (PBS) for 2 h at room temperature and then at 4°C overnight. 
Beads were resuspended and aliquoted (3 mL) into two 15 mL polypropylene centrifuge tubes 
(Fisher Scientific). After centrifugation at 1000 × g for 2 min, the pre-swollen beads were 
washed three times with PBS (10 mL/wash). About 1 mL of beads was resuspended in 3 mL of 
PBS, poured into a 1 cm glass column, and washed five times with 5 mL of 100 mM glycine-
HCl (pH 2.5) plus 10% ethylene glycol (25 mL total). Beads were equilibrated with 50 mL of 
PBS, resuspended in 2.5 mL of PBS, and stored at 4°C until use. Isolation of proteins from 
hemolymph that bound to the Protein-A Sepharose CL-4B utilized the same method as described 
above for the purification of serpin-proteinase complexes. Starting amount of plasma was 12 mL 
instead of 15 mL, and proteins were eluted with sixteen 1 mL aliquots of 100 mM glycine-HCl 
(pH 2.5), 10% ethylene glycol. Neutralized elution fractions were subjected to SDS-PAGE 
followed by Coomassie Blue staining. 
Protein identification by matrix assisted laser desorption ionization (MALDI) mass 
spectrometry 
Thirty microliters (6.9 µg) of a sample of plasma proteins that bound to a serpin-3 
antibody-coupled immunoaffinity column were treated with 6X SDS sample buffer containing β-
mercaptoethanol and were subjected to SDS-PAGE using a NuPAGE 4-12% Bis-Tris gel 
(Invitrogen). The gel was washed three times in deionized water (200 mL/wash) for 5 min, 
covered with Bio-Safe Coomassie G-250 stain (Bio-Rad 161-0786) for 1 h, and destained with 
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deionized water (200 mL) for at least 30 min. Bands of interest were excised with a clean razor 
blade and placed in individual 1.5 mL microcentrifuge tubes containing ~100 µL deionized 
water. Samples were sent to the Nevada Proteomics Center at the University of Nevada-Reno for 
analysis. 
Spots were digested using a previously described protocol with some modifications 
(Rosenfeld et al., 1992). Samples were washed twice with 25 mM ammonium bicarbonate and 
100% acetonitrile, reduced and alkylated using 10 mM dithiothreitol and 100 mM iodoacetamide 
and incubated with 75 ng sequencing grade modified porcine trypsin (Promega) in 25 mM 
ammonium bicarbonate for 6 hours at 37
o
C. Samples were spotted onto a MALDI target with 
ZipTipµ-C18 (Millipore Corp., MA). Samples were eluted with 70% acetonitrile, 0.2% formic 
acid and overlaid with 0.5 μl 5 mg/ml MALDI matrix (α-Cyano-4 hydroxycinnamic acid 10 mM 
ammonium phosphate). All mass spectrometric data were collected using an ABI 4700 
Proteomics Analyzer MALDI TOF/TOF mass spectrometer (Applied Biosystems, CA), using 
their 4000 Series Explorer software v. 3.6. The peptide masses were acquired in reflectron 
positive mode (1-keV accelerating voltage) from a mass range of 700 – 4000 Daltons, 1250 laser 
shots were averaged for each mass spectrum. Each sample was internally calibrated on trypsin’s 
autolysis peaks 842.51 and 2211.10 to within 20 ppm. Any sample failing to internally calibrate 
was analyzed under default plate calibration conditions of 150 ppm. Raw spectrum filtering/peak 
detection settings were S/N threshold of 3, and cluster area S/N optimization enabled at S/N 
threshold 10, baseline subtraction enabled at peak width 50. The twenty most intense ions from 
the MS analysis, which were not on the exclusion list, were subjected to MS/MS. The MS/MS 
exclusion list included known trypsin masses: 842.51, 870.54, 1045.56, 1126.56, 1420.72, 
1531.84, 1940.94, 2003.07, 2211.10, 2225.12, 2239.14, 2283.18, 2299.18, 2678.38, 2807.31, 
2914.51, 3094.62, 3337.76, and 3353.75. For MS/MS analysis the mass range was 70 to 
precursor ion with a precursor window resolution of -1 to +4 Da with an average 2500 laser shots 
for each spectrum, CID on, metastable suppressor on. Raw spectrum filtering/peak detection 
settings were S/N threshold of 5, and cluster area S/N optimization enabled at S/N threshold 6, 
baseline subtraction enabled at peak width 50. The data was then stored in an Oracle database 
(Oracle database schema v. 3.19.0 Data version 3.90.0). 
The data were extracted from the Oracle database and a peak list was created by GPS 
Explorer software v 3.6 (Applied Biosystems) from the raw data generated from the ABI 4700. 
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Analyses were performed as combination MS + MS/MS. MS peak filtering included mass range 
700-4000 Da, minimum S/N filter 10. A peak density filter of 50 peaks per 200 Da with a 
maximum number of peaks set to 65. MS/MS peak filtering included mass range of 60 Da to 20 
Da below each precursor mass. Minimum S/N filter 10, peak density filter of 50 peaks per 200 
Da, cluster area filter used with maximum number of peaks 65. The filtered data were searched 
by Mascot v 1.9.05 (Matrix Science) using NCBI nr database (NCBI 20090915), containing 
9,694,989 sequences. Searches were performed without restriction to protein species, Mr, or pI 
and with variable oxidation of methionine residues and carbamidomethylation of cysteines.  
Maximum missed cleavage was set to 1 and limited to trypsin cleavage sites. Precursor mass 
tolerance and fragment mass tolerance were set to 20 ppm and ± 0.2 Da, respectively.  
Two-dimensional electrophoresis 
Plasma proteins that bound to a serpin-3 antibody-coupled immunoaffinity column and 
from the control column of Protein-A Sepharose CL-4B beads without antibody were separated 
by two-dimensional electrophoresis at Kendrick Laboratories, Inc. (Madison, WI). The sample 
(200 µL = 46 µg) of plasma proteins that bound to a serpin-3 antibody-coupled immunoaffinity 
column was precipitated with trichloroacetic acid, redissolved in 25 µL of SDS Boiling Buffer 
(5% sodium dodecyl sulfate, 5% β-mercaptoethanol, 10% glycerol and 60 mM Tris, pH 6.8), 
heated in a boiling water bath for 3 min, and diluted with 25 µL of Urea Sample Buffer (9.5 M 
urea, 2% (w/v) Nonidet P-40, 5% β-mercaptoethanol, and 2% ampholines consisting of  2% pH 
2-11 (Servalytes, Serva, Heidelberg Germany)) before loading. The sample of plasma proteins 
that bound to a control column of Protein-A Sepharose CL-4B beads without antibody was 
treated similarly. For both samples, 46 µg of protein in 50 µL was used for the two-dimensional 
separation. 
Two-dimensional electrophoresis was performed according to the carrier ampholine 
method of isoelectric focusing (O’Farrell, 1975; Burgess-Cassler et al., 1989) at Kendrick 
Laboratories. Isoelectric focusing (IEF) was carried out in a glass tube of 2.3 mm (inner 
diameter) using a 2% pH 3.5-10 mix 4 L ampholines (GE Healthcare, Piscataway, NJ; Serva, 
Heidelberg, Germany) for 9600 volt-hrs. One microgram of an IEF internal standard, 
tropomyosin, was added to the sample. Tropomyosin migrates as a doublet and the lower 
polypeptide spot has a molecular weight of 33,000 and a pI of 5.2.  
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After equilibration for 10 min in 10% glycerol, 50 mM dithiothreitol, 2.3% SDS, 0.0625 
M Tris, pH 6.8, each tube gel was sealed to the top of a stacking gel on top of a 10% acrylamide 
slab gel (0.75 mm thick). SDS slab gel electrophoresis was carried out for about 4 h at 12.5 
mA/gel (serpin-3 immunoaffinity sample) or 15 mA/gel (control sample). Myosin (220,000), 
phosphorylase A (94,000), catalase (60,000), actin (43,000), carbonic anhydrase (29,000), and 
lysozyme (14,000) were used as molecular weight standards (Sigma Chemical Co., St. Louis, 
MO). Gels were stained with Coomassie Blue and shipped in dilute acetic acid. 
Electrospray ionization tandem mass spectrometry 
Gel spots excised from the two-dimensional gels were incubated a few times for 10 min 
in 100 μL of 50% acetonitrile at 30°C, followed by the addition of 50 μl of 100% acetonitrile for 
10 min. After discarding the solvent, the gel pieces were dried by speed vacuum concentrator  
and incubated with 200 ng of sequencing grade trypsin (Trypsin Gold, Promega, Madison, WI) 
in 20 mM ammonium bicarbonate (total volume = 20 µL). An additional 20 µL of 20 mM 
ammonium bicarbonate and 10% acetonitrile were added to gel pieces upon rehydration, 
followed by incubation at 30°C for 17 h. Tryptic peptides were recovered from gel plugs by 
extraction with 100 μL of 50% acetonitrile in 2% trifluoroacetic acid for 30 min at 30°C. 
Extracted peptides were concentrated by speed vacuum concentrator and added to 100 μL of 2% 
acetonitrile in 0.1% formic acid. 
Automatic nano-high performance liquid chromatography (nano-HPLC) was performed 
using a microcolumn switching device (Switchos, LC Packings) coupled to an autosampler 
(Famos, LC Packings) and a nanogradient generator (UltiMate Nano HPLC, LC Packings). 
Peptide solution (30 μL) was loaded on a C18 reversed-phase capillary column (75 μm inner 
diameter × 15 cm; PepMap, Dionex) in conjunction with an Acclaim C18 PepMap trapping 
column (300 μm inner diameter × 10 mm, Dionex). Peptides were separated by a nanoflow linear 
acetonitrile gradient using buffer A (0.1% formic acid, 2% acetonitrile) and buffer B (0.1% 
formic acid, 80% acetonitrile) starting from 5% buffer B to 60% over 45 min at a flow rate of 
200 nL/min.  Then, the column was washed with 95% buffer B for 5 min. This process was 
controlled by the system control software, Hystar 3.2. Eluted peptides were injected into an HCT 
Ultra Ion Trap Mass Spectrometer (Bruker Daltronics). The mass spectrometer was set up in the 
data dependent MS/MS mode to alternatively acquire full scans (m/z acquisition range from 300 
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to 1700 Da). The four most intense peaks in any full scan were selected as precursor ions and 
fragmented by collision energy. MS/MS spectra were interpreted and peak lists were generated 
by DataAnalysis 3.4 and Biotools 3.0 software (Bruker Daltronics). 
Peptide masses were searched by Mascot v 2.3.02 (Matrix Science) using NCBI nr 
database (NCBI 20110319), containing 13,254,464 sequences. After applying a taxonomy filter 
to include sequences from Manduca sexta only, 772 sequences were searched. Additionally, M. 
sexta ESTs (181,602) from NCBI and a pyrosequencing project (Zou et al., 2008; Zhang et al., 
2011) were searched for positive identifications. Searches were performed without restriction to 
Mr or pI, and with variable oxidation of methionine residues and dehydro of cysteine residues 
(indicates S-S linkage). Maximum missed cleavage was set to 2 and limited to trypsin cleavage 
sites. The peptide mass tolerance and fragment mass tolerance were set to ±1.2 Da and ±0.6 Da, 
respectively. A threshold of 0.05 was used to determine positive protein identifications and 
peptides scoring <20 were automatically rejected, ensuring that all protein identifications were 
based on reliable peptide identifications. 
Antibacterial activity assay 
Day 2 fifth instar larvae were injected with recombinant serpin-3, M. luteus, or with 
various control materials, as described in the figure legend. After 24 h, hemolymph was collected 
on ice and centrifuged at 7000 × g for 25 min at 4°C to remove hemocytes. Aliquots (200-300 
µL) of each plasma sample were heated at 95°C for 5 min, followed by centrifugation at 10000 × 
g for 8 min to remove large proteins. Supernatants were placed at -20°C until use.  
An overnight culture (3 mL) of E. coli strain XL1-Blue was started by inoculating a 
single colony from a streak plate into LB without antibiotics. The culture was grown at 37°C 
with shaking at 275 rpm. Fresh LB (3 mL) was inoculated with 60 µL of the overnight culture 
and grown at 37°C with shaking at 275 rpm for 4 h. To create a good bacterial lawn, 50 µL of E. 
coli was added to 20 mL of LB plus 1% agar held at 47°C and poured into a petri dish. Plates 
were held at room temperature for 10 min and then placed at 4°C for 30 min. Wells were made in 
the LB agar plates using a metal tool with a 4 mm diameter opening and removing the agar plug 
with a sterile toothpick. Liquid was removed from each well and 15 µL of each sample to be 
tested was added. Water was used as a negative control and plasma samples from larvae injected 
with M. luteus (100 µg) only were used as a positive control. Plates were placed in a 37°C 
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incubator for 19-21 h and were not inverted. The diameter of each zone of inhibition was 
measured three times, averaged, and divided by 2 to obtain the radius. The radius was used to 
calculate the area (A = πr2) of the zone of inhibition (= area of entire circle – area of sample 
well). 
Results 
Formation of serpin-proteinase complexes in plasma 
Injection of bacteria into larvae 24 h prior to hemolymph collection increases the 
synthesis and hemolymph concentration of many immune related proteins (Kanost et al., 2004), 
and the incubation of plasma with bacteria after collection stimulates activation of hemolymph 
proteinases that interact with each other and are inhibited by serpins (Kanost, 2007; Ragan et al., 
2009). To investigate if exposure of plasma to bacteria led to the activation of plasma proteinases 
and the formation of serpin-proteinase complexes, plasma collected from larvae 24 h after 
injection with M. luteus was incubated with filter-sterlized water or with M. luteus, followed by 
immunoblot analysis. Serpin-3, HP8, PAP-1, and PAP-3 antibodies detected bands in plasma, 
representing intact serpin-3 (~50 kDa), proHP8 (~42 kDa), proPAP-1 (~40 kDa), and proPAP-3 
(~44 kDa) (Figure 3-1). A band representing a potential serpin-proteinase complex (~70 kDa) 
was also observed for serpin-3, HP8, and PAP-1, and is most likely present due to spontaneous 
proteinase activation or activation caused by the injury of hemolymph collection. Smaller bands 
detected by serpin-3 antibody are consistent with cleaved serpin. After incubation of plasma with 
M. luteus, the intensity of the 50 kDa serpin-3 band was reduced, while an increase was observed 
for bands representing cleaved serpin, and two higher molecular weight bands (~70 kDa), 
consistent with the sizes of serpin-proteinase complexes, were detected by serpin-3 antibody. 
This result indicates that plasma proteinases were activated by exposure to bacteria and inhibited 
by serpin-3 to form SDS-stable serpin-3-proteinase complexes, which are larger than either the 
serpin or proteinase alone. The zymogen form of HP8 and PAP-3 completely disappeared, while 
the zymogen form of PAP-1 was reduced in intensity in plasma incubated with M. luteus. In 
addition, the PAP-3 antibody recognized a band representing the clip domain of this protein. In 
conjunction with these changes, a higher molecular weight band (~70 kDa) was observed for 
each proteinase. These results indicate that proHP8, proPAP-1, and proPAP-3 were activated by 
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the exposure to bacteria and then inhibited by an unidentified serpin to form an SDS-stable 
serpin-proteinase complex.  
Purification and identification of serpin-HP8 complexes in plasma 
To identify serpins that may inhibit HP8, complexes were purified from plasma by 
immunoaffinity chromatography using HP8 antibody. Proteins that bound to the column were 
analyzed by immunoblot using HP8, serpin-1, serpin-3, serpin-4, serpin-5, and serpin-6 
antibodies (Figure 3-2). Antibodies to HP8 recognized two bands with sizes (~70 kDa) consistent 
with that expected for a serpin-proteinase complex. This result suggests that HP8 may be 
inhibited by more that one serpin. Putative serpin-proteinase complexes were detected with 
serpin-1, serpin-3, and serpin-6 antibodies, but not with serpin-4 or serpin-5 antibodies in the 
sample purified using HP8 antibody. These results suggest that serpin-1, serpin-3, and serpin-6 
can form a SDS-stable serpin-proteinase complex with HP8 in plasma. 
Purification and identification of serpin-3-proteinase complexes in plasma 
To further investigate serpin-3 as an inhibitor of HP8 or other plasma proteinases, 
immunoaffinity chromatography was conducted using serpin-3 antibody to isolate serpin-3-
proteinase complexes found in plasma. Immunoblot analysis of plasma proteins that bound to the 
serpin-3 antibody column was carried out using antibodies to serpin-3, HP8, PAP-1, PAP-2, and 
PAP-3 (Figure 3-3A). Antibodies to serpin-3 recognized a band with a size (~70 kDa) consistent 
with that expected for a serpin-proteinase complex. Bands between 51 and 64 kDa recognized by 
the antibody may be cleaved serpin-proteinase complexes, while the band at ~50 kDa is intact 
serpin-3, and the band located below 50 kDa probably represents cleaved serpin-3. Bands at the 
sizes expected for serpin-proteinase complexes were detected with HP8, PAP-1, PAP-2, and 
PAP-3 antibodies (Figure 3-3A). The zymogen form of HP8 and PAP-1 observed in naïve 
plasma was not detected in the immunopurified sample. In addition, the PAP-1, PAP-2, and 
PAP-3 antibodies recognized a band representing the clip domain of these proteins. These results 
suggest that proHP8, proPAP-1, proPAP-2, and proPAP-3 activated in plasma by exposure to 
bacteria were inhibited by serpin-3. Antibodies specific for HP6, HP9, HP10, HP12, HP13, 
HP14, HP15, HP16, HP17, HP18, HP19, and HP21 were also tested, but no serpin-3-proteinase 
complexes were detected (data not shown). 
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To further identify plasma proteins isolated by serpin-3 immunoaffinity, proteins 
separated by SDS-PAGE were digested with trypsin and analyzed by MALDI-TOF/TOF. 
Resulting peptide masses for each sample were searched against the NCBInr protein sequence 
database using Mascot. Protein identifications are listed in Table 3-1. Each band number 
corresponds with bands excised from a one-dimensional gel (Figure 3-3B). Serpin-3 (~51 kDa) 
was identified in band 4. Matching peptides were distributed over the entire sequence (covering 
65%) and included peptides on the C-terminal side of the P1 Lys residue in the reactive center 
loop, all consistent with this band representing unmodified serpin-3. Band 2 contained tryptic 
peptides from PAP-3 and serpin-3. Identified tryptic peptides from PAP-3 covered 19% of the 
sequence and were located in the catalytic domain of the proteinase (none in the clip domain). 
This is consistent with the expectation that PAP-3 was activated by cleavage between the clip 
domain and catalytic domain prior to reacting with serpin-3. Moreover, no tryptic peptides were 
identified from serpin-3 after the P1 Lys residue, suggesting that serpin-3 was cleaved at this 
position by PAP-3, resulting in formation of the SDS-stable serpin-proteinase complex. Band 5, 
which only contained tryptic peptides from serpin-3, may be cleaved serpin-3. No tryptic 
peptides C-terminal to the P1 Lys residue were detected. Serpin-3 was also found in band 3, 
slightly smaller than the serpin-3-PAP-3 complex, and is predicted to be a cleaved serpin-3-
proteinase complex. No tryptic peptides for any proteinase were identified in band 3. However, 
band 3 did contain prophenoloxidase subunit 1 and prophenoloxidase subunit 2.  
A band at 200 kDa was apolipophorin-1, a subunit of a plasma lipid transfer protein 
(Figure 3-3B, band 1) (Kanost et al., 1990; Ryan and van der Horst, 2000). Intense bands (6 and 
7) between 28 and 39 kDa were identified as immulectins (Yu and Kanost, 2008). Band 6 
contains immulectin-2 and serine proteinase homolog-1. Band 7 included immulectin-3, -4, and -
III. Immulectins are pattern recognition proteins that associate with prophenoloxidase and serine 
proteinase homologs (Yu et al., 2003). To understand the difference between immulectin-3 and 
immulectin-III, a nucleotide blast (NCBI: BLASTN 2.2.25+) was completed using the nucleotide 
sequence for immulectin-III (AM293329.1) as the query. Immulectin-III was 96% identical to 
immulectin-4 (AY768812.2), suggesting that immulectin-III could be an allele of the same gene. 
Alternatively, immulectin-III could be encoded by a highly similar gene that arose from gene 
duplication. Antimicrobial peptides (Kanost et al., 2004; Ragan et al., 2009) were detected in 
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bands 8 and 9. Band 8 contained attacin-1, while attacin-II and gloverin (dVG-AP3-2) were 
detected in band 9.  
To gain higher resolution for protein identification, plasma proteins that bound to the 
serpin-3 antibody column (Figure 3-4A; Table 3-2) were separated by two-dimensional 
electrophoresis followed by electrospray ionization tandem mass spectrometry. As a control, 
plasma proteins eluting from a Protein-A Sepharose CL-4B column lacking antibody were 
similarly analyzed (Figure 3-4B, Table 3-3). Table 3-2 lists the top Mascot hits after searching 
the NCBI protein database restricted to sequences from M. sexta. Protein scores are a sum of 
individual ion scores that had a score greater than 22 (significant identity; p < 0.05). Only 
proteins with two or more MS/MS spectra are included in this table (MS/MS results are listed in 
Table B-2). 
Spots 22-26 (Figure 3-4A) are apparently intact serpin-3, and all of these spots contain 
peptides on the C-terminal side of the P1 Lys residue in the reactive center loop. Since plasma 
from 15-18 larvae was used for immunoaffinity purification, multiple spots of serpin-3 with 
small changes in pI are likely due to allelic variation.  
Serpin-3-proteinase complexes are expected to have a molecular weight of ~94 kDa. 
Spots 1-5 and 37-39 are good candidates for putative complexes (Figure 3-4A). Spot 1 contained 
serpin-3 and two peptides from the catalytic domain of HP8 (Figure 3-5). Both serpin-3 and 
PAP-3 were present in spots 2, 3, 4, and 39. No peptides C-terminal to the P1 Lys residue of 
serpin-3 were detected and only peptides in the catalytic domain of PAP-3 were identified 
(Figures 3-6, 3-7, 3-8, and 3-10). PAP-1 and serpin-3 were present in spot 5. Like the serpin-3-
PAP-3 complexes, no peptides were found after the P1 Lys residue of serpin-3 and only peptides 
from the catalytic domain of PAP-1 were detected (Figure 3-9). Percent sequence coverage was 
calculated by Mascot based on sequences in the NCBI database. In regard to proteinases, this 
means the zymogen sequence. However, proteinases are processed by activation cleavage before 
interacting with a serpin. This means that only the catalytic domain should be present in a serpin-
proteinase complex. Therefore, the percent sequence coverage for each proteinase in complex 
was recalculated using the residues in the catalytic domain only (Table 3-2; values in 
parentheses). Spots 37 and 38 are located at a molecular weight that is consistent with a serpin-
proteinase complex. The spots clearly contained serpin-3, but no proteinase was identified. These 
may represent proteinases in plasma that have not yet been discovered. 
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Spots 15-19, 43, and 52 all contained serpin-3 (Figure 3-4A; Table 3-2), and are at 
molecular weights that are consistent with cleaved serpin-proteinase complexes. In addition to 
serpin-3, spot 17 contained seven peptides from a protein similar to a gram-negative binding 
protein (Wang et al., 2011). Unexpectedly, serpin-3 in spots 16, 17, and 43 contained peptides C-
terminal to the P1 Lys residue, indicating that serpin-3a in these spots was not cleaved in the 
RCL. 
Spots 27-30 were located at a size smaller than intact serpin-3, but contained serpin-3 
peptides (Figure 3-4A; Table 3-2). These spots, with the exception of 27 did not contain peptides 
C-terminal to the P1 Lys residue, suggesting that they were cleaved in the RCL, but reacted as 
substrate rather than inhibitor. These spots also contained peptides from serine proteinase 
homologs 1b (spots 27, 30) and 4 (28-30).  
Other immune related proteins were also identified. Immulectins (2, 2a, 3, III, and 4), 
were found in spots 3, 4, 13, 15, 67, and in a series of very intensely stained spots 54-61. Serine 
proteinase homologs (1b, 2, and 4), which are necessary for prophenoloxidase activation, were 
found in spots 20-22, 27-30, 33-35, and 56. Prophenoloxidase subunit 1 was found in spots 7-9, 
and prophenoloxidase subunit 2 was found in spots 6, 10-14, 30, and 51. Attacin-1, an 
antimicrobial peptide, was in spots 66-68. Hemolymph proteinase 14, known to initiate a 
prophenoloxidase pathway, was identified in spot 41.  
To find additional proteins that do not have sequences in the NCBI protein database, the 
ESI-MS/MS data was searched against M. sexta expressed sequence tags (ESTs) compiled from 
NCBI and a new pyrosequencing EST project (Zou et al., 2008; Zhang et al., 2011). Table 3-4 
lists the top Mascot hits, and protein scores composed of individual ion scores that had a score 
greater than 46 were considered to have significant identity (p < 0.05). Identification of ESTs 
based on BLAST searches against the NCBI database was consistent with results obtained by 
searching the NCBI protein database restricted to M. sexta. Additional protein identifications 
were made for several spots. Two peptides for alpha tubulin from Bombyx mori and M. sexta 
were matched from spot 19. Eukaryotic initiation factor-4a from M. sexta was identified in spots 
22 and 26; however, this identification was based on one peptide. Protein scores were 78 and 80, 
respectively. Inter-alpha trypsin inhibitor was identified by four peptides in spot 32 (protein 
score = 445) and a Kazal family serine proteinase inhibitor was detected by one peptide in spot 
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51. The latter match had a protein score of 47, which is just above the significance threshold of 
46. 
To investigate the potential for plasma proteins to non-specifically interact with serpin-3, 
a control column of Protein-A Sepharose CL-4B without antibody was prepared. Plasma proteins 
that bound to the control column were identified by using Mascot to search the NCBI protein 
database restricted to sequences from M. sexta (Figure 3-4B; Table 3-3). Protein scores are a sum 
of individual ion scores that had a score greater than 22 (significant identity; p < 0.05). Detailed 
MS/MS data are included in Table B-3.  
Immulectins (2b, 3, III, and 4) were very prominent proteins that bound to the Protein-A 
Sepharose CL-4B beads lacking antibody (Table 3-3; Figure 3-4B). Spots containing 
immulectins included 1c-6c, 12c-21c, and 23c-30c. Identification of immulectins in spots 12c-
14c are most likely a separation artifact as their location is not consistent with the expected pI of 
immulectin-2b (pI = 5.76) or immulectin-3 (pI = 5.86). However, spot 13c also contained 
immulectin-III, which has a pI of 9.23. Prophenoloxidase subunit 2 was found in spot 11c, but 
prophenoloxidase subunit 1 was not identified. Serine proteinase homologs were present in spots 
22c (SPH-2) and 28c (SPH-1b). Four peptides for endochitinase were found in spot 10c and one 
peptide was found for serpin-1 in spot 9c and scolexin A in spot 17c. No protein match was 
found for spots 7c and 8c.  
These ESI-MS/MS data were also searched against M. sexta expressed sequence tags 
(ESTs) compiled from NCBI and a new pyrosequencing EST project (Zou et al., 2008; Zhang et 
al., 2011) to find additional proteins that do not have sequences in the NCBI protein database. 
Table 3-5 lists the top Mascot hits, and protein scores composed of individual ion scores that had 
a score greater than 46 were considered to have significant identity (p < 0.05). Identification of 
ESTs was based on BLAST searches against the NCBI database. Protein identification for spots 
1c-6c, 9c, 11-13c, 15c, 17c-18c, and 23c-30c (Tables 3-4 and 3-5) were similar to those obtained 
by searching the NCBI protein database restricted to sequences from M. sexta. Spots 7c-8c, 10c, 
14c, 16c, 19c-22c did not have an EST hit (Table 3-5). 
Purification of recombinant HP8-Xa 
To investigate potential inhibition of HP8 by serpin-3, I prepared a recombinant form of 
HP8 mutated to permit activation by bovine factor Xa as previously described (An et al., 2009; 
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An et al., 2010b; An et al., 2011). Recombinant HP8-Xa expressed in Drosophila S2 cells was 
secreted into the culture medium utilizing its own secretion signal peptide. Medium was 
incubated with Affi-gel Blue Gel beads to remove bovine serum albumin and then applied to a 
column of concanavalin A-Sepharose 4B. Protein eluted from the concanavalin A column was 
further purified by anion exchange chromatography using a Q-Sepharose
TM
 Fast Flow column 
followed by gel permeation chromatography on a Sephacryl-S100 High Resolution column. 
Analysis by SDS-PAGE followed by silver staining or immunoblot indicated that two forms of 
HP8-Xa were present, a full-length (42 kDa) and truncated protein (37 kDa) in approximately 
equal amounts (Figure 3-11). Previous analysis of the 37 kDa band by Edman degradation 
revealed that HP8-Xa had been cleaved after Arg
59
 (An et al., 2010b). A total of 26.5 µg of 
protein was purified from a starting culture volume of 365 mL. 
Complex formation between purified, recombinant HP8 and serpin-3 
After recombinant serpin-3 was mixed with activated HP8-Xa, immunoblot analysis 
detected the appearance of a higher molecular weight complex (~70 kDa) using antisera to 
serpin-3 or HP8 (Figure 3-13). When serpin-3 was mixed with proHP8-Xa, anti-HP8 antibodies 
recognized only the 42 kDa proHP8-Xa zymogen and 37 kDa truncated form of HP8. After 
incubation with factor Xa, the proHP8-Xa zymogen disappeared, and the 34 kDa HP8 catalytic 
domain was detected. Mixing serpin-3 with active HP8-Xa resulted in decreased intensity of the 
34 kDa catalytic domain and the appearance of a new immunoreactive band at 70 kDa, consistent 
with the expected size for a serpin-proteinase complex. This serpin-proteinase complex band was 
absent in lanes for negative controls containing only serpin-3, proHP8 plus serpin-3, serpin-3 
plus factor Xa, or proHP8-Xa plus factor Xa. These results indicate that serpin-3 forms a 
covalent complex with active HP8-Xa and that HP8-Xa was activated by bovine factor Xa. 
Inhibition of HP8 by serpin-3 in plasma 
Two different pooled samples of naïve plasma were used to investigate the hypothesis 
that more serpin-3-HP8 complex would be observed when exogenous recombinant serpin-3 was 
added to plasma in which proteinases were activated by treatment with curdlan. In plasma 
sample 1, some serpin-HP8 complex was observed in all samples (Figure 3-12), and the expected 
catalytic domain of HP8 (~34 kDa) was observed in plasma incubated with curdlan. After 
plasma was pre-incubated with recombinant serpin-3 followed by incubation with curdlan, HP8 
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antibody recognized two putative complex bands, and the intensity of these bands was greater 
than that in lanes not containing recombinant serpin-3. This increased band intensity indicates 
greater inhibition of HP8. The lack of glycosylation in recombinant serpin-3 may explain the 
detection of two complex bands (one containing natural serpin-3 and one with recombinant 
serpin-3). In addition, the band representing the catalytic domain disappeared in samples pre-
incubated with serpin-3, indicating that active HP8 was in complex with serpin-3. Observation of 
the catalytic domain in plasma not activated by curdlan was surprising and is best explained by 
spontaneous activation of HP8 during the collection of this hemolymph sample. 
The expected HP8 zymogen (~42 kDa) was observed in the second plasma sample (6 
larvae; Figure 3-12). When curdlan was added to this plasma, the HP8 zymogen disappeared, the 
catalytic domain was observed, and some serpin-HP8 complex was detected. HP8 zymogen, but 
not the catalytic domain of HP8, was detected in plasma pre-incubated with recombinant serpin-
3. However, after stimulation by curdlan, the zymogen form of HP8 was reduced, and a higher 
molecular weight band corresponding to a serpin-3-HP8 complex was observed. These results 
indicate that HP8 activated by curdlan in plasma was inhibited by serpin-3. 
Production of antimicrobial peptides is not inhibited by injection of serpin-3 
To determine if serpin-3 could regulate Spätzle activation by serving as a biologically 
relevant inhibitor of HP8, I injected larvae with purified recombinant serpin-3 followed by 
injection with bacteria to stimulate proteinase cascade activation, and assayed the plasma for 
antibacterial activity. If serpin-3 regulates the activity of HP8 in vivo, I expected samples from 
insects injected with exogenous serpin-3 to have higher levels of antibacterial activity than 
controls. However, plasma samples from larvae with enhanced serpin-3 concentration did not 
differ in antibacterial activity from larvae injected with bovine serum albumin as a control 
(Figure 3-14, panels A/B). Plasma samples from larvae injected with serpin-3 did not exhibit 
melanization, whereas plasma from control larvae melanized within a few hours (Figure 3-14C). 
This confirmed that the activity of serpin-3 to inhibit PAP-1, PAP-2, and PAP-3 effectively 
regulates melanization of hemolymph (Zhu et al., 2003b). 
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Discussion 
Previous studies to identify proteinase targets of serpin-3 (Zhu et al., 2003b) were 
completed prior to obtaining sequences of many hemolymph proteinases (Jiang et al., 2005; 
Wang et al., 2006). PAP-1 and PAP-3 were identified as targets of serpin-3 by immunoaffinity 
chromatography followed by immunoblot analysis (Zhu et al., 2003b). In the current study, I re-
analyzed serpin-3 and its proteinase targets by purifying serpin-3-proteinase complexes from 
plasma activated by treatment with bacteria, using a serpin-3 immunoaffinity column. Proteinase 
components were identified by immunoblot analysis and analysis of tryptic peptides by MALDI-
TOF/TOF or ESI-MS/MS after separation by one- or two-dimensional SDS-PAGE. Both of 
these strategies have been utilized to identify proteinase targets of other M. sexta serpins (Tong 
et al., 2005; Ragan et al., 2010). One-dimensional SDS-PAGE followed by immunoblot and 
MALDI-TOF analysis was used to identify serpin-4 or serpin-5-proteinase complexes in plasma. 
Serpin-4 formed a complex with HP1, HP6, and HP21, whereas serpin-5 formed a complex with 
HP1 and HP6 (Tong et al., 2005). Two-dimensional SDS-PAGE followed by immunoblot and 
MALDI-TOF/TOF analysis identified serpin-1A, -1E, and -1J in complex with HP8, and an 
unidentified serpin-1 isoform complexed with HP1 (Ragan et al., 2010).  
Serpin-3-proteinase complexes identified in plasma 
Results in this study demonstrated that serpin-3 formed complexes in plasma with four 
proteinases, HP8, PAP-1, PAP-2, and PAP-3. These are all clip domain serine proteinases with at 
least one amino-terminal clip domain and a C-terminal serine proteinase domain (Jiang et al., 
2005). Since all have predicted trypsin-like specificity (Jiang et al., 2005) and the P1 residue of 
serpin-3 is a Lys residue (Zhu et al., 2003b), it is not surprising that all four proteinases 
interacted with serpin-3. All four complexes were confirmed by immunoblot analysis using 
appropriate antibodies. Identification of serpin-3-PAP-1 and serpin-3-PAP-3 complexes by 
immunoblot analysis is consistent with results obtained by Zhu et al. (2003b). One-dimensional 
SDS-PAGE followed by trypsin digestion and MALDI-TOF/TOF analysis of selected bands 
identified tryptic peptides of both serpin-3 and PAP-3 in the same band; however, tryptic 
peptides for HP8, PAP-1, or PAP-2 were not identified by this method. To achieve better 
separation, two-dimensional SDS-PAGE was performed and followed by ESI-MS/MS analysis. 
In two-dimensional SDS-PAGE, proteins are first separated by electric charge differences 
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(isoelectic focusing) and then by molecular weight. Eight spots (1-5, 37-39) were consistent with 
the size of a serpin-3 proteinase complex. Two to five tryptic peptides for the catalytic domain of 
PAP-3 were found in spots 2, 3, 4, and 39 along with serpin-3. A total of six tryptic peptides for 
PAP-1 were found with serpin-3 in spot 5. Spot 1 contained serpin-3 and two tryptic peptides 
from the catalytic domain of HP8. Although immunoblot analysis detected a serpin-3-PAP-2 
complex in plasma, no tryptic peptides from PAP-2 were detected by mass spectrometry. 
Detection of six or fewer peptides from proteinases found in the same spot as serpin-3 indicated 
that not all potential tryptic peptides in the catalytic domain of each proteinase were detected. 
Lack of detection could be due to the size of the tryptic peptides. If a peptide was too small or 
too large, it would not be identified by mass spectrometry. Spots 37 and 38 contained serpin-3, 
but no proteinase components were identified. These may represent proteinases in plasma that 
have not yet been identified. I hypothesize that other clip domain proteinases exhibiting 
predicted trypsin-like specificity (e.g. HP1, 2, 6, 12, 13, 15, 17, 18, and 22-24 (Jiang et al., 2005; 
Wang et al., 2006)) might be regulated by serpin-3. Such complexes were not identified by 
immunoblot analysis or using the database search parameters described in the materials and 
methods section (i.e. peptide mass tolerance and fragment mass tolerance were set to ±1.2 Da 
and ±0.6 Da, respectively). However, if I were to change these parameters, additional serpin-3-
proteinase complex identifications might be made and significance would be determined based 
on a set identity threshold. 
Other proteins identified in plasma by mass spectrometry 
Full-length serpin-3 was identified in spots 22-26 (2D gel) and spot 4 (1D gel). Allelic 
variation involving charged amino acids is one possible explanation for the five distinct serpin-3 
spots observed after two-dimensional SDS-PAGE. Another possible explanation is changes in 
post-translational modifications such as N-linked glycosylation. Differences in glycosylation 
were shown to change the pI, but not the apparent molecular weight of glycoproteins found in 
human plasma (Packer et al., 1996).  
Immulectins, prophenoloxidase subunits 1 and 2, and serine proteinase homologs co-
purified with serpin-3-proteinase complexes. These proteins are all known components of the 
prophenoloxidase activation pathway. A large amount of immulectin-2 and smaller amounts of 
immulectin-3, -III, and -4 were purified from the serpin-3 immunoaffinity column. This result is 
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consistent with immunoaffinity purification of serpin-4 or -5-proteinase complexes (Tong et al., 
2005). Immulectin-2 binds to lipopolysaccharide from gram-negative bacteria and stimulates the 
activation of prophenoloxidase (Yu and Kanost, 2000). Tong et al. (2005) speculated that 
immulectin-2 might recognize carbohydrates on the surface of bacteria or function as a linker to 
localize components of the prophenoloxidase activation system. Serine proteinase homologs bind 
to immulectin-2 and prophenoloxidase (Yu et al., 2003) suggesting the formation of proteinase 
complexes, including proteinases inhibited by serpins, held together by their interaction with 
serine proteinase homologs and immulectins (Tong et al., 2005). As a control, I ran a column of 
Protein-A Sepharose CL-4B beads without antibody to determine what proteins in plasma bound. 
The most prominent bound protein was immulectin-2 with lesser amounts of immulectins-3, -III, 
and -4. Prophenoloxidase subunit 2 was found in two spots while serine proteinase homologs 1 
and 2 were each found in one spot. These results do not support the hypothesis presented by 
Tong et al. (2005). They suggest that immulectins bind to carbohydrates present on the Protein-A 
Sepharose CL-4B beads and that serine proteinase homologs and prophenoloxidase interact with 
bound immulectins and that the binding of those components to the column is independent of 
interaction with serpins of serpin-proteinase complexes. 
Seven tryptic peptides corresponding to a gram-negative binding protein, named microbe 
binding protein, were detected in spot 17. Microbe binding protein is a new member of the β-1,3-
glucanase-related protein superfamily (Wang et al., 2011). The sequence of microbe binding 
protein is 61% identical to B. mori gram-negative binding protein and 34-36% identical to M. 
sexta β-1,3-glucan recognition protein-1 and -2. Microbe binding protein bound to a variety of 
microbial cells and cell surface components which indicates that microbe binding protein serves 
as a pattern recognition protein during infection. In addition, the ability of microbe binding 
protein to enhance proPO activation indicates that this protein works in concert with other 
defense molecules to stimulate the activation of proPO (Wang et al., 2011).  
Three tryptic peptides from HP14 were found in spot 41. HP14 consists of five low-
density lipoprotein receptor class A domains, a Sushi domain, a cysteine-rich region (Wonton), 
and C-terminal serine proteinase domain (Ji et al., 2004). HP14 autoactivates in the presence of 
peptidoglycan (Ji et al., 2004) or β-1,3-glucan and βGRP2 to stimulate the activation of 
prophenoloxidase (Wang and Jiang, 2006). However, all tryptic peptides were found in the 
amino-terminal region of HP14 and the molecular size of this spot is consistent with that of 
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HP14 zymogen (~73 kDa), suggesting that HP14 was not cleaved. The low-density lipoprotein 
receptor class A, Sushi, and Wonton domains of HP14 all bound to Lys-type peptidoglycan 
while the Sushi and Wonton domains also bound to β-1,3-glucan recognition protein-1 (Wang 
and Jiang, 2010). This knowledge leads me to speculate that HP14 may bind to microbe binding 
protein described above. Alternatively, the detection of HP14 could be due to a non-specific 
interaction with other identified proteins. 
Attacin-1 was identified in spots 66-68 (2D gel) and spot 8 (1D gel) while attacin-II and 
gloverin were found in spot 9 (1D gel). Attacin and gloverin are both immune-inducible glycine-
rich antibacterial peptides. These antibacterial peptides inhibit the synthesis of outer membrane 
components, which increases the permeability of the outer membrane (Engström et al., 1984; 
Carlsson et al., 1991; Axén et al., 1997). Detection of antibacterial peptides was unexpected. It is 
likely that these peptides were detected due to interactions with other proteins as I do not expect 
an interaction with serpin-3. 
Spot 32 contained serpin-3 and inter-α-trypsin inhibitor heavy chain from M. sexta. Inter-
α-trypsin inhibitor was originally identified in M. sexta by substractive suppression hybridization 
(Zhu et al., 2003a). It is similar to mouse and human inter-α-trypsin inhibitor heavy chain 4 (Cai 
et al., 1998), which is thought to function in inflammatory responses (Salier et al., 1996). This 
inhibitor is a member of the inter-α-inhibitor family, which belongs to the Kunitz-type proteinase 
inhibitor superfamily (Salier, 1990). In M. sexta, expression of inter-α-trypsin inhibitor, detected 
by Northern blot analysis, was dramatically increased after exposure to bacteria (Zhu et al., 
2003a). 
An interesting match to a Kazal family serine proteinase inhibitor was found by EST 
search of spot 51. Kazal family serine proteinase inhibitors contain one or more Kazal-type 
domains, which are 40-60 amino acid residues in length. A typical Kazal domain is recognized 
by the general amino acid sequence C-Xa-C-Xb-PVCG-Xc-Y-Xd-C-Xe-C-Xf-C where subscript 
letters represent an integral number of amino acid residues, and the six cysteine residues form 
three intradomain disulfide bonds (Rimphanitchayakit and Tassanakajon, 2010). Substractive 
suppression hybridization identified this proteinase inhibitor in M. sexta (Zhu et al., 2003a) and 
BLAST results indicated that it is similar to rhodniin from Rhodnius prolixus (Friedrich et al., 
1993). Rhodniin prevents blood clotting by inhibiting thrombin to facilitate the insect’s ability to 
take a blood meal. Other insects, including Drosophila melanogaster (Niimi et al., 1999), 
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Galleria mellonella (Nirmala et al., 2001), Triatoma infestans (Campos et al., 2004), Bombyx 
mori (Zheng et al., 2007), and Aedes aegypti (Watanabe et al., 2010) possess Kazal-type 
inhibitors. Kazal-type inhibitors from T. infestans inhibit thrombin and factor XIIa to control 
blood coagulation during blood feeding (Campos et al., 2004), and silk proteinase inhibitor 1 
from G. mellonella inhibits subtilisin and proteinase K to prevent the destruction of silk proteins 
for cocoon formation by microbial invaders (Nirmala et al., 2001). Kazal family serine 
proteinase inhibitors are also found in crayfish (Johansson et al., 1994) and shrimp (Somprasong 
et al., 2006). Subtilisin was inhibited by Kazal-type inhibitors from both organisms, while 
chymotrypsin and elastase were inhibited by inhibitors from crayfish and shrimp, respectively 
(Johansson et al., 1994; Somprasong et al., 2006). 
Interaction of serpin-3 and HP8 
After identifying HP8 as a proteinase target for serpin-3, my goal was to biochemically 
characterize the interaction between the two proteins. The first step towards this goal was the 
production of purified recombinant HP8-Xa in Drosophila S2 cells and serpin-3 in E.coli. Both 
proteins were successfully purified, but the concentration of HP8-Xa was very low and a 
truncated version of HP8-Xa was present (An et al., 2010b). Due to the low concentration and 
stability of the protein, I was only able to conduct one experiment with purified HP8-Xa. 
Formation of an SDS-stable complex is a hallmark feature of a serpin-proteinase interaction and 
was tested by incubating recombinant serpin-3 with active HP8-Xa. I determined that serpin-3 
and HP8 form a complex in vitro. Samples containing factor Xa alone did not result in complex 
formation, indicating that the observed complex was due to the interaction of serpin-3 with 
active HP8-Xa and not factor Xa. Similar in vitro complexes have been detected for serpin-1J 
and PAP-3 (Jiang et al., 2003), serpin-3 and PAP-1/PAP-3 (Zhu et al., 2003b), serpins-4 and -5 
with PAP-1 (Tong and Kanost, 2005), serpin-1I and HP14 (Wang and Jiang, 2006), serpin-6 and 
PAP-3 (Zou and Jiang, 2005), serpin-4 and HP21 (Wang and Jiang, 2007), serpins-4 and -5 with 
HP6 (An and Kanost., 2010), and serpin-1J and HP8 (An et al., 2011). This result further 
supports the hypothesis that serpin-3 might be a biologically relevant inhibitor of HP8 in 
hemolymph. 
Next, I determined that exogenous purified recombinant serpin-3 could form a complex 
with endogenous HP8 in plasma when curdlan was used as an elicitor to stimulate proteinase 
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activation. Two different pooled plasma samples were used in this experiment. With pooled 
plasma sample #1, a serpin-3-HP8 complex was detected by HP8 antibody in all samples, and 
the intensity of the detected complex was greater in samples containing exogenous serpin-3. 
Mixtures lacking active HP8 (lanes without curdlan) were not expected to exhibit complex 
formation. The best explanation for this result is that spontaneous activation of HP8 in plasma 
took place in this sample during the collection of hemolymph (i.e. wounding from clipping the 
posterior horn). In pooled plasma sample #2, HP8 was not activated in the absence of curdlan. 
When this plasma was incubated with curdlan, serpin-3-HP8 complexes were observed in the 
presence and absence of exogenous serpin-3. In the presence of serpin-3, less HP8 zymogen was 
converted to active HP8. This suggests that serpin-3 may inhibit activation of HP8. In mixtures 
containing exogenous serpin-3, two bands corresponding to the serpin-3-HP8 complex observed 
are likely due to differences in glycosylation. Serpin-3 in plasma undergoes post-translational 
modification (N-linked glycosylation) while serpin-3 expressed in E. coli does not. 
HP6 activates HP8 to stimulate the production of antimicrobial peptides (An et al., 2009; 
An et al., 2010b). Knowing this and discovering that serpin-3 inhibits HP8, I hypothesized that 
serpin-3 may be a biologically relevant inhibitor of HP8 and could regulate Spätzle activation. If 
my hypothesis was correct, serpin-3 should inhibit HP8, and a decrease in antibacterial activity 
should be observed. However, there was no difference in antibacterial activity in plasma samples 
from insects with or without injected recombinant serpin-3 (Figure 3-14, panels A/B). One 
possible explanation is that serpin-3 inhibited HP8, but additional unknown proteinases with 
redundant function in antimicrobial production were activated and are not regulated by serpin-3. 
Another possibility is that serpin-3 is not an efficient inhibitor of HP8 (i.e. stoichiometry of 
inhibition is high), but this remains to be tested. I observed that plasma samples from larvae 
injected with serpin-3 did not melanized, whereas plasma from control larvae melanized within a 
few hours (Figure 3-14C). This in vivo result confirms that serpin-3 is an efficient regulator of 
melanization through its inhibition of prophenoloxidase-activating proteinases (Zhu et al., 
2003b). Taken together, the results of these experiments indicate that serpin-3 plays a significant 
role in the inhibition of prophenoloxidase activation, but do not indicate that inhibition of HP8 
by serpin-3 regulates the production of antimicrobial peptides. 
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Bacterial challenge stimulates the formation of serpin-proteinase complexes in plasma 
Serine proteinase cascade pathways are involved in innate immune responses of 
vertebrates and invertebrates, and promote rapid, non-specific responses to infection and 
wounding (Krem and Di Cera, 2002; Kanost and Clarke, 2005; Cerenius et al., 2010). After 
active proteinases perform their functions, they are inactivated by serpins to prevent damage to 
the organism (Silverman et al., 2001; Gettins, 2002). In insects, serpins have a role in regulating 
serine proteinases involved in the Toll pathway (Levashina et al., 1999; Zou and Jiang, 2005; 
Shin et al., 2006; Ahmad et al., 2009; Jiang et al., 2009; An and Kanost, 2010; An et al., 2011; 
Park et al., 2011). Regulation of prophenoloxidase activation by serpins, including two orthologs 
to M. sexta serpin-3 (Drosophila serpin-27A (De Gregorio et al., 2002; Ligoxygakis et al., 2002) 
and Anopheles gambiae serpin-2 (An et al., 2010a)), in insects has also been observed (Jiang et 
al., 2003; Zhu et al., 2003b; Wang and Jiang, 2004; Abraham et al., 2005; Tong and Kanost, 
2005; Tong et al., 2005; Zou and Jiang, 2005; Michel et al., 2006; Wang and Jiang, 2006; 
Scherfer et al., 2008; Tang et al., 2008; Jiang et al., 2009; An and Kanost, 2010; Zou et al., 2010; 
Park et al., 2011). 
Synthesis and hemolymph concentration of many immune related proteins increase after 
injection of bacteria into larvae 24 h prior to hemolymph collection (Kanost et al., 2004). The 
incubation of plasma with bacteria after collection stimulates activation of hemolymph 
proteinases that interact with each other and are inhibited by serpins (Kanost, 2007; Ragan et al., 
2009). Inhibition of a proteinase by a serpin is characterized by cleavage of the serpin, resulting 
in the formation of an SDS-stable serpin-proteinase complex. In this study, serpin-proteinase 
complexes were detected with serpin-3, HP8, PAP-1, and PAP-3 antibodies, suggesting that the 
hemolymph proteinases were activated by bacterial challenge and then interacted with serpins to 
form a stable serpin-proteinase complex (Figure 3-1).  
In previous studies, PAP-3 was inhibited by serpin-1J (Jiang et al., 2003), serpin-3 (Zhu 
et al., 2003b), and serpin-6 (Wang and Jiang, 2004; Zou and Jiang, 2005) to regulate 
prophenoloxidase activation, indicating that key proteinases in a serine proteinase cascade may 
be regulated by multiple serpins (Zou and Jiang, 2005). This also suggests that the serpin-PAP-3 
complex detected by immunoblot, in the current study, could represent PAP-3 with any one of 
these serpins. In addition, serpin-3 inhibited PAP-1 (Zhu et al., 2003b), suggesting that serpin-3 
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may inhibit more than one proteinase. Detection of two bands (~70 kDa) by serpin-3 antibody in 
this study further supports inhibition of multiple proteinases by one serpin. 
Future Directions 
Two-dimensional SDS-PAGE, ESI-MS/MS, and immunoblot analysis strategies used to 
identify serpin-3-proteinase complexes in the the hemolymph of M. sexta confirmed serpin-3-
PAP-1 and serpin-3-PAP-3 complexes identified in previous studies and identified a previously 
undiscovered complex between serpin-3 and HP8. The next step in understanding the inhibitor 
relationship between serpin-3 and HP8 is to investigate the inhibitory activity of serpin-3 against 
HP8 by biochemical experiments using purified recombinant proteins. Specific goals and 
questions to be answered are as follows: 
(1) There is a need for a substantially improved expression system to produce 
recombinant HP8-Xa. 
(2) What is the stoichiometry of inhibition? 
(3) What is the association rate constant of inhibition for HP8? 
 
When producing recombinant proteinases, including HP8-Xa, the goal is to obtain protein 
of expected size and of high purity. Although recombinant HP8-Xa was successfully purified 
from Drosophila S2 cells, analysis by SDS-PAGE followed by immunoblot indicated that two 
forms of HP8-Xa were present, a full-length (42 kDa) and truncated protein (37 kDa) in 
approximately equal amounts (Figure 3-11). Previous analysis of the 37 kDa band by Edman 
degradation revealed that HP8-Xa had been cleaved after Arg
59
 (An et al., 2010b). Therefore, to 
use HP8-Xa in future experiments, the search for a new expression system has started, with the 
goal to find an expression system that will not result in truncated HP8-Xa and will produce a 
usable amount of highly pure protein. 
Efficiency of the inhibition of HP8 by serpin-3 will be characterized by deterimining the 
stoichiometry of inhibition and the association rate constant of inhibition of HP8. The 
stoichiometry of inhibition indicates if the serpin is acting as an inhibitor or substrate. Strong 
inhibitors exhibit a stoichiometry of inhibition close to one, while serpins acting as substrates 
have a stoichiometry of inhibition greater than one (Schick et al., 1997) in which the 
predominant reaction is cleavage of the serpin reactive center loop without formation of a stable 
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complex and inhibition of the proteinase. The association rate constant will indicate how fast 
complex formation occurs between serpin-3 and HP8 (Schick et al., 1997). If complex formation 
between serpin-3 and HP8 occurs quickly, the association rate constant should be large. Results 
obtained from these two experiments will further indicate if serpin-3 is a relevant inhibitor of 
HP8. 
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Figures 
 
Figure 3-1. Treatment of plasma with bacteria promotes formation of serpin-proteinase 
complexes. 
Plasma (8 µL) obtained from larvae 24 h post-injection of M. luteus (100 µg) was incubated with 
2 µL of filter-sterilized water (lane 1) or 2 µL M. luteus (lane 2; final concentration = 0.1 µg/µL) 
for 1 h at room temperature. Samples were prepared so that an equivalent of 1 µL of plasma was 
loaded in each lane and were subjected to SDS-PAGE under reducing conditions followed by 
immunoblot analysis with antibodies to serpin-3, HP8, PAP-1, or PAP-3. Antibodies were used 
at a 1:2000 dilution except for PAP-3, which was used at a 1:750 dilution. 
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Figure 3-2. Complex formation between HP8 and serpin-1, serpin-3, and serpin-6 in 
plasma. 
Naïve plasma (lane 1) and a sample of plasma proteins that bound to a HP8 antibody affinity 
column (lane 2) were subjected to SDS-PAGE under reducing conditions followed by 
immunoblot analysis with HP8, serpin-1, serpin-3, serpin-4, serpin-5, or serpin-6 antibodies. 
Work by Dr. Chunju An. 
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Figure 3-3. Complex formation between serpin-3 and HP8, PAP-1, PAP-2, and PAP-3 in 
plasma. 
Fifth-instar, day 3 naïve plasma (lane 1) and a sample of plasma proteins that bound to a serpin-3 
antibody affinity column (lane 2) were subjected to SDS-PAGE under reducing conditions 
followed by immunoblot analysis with serpin-3, HP8, PAP-1, PAP-2, and PAP-3 antibodies (A) 
and Coomassie Blue staining (B). Coomassie Blue stained bands were excised for trypsin 
digestion followed by MALDI-TOF and MALDI-TOF/TOF mass spectrometry analysis. 
Numbers in parentheses correspond to the band number in Table 3-1. 
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Figure 3-4. Serpin-3 forms a covalent complex with HP8, PAP-1, and PAP-3 in plasma. 
A sample of plasma proteins that bound to a serpin-3 antibody-coupled immunoaffinity column (A) and a control column of Protein-A 
Sepharose CL-4B beads without antibody (B) was separated by two-dimensional gel electrophoresis, using a pH range of 3.5-10  for 
isoelectric focusing (tropomyosin: pI = 5.2) and a 10% acrylamide slab gel for molecular weight separation. Numbers indicate selected 
Coomassie Blue stained spots that were subjected to trypsin digestion followed by ESI-MS/MS mass spectrometry (Tables 3-2, 3-3, 3-
4, 3-5). Spots 22-26 contain unprocessed serpin-3. Spot 1 contains serpin-3 and HP8, spots 2, 3, 4, and 39 contain serpin-3 and PAP-3, 
spot 5 contains serpin-3 and PAP-1. Spots 37 and 38 contain serpin-3, but no peptides for known M. sexta proteinases.
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Serpin 3 
 
1   MTSTIYFAFF VAPLLLCSLA DDVDPNTLRA VFGYSALDQA ALVGAESNKQ  
51  AATVTPDNGT LVDPDYWDTE EFQPSTADYD IFDWVLTKRV ASTSNANFLL 
101 SPLGLKLALA ILTEAATGST RSELASALGF GLDRTEVRRK FSTIIESLKR 
151 ESPDYILNLG SRIYMGEGVQ PRQRFAAIAQ EFYKTELKTT NFFKPEVAAR  
201 EINNWVSNAT QGKIPNLVEA DDVADVILLI LNTLYFKGTW RHQFAPNATK  
251 PGPFYVSPQL QKTVPFMNVK DNFYYVDSSR FDAKILRLPY RGNKYAMYIV 
301 VPNSLTGLPR VLNNLSELRT EMIYLQERLV DVILPKFQFE YMSRLEGVLR 
351 EMGVREAFED TASFPGIARG QLLYQRLRVS KVFQRTGIEV NELGSVAFSA  
401 TQIGIQNKFG EDSDINYEVV ANKPFMFFIQ EESTRQTLFT GRVSDPALVD  
451 GAFKA 
 
 
Hemolymph proteinase 8 
 
1   MNILYVKTTV VTCILVITFS NVVGQSCNGG ADCIALDKCS GLYRQLQKGS  
51  TPALTRLLRS LHCGFENANM PKICCPPEFL AQRGAFGNDQ GSARENPLAL  
101 LPNRRECGIQ NNDRIVGGIQ TEIDEHPWMV LLRYDKPSGW GFYCGGVLIS  
151 SKYVLTAAHC VKGSDLPPNW KLSQVRLGEW NTSSQVDCVG DDCSQPVQDI  
201 RIEQIVAHES YDPEDNNQQN DIALLRLAQN VHLNDFVKPI CLPTTEDLRD 
251 SNFDGLEMEV AGWGKTETRT ESDVKLKVRV PVVSRRLCKS VYERVERLIT  
301 DKQLCAGGVE GKDSCRGDSG GALMGQAPSA NNWLVVGVVS YGPSPCGTPG  
351 WPGVYTRVGA FMDWILSKLR P 
 
Figure 3-5. Complex spot 1 contains serpin-3 and hemolymph proteinase 8. 
Sequence coverage of serpin-3 and hemolymph proteinase 8 from spot 1 (Figure 3-4A). Tryptic 
peptides identified by mass spectrometry are shown in red letters. The serpin-3 P1 residue is bold 
and underlined and the activation site of hemolymph proteinase 8 is highlighted in cyan. Signal 
peptides of each protein are italicized. 
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Serpin 3 
 
1   MTSTIYFAFF VAPLLLCSLA DDVDPNTLRA VFGYSALDQA ALVGAESNKQ  
51  AATVTPDNGT LVDPDYWDTE EFQPSTADYD IFDWVLTKRV ASTSNANFLL 
101 SPLGLKLALA ILTEAATGST RSELASALGF GLDRTEVRRK FSTIIESLKR 
151 ESPDYILNLG SRIYMGEGVQ PRQRFAAIAQ EFYKTELKTT NFFKPEVAAR 
201 EINNWVSNAT QGKIPNLVEA DDVADVILLI LNTLYFKGTW RHQFAPNATK  
251 PGPFYVSPQL QKTVPFMNVK DNFYYVDSSR FDAKILRLPY RGNKYAMYIV 
301 VPNSLTGLPR VLNNLSELRT EMIYLQERLV DVILPKFQFE YMSRLEGVLR 
351 EMGVREAFED TASFPGIARG QLLYQRLRVS KVFQRTGIEV NELGSVAFSA 
401 TQIGIQNKFG EDSDINYEVV ANKPFMFFIQ EESTRQTLFT GRVSDPALVD  
451 GAFKA 
 
 
Prophenoloxidase-activating proteinase-3 
 
1   MANLVYVLLL ASYFCFVSGQ SCTTPNNGKG TCKSIYECEE LLKLVYKKDR  
51  TQQDTDYLKK SQCGFMGNTP TVCCPNPCIT PQGEPGQCVS IYECTNLANL  
101 LKPPITADTY NYVQKSRCQG ADQYSVCCGS APNFPSTGDC KASVSAFPPD  
151 PKSKCCGVDS RVGNKIIGGN ATDVDQYPWL TIIEYVKTGP IKLLCGGVLI  
201 SGKYVLTAGH CLTGPVLQIG TPTNVRLGEY NTKNDGADCV TVEAGGMDCT  
251 EGAVIVPIEK TIPHPEYNPI SRTRRNDIGL IRLKEMAPFT DFIRPICLPS  
301 LDLTQAPPVN FTLYAAGWGA VSTSQPSSNV KLHVQLPFIS YERCQPSYAV  
351 QNRQIELWEK QVCAGGEAGK DSCKGDSGGP LMYENGQTYE VIGIVSFGPT  
401 PCGMQDIPGV YTKVHSYKDW IISNIKP 
Figure 3-6. Complex spot 2 contains serpin-3 and prophenoloxidase-activating proteinase-
3. 
Sequence coverage of serpin-3 and prophenoloxidase-activating proteinase-3 from spot 2 (Figure 
3-4A). Tryptic peptides identified by mass spectrometry are shown in red letters. The P1 residue 
of serpin-3 is bold and underlined and the activation site of prophenoloxidase-activating 
proteinase-3 is highlighted in cyan. Signal peptides for both proteins are italicized. 
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Serpin 3 
 
1   MTSTIYFAFF VAPLLLCSLA DDVDPNTLRA VFGYSALDQA ALVGAESNKQ  
51  AATVTPDNGT LVDPDYWDTE EFQPSTADYD IFDWVLTKRV ASTSNANFLL 
101 SPLGLKLALA ILTEAATGST RSELASALGF GLDRTEVRRK FSTIIESLKR 
151 ESPDYILNLG SRIYMGEGVQ PRQRFAAIAQ EFYKTELKTT NFFKPEVAAR 
201 EINNWVSNAT QGKIPNLVEA DDVADVILLI LNTLYFKGTW RHQFAPNATK  
251 PGPFYVSPQL QKTVPFMNVK DNFYYVDSSR FDAKILRLPY RGNKYAMYIV 
301 VPNSLTGLPR VLNNLSELRT EMIYLQERLV DVILPKFQFE YMSRLEGVLR 
351 EMGVREAFED TASFPGIARG QLLYQRLRVS KVFQRTGIEV NELGSVAFSA 
401 TQIGIQNKFG EDSDINYEVV ANKPFMFFIQ EESTRQTLFT GRVSDPALVD  
451 GAFKA 
 
 
Prophenoloxidase-activating proteinase-3 
 
1   MANLVYVLLL ASYFCFVSGQ SCTTPNNGKG TCKSIYECEE LLKLVYKKDR  
51  TQQDTDYLKK SQCGFMGNTP TVCCPNPCIT PQGEPGQCVS IYECTNLANL  
101 LKPPITADTY NYVQKSRCQG ADQYSVCCGS APNFPSTGDC KASVSAFPPD  
151 PKSKCCGVDS RVGNKIIGGN ATDVDQYPWL TIIEYVKTGP IKLLCGGVLI  
201 SGKYVLTAGH CLTGPVLQIG TPTNVRLGEY NTKNDGADCV TVEAGGMDCT  
251 EGAVIVPIEK TIPHPEYNPI SRTRRNDIGL IRLKEMAPFT DFIRPICLPS  
301 LDLTQAPPVN FTLYAAGWGA VSTSQPSSNV KLHVQLPFIS YERCQPSYAV  
351 QNRQIELWEK QVCAGGEAGK DSCKGDSGGP LMYENGQTYE VIGIVSFGPT  
401 PCGMQDIPGV YTKVHSYKDW IISNIKP 
Figure 3-7. Complex spot 3 contains serpin-3 and prophenoloxidase-activating proteinase-
3. 
Sequence coverage of serpin-3 and prophenoloxidase-activating proteinase-3 from spot 3 (Figure 
3-4A). Tryptic peptides identified by mass spectrometry are shown in red letters. The P1 residue 
of serpin-3 is bold and underlined and the activation site of prophenoloxidase-activating 
proteinase-3 is highlighted in cyan. Signal peptides for both proteins are italicized. 
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Serpin 3 
 
1   MTSTIYFAFF VAPLLLCSLA DDVDPNTLRA VFGYSALDQA ALVGAESNKQ  
51  AATVTPDNGT LVDPDYWDTE EFQPSTADYD IFDWVLTKRV ASTSNANFLL 
101 SPLGLKLALA ILTEAATGST RSELASALGF GLDRTEVRRK FSTIIESLKR 
151 ESPDYILNLG SRIYMGEGVQ PRQRFAAIAQ EFYKTELKTT NFFKPEVAAR 
201 EINNWVSNAT QGKIPNLVEA DDVADVILLI LNTLYFKGTW RHQFAPNATK  
251 PGPFYVSPQL QKTVPFMNVK DNFYYVDSSR FDAKILRLPY RGNKYAMYIV 
301 VPNSLTGLPR VLNNLSELRT EMIYLQERLV DVILPKFQFE YMSRLEGVLR 
351 EMGVREAFED TASFPGIARG QLLYQRLRVS KVFQRTGIEV NELGSVAFSA 
401 TQIGIQNKFG EDSDINYEVV ANKPFMFFIQ EESTRQTLFT GRVSDPALVD  
451 GAFKA 
 
 
Prophenoloxidase-activating proteinase-3 
 
1   MANLVYVLLL ASYFCFVSGQ SCTTPNNGKG TCKSIYECEE LLKLVYKKDR  
51  TQQDTDYLKK SQCGFMGNTP TVCCPNPCIT PQGEPGQCVS IYECTNLANL  
101 LKPPITADTY NYVQKSRCQG ADQYSVCCGS APNFPSTGDC KASVSAFPPD  
151 PKSKCCGVDS RVGNKIIGGN ATDVDQYPWL TIIEYVKTGP IKLLCGGVLI  
201 SGKYVLTAGH CLTGPVLQIG TPTNVRLGEY NTKNDGADCV TVEAGGMDCT  
251 EGAVIVPIEK TIPHPEYNPI SRTRRNDIGL IRLKEMAPFT DFIRPICLPS  
301 LDLTQAPPVN FTLYAAGWGA VSTSQPSSNV KLHVQLPFIS YERCQPSYAV  
351 QNRQIELWEK QVCAGGEAGK DSCKGDSGGP LMYENGQTYE VIGIVSFGPT  
401 PCGMQDIPGV YTKVHSYKDW IISNIKP 
 
Figure 3-8. Complex spot 4 contains serpin-3 and prophenoloxidase-activating proteinase-
3. 
Sequence coverage of serpin-3 and prophenoloxidase-activating proteinase-3 from spot 4 (Figure 
3-4A). Tryptic peptides identified by mass spectrometry are shown in red letters. The P1 residue 
of serpin-3 is bold and underlined and the activation site of prophenoloxidase-activating 
proteinase-3 is highlighted in cyan. Signal peptides for both proteins are italicized. 
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Serpin 3 
 
1   MTSTIYFAFF VAPLLLCSLA DDVDPNTLRA VFGYSALDQA ALVGAESNKQ  
51  AATVTPDNGT LVDPDYWDTE EFQPSTADYD IFDWVLTKRV ASTSNANFLL 
101 SPLGLKLALA ILTEAATGST RSELASALGF GLDRTEVRRK FSTIIESLKR 
151 ESPDYILNLG SRIYMGEGVQ PRQRFAAIAQ EFYKTELKTT NFFKPEVAAR 
201 EINNWVSNAT QGKIPNLVEA DDVADVILLI LNTLYFKGTW RHQFAPNATK  
251 PGPFYVSPQL QKTVPFMNVK DNFYYVDSSR FDAKILRLPY RGNKYAMYIV 
301 VPNSLTGLPR VLNNLSELRT EMIYLQERLV DVILPKFQFE YMSRLEGVLR 
351 EMGVREAFED TASFPGIARG QLLYQRLRVS KVFQRTGIEV NELGSVAFSA 
401 TQIGIQNKFG EDSDINYEVV ANKPFMFFIQ EESTRQTLFT GRVSDPALVD  
451 GAFKA 
 
 
Prophenoloxidase-activating proteinase-1 
 
1   MKNHTVFIVF AVYWTCVFSQ SCTTPQGVDS NCISLYECPQ LLSAFEQRPL  
51  PSPVVNYLRK SQCGFDGYTP RVCCGPLPQQ ASRPQPTPAP VPTRAPPVNP  
101 GGVDPTYDED SSPAPRNQCG VDMNGDRIYG GQITDLDEFP WMALLGYLTR  
151 TGSTTYQCGG VLINQRYVLT AAHCTIGAVE REVGKLITVR LGEYDTQNSV  
201 DCVDDVCADP PQNIPIEVAY PHSGYSDNNK NRKDDIALVR LTRRAQYTYY  
251 VKPICLANNN ERLATGNDVF VAGWGKTLSG KSSPIKLKLG MPIFDKSDCA  
301 SKYRNLGAEL TDKQICAGGV FAKDTCRGDS GGPLMQRRPE GIWEVVGIVS  
351 FGNRCGLDGW PGVYSSVAGY SDWILSTLRS TNV 
 
Figure 3-9. Complex spot 5 contains serpin-3 and prophenoloxidase-activating proteinase-
1. 
Sequence coverage of serpin-3 and prophenoloxidase-activating proteinase-1 from spot 5 (Figure 
3-4A). Tryptic peptides identified by mass spectrometry are shown in red letters. The P1 residue 
of serpin-3 is bold and underlined and the activation site of prophenoloxidase-activating 
proteinase-1 is highlighted in cyan. Signal peptides for both proteins are italicized. 
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Serpin 3 
 
1   MTSTIYFAFF VAPLLLCSLA DDVDPNTLRA VFGYSALDQA ALVGAESNKQ  
51  AATVTPDNGT LVDPDYWDTE EFQPSTADYD IFDWVLTKRV ASTSNANFLL  
101 SPLGLKLALA ILTEAATGST RSELASALGF GLDRTEVRRK FSTIIESLKR 
151 ESPDYILNLG SRIYMGEGVQ PRQRFAAIAQ EFYKTELKTT NFFKPEVAAR 
201 EINNWVSNAT QGKIPNLVEA DDVADVILLI LNTLYFKGTW RHQFAPNATK  
251 PGPFYVSPQL QKTVPFMNVK DNFYYVDSSR FDAKILRLPY RGNKYAMYIV  
301 VPNSLTGLPR VLNNLSELRT EMIYLQERLV DVILPKFQFE YMSRLEGVLR 
351 EMGVREAFED TASFPGIARG QLLYQRLRVS KVFQRTGIEV NELGSVAFSA  
401 TQIGIQNKFG EDSDINYEVV ANKPFMFFIQ EESTRQTLFT GRVSDPALVD  
451 GAFKA 
 
 
Prophenoloxidase-activating proteinase-3 
 
1   MANLVYVLLL ASYFCFVSGQ SCTTPNNGKG TCKSIYECEE LLKLVYKKDR  
51  TQQDTDYLKK SQCGFMGNTP TVCCPNPCIT PQGEPGQCVS IYECTNLANL  
101 LKPPITADTY NYVQKSRCQG ADQYSVCCGS APNFPSSGDC KASVSAFPPD  
151 PKSKCCGVDS RVGNKIIGGN ATDVDQYPWL TIIEYVKTGP IKLLCGGVLI  
201 SGKYVLTAGH CLTGPVLQIG TPTNVRLGEY NTKNDGADCV TVEAGGMDCT  
251 EGAVIVPIEK TIPHPEYNPI SRTRRNDIGL IRLKEMAPFT DFIRPICLPS  
301 LDLTQAPPVN FTLYAAGWGA VSTSQPSSNV KLHVQLPFIS YERCQPSYAV  
351 QNRQIELWEK QVCAGGEAGK DSCKGDSGGP LMFENGQTYE VIGIVSFGPT  
401 PCGMQDIPGV YTKVHSYKDW IISNIKP 
 
Figure 3-10. Complex spot 39 contains serpin-3 and prophenoloxidase-activating 
proteinase-3. 
Sequence coverage of serpin-3 and prophenoloxidase-activating proteinase-3 from spot 39 
(Figure 3-4A). Tryptic peptides identified by mass spectrometry are shown in red letters. The P1 
residue of serpin-3a is bold and underlined and the activation site of prophenoloxidase-activating 
proteinase-3 is highlighted in cyan. Signal peptides for both proteins are italicized. 
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Figure 3-11. Analysis of recombinant HP8-Xa. 
A mutant (named HP8-Xa) at the putative activation site of HP8 with residues NNDR
90
 changed 
to IEAR
90
 by site directed mutagenesis was expressed in S2 cells and purified (An et al., 2009; 
An et al., 2010b). For each purification step, 100 ng of total protein was mixed with sample 
buffer containing β-mercaptoethanol and separated by SDS-PAGE (4-12% Bis-Tris gel), 
followed by silver staining (left) and immunoblotting with HP8 antibody (right). Media post-
dialysis (lane 1), after Affi-gel Blue Gel (lane 2), after ConA sepharose and dialysis (lane 3), 
after Q sepharose (lane 4), after gel permeation chromatography (lane 5). 
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Figure 3-12. Active HP8 in plasma forms a complex with serpin-3. 
Samples of plasma pooled from 7 (#1) or 6 naïve larvae (#2) were incubated with or without 
recombinant serpin-3 (final concentration = 0.1 µg/µL) in buffer (20 mM Tris-HCl, 250 mM 
NaCl, pH 8.0) containing diethyldithiocarbamic acid (final concentration = 2.25 mg/mL) for 5 
min, followed by incubation with filter-sterilized water or curdlan (20 µg) for 1 h at room 
temperature. An equivalent of 1 µL of plasma loaded in each lane was subjected to SDS-PAGE 
under reducing conditions followed by immunoblot analysis with HP8 antibody (OSU 3; 1:2000 
dilution). The bands of proHP8 (zymogen), catalytic domain, and putative serpin complexes are 
indicated by solid arrows. 
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Figure 3-13. Recombinant HP8-Xa and serpin-3 form a complex in vitro. 
Recombinant proHP8-Xa (50 ng=1.3 pmol) was incubated with bovine factor Xa (100 ng) and 
0.05% Tween-20 (final concentration = 0.005%) in 20 mM Tris-HCl, 150 mM NaCl, pH 8.0 for 
23.5 h at 37 °C. Recombinant serpin-3 (636.3 ng=13 pmol) was added to the activated mixture 
and incubated for 10 min at room temperature. Mixtures were subjected to SDS-PAGE under 
reducing conditions followed by immunoblot analysis with serpin-3 (KSU 114) and HP8 (OSU 
3) antibodies.  
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Figure 3-14. Production of antimicrobial peptides is not inhibited by injection of serpin-3. 
Antimicrobial activity of plasma assayed against E. coli. (A) Plasma from larvae injected with 
BSA (200 µg in 200 µL) or serpin-3 (200 µg in 200 µL) followed by filter sterilized water (50 
µL) or M. luteus (100 ng in 50 µL). (B) Plasma from larvae injected with BSA (200 µg in 200 
µL) or serpin-3 (200 µg in 200 µL) followed by filter sterilized water (50 µL) or M. luteus (3000 
ng in 50 µL). Larvae were held at room temperature for 25 min and placed on ice for 5 min 
before the second injection. In panels A and B, the positive control was plasma injected with M. 
luteus (100 µg) only. (C) Non-heated plasma samples from larvae described in panel A after 2 h 
of incubation at 37°C. The bars represent mean ± SD (n = 9 (A); n = 6 (B)). Bars labeled with 
different letters are significantly different (Analysis of Variance and Newman-Keuls test, p < 
0.05).  
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Tables 
Table 3-1. NCBInr database identification of plasma proteins that bound to a serpin-3 antibody-coupled immunoaffinity 
column separated by 1D gel electrophoresis. 
Bands as marked in Figure 3-3. List of top Mascot PMF hits from the NCBInr database for bands identified as M. sexta protein. 
Mascot scores are for the entire protein sequences, CI% is the confidence interval. Sequence coverages are based on the entire 
sequence in the database. MS/MS results listed in more detail in Table B-1. 
Band Protein name GenInfo 
identifier 
Protein 
score 
Protein score 
C.I.% 
Peptide 
count 
Total ion 
score 
Total ion score 
C.I.% 
% sequence 
coverage 
1 apolipophorin-1 gi|2498144 178 100 38 21 0 12 
2 serpin-3a gi|27733415 857 100 21 678 100 54 
2 PAP-3 gi|60299972 164 100 8 130 100 19 
3 serpin-3a gi|27733415 594 100 18 460 100 45 
3 proPO-p2 gi|75038472 199 100 18 105 100 25 
3 proPO-p1 gi|74763772 85 97.0 12 29 0 17 
4 serpin-3a gi|27733415 1240 100 26 981 100 65 
5 serpin-3a gi|27733415 1050 100 22 841 100 54 
6 immulectin-2 gi|237869126 351 100 11 285 100 44 
6 immulectin-2a  gi|224381229 330 100 11 262 100 44 
6 SPH-1 gi|242351233 59 0 6 42 5.2 12 
7 immulectin-3 gi|55139125 626 100 15 489 100 70 
7 immulectin-4  gi|237861314 76 73.9 7 44 50.3 18 
7 immulectin-III  gi|110649250 68 0 7 44 50.3 19 
8 attacin-1 gi|67906420 423 100 14 286 100 54 
9 attacin-II gi|110649242 163 100 10 59 97.6 55 
9 dVG-AP3-2 
(gloverin) 
gi|110649228 112 99.9 7 29 0 57 
PAP-3 = prophenoloxidase-activating proteinase-3; proPO-p2 = prophenoloxidase subunit 2; proPO-p1 = prophenoloxidase subunit 1; SPH-1 = serine proteinase homolog-1 
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Table 3-2. ESI-MS/MS results using Mascot and NCBI database restricted to Manduca 
sexta for plasma proteins that bound to a serpin-3 antibody-coupled immunoaffinity 
column separated by 2D-PAGE. 
List of top Mascot hits for spots marked in Figure 3-4A. Percent sequence coverage values in 
parentheses are calculated by using the residues in the catalytic domain of the proteinase only. 
Protein scores (sum of ion scores) > 22 indicate significant identity (p < 0.05). MS/MS results 
listed in more detail in Table B-2. 
Spot Protein name GenInfo 
identifier 
Protein MW Protein score Peptide count % sequence 
coverage 
1 serpin 3a  gi|27733415 51096 1311 19 45.7 
 
HP8 gi|56418397 40710 122 2 6.7 (9.7) 
2 serpin 3a  gi|27733415 51096 1390 22 54.1 
 
PAP-3 gi|35277829 46240 119 2 4.7 (7.3) 
3 serpin 3a  gi|27733415 51096 1459 22 52.5 
 
immulectin-2b  gi|224381231 37069 190 4 11.9 
 
PAP-3 gi|35277829 46240 180 4 9.6 (15.3) 
4 serpin 3a  gi|27733415 51096 1462 23 52.7 
 
immulectin-2b  gi|224381231 37069 249 6 19.6 
 
PAP-3 gi|35277829 46240 200 5 10.5 (17.2) 
 
immulectin-2a  gi|224381229 37179 171 5 15.3 
5 serpin 3a  gi|27733415 51096 1495 23 56 
 
PAP-1 gi|60299968 42785 356 6 13.3 (19.9) 
6 proPO-p2 gi|75038472 80010 1297 22 31.9 
 
serpin 3a gi|27733415 51096 401 5 15.2 
7 proPO-p1 gi|74763772 78915 1270 23 34 
8 proPO-p1 gi|74763772 78915 1232 24 32.7 
9 proPO-p1 gi|74763772 78915 864 15 27.6 
10 proPO-p2 gi|75038472 80010 809 14 22.4 
 
serpin 3a gi|27733415 51096 551 9 26.2 
11 proPO-p2 gi|75038472 80010 781 13 21.9 
 
serpin 3a  gi|27733415 51096 104 2 8.1 
12 proPO-p2 gi|75038472 80010 890 16 24.9 
13 serpin 3a  gi|27733415 51096 607 10 24.6 
 
proPO-p2 gi|75038472 80010 239 5 8.3 
14 serpin 3a  gi|27733415 51096 870 14 37.4 
 
proPO-p2 gi|75038472 80010 260 5 7.3 
15 serpin 3a  gi|27733415 51096 715 12 35.8 
16 serpin 3a  gi|27733415 51096 1489 22 46.8 
17 serpin 3a  gi|27733415 51096 1491 23 53.8 
 
GNBP-like 
protein  
gi|315142915 53653 323 7 12.7 
18 serpin 3a  gi|27733415 51096 229 4 13.2 
19 serpin 3a  gi|27733415 51096 179 4 7.5 
20 beta-1-tubulin gi|12585365 50198 169 3 8.1 
 
SPH-1b  gi|242351233 45594 114 4 8.2 
21 SPH-1b gi|242351233 45594 252 6 12 
22 serpin 3a  gi|27733415 51096 1212 19 36.7 
 
SPH-1b  gi|242351233 45594 147 5 9.6 
23 serpin 3a gi|27733415 51096 1329 21 43.7 
24 serpin 3a gi|27733415 51096 1380 21 42 
25 serpin 3a gi|27733415 51096 1110 17 34.3 
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Spot Protein name GenInfo 
identifier 
Protein MW Protein score Peptide count % sequence 
coverage 
26 serpin 3a gi|27733415 51096 1244 19 38.7 
27 serpin 3a gi|27733415 51096 1087 17 36.7 
 
SPH-1b  gi|242351233 45594 104 3 6.7 
28 serpin 3a gi|27733415 51096 954 15 33.6 
 
SPH-4 gi|56418466 43122 156 5 6.7 
29 serpin 3a  gi|27733415 51096 1204 19 40.9 
 
SPH-4  gi|56418466 43122 160 5 6.7 
30 serpin 3a gi|27733415 51096 899 15 32.1 
 
proPO-p2 gi|75038472 80010 120 2 2.9 
 
serpin-4a  gi|45594224 46452 102 2 4.7 
 
SPH-1b gi|242351233 45594 74 2 4.6 
 
SPH-4  gi|56418466 43122 56 2 4.6 
31 serpin 3a  gi|27733415 51096 286 6 13 
32 serpin 3a  gi|27733415 51096 317 7 14.3 
33 SPH-2  gi|21630233 43461 414 9 17.8 
34 SPH-2  gi|21630233 43461 457 10 20.4 
35 SPH-4  gi|56418466 43122 254 6 11.1 
36 serpin 3a  gi|27733415 51096 176 4 8.8 
37 serpin 3a  gi|27733415 51096 935 16 33.4 
38 serpin 3a  gi|27733415 51096 1291 21 46.2 
39 serpin 3a  gi|27733415 51096 873 15 28.8 
 
PAP-3 gi|35277829 46240 79 2 4.4 (7.3) 
41 PRSP (HP14) gi|39655053 73623 100 3 3.8 
43 serpin 3a  gi|27733415 51096 476 8 19.6 
51 proPO-p2 gi|75038472 80010 140 3 4.2 
 
serpin 3a  gi|27733415 51096 119 2 4.6 
52 serpin 3a  gi|27733415 51096 589 10 22.2 
54 immulectin-2b  gi|224381231 37069 432 7 22.9 
 
immulectin-2a  gi|224381229 37179 377 6 19.9 
55 immulectin-2b  gi|224381231 37069 452 7 27.8 
56 immulectin-2b  gi|224381231 37069 211 5 19.6 
 
immulectin-2a  gi|224381229 37069 211 5 19.6 
 
SPH-1b  gi|242351233 45594 204 4 7 
 
immulectin III  gi|110649250 34789 80 2 4.6 
57 immulectin-4 gi|237861314 35559 279 5 15.4 
 
immulectin III gi|110649250 34789 277 4 11.1 
 
immulectin-2b gi|224381231 37069 114 3 10.4 
 
dVA-AP7  gi|110649220 16486 106 2 14 
58 immulectin-3  gi|55139125 33846 139 3 10.6 
59 immulectin III  gi|110649250 34789 210 4 11.1 
 
immulectin-2a gi|224381229 37179 141 3 10.4 
 
immulectin-2b  gi|224381231 37069 131 3 10.4 
60 immulectin-2b  gi|224381231 37069 168 4 13.8 
61 PAP-1 gi|60299968 42785 182 2 5.7 
 
immulectin-3 gi|55139125 33846 65 2 6.1 
66 attacin-1  gi|67906420 24232 96 3 13.8 
67 immulectin-2b  gi|224381231 37069 215 5 16.2 
 
attacin-1  gi|67906420 24232 147 3 17.8 
68 attacin-1  gi|67906420 24232 406 8 34.2 
*Spots are listed in sequential order. Gaps between numbers indicate that no M. sexta protein was identified in those 
spots (data also excluded from Figure 3-4A). 
HP = hemolymph proteinase; PAP = prophenoloxidase-activating proteinase; proPO = prophenoloxidase;  
GNBP = gram-negative binding protein; SPH = serine proteinase homolog; PRSP = pattern recognition serine 
proteinase 
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Table 3-3. ESI-MS/MS results using Mascot and NCBI database restricted to Manduca 
sexta for plasma proteins that bound to a control column of Protein-A Sepharose CL-4B 
beads without antibody separated by 2D-PAGE. 
List of top Mascot hits for spots marked in Figure 3-4B. Protein scores (sum of ion scores) > 22 
indicate significant identity (p < 0.05). MS/MS results listed in more detail in Table B-3. 
Spot Protein name GenInfo 
identifier 
Protein MW Protein score Peptide count % sequence 
coverage 
1c immulectin-2b  gi|224381231 37069 377 7 22.9 
2c immulectin-2b  gi|224381231 37069 265 5 17.7 
3c immulectin-2b  gi|224381231 37069 296 6 19 
4c immulectin-2b  gi|224381231 37069 87 2 6.1 
5c immulectin-2b  gi|224381231 37069 201 4 15 
6c immulectin-2b  gi|224381231 37069 85 2 6.7 
7c no match 
     8c no match 
     9c serpin-1 gi|134436 43483 50 1 3.3 
10c endochitinase gi|544013 62164 163 4 7.4 
11c proPO-p2 gi|75038472 80010 300 5 7.6 
12c immulectin-2b  gi|224381231 37069 231 4 18.7 
13c immulectin-2b  gi|224381231 37069 84 2 6.7 
 
immulectin III gi|110649250 34789 66 2 6.5 
 
immulectin-3  gi|55139125 33846 25 1 3.9 
14c immulectin-3  gi|55139125 33846 55 2 6.1 
 
immulectin-2b  gi|224381231 37069 42 1 3.1 
15c immulectin-2b  gi|224381231 37069 221 5 18.7 
16c immulectin-2b  gi|224381231 37069 86 2 6.7 
17c immulectin-2b  gi|224381231 37069 182 4 13.8 
 
scolexin A  gi|4262357 30353 47 1 3.2 
18c immulectin-3  gi|55139125 33846 24 1 2.3 
19c proPO-p2 gi|75038472 80010 38 1 1 
 
immulectin-3  gi|55139125 33846 31 1 2.3 
20c immulectin-3  gi|55139125 33846 36 1 2.3 
21c immulectin-3  gi|55139125 33846 27 1 2.3 
22c SPH-2 gi|21630233 43461 102 3 8.5 
23c immulectin-2b  gi|224381231 37069 190 4 13.8 
 
immulectin-3  gi|55139125 33846 31 1 2.3 
24c immulectin-3  gi|55139125 33846 27 1 2.3 
25c immulectin-2b  gi|224381231 37069 119 2 9.8 
 
immulectin-3  gi|55139125 33846 75 2 6.1 
26c immulectin-2b  gi|224381231 37069 172 4 13.8 
 
immulectin III  gi|110649250 34789 94 2 6.5 
 
immulectin-3 gi|55139125 33846 64 2 6.1 
27c immulectin-2b  gi|224381231 37069 424 7 27.8 
28c immulectin-2b  gi|224381231 37069 250 5 17.4 
 
SPH-1b gi|242351233 45594 99 3 10.3 
29c immulectin III  gi|110649250 34789 219 4 11.1 
 
immulectin-4  gi|237861314 35559 201 4 11 
 
immulectin-3 gi|55139125 33846 27 1 3.9 
30c immulectin-3 gi|55139125 33846 69 2 6.1 
 proPO = prophenoloxidase; SPH = serine proteinase homolog
 151 
 
Table 3-4. EST database identification of plasma proteins bound to a serpin-3 antibody-coupled immunoaffinity column 
separated by 2D-PAGE. 
The Mascot program was used to search ESI-MS/MS data against compiled M. sexta ESTs from NCBI and a pyrosequencing EST 
project (Haobo Jiang). Identification of the ESTs is based on BLAST searches against the NCBI database (tblastx = no highlight, 
nucleotide collection; blastn = light purple highlight, non-mouse and non-human EST entries).  
Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
1 serpin-3a/3b contig09983 1309 14 37.2 
 
 
HP8 contig00781 122 1 7.4 
 
 
HP8 contig10728 90 1 9.2 
 
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(Bombyx mori)           
2 serpin-3a/3b contig09983 1386 17 44 
 
 
PAP-3 contig00625 93 1 2.8 
 
 
HP8 contig10728 53 1 6.5 
 
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
3 serpin-3a/3b contig09983 1453 18 42.8 
 
 
immulectin-2 contig00874 190 3 9.5 
 
 
PAP-3 contig00625 178 1 6.1 
 4 serpin-3a/3b contig09983 1458 20 42.9 
 
 
immulectin-2 contig00874 249 2 15.6 
 
 
PAP-3 contig00625 198 1 6.7 
 5 serpin-3a/3b contig09983 1491 18 45.6 
 
 
PAP-1 contig00173 355 4 10.3 
 
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
6 proPO gi|119434460 402 5 26.3 
 
 
serpin-3a/3b contig09983 401 5 12.3 
 
 
proPO contig21993 175 1 51.1 
 
 
proPO contig20740 159 1 29.2 
 
 
proPO contig24654 142 2 28.4 
 
 
proPO contig19763 109 1 36.6 
 
 
proPO gi|119434509 56 1 4.3 
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       Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
7 proPO-p1 contig21092 149 1 41.3 
 
 
proPO-p1 contig09675 139 2 34.3 
 
 
proPO-p1 contig20765 124 1 50 
 
 
proPO-p1 contig19861 122 2 30.2 
 
 
proPO-p1 contig18477 99 1 16.3 
 
 
proPO-p1 contig18610 65 1 24.3 
 
 
proPO-p1 contig19396 62 1 34.3 
 
 
unknown protein contig00018 57 1 10.8 gi|188459103 
 
(Antheraea assama)           
8 proPO-p1 contig20765 126 1 50 
 
 
proPO-p1 contig09675 115 1 34.3 
 
 
proPO-p1 contig19861 113 2 30.2 
 
 
proPO-p1 contig21092 109 1 41.3 
 
 
proPO-p1 contig18477 100 2 16.3 
 
 
proPO-p1 contig18610 66 1 24.3 
 
 
proPO-p1 contig19396 64 1 34.3 
 
 
proPO contig05761 58 1 2.8 
 9 proPO-p1 contig20765 126 1 50 
 
 
proPO-p1 contig19861 99 1 30.2 
 
 
proPO-p1 contig09675 98 1 34.3 
 
 
proPO-p1 contig19396 70 1 34.3 
 
 
proPO-p1 contig18610 59 1 24.3 
 
 
proPO-p1 contig18610 59 1 24.3 
 
 
proPO-p1 contig21092 58 1 41.3 
 
 
proPO-p1 contig18477 57 1 9.2 
 10 serpin-3a/3b contig09983 549 8 21.3 
 
 
proPO gi|119434460 367 3 25.9 
 
 
unknown protein contig10237 111 1 6.7 gi|91833685 
 
(B. mori)           
 
unknown protein contig10239 91 1 11.1 gi|189551604 
 
(Antheraea assama)           
 
proPO contig19763 87 1 36.6 
 
 
proPO contig19763 87 1 36.6 
 
 
proPO contig20740 68 1 11.5 
 
 
proPO gi|119434509 57 1 4.3 
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Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
11 proPO gi|119434460 329 3 25.9 
 
 unknown protein contig10239 150 2 20 gi|189551604 
 
(Antheraea assama)           
 serpin-3a/3b contig09983 104 1 6.6 
 
 
proPO contig19763 85 1 36.6  
 
proPO contig24654 70 1 15.8 
 
 
proPO contig20740 70 1 11.5 
 
 
proPO contig10922 48 1 5.3 
 12 proPO gi|119434460 282 3 21.5 
 
 
proPO contig19763 113 1 36.6 
 
 
proPO contig20740 97 1 19.2 
 
 
proPO contig21993 84 1 36.2 
 
 
proPO contig24654 68 1 15.8 
 
 
proPO gi|119434509 52 1 4.3 
 13 serpin-3a/3b contig09983 605 7 20 
 
 
proPO gi|119434460 156 2 14.9 
 
 
immulectin-3 contig18028 107 1 14.3 
 
 
PAP-1 contig00173 93 1 2.8 
 
 
unknown protein contig10840 83 1 2.6 gi|282377349 
 
(Choristoneura fumiferana)           
14 serpin-3a/3b contig09983 868 11 30.4 
 
 
proPO gi|119434460 216 2 18 
 
 
PAP-1 contig00173 98 1 2.8 
 15 serpin-3a/3b contig09983 713 9 29.2 
 
 
unknown protein contig11562 223 1 19.4 gi|167500278 
 
(Raphanus raphanistrum)           
 
unknown protein contig14828 141 1 9.9 gi|255978320 
 
(Manduca sexta)           
 
immulectin-2 contig00874 52 1 2.4 
 
 
ubiquitin/ribosomal  protein 
S27A 
contig15324 51 1 5.3 
 16 serpin-3a/3b contig09983 1485 16 38.1 
 
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
17 serpin-3a/3b contig09983 1485 18 43.8 
 
 
GNBP-like protein contig06029 323 3 12.5 
 18 serpin-3a/3b contig09983 227 4 10.7 
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       Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
19 alpha tubulin contig09663 222 2 8.9 gi|112983500 
 
(B. mori) 
     
 
serpin-3a/3b contig09983 179 1 6.1 
 
 
alpha tubulin gi|3827974 152 2 18 gi|3827974 
 
(M. sexta)           
 
unknown protein gi|255980816 118 1 14.1 gi|255980816 
 
(M. sexta)           
 
SPH-1b contig00488 59 1 2.5 
 20 beta-1 tubulin gi|10763921 134 2 10.6 
 21 SPH-1b contig00488 252 1 9.5 
 
 
beta-1 tubulin contig10459 59 1 5.9 
 22 serpin-3a/3b contig09983 1208 14 29.9 
 
 
serpin-3a/3b gi|14860734 320 3 28.2 
 
 
eukaryotic initiation  contig00160 78 1 2.3 gi|10763918 
 
factor-4a (M. sexta)           
23 serpin-3a/3b contig09983 1325 16 35.6 
 
 
serpin-3a/3b gi|14860734 390 4 31.3 
 
 
hypothetical protein contig15079 62 1 0.8 gi|282363237 
 
(Choristoneura fumiferana)           
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
24 serpin-3a/3b contig09983 1376 17 34.2 
 
 
serpin-3a/3b gi|14860734 486 5 37.4 
 25 serpin-3a/3b contig09983 1106 13 27.9 
 
 
SPH-1b contig00488 63 1 2.5 
 26 serpin-3a/3b contig09983 1240 16 31.5 
 
 
eukaryotic initiation  contig00160 80 1 2.3 gi|10763918 
 
factor-4a (M. sexta)           
27 serpin-3a/3b contig09983 1083 15 29.9 
 
 
serpin-3a/3b gi|14860734 247 3 27.6 
 
 
SPH-1b contig00488 104 1 5.3 
 
 
proPO gi|119434509 65 1 4.3 
 28 serpin-3a/3b contig09983 950 12 27.4 
 29 serpin-3a/3b contig09983 1200 14 33.3 
 
 
proPO contig19763 51 1 14.1 
 
       
 155 
Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
29 unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
30 serpin-3a/3b contig09983 895 11 26.1 
 
 serpin-4a/4b contig07207 74 1 1.3 
 
 
proPO contig19763 67 1 14.1  
 proPO contig19763 67 1 14.1  
 
unknown protein contig01320 63 1 3.1 gi|29533080 
 
(B. mori)           
 
proPO gi|119434509 53 1 4.3 
 31 serpin-3a/3b contig09983 286 4 10.6 
 32 inter-alpha trypsin contig10831 445 4 10.4 gi|14860668 
 
inhibitor (M. sexta)           
 
serpin-3a/3b contig09983 315 2 11.6 
 33 SPH-2 contig09999 412 3 13.6 
 34 SPH-2 contig09999 455 3 15.5 
 35 SPH-4 contig09788 254 1 7.7 
 36 serpin-3a/3b contig09983 176 1 7.2 
 37 serpin-3a/3b contig09983 931 10 27.2 
 
 
unknown protein contig15549 55 1 2.5 gi|119435450 
 
(M. sexta)           
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
38 serpin-3a/3b contig09983 1285 16 37.6 
 
 
unknown protein contig15549 51 1 2.5 gi|119435450 
 
(M. sexta)           
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
39 serpin-3a/3b contig09983 869 11 23.4 
 
 
unknown protein contig02455 57 1 2.8 gi|295265638 
 
(Spodoptera frugiperda)           
 
no BLAST hit contig19330 57 1 12.9 
 
 
unknown protein contig15549 51 1 2.5 gi|119435450 
 
(M. sexta)           
43 serpin-3a/3b contig09983 453 5 14.5 
 
 
unknown protein contig01320 50 1 3.1 gi|29533080 
 
(B. mori)           
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Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
46 unknown protein contig15297 165 2 7.9 gi|285007385 
 
(M. sexta)           
 
unknown protein contig18435 131 1 16 gi|285007385 
 
(M. sexta)           
51 proPO gi|119434460 142 1 12.7  
 
serpin-3a/3b contig09983 117 2 3.8  
 
Kazal family serine contig14641 47 1 2.1 gi|14860836 
 
proteinase inhibitor           
 
(M. sexta)           
52 serpin-3a/3b contig09983 587 8 18.1 
 
 
unknown protein contig01320 63 1 3.1 gi|29533080 
 
(B. mori)           
 
PRSP (HP14) contig10343 60 1 3.2 
 
 
unknown protein contig15549 56 1 2.5 gi|119435450 
 
(M. sexta)           
54 immulectin-2 contig00874 432 7 18.3 
 
 
PAP-3 contig00625 51 1 1.3 
 55 immulectin-2 contig00874 452 7 22.2 
 56 immulectin-3 contig13019 218 3 22.2 
 
 
immulectin-2 contig00874 211 2 15.6 
 
 
SPH-1b contig00488 204 2 5.5 
 
 
immulectin-4 gi|14863326 80 1 14.3 
 57 immulectin-4 contig14268 382 3 18.3 
 
 
immulectin-3 contig18028 131 2 14.3 
 
 
immulectin-3 contig12030 55 1 6.1 
 58 immulectin-3 contig10887 139 1 5.3 
 
 
immulectin-3 contig12425 84 1 11.1 
 59 immulectin-4 contig14268 207 2 9 
 
 
immulectin-3 contig18028 131 2 14.3 
 60 immulectin-2 contig00874 168 1 11 
 
 
immulectin-3 contig18028 146 2 14.3 
 61 PAP-1 contig00173 182 2 4.4 
 
 
immulectin-3 contig12425 65 1 11.1 
 62 immulectin-3 contig13019 67 1 7.9 
 63 immulectin-3 contig13019 48 1 7.9 
 66 attacin-1 contig00567 155 1 17.5 
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Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
66 ferritin heavy chain-
like protein  
contig11084 75 1 2.2 
 
67 immulectin-2 contig00874 215 2 13  
 
attacin-1 gi|14860782 147 2 22  
68 attacin-1 gi|14860782 275 3 24.7 
 
 
attacin-1 contig00567 257 3 22 
 
 
attacin-1 contig12089 195 2 59.8 
 68 attacin-2 contig14717 132 2 19.3 
 
 
attacin-1 contig11045 131 1 37.2 
 
 
attacin-1 contig10503 121 1 37.1 
 
 
attacin-1 contig17095 119 1 64 
 a: Sum of individual ion scores excluding duplicate matches. Scores > 46 indicate significant identity (p < 0.05) 
b: GenInfo identifier of protein identifications made by BLAST searching non-mouse and non-human EST entries in NCBI or the nucleotide 
collection database (for alpha tubulin from B. mori in spot 19 only). 
 
HP = hemolymph proteinase; PAP = prophenoloxidase-activating proteinase; proPO = prophenoloxidase; GNBP = gram-negative binding protein; 
SPH = serine proteinase homolog; PRSP = pattern recognition serine proteinase 
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Table 3-5. EST database identification of plasma proteins that bound to a control column of Protein-A Sepharose CL-4B 
beads without antibody separated by 2D-PAGE. 
The Mascot program was used to search ESI-MS/MS data against compiled M. sexta ESTs from NCBI and a pyrosequencing EST 
project (Haobo Jiang). Identification of the ESTs is based on BLAST searches against the NCBI database (tblastx = no highlight, 
nucleotide collection; blastn = light purple highlight, non-mouse and non-human EST entries).  
Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
1c immulectin-2 contig00874 377 4 18.3 
 2c immulectin-2 contig00874 265 4 14.2 
 3c immulectin-2 contig00874 296 3 15.2 
 4c immulectin-2 contig00874 87 1 4.9 
 5c immulectin-2 contig00874 201 2 12 
 
 
unknown protein contig06962 48 1 0.7 gi|300744602 
 
(Spodoptera littoralis)           
6c unknown protein contig19852 126 1 16.3 gi|68276617 
 
(Caenorhabditis remanei)           
 
immulectin-2 contig00874 85 1 5.4 
 
 
zinc finger protein contig20460 50 1 8.2 gi|7795340 
 
(Glycine max)           
7c 
 
no EST hit 
    8c 
 
no EST hit 
    9c serpin-1 contig10071 50 1 3.5 
 10c 
 
no EST hit 
    11c proPO gi|119434460 195 2 13.2 
 
 
proPO contig19763 62 1 14.1 
 12c immulectin-2 contig00874 231 4 14.9 
 13c immulectin-2 contig00874 84 1 5.4 
 14c 
 
no EST hit 
    15c immulectin-2 contig00874 221 1 14.9 
 16c 
 
no EST hit 
    17c immulectin-2 contig00874 182 2 11 
 18c immulectin-3 contig18028 51 1 6.4 
 19c 
 
no EST hit 
    20c 
 
no EST hit 
    21c 
 
no EST hit 
    22c 
 
no EST hit 
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       Spot Protein name Contig/GenInfo identifier Protein score
a
 Peptide count % sequence coverage Other
b
 
23c immulectin-2 contig00874 190 2 11 
 24c immulectin-3 contig18028 55 1 6.4 
 25c immulectin-2 contig00874 119 2 7.8 
 26c immulectin-2 contig00874 172 2 11 
 
 
immulectin-3 contig18028 117 1 14.3 
 
 
immulectin-4 contig14268 94 1 5.3 
 27c immulectin-2 contig00874 424 7 22.2 
 28c immulectin-3 contig13019 330 4 24.1 
 
 
immulectin-2 contig00874 250 3 13.9 
 29c immulectin-4 contig14268 238 3 12.2 
 
 
immulectin-3 contig18028 134 2 14.3 
 30c immulectin-3 contig13019 61 1 7.9 
 a: Sum of individual ion scores excluding duplicate matches. Scores > 46 indicate significant identity (p < 0.05) 
b: GenInfo identifier of protein identifications made by BLAST searching non-mouse and non-human EST entries in NCBI. 
proPO = prophenoloxidase 
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Appendix A - HP16: Unexpected Results from a Hypothesis Tested  
Prophenoloxidase Activation by HP16 and NT16 
Upon invasion by bacteria or other pathogens, the activation of two proteinase cascades 
(prophenoloxidase or Toll) can be stimulated. Hemolymph proteinase 16 protein and mRNA 
levels increased upon injection of larvae with M. luteus or E.coli, which suggested that HP16 
might be involved in the activation of one or both of these pathways. I hypothesized that HP16 
might be a component of a proteinase cascade involved in prophenoloxidase activation, and I 
tested this hypothesis by conducting a prophenoloxidase activation assay. 
Materials and methods 
To prepare a plasma sample suitable to test for prophenoloxidase activation, thirty day 2 
fifth instar larvae (naïve) were checked for low basal levels of PO activity that dramatically 
increased after incubation with M. luteus as described by Tong and Kanost (2005), with 
modification. Larvae were chilled on ice for at least 20 min and wiped off with 70% ethanol. 
Hemolymph was collected on ice into individual 1.5 mL microcentrifuge tubes by clipping the 
posterior horn. Tubes were centrifuged at 8,000 × g for 7.5 min at 4°C to remove hemocytes and 
the resulting plasma was placed into a new 1.5 mL microcentrifuge tubes. All plasma was frozen 
at -80°C except for a 15 µL aliquot to be tested for PO activity. Plasma (4 µL) was incubated in 
0.6 mL microcentrifuge tubes with Nuclease free water (2 µL) or M. luteus (2 µL of 1 µg/µL) for 
10 min at room temperature and then transferred to a 96-well plate. PO activity was measured by 
adding 200 µL of 2 mM dopamine in 50 mM sodium phosphate buffer, pH 6.5 and monitoring 
absorbance at 470 nm for 15 min in a PowerWave XS plate reader (BioTek). One unit of PO 
activity was defined as a change in A470 of 0.001/min. Plasma samples with low endogenous PO 
activity, but high PO activity after incubation with M. luteus were pooled and stored at -80°C. 
When necessary, purified recombinant HP16-Xa (100 ng) was incubated in the presence 
of  100 ng bovine factor Xa (New England Biolabs) in buffer (20 mM Tris-HCl, 150 mM NaCl, 
pH 8.4) plus CaCl2 (final concentration = 2 mM) for 4 h at 25°C. Details of the reaction mixtures 
are provided in the figure and corresponding figure legend (Figures A-1). After incubation for 10 
min at room temperature, PO activity was measured by adding 200 µL of 2 mM dopamine in 50 
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mM sodium phosphate buffer, pH 6.5 and monitoring absorbance at 470 nm for 30 min in a 
PowerWave XS plate reader (BioTek). One unit of PO activity was defined as a change in A470 
of 0.001/min. 
Results and conclusions 
The addition of HP16-Xa activated by bovine factor Xa abolished PO activity in the 
presence of M. luteus, while addition of proHP16-Xa or factor Xa had no impact when compared 
to plasma mixed with M. luteus (Figure A-1A). To see if I could explain what looked like 
inhibition of PO activity or activation, I tested the effect of salt concentration on PO activity 
because samples containing active HP16-Xa had a higher salt concentration (37 mM NaCl) than 
controls (17, 14.4, 27.4, and 14.4 mM NaCl). It is obvious that the gel filtration buffer (20 mM 
Tris-HCl, 150 mM NaCl, pH 8.0) used in the activation mixture of HP16-Xa resulted in low 
levels of PO activity (Figure A-1B). NaCl concentrations were 10, 49, and 53 mM, respectively. 
Morever, PO activity decreased with increasing NaCl concentration (Figure A-1C). PO activity 
decreased by ~50% with the addition of 20 mM NaCl and ~83% with the addition of 27 mM 
NaCl. Therefore, I concluded that the NaCl concentration of the gel filtration buffer was 
responsible for the inhibition of PO activation and PAP-3 activation (data not shown), not HP16-
Xa activated by bovine factor Xa. 
I also tested the effect of NT16 on prophenoloxidase activation (Figure A-2) in the 
presence of M. luteus or zymosan. Plasma mixed with NT16 alone or plasma incubated with M. 
luteus in the presence or absence of NT16 did not increase PO activity when compared to plasma 
alone. Using zymosan as an elicitor instead of M. luteus produced high levels of PO activity in 
the presence or absence of NT16. Therefore, I concluded that zymosan is a good elicitor of PO 
activity and that NT16 does not impact prophenoloxidase activation in plasma. 
References 
Tong Y, Jiang H, & Kanost MR (2005) Identification of plasma proteases inhibited by Manduca 
sexta serpin-4 and serpin-5 and their association with components of the prophenol oxidase 
activation pathway. J Biol Chem 280: 14932-14942  
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Figures 
 
 
 
Figure A-1. Involvement of HP16 in prophenoloxidase activation. 
A) Samples of plasma (3 µL) were mixed with buffer (20 mM Tris-HCl, 20 mM NaCl, 6.7 mM 
CaCl2, pH 7.5), M. luteus (2 µg), or with M. luteus plus proHP16-Xa (100 ng), factor Xa (100 
ng), or HP16-Xa (100 ng) activated by factor Xa (100 ng). After incubation for 10 min at room 
temperature, PO activity was measured as described under “Materials and methods.” The bars 
represent mean ± SD (n = 2). Bars labeled with different letters are significantly different 
(Analysis of Variance and Newman-Keuls test, p < 0.05).  
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B) Plasma samples (3 µL) were mixed with M. luteus (2 µg), GF buffer (20 mM Tris-HCl, 150 
mM NaCl, pH 8.0), or M. luteus plus GF buffer. Mixtures were incubated and assayed for PO 
activity as described under “Materials and methods.” Buffer = 20 mM Tris-HCl, 20 mM NaCl, 
6.7 mM CaCl2, pH 7.5, GF = gel filtration buffer 
C) Plasma samples (2 µL) were mixed with buffer (20 mM Tris-HCl, 20 mM NaCl, 6.7 mM 
CaCl2, pH 7.5), M. luteus (2 µg) or saline, and different concentrations of NaCl. After incubation 
for 10 min at room temperature, PO activity was measured as described under “Materials and 
methods.” Each point represents mean ± SD (n = 3 for M. luteus; n = 2 for saline). Work 
completed by Dr. Di Wu. 
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Figure A-2. Prophenoloxidase activation assay conducted with NT16. 
Samples of plasma (3 µL) were mixed with buffer (20 mM Tris-HCl, 20 mM NaCl, 6.7 mM 
CaCl2, pH 7.5), M. luteus (2 µg), zymosan (2 µg), NT16 (100 ng), M. luteus plus NT16, or 
zymosan plus NT16. After incubation for 10 min at room temperature, PO activity was measured 
as described under “Materials and methods.” The bars represent mean ± SD (n = 3). Bars labeled 
with different letters are significantly different (Analysis of Variance and Newman-Keuls test, p 
< 0.05). 
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Appendix B - Serpin-3 
Antibacterial Activity Assay 
HP8 cleaves the cytokine precursor proSpätzle to stimulate the production of 
antimicrobial peptides (An et al., 2009), and serpin-1J inhibits HP8 to regulate this process (An 
et al., 2011). In addition, results presented in this dissertation revealed that serpin-3 also forms a 
complex with HP8 (Figures 3-2 and 3-3). Therefore, I tested the hypothesis that serpin-3 might 
be a biologically relevant inhibitor of HP8.  
Materials and methods 
Day 2 fifth instar larvae (8 larvae/treatment) were injected with antiserum to serpin-3 (50 
µL), 0.85% NaCl (saline; 50 µL), or pre-immune serpin-3 serum as a control (50 µL) Larvae 
were held at room temperature for 25 min, placed on ice for 5 min, and then injected with M. 
luteus (100 ng in 50 µL) or filter sterilized water (50 µL). After 24 h, hemolymph was collected 
on ice and centrifuged at 7000 × g for 25 min at 4°C to remove hemocytes. Aliquots (200-300 
µL) of each plasma sample were heated at 95°C for 5 min, followed by centrifugation at 10000 × 
g for 8 min to remove large proteins. Supernatants were placed at -20°C until use.  
An overnight culture (3 mL) of E. coli strain XL1-Blue was started by inoculating a 
single colony from a streak plate into LB without antibiotics. The culture was grown at 37°C 
with shaking at 275 rpm. Fresh LB (3 mL) was inoculated with 60 µL of the overnight culture 
and grown at 37°C with shaking at 275 rpm for 4 h. To create a good bacterial lawn, 50 µL of E. 
coli was added to 20 mL of LB plus 1% agar held at 47°C and poured into a petri dish. Plates 
were held at room temperature for 10 min and then placed at 4°C for 30 min. Wells were made in 
the LB agar plates using a metal tool with a 4 mm diameter opening and removing the agar plug 
with a sterile toothpick. Liquid was removed from each well and 15 µL of each sample to be 
tested was added. Water was used as a negative control and plasma samples from larvae injected 
with M. luteus (100 µg) only were used as a positive control. Plates were placed in a 37°C 
incubator for 19-21 h and were not inverted. The diameter of each zone of inhibition was 
measured three times, averaged, and divided by 2 to obtain the radius. The radius was used to 
calculate the area (A = πr2) of the zone of inhibition (= area of entire circle – area of sample 
well). 
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Results and conclusions 
Injection of serpin-3 antibody was based on the idea that the antibody should inactivate 
serpin-3 protein in the hemolymph, which might result in increased antimicrobial activity due to 
poor regulation of HP8. However, there was no difference in plasma samples from larvae 
injected with serpin-3 antibody or pre-immune serum in anti-E. coli activity (Figure B-1). To test 
whether the serpin-3 antibody recognizes native serpin-3 protein in plasma, I used the 
Ouchterlony method to analyze the interaction of serpin-3 antiserum with recombinant serpin-3 
and serpin-3 in plasma. There was no detectable precipitin line for serpin-3 interaction with 
antibody, even though this antibody binds to denatured serpin-3. This result indicates that this 
antiserum probably does not inactivate serpin-3 and thus, the in vivo experiment with injection of 
serpin-3 antiserum cannot be interpreted. 
Impact of Heparin on the Inhibitory Activity of Serpin-3  
Heparin increases the inhibitory activity of antithrombin against thrombin to regulate the 
blood coagulation cascade in vertebrates (Olson et al., 2010). Upon binding of heparin 
pentasaccharide to antithrombin, antithrombin undergoes a conformational change to expose the 
hinge region of the reactive center loop from β-sheet A, which makes the P1-P1’ site accessible 
for recognition and cleavage by thrombin (Li et al., 2004). Like antithrombin, SPN48 from 
Tenebrio molitor contains a partially inserted reactive center loop, and the addition of full-length 
heparin, but not the pentasaccharide unit of heparin, enhanced the reactivity of SPN48 with 
Spätzle-processing enzyme (Park et al., 2011). Although it is not known if the hinge region of 
serpin-3 is partially inserted into β-sheet A, I designed experiments to investigate the hypothesis 
that the addition of heparin may enhance the inhibitory activity of serpin-3 against PAP-1 and 
PAP-3.  
Materials and methods-PAP-1/PAP-3 
For PAP-1 a molar ratio of 1:1 (0.63 pmol serpin-3/0.63 pmol PAP-1) was used while a 
molar ratio of 0.5:1 (0.77 pmol serpin-3/1.5 pmol PAP-3) was used for PAP-3. Regardless of the 
proteinase under investigation, serpin-3 was incubated with 250 ng of heparin (Sigma H3393-
50KU) in buffer (20 mM Tris-HCl, 250 mM NaCl, pH 8.0) for 10 min at room temperature, 
followed by the addition of bovine serum albumin (2 µg) and PAP-1/PAP-3 and incubation for 
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another 10 min. All mixtures were in a total volume of 11.6 µL for PAP-1 and 22.3 µL for PAP-
3 (adjusted with 20 mM Tris-HCl, 250 mM NaCl, pH 8.0 before incubation). Samples were 
spotted into a 96-well plate and 200 µL of 50 µM IEARpNa in 0.1 M Tris-HCl, 0.1 M NaCl, 5 
mM CaCl2, pH 8.0. Absorbance at 405 nm was measured continuously for 30 min in a 
PowerWave XS plate reader (BioTek). One unit of activity was defined as a change in A405 of 
0.001/min. Percent inhibition was determined using the following formula: [1 – (slope serpin-
3/slope PAP-1/PAP-3 only)]*100 and residual PAP-1 or PAP-3 activity (%) was calculated as 
100 – percent inhibition. 
Results and conclusions 
At a molar ratio of 1:1, serpin-3 inhibited PAP-1 amidase activity by 64-80% which 
resulted in an average residual activity of 28% (Figure B-2A). When serpin-3 was pre-incubated 
with heparin before addition of PAP-1, percent inhibition by serpin-3 was 38-40% and average 
residual PAP-1 activity was 61%. Similar results were obtained when the proteinase was 
changed from PAP-1 to PAP-3 (Figure B-2B). At a molar ratio of 0.5:1, serpin-3 inhibited PAP-
3 amidase activity by 89-94% which resulted in an average residual PAP-3 activity of 8.5%. 
Incubation of serpin-3 with heparin before the addition of PAP-3 resulted in lower levels of 
inhibition by serpin-3 (57-70%) and higher levels of average residual PAP-3 activity (37.5%). 
Although these results suggest that heparin does not increase the efficiency of serpin-3 as an 
inhibitor of PAP-1 or PAP-3, kinetic experiments (e.g. determination of the association rate 
constant with and without heparin) are needed to provide a conclusive answer to the hypothesis 
tested (Huang et al., 2011). 
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Figures 
 
 
 
Figure B-1. Production of antimicrobial peptides is not stimulated by injection of 
antiserum to serpin-3. 
Antimicrobial activity of plasma assayed against E. coli. Plasma from larvae injected with 0.85% 
NaCl (saline; 50 µL), antiserum to serpin-3 (50 µL), or pre-immune serpin-3 serum (50 µL) 
followed by filter sterilized water (50 µL) of M. luteus (100 ng in 50 µL). The positive control 
was plasma injected with M. luteus (100 µg) only. The bars represent mean ± SD (n = 8). Bars 
labeled with different letters are significantly different (Analysis of Variance and Newman-Keuls 
test, p < 0.05). PB = pre-immune serum 
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Figure B-2. Residual PAP-1 and PAP-3 activity in the presence of serpin-3 and heparin. 
Residual PAP-1 (A) or PAP-3 (B) activity was measured with serpin-3 (1:1 or 0.5:1 molar ratio, 
respectively), BSA (2 µg), and with heparin (250 ng). PAP-1 or PAP-3 alone was used as a 
control. Serpin-3 and heparin were incubated for 10 min followed by incubation with PAP-1 or 
PAP-3 for another 10 min. Samples were mixed with 200 µL of 50 µM IEARpNa in 0.1 M Tris-
HCl, 0.1 M NaCl, 5 mM CaCl2, pH 8.0. Absorbance at 405 nm was measured continuously for 
30 min in a PowerWave XS plate reader (BioTek). One unit of activity was defined as a change 
in A405 of 0.001/min. Percent inhibition was determined using the following formula: [1 – (slope 
serpin-3/slope PAP-1/PAP-3 only)]*100 and residual PAP-1 or PAP-3 activity (%) was 
calculated as 100 – percent inhibition. The bars represent mean ± SD (n = 2). Bars labeled with 
different letters are significantly different (Analysis of Variance and Newman-Keuls test, p < 
0.05). 
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Tables 
Table B-1. MS/MS results for immunoaffinity purified proteins identified in Table 3-1. 
Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
1 apolipophorin-1 38 675.3209 675.3332 0.0123 18 2428 2432 AEWNR 
  
   
696.3715 696.3672 -0.0043 -6 2415 2420 AAPYFK 
  
   
749.4192 749.4098 -0.0094 -13 1200 1205 INFDLK 
  
   
758.4155 758.4235 0.008 11 1255 1260 NNLEIR 
  
   
800.4624 800.4606 -0.0018 -2 1121 1127 IDGQVIR 
  
   
907.4631 907.4647 0.0016 2 2421 2427 KVEDNFR 
  
   
917.4686 917.4824 0.0138 15 2407 2414 DVEAVTQR 
  
   
949.5717 949.5607 -0.011 -12 1233 1240 ITFSQILK 
  
   
952.4669 952.4696 0.0027 3 2291 2297 TQQCLFR 
  
   
987.5621 987.5593 -0.0028 -3 3051 3059 VFLVGHTSK 
  
   
999.5945 999.5973 0.0028 3 809 818 LNLIGAATAR 16 0 
   
1037.5626 1037.5737 0.0111 11 1616 1624 NLQSTFSLK 
  
   
1037.5779 1037.5737 -0.0042 -4 3085 3092 YDRIPFVK 
  
   
1126.5851 1126.6042 0.0191 17 1578 1588 RGSGASTISYK 
  
   
1129.6212 1129.6255 0.0043 4 819 828 LDVATNIDIR 
  
   
1160.6058 1160.6061 0.0003 0 829 838 QIFQSPQNAK 
  
   
1192.6361 1192.6287 -0.0074 -6 1347 1356 YELSGFVLHK 
  
   
1215.652 1215.6569 0.0049 4 2204 2214 AVAEIGFFHPK 
  
   
1226.6237 1226.634 0.0103 8 2103 2112 DEVSDRRPPR 
  
   
1243.6178 1243.6294 0.0116 9 1085 1095 LGFSVQGNEHR 
  
   
1258.6313 1258.6445 0.0132 10 1698 1707 YLDDYTLTVR 21 0 
   
1344.6655 1344.6671 0.0016 1 1962 1972 RLEFHATNDNK 
  
   
1433.7131 1433.7307 0.0176 12 1312 1324 ANLNNANLEAFSR 6 0 
   
1435.7903 1435.7817 -0.0086 -6 1535 1547 AHTVAELVLPTER 
  
   
1438.7583 1438.7559 -0.0024 -2 484 496 LVHCAVDNNVKAR 
  
   
1474.7577 1474.7802 0.0225 15 3060 3071 HPYPILYDTDLK 
  
   
1500.7805 1500.7858 0.0053 4 2113 2124 FTLDLHINKEDR 
  
   
1500.7845 1500.7858 0.0013 1 2377 2388 ENFNYFLNALKK 
  
   
1535.6431 1535.6671 0.024 16 2881 2893 ICSSESEFGNSYR 
  
   
1539.839 1539.8508 0.0118 8 3256 3268 QFIQTAAHNIIQR 
  
   
1615.8439 1615.8401 -0.0038 -2 1185 1199 GSDVVLAFNNQLNPK 
  
   
1638.8962 1638.881 -0.0152 -9 1357 1371 TKPNDVNVGFIGHLK 
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Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
1 apolipophorin-1 
 
1652.9119 1652.9178 0.0059 4 2355 2369 NIAHGALFLQDNLVK 
  
   
1659.8601 1659.8726 0.0125 8 2735 2749 AVVVNGQHIFTFDGR 10 0 
   
1703.8018 1703.8121 0.0103 6 2237 2252 IESSASLCHSALGTDR 
  
   
1704.83 1704.829 -0.001 -1 2276 2290 AIDVEGSFNVNQQQR 
  
   
1793.8817 1793.8896 0.0079 4 1874 1889 AHPVLDIQYHSPSSDK 
  
   
1851.0083 1851.0197 0.0114 6 1518 1534 RTEVNIHQDGILAVTGK 
  
            2 serpin-3a 21 686.4195 686.4189 -0.0006 -1 345 350 LEGVLR 36 0 
   
877.489 877.491 0.002 2 370 376 GQLLYQR 31 0 
   
896.5815 896.5709 -0.0106 -12 329 336 LVDVILPK 
  
   
935.5018 935.4923 -0.0095 -10 263 270 TVPFMNVK 
  
   
1057.6 1057.604 0.004 4 311 319 VLNNLSELR 41 0 
   
1107.4928 1107.5018 0.009 8 337 344 FQFEYMSR 39 0 
   
1149.5721 1149.5765 0.0044 4 163 172 IYMGEGVQPR 34 0 
   
1182.5824 1182.5845 0.0021 2 320 328 TEMIYLQER 
  
   
1187.6095 1187.6061 -0.0034 -3 175 184 FAAIAQEFYK 
  
   
1193.6888 1193.6949 0.0061 5 141 150 FSTIIESLKR 35 0 
   
1265.5433 1265.548 0.0047 4 271 280 DNFYYVDSSR 73 99.896 
   
1335.6903 1335.6964 0.0061 5 122 134 SELASALGFGLDR 91 99.999 
   
1363.6852 1363.6908 0.0056 4 151 162 ESPDYILNLGSR 56 95.632 
   
1380.7271 1380.7319 0.0048 3 189 200 TTNFFKPEVAAR 44 22.858 
   
1460.7128 1460.723 0.0102 7 201 213 EINNWVSNATQGK 
  
   
1487.8428 1487.8501 0.0073 5 107 121 LALAILTEAATGSTR 66 99.544 
   
1510.7173 1510.7234 0.0061 4 356 369 EAFEDTASFPGIAR 70 99.791 
   
1731.9639 1731.96 -0.0039 -2 90 106 VASTSNANFLLSPLGLK 61 98.496 
   
1793.9618 1793.9669 0.0051 3 295 310 YAMYIVVPNSLTGLPR 
  
   
2011.0131 2011.0067 -0.0064 -3 30 49 AVFGYSALDQAALV 
  
         
GAESNK 
  
   
2376.2405 2376.2366 -0.0039 -2 386 408 TGIEVNELGSVAFSAT 
  
         
QIGIQNK 
  
 
PAP-3 8 800.4624 800.4647 0.0023 3 276 282 NDIGLIR 32 0 
   
945.504 945.4991 -0.0049 -5 354 360 QIELWEK 
  
   
956.5635 956.5653 0.0018 2 275 282 RNDIGLIR 28 0 
   
1116.6445 1116.6364 -0.0081 -7 193 203 LLCGGVLISGK 
  
   
1222.5634 1222.5707 0.0073 6 344 353 CQPSYAVQNR 37 0 
   
1423.7329 1423.741 0.0081 6 261 272 TIPHPEYNPISR 32 0 
   
1501.8162 1501.824 0.0078 5 332 343 LHVQLPFISYER 
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Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
2 PAP-3 
 
2467.3125 2467.2949 -0.0176 -7 204 226 YVLTAGHCLTGPVLQI 
  
         
GTPTNVR 
  
            3 serpin-3a 18 686.4195 686.4183 -0.0012 -2 345 350 LEGVLR 23 0 
   
877.489 877.4916 0.0026 3 370 376 GQLLYQR 25 0 
   
951.4968 951.4933 -0.0035 -4 263 270 TVPFMNVK 
  
   
1057.6 1057.6083 0.0083 8 311 319 VLNNLSELR 42 0 
   
1107.4928 1107.5112 0.0184 17 337 344 FQFEYMSR 
  
   
1165.567 1165.5691 0.0021 2 163 172 IYMGEGVQPR 18 0 
   
1182.5824 1182.5913 0.0089 8 320 328 TEMIYLQER 
  
   
1187.6095 1187.6122 0.0027 2 175 184 FAAIAQEFYK 60 98.144 
   
1193.6888 1193.6975 0.0087 7 141 150 FSTIIESLKR 
  
   
1265.5433 1265.5508 0.0075 6 271 280 DNFYYVDSSR 70 99.789 
   
1335.6903 1335.7009 0.0106 8 122 134 SELASALGFGLDR 57 96.537 
   
1363.6852 1363.6947 0.0095 7 151 162 ESPDYILNLGSR 39 0 
   
1380.7271 1380.7345 0.0074 5 189 200 TTNFFKPEVAAR 35 0 
   
1487.8428 1487.8552 0.0124 8 107 121 LALAILTEAATGSTR 41 0 
   
1510.7173 1510.7258 0.0085 6 356 369 EAFEDTASFPGIAR 50 80.254 
   
1731.9639 1731.962 -0.0019 -1 90 106 VASTSNANFLLSPLGLK 
  
   
1809.9568 1809.9602 0.0034 2 295 310 YAMYIVVPNSLTGLPR 
  
   
2011.0131 2011.0167 0.0036 2 30 49 AVFGYSALDQAALV 
  
         
GAESNK 
  
 
proPO-p2 18 662.362 662.3708 0.0088 13 476 481 GPVYAR 
  
   
688.4391 688.4264 -0.0127 -18 509 514 IFIAPK 
  
   
708.3828 708.3824 -0.0004 -1 202 206 LAYWR 
  
   
809.3787 809.3787 0 0 469 475 GLDFSDR 
  
   
809.5243 809.522 -0.0023 -3 183 189 TPIIIPR 18 0 
   
844.3987 844.4012 0.0025 3 401 406 DPFFYR 
  
   
1067.464 1067.4773 0.0133 12 52 60 FGDEEEVSR 
  
   
1087.5378 1087.5468 0.009 8 567 576 DLSIQGSDPR 
  
   
1127.5691 1127.5687 -0.0004 0 682 691 LSDVTEPNPR 
  
   
1199.6167 1199.6123 -0.0044 -4 519 528 NLPWALSDQR 
  
   
1279.6681 1279.67 0.0019 1 149 159 VQNYAEIFPAK 
  
   
1311.6692 1311.6791 0.0099 8 160 170 FLDSQVFTQAR 46 46.485 
   
1324.7021 1324.7091 0.007 5 482 491 FTHLNHRPFR 6 0 
   
1478.6394 1478.6515 0.0121 8 190 201 DYTATDLEEEHR 
  
   
1503.8165 1503.8278 0.0113 8 537 550 FVVPLSAGENTITR 
  
   
1745.8486 1745.855 0.0064 4 305 319 RPVDGLNVTIDDMER 
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Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
3 proPO-p2 
 
1870.9181 1870.9237 0.0056 3 551 566 QSTESSLTIPFEQTFR 41 0 
   
1897.9119 1897.9202 0.0083 4 267 281 FSDWREPIPEAYYPK 
  
 
proPO-p1 12 656.3514 656.3579 0.0065 10 284 288 TWPPR 
  
   
783.4147 783.4184 0.0037 5 289 295 FAGSVFR 29 0 
   
803.4409 803.4422 0.0013 2 428 434 LDFPGVR 15 0 
   
805.4202 805.4252 0.005 6 462 468 GLDFTPR 
  
   
844.3987 844.4012 0.0025 3 399 404 DPFFYR 
  
   
1127.5587 1127.5687 0.01 9 96 104 LIDIFMGMR 
  
   
1259.6306 1259.6298 -0.0008 -1 408 417 FVDDVFNIYK 
  
   
1352.6692 1352.6796 0.0104 8 546 557 SVDSSVTIPYER 
  
   
1417.7434 1417.7543 0.0109 8 450 461 TLWQQSTVELGR 
  
   
1555.855 1555.8632 0.0082 5 435 449 VSSVGIEGARPNTLR 
  
   
1754.8683 1754.8617 -0.0066 -4 232 245 GELFYYMHQQIIGR 
  
   
2190.0496 2190.0586 0.009 4 177 195 MPVNVPINYTANTTEPEQR 
  
            4 serpin-3a 26 686.4195 686.4213 0.0018 3 345 350 LEGVLR 32 0 
   
822.4468 822.4508 0.004 5 436 442 QTLFTGR 56 94.945 
   
877.489 877.4942 0.0052 6 370 376 GQLLYQR 36 0 
   
896.5815 896.5745 -0.007 -8 329 336 LVDVILPK 
  
   
935.5018 935.4984 -0.0034 -4 263 270 TVPFMNVK 
  
   
1037.5878 1037.5886 0.0008 1 141 149 FSTIIESLK 
  
   
1057.6 1057.6075 0.0075 7 311 319 VLNNLSELR 42 0 
   
1107.4928 1107.5023 0.0095 9 337 344 FQFEYMSR 51 86.946 
   
1149.5721 1149.5814 0.0093 8 163 172 IYMGEGVQPR 17 0 
   
1182.5824 1182.5909 0.0085 7 320 328 TEMIYLQER 
  
   
1187.6095 1187.6112 0.0017 1 175 184 FAAIAQEFYK 
  
   
1193.6888 1193.6973 0.0085 7 141 150 FSTIIESLKR 35 0 
   
1218.6365 1218.6389 0.0024 2 443 454 VSDPALVDGAFK 
  
   
1265.5433 1265.5524 0.0091 7 271 280 DNFYYVDSSR 76 99.959 
   
1289.6736 1289.6711 -0.0025 -2 443 455 VSDPALVDGAFKA 
  
   
1335.6903 1335.7021 0.0118 9 122 134 SELASALGFGLDR 96 100 
   
1363.6852 1363.6971 0.0119 9 151 162 ESPDYILNLGSR 72 99.888 
   
1380.7271 1380.7406 0.0135 10 189 200 TTNFFKPEVAAR 56 95.161 
   
1460.7128 1460.7164 0.0036 2 201 213 EINNWVSNATQGK 
  
   
1487.8428 1487.8572 0.0144 10 107 121 LALAILTEAATGSTR 59 97.586 
   
1510.7173 1510.7324 0.0151 10 356 369 EAFEDTASFPGIAR 75 99.947 
   
1731.9639 1731.9697 0.0058 3 90 106 VASTSNANFLLSPLGLK 108 100 
   
1809.9568 1809.9647 0.0079 4 295 310 YAMYIVVPNSLTGLPR 26 0 
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Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
4 serpin-3a 
 
2011.0131 2011.0197 0.0066 3 30 49 AVFGYSALDQAALV 143 100 
         
GAESNK 
  
   
2376.2405 2376.2456 0.0051 2 386 408 TGIEVNELGSVAFSAT 
  
         
QIGIQNK 
  
   
3228.4829 3228.4836 0.0007 0 409 435 FGEDSDINYEVVANKPFM 
  
         
FFIQEESTR 
  
            5 serpin-3a 22 686.4195 686.4189 -0.0006 -1 345 350 LEGVLR 35 0 
   
877.489 877.4921 0.0031 4 370 376 GQLLYQR 36 0 
   
896.5815 896.5699 -0.0116 -13 329 336 LVDVILPK 
  
   
951.4968 951.4894 -0.0074 -8 263 270 TVPFMNVK 15 0 
   
1037.5878 1037.5834 -0.0044 -4 141 149 FSTIIESLK 
  
   
1057.6 1057.6055 0.0055 5 311 319 VLNNLSELR 43 0.839 
   
1107.4928 1107.5028 0.01 9 337 344 FQFEYMSR 26 0 
   
1165.567 1165.5658 -0.0012 -1 163 172 IYMGEGVQPR 13 0 
   
1182.5824 1182.5892 0.0068 6 320 328 TEMIYLQER 
  
   
1187.6095 1187.6093 -0.0002 0 175 184 FAAIAQEFYK 45 32.026 
   
1193.6888 1193.6957 0.0069 6 141 150 FSTIIESLKR 
  
   
1265.5433 1265.5499 0.0066 5 271 280 DNFYYVDSSR 83 99.991 
   
1335.6903 1335.6995 0.0092 7 122 134 SELASALGFGLDR 85 99.993 
   
1363.6852 1363.6936 0.0084 6 151 162 ESPDYILNLGSR 76 99.951 
   
1380.7271 1380.7372 0.0101 7 189 200 TTNFFKPEVAAR 63 98.918 
   
1460.7128 1460.7144 0.0016 1 201 213 EINNWVSNATQGK 
  
   
1487.8428 1487.8544 0.0116 8 107 121 LALAILTEAATGSTR 56 95.042 
   
1510.7173 1510.7286 0.0113 7 356 369 EAFEDTASFPGIAR 75 99.931 
   
1731.9639 1731.9664 0.0025 1 90 106 VASTSNANFLLSPLGLK 83 99.989 
   
1809.9568 1809.965 0.0082 5 295 310 YAMYIVVPNSLTGLPR 30 0 
   
2011.0131 2011.0162 0.0031 2 30 49 AVFGYSALDQAALV 94 100 
         
GAESNK 
  
   
2376.2405 2376.2458 0.0053 2 386 408 TGIEVNELGSVAFSAT 
  
         
QIGIQNK 
  
            6 immulectin-2 11 1174.5669 1174.5679 0.001 1 71 80 FAMASMMILK 
  
   
1239.6078 1239.621 0.0132 11 30 39 YLDVIDGWMK 
  
   
1308.6833 1308.6892 0.0059 5 97 108 GDFFSVEGIPLK 
  
   
1436.7783 1436.7878 0.0095 7 97 109 GDFFSVEGIPLKK 38 0 
   
1450.7438 1450.7612 0.0174 12 84 96 QSVFTGIHATFSR 57 96.743 
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Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
6 immulectin-2 
 
1472.7394 1472.7573 0.0179 12 40 51 LHEIPANWHEAR 45 49.896 
   
1513.645 1513.6583 0.0133 9 141 152 SCSATFNYICYK 23 0 
   
1822.948 1822.9462 -0.0018 -1 54 70 CHLEGAVLASPLNSNLK 56 95.586 
   
1990.9844 1991.0005 0.0161 8 217 233 EIFAQHLPASMVGNFWK 19 0 
   
2091.9724 2091.9841 0.0117 6 192 210 AYMTCAAEGGYLTIINSEK 
  
   
2408.0923 2408.094 0.0017 1 304 324 DPNSLLCDPTSDSFDDIIDIR 47 69.46 
 
immulectin-2a 11 1225.5922 1225.6074 0.0152 12 30 39 YLDVVDGWMK 
  
   
1308.6833 1308.6892 0.0059 5 97 108 GDFFSVEGIPLK 
  
   
1436.7783 1436.7878 0.0095 7 97 109 GDFFSVEGIPLKK 38 0 
   
1450.7438 1450.7612 0.0174 12 84 96 QSVFTGIHATFSR 57 96.743 
   
1472.7394 1472.7573 0.0179 12 40 51 LHEIPANWHEAR 45 49.896 
   
1539.697 1539.7148 0.0178 12 141 152 LCSATFNYICYK 
  
   
1822.948 1822.9462 -0.0018 -1 54 70 CHLEGAVLASPLNSNLK 56 95.586 
   
1990.9844 1991.0005 0.0161 8 217 233 EIFAQHLPASMVGNFWK 19 0 
   
2091.9724 2091.9841 0.0117 6 192 210 AYMTCAAEGGYLTIINSEK 
  
   
2408.0923 2408.094 0.0017 1 304 324 DPNSLLCDPTSDSFDDIIDIR 47 69.46 
   
2944.5457 2944.501 -0.0447 -15 54 80 CHLEGAVLASPLNSNLKF 
  
         
AMSSIMILK 
  
 
SPH-1b 6 926.5305 926.5455 0.015 16 310 317 IEVPVVDR 
  
   
1054.6255 1054.6426 0.0171 16 309 317 KIEVPVVDR 
  
   
1067.4792 1067.4946 0.0154 14 227 234 EPYPYQDR 42 5.186 
   
1468.6914 1468.7181 0.0267 18 172 184 IEPVNENEPDGQK 
  
   
1524.7078 1524.7241 0.0163 11 227 238 EPYPYQDRDVSR 
  
   
1865.8334 1865.85 0.0166 9 353 369 GDGGSPLVCPSEYEKDR 
  
            7 immulectin-3 15 766.4093 766.4072 -0.0021 -3 168 174 GYQLSAK 
  
   
791.4661 791.4618 -0.0043 -5 221 227 YPTGLIK 45 56.882 
   
892.4596 892.4558 -0.0038 -4 292 298 VPFICEK 42 17.651 
   
1163.5361 1163.5365 0.0004 0 281 291 SGQLDDIGCAK 42 14.953 
   
1361.6631 1361.6565 -0.0066 -5 299 310 HPNNIMPVPNNV 37 0 
   
1541.6823 1541.6815 -0.0008 -1 154 167 TAELSMTECGTVDK 
  
   
1736.8907 1736.8969 0.0062 4 181 194 FHNYGLPWSLAYLR 34 0 
   
1802.7108 1802.7159 0.0051 3 115 129 DMFTEEYSSGPHCAR 56 96.455 
   
2059.8596 2059.8618 0.0022 1 113 129 TRDMFTEEYSSGPHCAR 20 0 
   
2156.1379 2156.1387 0.0008 0 195 215 CIAEGGQLAVINSAV 96 100 
         
EANVLK 
  
   
2305.0686 2305.0789 0.0103 4 154 174 TAELSMTECGTVDKG 
  
         
YQLSAK 
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Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
7 immulectin-3 
 
2352.0693 2352.0681 -0.0012 -1 228 248 GGYAGGAFLGFHDWN 67 99.73 
         
NNNVWR 
  
   
2454.2043 2454.2114 0.0071 3 130 151 LIPQEGLVAGSCSDALP 51 87.848 
         
YICYK 
  
   
3560.5803 3560.5903 0.01 3 249 280 TVNGQTLEEAGYANWGV 
  
         
TQPDSSVQNCGQMFR 
  
   
3676.981 3676.9377 -0.0433 -12 78 112 IEHLSTGVHTGVHNTISPVV 
  
         
FNSIEGVPLSALPVR 
  
 
immulectin-4 7 739.3555 739.3571 0.0016 2 127 131 QYCLR 
  
   
1041.457 1041.4591 0.0021 2 280 287 QYHGAMYR 
  
   
1131.5542 1131.5597 0.0055 5 244 252 DLNQSNVWR 44 50.266 
   
1365.7274 1365.7318 0.0044 3 38 49 LHLVPATWSDAR 
  
   
1387.6384 1387.6451 0.0067 5 143 153 CSEALPYICFK 
  
   
1420.7583 1420.765 0.0067 5 231 243 GSEPVNVIFVGFR 
  
   
1548.8533 1548.8633 0.01 6 230 243 KGSEPVNVIFVGFR 
  
 
immulectin-III 7 739.3555 739.3571 0.0016 2 123 127 QYCLR 
  
   
1041.457 1041.4591 0.0021 2 269 276 QYHGAMYR 
  
   
1131.5542 1131.5597 0.0055 5 233 241 DLNQSNVWR 44 50.266 
   
1420.7583 1420.765 0.0067 5 220 232 GSEPVNVIFVGFR 
  
   
1428.6318 1428.6302 -0.0016 -1 112 122 GIYYEQYDYSK 
  
   
1548.8533 1548.8633 0.01 6 219 232 KGSEPVNVIFVGFR 
  
   
1658.76 1658.7272 -0.0328 -20 1 13 MNRCLGWTCVFSK 
  
            8 attacin-1 14 662.3984 662.3971 -0.0013 -2 185 189 LNLFR 33 0 
   
848.4148 848.4221 0.0073 9 57 64 VPFAGDDK 
  
   
928.4232 928.4226 -0.0006 -1 204 210 FEMPNFK 
  
   
1056.5183 1056.5178 -0.0005 0 203 210 KFEMPNFK 33 0 
   
1274.59 1274.5928 0.0028 2 192 202 TTSLDFNADYK 
  
   
1348.7107 1348.7158 0.0051 4 65 77 NVFSAIGGLDLDK 
  
   
1485.7008 1485.7021 0.0013 1 211 223 SDWTPNIGFSFSK 37 0 
   
1499.7601 1499.7688 0.0087 6 162 176 VGASASAAHTPLFDR 64 99.229 
   
1517.7118 1517.7067 -0.0051 -3 190 202 DKTTSLDFNADYK 22 0 
   
1678.8296 1678.8342 0.0046 3 118 131 LNVFHNDNHNLDVK 76 99.951 
   
1742.882 1742.8871 0.0051 3 160 176 DKVGASASAAHTPLFDR 4 0 
   
2178.1077 2178.1094 0.0017 1 57 77 VPFAGDDKNVFSAI 1 0 
         
GGLDLDK 
  
   
2320.1316 2320.1331 0.0015 1 162 184 VGASASAAHTPLFDRN 2 0 
         
DYSVGGK 
  
 178 
            
Band Protein name Peptide 
count 
Calc. 
mass 
Obsrv. 
mass 
± da ± ppm Start End Peptide sequence Ion 
score 
C. I. % 
8 attacin-1 
 
2589.1423 2589.1633 0.021 8 137 159 TMPDIPHAPDFNTFGG 
  
         
GVDYMFK 
  
            9 attacin-II 10 662.3984 662.4 0.0016 2 169 173 LNLFR 20 0 
   
718.3882 718.3918 0.0036 5 41 47 VPFGGNK 
  
   
929.4185 929.4253 0.0068 7 188 194 FDTPFMR 4 0 
   
1057.5135 1057.5251 0.0116 11 187 194 KFDTPFMR 1 0 
   
1387.7539 1387.7654 0.0115 8 65 78 LSSATAGVALDNIR 30 0 
   
1397.6696 1397.6749 0.0053 4 174 186 NPSTSLDFNAGFK 
  
   
1528.7866 1528.7988 0.0122 8 146 160 VGASLGAAHTDFINR 
  
   
1751.8711 1751.8807 0.0096 5 79 95 GHGLSLTDTHIPGFGDK 
  
   
1789.8616 1789.8688 0.0072 4 48 64 NNIFSAIGGADFNANHK 
  
   
2183.074 2183.0752 0.0012 1 102 120 LNLFHNNNHDLTANAFATR 1 0 
9 dVG-AP3-2 7 662.3984 662.4 0.0016 2 100 104 LNLFR 20 0 
 
(gloverin) 
 
929.4185 929.4253 0.0068 7 119 125 FDTPFMR 4 0 
   
1057.5135 1057.5251 0.0116 11 118 125 KFDTPFMR 1 0 
   
1397.6696 1397.6749 0.0053 4 105 117 NPSTSLDFNAGFK 
  
   
1528.7866 1528.7988 0.0122 8 77 91 VGASLGAAHTDFINR 28 0 
   
1751.8711 1751.8807 0.0096 5 10 26 GHGLSLTDTHIPGFGDK 
  
   
2183.074 2183.0752 0.0012 1 33 51 LNLFHNNNHDLTANAFATR 1 0 
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Table B-2. MS/MS results for immunoaffinity purified proteins identified in Table 3-2. 
Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
1 serpin 3a  19 685.4123 685.7074 0.2952 345 350 LEGVLR 31.54 0.0056 
   
876.4817 876.6934 0.2117 370 376 GQLLYQR 44.45 0.00034 
   
895.5742 895.8234 0.2492 329 336 LVDVILPK 60.32 9.20E-06 
   
1036.5804 1036.7894 0.209 141 149 FSTIIESLK 41.5 0.00096 
   
1056.5927 1056.8774 0.2847 311 319 VLNNLSELR 69.51 1.20E-06 
   
1148.5648 1148.8834 0.3186 163 172 IYMGEGVQPR 76.34 3.20E-07 
   
1186.6022 1186.9194 0.3172 175 184 FAAIAQEFYK 58.45 1.60E-05 
   
1192.6815 1192.9734 0.2919 141 150 FSTIIESLKR 46.88 0.00018 
   
1197.5699 1197.8434 0.2735 320 328 TEMIYLQER 65.48 3.60E-06 
   
1264.536 1264.8214 0.2854 271 280 DNFYYVDSSR 71.35 1.10E-06 
   
1320.7765 1321.5442 0.7677 140 150 KFSTIIESLKR 31.67 0.0071 
   
1334.683 1335.0754 0.3924 122 134 SELASALGFGLDR 83.79 3.50E-08 
   
1362.6779 1363.5894 0.9115 151 162 ESPDYILNLGSR 77.48 1.60E-07 
   
1459.7055 1460.0834 0.3779 201 213 EINNWVSNATQGK 78.05 1.70E-07 
   
1486.8355 1487.6754 0.84 107 121 LALAILTEAATGSTR 103.34 6.00E-10 
   
1509.71 1510.1354 0.4255 356 369 EAFEDTASFPGIAR 59.45 1.00E-05 
   
1730.9567 1731.8314 0.8748 90 106 VASTSNANFLLSPLGLK 84.34 3.60E-08 
   
1808.9495 1810.0254 1.076 295 310 YAMYIVVPNSLTGLPR 84.41 3.20E-08 
   
2010.0058 2011.0214 1.0156 30 49 AVFGYSALDQAAL 124.9 5.00E-12 
        
VGAESNK 
  
 
HP8 2 1012.4978 1012.6834 0.1857 163 171 GSDLPPNWK 27.66 0.024 
   
1769.7567 1770.2454 0.4888 250 265 DSNFDGLEMEVAGWGK 94.12 4.60E-09 
           2 serpin 3a  22 685.4123 685.6494 0.2372 345 350 LEGVLR 28.92 0.011 
   
876.4817 876.6874 0.2057 370 376 GQLLYQR 42.05 0.0006 
   
895.5742 895.8094 0.2352 329 336 LVDVILPK 60.21 9.40E-06 
   
1036.5804 1036.8074 0.227 141 149 FSTIIESLK 35.93 0.0035 
   
1056.5927 1056.8814 0.2887 311 319 VLNNLSELR 70.28 1.00E-06 
   
1106.4855 1106.6694 0.1839 337 344 FQFEYMSR 34.82 0.0039 
   
1148.5648 1148.7714 0.2066 163 172 IYMGEGVQPR 78.63 2.00E-07 
   
1186.6022 1186.9614 0.3592 175 184 FAAIAQEFYK 50.18 0.00011 
   
1192.6815 1193.2852 0.6036 141 150 FSTIIESLKR 29.19 0.0087 
   
1197.5699 1197.7854 0.2155 320 328 TEMIYLQER 62.55 7.50E-06 
   
1264.536 1264.7834 0.2474 271 280 DNFYYVDSSR 51.57 0.00011 
   
1334.683 1335.0294 0.3464 122 134 SELASALGFGLDR 80.83 7.20E-08 
   
1362.6779 1363.0294 0.3515 151 162 ESPDYILNLGSR 77.52 1.50E-07 
   
1379.7197 1380.5234 0.8037 189 200 TTNFFKPEVAAR 57.52 2.40E-05 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
2 serpin 3a 
 
1459.7055 1459.9834 0.2779 201 213 EINNWVSNATQGK 72.68 6.00E-07 
   
1486.8355 1487.1334 0.298 107 121 LALAILTEAATGSTR 103.31 6.00E-10 
   
1509.71 1510.3974 0.6875 356 369 EAFEDTASFPGIAR 60.09 8.20E-06 
   
1730.9567 1731.9154 0.9588 90 106 VASTSNANFLLSPLGLK 93.71 4.00E-09 
   
1808.9495 1809.9854 1.036 295 310 YAMYIVVPNSLTGLPR 81.12 7.00E-08 
   
1819.9428 1820.7472 0.8044 122 138 SELASALGFGLDRTEVR 54.68 4.80E-05 
   
2010.0058 2011.0234 1.0176 30 49 AVFGYSALDQAALV 104.97 4.90E-10 
        
GAESNK 
  
   
2375.2332 2376.3322 1.0989 386 408 TGIEVNELGSVAFSAT 60.73 9.00E-06 
        
QIGIQNK 
  
 
PAP-3 2 799.4552 799.5854 0.1303 276 282 NDIGLIR 36.69 0.0031 
   
1500.8089 1501.8472 1.0383 332 343 LHVQLPFISYER 58.43 2.10E-05 
           3 serpin 3a  22 685.4123 685.6314 0.2192 345 350 LEGVLR 26.81 0.018 
   
876.4817 876.6514 0.1697 370 376 GQLLYQR 47.48 0.00018 
   
895.5742 895.7914 0.2172 329 336 LVDVILPK 60.36 9.10E-06 
   
1036.5804 1036.7834 0.203 141 149 FSTIIESLK 39.24 0.0016 
   
1056.5927 1056.8414 0.2487 311 319 VLNNLSELR 72.26 6.60E-07 
   
1148.5648 1148.8514 0.2866 163 172 IYMGEGVQPR 78.41 2.00E-07 
   
1181.575 1181.8494 0.2744 320 328 TEMIYLQER 67.57 1.80E-06 
   
1186.6022 1186.9934 0.3912 175 184 FAAIAQEFYK 52.05 6.90E-05 
   
1192.6815 1193.0034 0.3219 141 150 FSTIIESLKR 47.34 0.00016 
   
1264.536 1264.8614 0.3254 271 280 DNFYYVDSSR 71.41 1.00E-06 
   
1320.7765 1321.6642 0.8877 140 150 KFSTIIESLKR 54.59 3.60E-05 
   
1334.683 1335.6414 0.9584 122 134 SELASALGFGLDR 93.96 3.90E-09 
   
1362.6779 1363.0654 0.3875 151 162 ESPDYILNLGSR 77.51 1.50E-07 
   
1379.7197 1379.8954 0.1757 189 200 TTNFFKPEVAAR 47.08 0.00023 
   
1459.7055 1460.1314 0.4259 201 213 EINNWVSNATQGK 80.75 9.20E-08 
   
1486.8355 1487.1254 0.29 107 121 LALAILTEAATGSTR 103.37 6.00E-10 
   
1509.71 1509.9354 0.2255 356 369 EAFEDTASFPGIAR 63.41 4.20E-06 
   
1730.9567 1731.8452 0.8885 90 106 VASTSNANFLLSPLGLK 69.05 1.80E-06 
   
1808.9495 1810.0934 1.144 295 310 YAMYIVVPNSLTGLPR 65.65 2.50E-06 
   
1819.9428 1821.0352 1.0924 122 138 SELASALGFGLDRTEVR 65.23 3.90E-06 
   
2010.0058 2010.3594 0.3537 30 49 AVFGYSALDQAALV 122.16 6.90E-12 
        
GAESNK 
  
   
2375.2332 2376.1874 0.9542 386 408 TGIEVNELGSVAFSAT 56.76 1.80E-05 
        
QIGIQNK 
  
 
immulectin-2b  4 851.3926 851.5694 0.1769 170 175 YVHYDR 40.2 0.00076 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
3 immulectin-2b  
 
1157.5647 1157.8334 0.2688 71 80 FAMASMMILK 48.97 0.00016 
   
1238.6005 1238.8854 0.2849 30 39 YLDVIDGWMK 51.52 7.70E-05 
   
1449.7365 1450.4542 0.7177 84 96 QSVFTGIHATFSR 49.01 0.0001 
 
PAP-3 4 799.4552 799.6554 0.2003 276 282 NDIGLIR 36.35 0.0034 
   
1084.5917 1084.9154 0.3238 419 427 DWIISNIKP 32.68 0.0055 
   
1422.7255 1423.0354 0.3099 261 272 TIPHPEYNPISR 38.52 0.0012 
   
1500.8089 1501.6702 0.8613 332 343 LHVQLPFISYER 50.58 0.00013 
           4 serpin 3a  23 685.4123 685.6214 0.2092 345 350 LEGVLR 29.98 0.0085 
   
876.4817 876.6874 0.2057 370 376 GQLLYQR 44.36 0.00035 
   
895.5742 895.8534 0.2792 329 336 LVDVILPK 54.51 3.50E-05 
   
1036.5804 1036.8814 0.301 141 149 FSTIIESLK 30.46 0.012 
   
1056.5927 1056.8654 0.2727 311 319 VLNNLSELR 68.26 1.60E-06 
   
1148.5648 1148.8254 0.2606 163 172 IYMGEGVQPR 81.16 1.10E-07 
   
1181.575 1181.8434 0.2684 320 328 TEMIYLQER 62.25 6.10E-06 
   
1186.6022 1186.9454 0.3432 175 184 FAAIAQEFYK 53.14 5.40E-05 
   
1192.6815 1192.9834 0.3019 141 150 FSTIIESLKR 54.89 2.80E-05 
   
1264.536 1264.9054 0.3694 271 280 DNFYYVDSSR 71.4 9.80E-07 
   
1320.7765 1321.4842 0.7077 140 150 KFSTIIESLKR 50.24 9.60E-05 
   
1334.683 1334.9694 0.2864 122 134 SELASALGFGLDR 89.09 1.10E-08 
   
1362.6779 1363.0654 0.3875 151 162 ESPDYILNLGSR 77.57 1.50E-07 
   
1379.7197 1380.5554 0.8357 189 200 TTNFFKPEVAAR 50.13 0.00014 
   
1459.7055 1460.0154 0.3099 201 213 EINNWVSNATQGK 70.99 9.00E-07 
   
1486.8355 1487.1634 0.328 107 121 LALAILTEAATGSTR 103.41 5.80E-10 
   
1509.71 1509.9154 0.2055 356 369 EAFEDTASFPGIAR 57.55 1.60E-05 
   
1730.9567 1731.2474 0.2908 90 106 VASTSNANFLLSPLGLK 88.44 1.40E-08 
   
1808.9495 1809.1374 0.188 295 310 YAMYIVVPNSLTGLPR 56.85 2.20E-05 
   
1819.9428 1820.8042 0.8614 122 138 SELASALGFGLDRTEVR 50.64 0.00012 
   
1887.0578 1888.1632 1.1054 89 106 RVASTSNANFLLSPLGLK 54 5.90E-05 
   
2010.0058 2010.9994 0.9937 30 49 AVFGYSALDQAALV 108.61 2.10E-10 
        
GAESNK 
  
   
2375.2332 2376.3202 1.0869 386 408 TGIEVNELGSVAFSAT 57.26 2.00E-05 
        
QIGIQNK 
  
 
immulectin-2b  6 851.3926 851.5594 0.1669 170 175 YVHYDR 35.75 0.0021 
   
1141.5697 1141.9034 0.3337 71 80 FAMASMMILK 52.19 6.60E-05 
   
1254.5955 1254.9374 0.342 30 39 YLDVIDGWMK 51.23 7.80E-05 
   
1435.7711 1435.9374 0.1663 97 109 GDFFSVEGIPLKK 35.16 0.0038 
   
1449.7365 1450.6192 0.8827 84 96 QSVFTGIHATFSR 36.23 0.0023 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
4 immulectin-2b 
 
1471.732 1472.1982 0.4662 40 51 LHEIPANWHEAR 38 0.0017 
 
PAP-3 5 799.4552 799.6594 0.2043 276 282 NDIGLIR 30.34 0.014 
   
1084.5917 1084.9814 0.3898 419 427 DWIISNIKP 40.6 0.00085 
   
1422.7255 1423.7294 1.0039 261 272 TIPHPEYNPISR 44.82 0.00031 
   
1500.8089 1501.8234 1.0146 332 343 LHVQLPFISYER 60.74 1.00E-05 
   
1698.9093 1699.6012 0.6919 414 427 VHSYKDWIISNIKP 23.76 0.042 
 
immulectin-2a  5 769.3871 769.5814 0.1943 182 187 FHDVPR 25.81 0.022 
   
851.3926 851.5594 0.1669 170 175 YVHYDR 35.75 0.0021 
   
1435.7711 1435.9374 0.1663 97 109 GDFFSVEGIPLKK 35.16 0.0038 
   
1449.7365 1450.6192 0.8827 84 96 QSVFTGIHATFSR 36.23 0.0023 
   
1471.732 1472.1982 0.4662 40 51 LHEIPANWHEAR 38 0.0017 
           5 serpin 3a  23 685.4123 685.5994 0.1872 345 350 LEGVLR 32.5 0.0047 
   
876.4817 876.6634 0.1817 370 376 GQLLYQR 44.61 0.00034 
   
895.5742 895.8074 0.2332 329 336 LVDVILPK 52.12 6.00E-05 
   
1036.5804 1036.7574 0.177 141 149 FSTIIESLK 42.29 0.00081 
   
1056.5927 1056.7954 0.2027 311 319 VLNNLSELR 66.08 2.90E-06 
   
1106.4855 1106.6734 0.1879 337 344 FQFEYMSR 28.96 0.015 
   
1148.5648 1148.7654 0.2006 163 172 IYMGEGVQPR 86.3 3.50E-08 
   
1186.6022 1186.9574 0.3552 175 184 FAAIAQEFYK 51.14 8.60E-05 
   
1192.6815 1193.7194 1.0379 141 150 FSTIIESLKR 31.78 0.0069 
   
1197.5699 1197.7754 0.2055 320 328 TEMIYLQER 62.57 7.40E-06 
   
1264.536 1264.7674 0.2314 271 280 DNFYYVDSSR 71.4 1.10E-06 
   
1320.7765 1321.4932 0.7167 140 150 KFSTIIESLKR 51.5 7.20E-05 
   
1334.683 1335.0654 0.3824 122 134 SELASALGFGLDR 83.81 3.60E-08 
   
1362.6779 1363.0414 0.3635 151 162 ESPDYILNLGSR 77.53 1.50E-07 
   
1379.7197 1379.8954 0.1757 189 200 TTNFFKPEVAAR 50.15 0.00011 
   
1459.7055 1459.9894 0.2839 201 213 EINNWVSNATQGK 77.38 2.00E-07 
   
1486.8355 1487.2454 0.41 107 121 LALAILTEAATGSTR 103.4 5.90E-10 
   
1509.71 1510.2774 0.5675 356 369 EAFEDTASFPGIAR 62.69 4.30E-06 
   
1730.9567 1731.8314 0.8748 90 106 VASTSNANFLLSPLGLK 101.55 6.80E-10 
   
1808.9495 1810.0714 1.122 295 310 YAMYIVVPNSLTGLPR 58.35 1.30E-05 
   
1819.9428 1820.8852 0.9424 122 138 SELASALGFGLDRTEVR 57.87 2.20E-05 
   
2010.0058 2010.2154 0.2097 30 49 AVFGYSALDQAALV 121.71 7.90E-12 
        
GAESNK 
  
   
2375.2332 2376.3802 1.1469 386 408 TGIEVNELGSVAFSAT 61.63 7.00E-06 
        
QIGIQNK 
  
 
PAP-1 6 928.5342 928.7254 0.1913 233 240 KDDIALVR 51.03 8.80E-05 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
5 PAP-1 
 
935.4786 935.7094 0.2308 289 296 LGMPIFDK 55.93 2.70E-05 
   
959.4924 959.7374 0.2451 305 313 NLGAELTDK 32.41 0.0067 
   
1016.4709 1016.6114 0.1405 328 337 GDSGGPLMQR 74.42 5.20E-07 
   
1198.6782 1199.1712 0.493 231 240 NRKDDIALVR 42.05 0.00089 
   
1433.7303 1434.9234 1.1931 263 276 LATGNDVFVAGWGK 103.89 5.70E-10 
           6 proPO-p2 22 613.4527 613.5934 0.1408 61 65 KIILK 32.75 0.0059 
   
687.4319 687.7394 0.3075 509 514 IFIAPK 33.82 0.0051 
   
808.5171 808.7014 0.1844 183 189 TPIIIPR 41.19 0.00092 
   
861.4556 861.7114 0.2559 282 289 LDSLTSAR 35.1 0.0055 
   
956.4096 956.6414 0.2319 530 536 MFIEMDR 39.21 0.002 
   
1066.4567 1066.6274 0.1707 52 60 FGDEEEVSR 65.96 3.40E-06 
   
1086.5305 1086.7294 0.1989 567 576 DLSIQGSDPR 47.21 0.00027 
   
1126.5618 1126.7594 0.1976 682 691 LSDVTEPNPR 56.03 3.30E-05 
   
1198.6095 1198.7674 0.158 519 528 NLPWALSDQR 46.89 0.00032 
   
1199.655 1199.8994 0.2444 66 75 NLDKIPEFPK 56.62 2.90E-05 
   
1278.6608 1279.0514 0.3906 149 159 VQNYAEIFPAK 69.74 8.70E-07 
   
1310.6619 1311.0854 0.4235 160 170 FLDSQVFTQAR 87.72 1.70E-08 
   
1326.7044 1327.0194 0.315 519 529 NLPWALSDQRK 55 3.60E-05 
   
1451.7157 1452.3262 0.6104 469 481 GLDFSDRGPVYAR 40.28 0.00075 
   
1477.6321 1477.8674 0.2354 190 201 DYTATDLEEEHR 80.89 8.20E-08 
   
1502.8093 1503.6334 0.8242 537 550 FVVPLSAGENTITR 97.16 1.80E-09 
   
1590.7831 1591.0634 0.2804 407 419 VHAWVDDIFQSFK 63.2 4.50E-06 
   
1695.9043 1696.3114 0.4072 323 338 NIEEAIATGNVILPDK 78.59 1.50E-07 
   
1744.8414 1745.0254 0.184 305 319 RPVDGLNVTIDDMER 72.32 8.30E-07 
   
1869.9109 1870.3554 0.4446 551 566 QSTESSLTIPFEQTFR 61.86 7.10E-06 
   
1896.9046 1897.9162 1.0116 267 281 FSDWREPIPEAYYPK 33.25 0.0055 
   
2012.0789 2012.9032 0.8242 323 341 NIEEAIATGNVILPDKSTK 69.21 1.50E-06 
 
serpin 3a  5 1148.5648 1148.7674 0.2026 163 172 IYMGEGVQPR 76.22 3.50E-07 
   
1334.683 1334.9934 0.3104 122 134 SELASALGFGLDR 86.18 2.20E-08 
   
1486.8355 1487.0214 0.186 107 121 LALAILTEAATGSTR 91.9 8.50E-09 
   
1509.71 1509.9274 0.2175 356 369 EAFEDTASFPGIAR 63.83 3.80E-06 
   
1730.9567 1732.0334 1.0768 90 106 VASTSNANFLLSPLGLK 82.78 5.00E-08 
           7 proPO-p1 23 782.4075 782.6154 0.2079 289 295 FAGSVFR 43.7 0.00059 
   
802.4337 802.6314 0.1977 428 434 LDFPGVR 39.26 0.002 
   
804.413 804.6114 0.1984 462 468 GLDFTPR 41.1 0.0015 
   
921.4668 921.6474 0.1806 52 59 FGNEATKR 47.77 0.00023 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
7 proPO-p1 
 
990.5094 990.6634 0.154 43 51 SLSNTLSNR 33.02 0.0049 
   
1090.5659 1090.7594 0.1936 316 324 DQFLEAIQK 55 4.70E-05 
   
1094.5616 1094.8514 0.2898 96 104 LIDIFMGMR 65.05 3.00E-06 
   
1145.604 1145.8154 0.2114 166 176 EVSNVVISGSR 61.85 8.30E-06 
   
1350.5874 1351.5934 1.006 509 520 VDDNGQPMSFNK 61.53 7.70E-06 
   
1372.7423 1372.9494 0.2072 164 176 AREVSNVVISGSR 59.94 1.10E-05 
   
1416.7361 1417.1374 0.4013 450 461 TLWQQSTVELGR 83.17 4.90E-08 
   
1459.7896 1460.6692 0.8796 531 543 FSQALRPGTNTIR 34.37 0.0055 
   
1507.7631 1508.2612 0.4981 545 557 RSVDSSVTIPYER 29.32 0.02 
   
1515.7609 1515.9274 0.1665 408 419 FVDDVFNIYKEK 59.83 1.30E-05 
   
1554.8478 1555.8622 1.0144 435 449 VSSVGIEGARPNTLR 43.3 0.00059 
   
1730.8086 1731.7372 0.9285 635 648 KYPDKQAMGYPFDR 29.13 0.017 
   
1753.861 1754.5762 0.7152 232 245 GELFYYMHQQIIGR 33.95 0.0043 
   
1764.7923 1765.6972 0.9048 383 398 HLEQFGVMGDSATAMR 79.37 1.40E-07 
   
1769.8559 1770.4612 0.6053 232 245 GELFYYMHQQIIGR 40.64 0.0011 
   
1780.7873 1781.4142 0.6269 383 398 HLEQFGVMGDSATAMR 70.79 8.90E-07 
   
1925.957 1926.9472 0.9902 231 245 RGELFYYMHQQIIGR 56.44 2.90E-05 
   
2092.0193 2092.1872 0.1678 650 668 MANDAATLSDFLRPN 49.72 0.00013 
        
MAVR 
  
   
2189.0423 2190.1134 1.0712 177 195 MPVNVPINYTANTTE 148.67 1.10E-14 
        
PEQR 
  
           8 proPO-p1 24 782.4075 782.6254 0.2179 289 295 FAGSVFR 47.6 3.30E-05 
   
802.4337 802.6354 0.2017 428 434 LDFPGVR 42.05 0.0011 
   
804.413 804.6274 0.2144 462 468 GLDFTPR 43.42 0.00087 
   
921.4668 921.9052 0.4384 52 59 FGNEATKR 26.66 0.019 
   
1083.4808 1083.7574 0.2767 640 648 QAMGYPFDR 29.2 0.011 
   
1090.5659 1090.7794 0.2136 316 324 DQFLEAIQK 52.25 8.80E-05 
   
1094.5616 1094.8194 0.2578 96 104 LIDIFMGMR 65.52 2.70E-06 
   
1145.604 1145.8174 0.2134 166 176 EVSNVVISGSR 61.45 9.10E-06 
   
1227.5706 1227.8594 0.2888 640 649 QAMGYPFDRK 22.19 0.06 
   
1258.6234 1259.0214 0.3981 408 417 FVDDVFNIYK 73.78 5.30E-07 
   
1351.662 1351.7254 0.0635 546 557 SVDSSVTIPYER 40.16 0.0011 
   
1366.5823 1367.4354 0.8531 509 520 VDDNGQPMSFNK 64.18 3.40E-06 
   
1372.7423 1373.7374 0.9952 164 176 AREVSNVVISGSR 51.98 6.50E-05 
   
1416.7361 1417.0814 0.3453 450 461 TLWQQSTVELGR 83.01 5.40E-08 
   
1459.7896 1460.5402 0.7506 531 543 FSQALRPGTNTIR 34.69 0.0052 
   
1507.7631 1507.8874 0.1244 545 557 RSVDSSVTIPYER 26.44 0.02 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
8 proPO-p1 
 
1507.7631 1508.2582 0.4951 545 557 RSVDSSVTIPYER 36.61 0.0037 
   
1515.7609 1516.5142 0.7532 408 419 FVDDVFNIYKEK 40.75 0.00088 
   
1554.8478 1555.8772 1.0294 435 449 VSSVGIEGARPNTLR 44.58 0.00044 
   
1714.8137 1715.6182 0.8045 635 648 KYPDKQAMGYPFDR 37.4 0.0022 
   
1748.7974 1749.8542 1.0567 383 398 HLEQFGVMGDSATAMR 88.21 1.60E-08 
   
1769.8559 1770.8962 1.0403 232 245 GELFYYMHQQIIGR 40.33 0.0014 
   
2092.0193 2092.6672 0.6478 650 668 MANDAATLSDFLRPN 69.05 1.10E-06 
        
MAVR 
  
   
2173.0473 2174.0994 1.0521 177 195 MPVNVPINYTANTTE 109.39 1.30E-10 
        
PEQR 
  
           9 proPO-p1 15 802.4337 802.6214 0.1877 428 434 LDFPGVR 35.24 0.0052 
   
804.413 804.5774 0.1644 462 468 GLDFTPR 43.05 0.001 
   
1090.5659 1090.7314 0.1656 316 324 DQFLEAIQK 57.48 2.80E-05 
   
1094.5616 1094.8674 0.3058 96 104 LIDIFMGMR 59.37 1.10E-05 
   
1145.604 1145.7874 0.1834 166 176 EVSNVVISGSR 61.84 8.40E-06 
   
1258.6234 1258.9594 0.3361 408 417 FVDDVFNIYK 73.75 5.40E-07 
   
1350.5874 1350.7414 0.154 509 520 VDDNGQPMSFNK 69.77 1.50E-06 
   
1372.7423 1373.0422 0.2999 164 176 AREVSNVVISGSR 37.54 0.002 
   
1416.7361 1417.0874 0.3513 450 461 TLWQQSTVELGR 82.94 5.40E-08 
   
1459.7896 1460.7502 0.9606 531 543 FSQALRPGTNTIR 27.49 0.026 
   
1554.8478 1555.8292 0.9814 435 449 VSSVGIEGARPNTLR 38.53 0.0018 
   
1753.861 1754.4262 0.5652 232 245 GELFYYMHQQIIGR 21.2 0.077 
   
1780.7873 1781.3572 0.5699 383 398 HLEQFGVMGDSATAMR 82.21 6.40E-08 
   
2108.0143 2108.9032 0.8889 650 668 MANDAATLSDFLRPN 55.89 3.60E-05 
        
MAVR 
  
   
2189.0423 2190.2002 1.1579 177 195 MPVNVPINYTANTTE 57.7 1.90E-05 
        
PEQR 
  
           10 proPO-p2 14 797.4647 797.6854 0.2208 171 178 EAAAVIPK 45.31 0.00033 
   
808.5171 808.7054 0.1884 183 189 TPIIIPR 30.6 0.01 
   
1086.5305 1087.6594 1.1289 567 576 DLSIQGSDPR 24.91 0.04 
   
1126.5618 1126.7574 0.1956 682 691 LSDVTEPNPR 57.1 2.60E-05 
   
1199.655 1199.8394 0.1844 66 75 NLDKIPEFPK 47.25 0.00025 
   
1278.6608 1279.0034 0.3426 149 159 VQNYAEIFPAK 66.03 2.10E-06 
   
1310.6619 1311.0274 0.3655 160 170 FLDSQVFTQAR 79.13 1.20E-07 
   
1451.7157 1452.3562 0.6404 469 481 GLDFSDRGPVYAR 33.27 0.0038 
   
1477.6321 1477.8474 0.2154 190 201 DYTATDLEEEHR 77.75 1.70E-07 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
10 proPO-p2 
 
1502.8093 1503.0914 0.2822 537 550 FVVPLSAGENTITR 95.18 3.10E-09 
   
1695.9043 1697.0122 1.1079 323 338 NIEEAIATGNVILPDK 39.42 0.0012 
   
1728.8465 1729.7932 0.9467 305 319 RPVDGLNVTIDDMER 68.43 1.60E-06 
   
1869.9109 1870.8814 0.9706 551 566 QSTESSLTIPFEQTFR 62.23 8.70E-06 
   
2012.0789 2013.0892 1.0102 323 341 NIEEAIATGNVILPDKSTK 64.58 3.90E-06 
 
serpin 3a 9 1056.5927 1056.8254 0.2327 311 319 VLNNLSELR 63.27 5.30E-06 
   
1164.5597 1164.8894 0.3297 163 172 IYMGEGVQPR 68.8 1.10E-06 
   
1264.536 1264.5094 -0.0266 271 280 DNFYYVDSSR 52.67 8.60E-05 
   
1334.683 1335.0194 0.3364 122 134 SELASALGFGLDR 72.16 5.40E-07 
   
1362.6779 1362.9054 0.2275 151 162 ESPDYILNLGSR 70.24 8.80E-07 
   
1459.7055 1459.9354 0.2299 201 213 EINNWVSNATQGK 60.32 1.00E-05 
   
1486.8355 1487.0794 0.244 107 121 LALAILTEAATGSTR 43.79 0.00054 
   
1509.71 1509.8474 0.1375 356 369 EAFEDTASFPGIAR 53.14 4.50E-05 
   
2375.2332 2376.1642 0.9309 386 408 TGIEVNELGSVAFSAT 70.94 8.90E-07 
        
QIGIQNK 
  
           11 proPO-p2 13 687.4319 687.7054 0.2735 509 514 IFIAPK 29.44 0.014 
   
797.4647 797.6594 0.1948 171 178 EAAAVIPK 37.97 0.0017 
   
808.5171 808.7054 0.1884 183 189 TPIIIPR 43.63 0.00052 
   
1199.655 1199.8914 0.2364 66 75 NLDKIPEFPK 48.49 0.00019 
   
1278.6608 1279.0114 0.3506 149 159 VQNYAEIFPAK 69.75 8.80E-07 
   
1310.6619 1311.0274 0.3655 160 170 FLDSQVFTQAR 87.73 1.70E-08 
   
1451.7157 1452.4732 0.7574 469 481 GLDFSDRGPVYAR 48.38 0.00014 
   
1477.6321 1478.1802 0.5481 190 201 DYTATDLEEEHR 41.51 0.00091 
   
1502.8093 1503.1174 0.3082 537 550 FVVPLSAGENTITR 89.12 1.20E-08 
   
1695.9043 1696.2194 0.3152 323 338 NIEEAIATGNVILPDK 69.88 1.20E-06 
   
1744.8414 1745.8192 0.9778 305 319 RPVDGLNVTIDDMER 69.52 1.00E-06 
   
1869.9109 1870.9894 1.0786 551 566 QSTESSLTIPFEQTFR 62.62 7.80E-06 
   
2012.0789 2013.1342 1.0552 323 341 NIEEAIATGNVILPDKSTK 66.42 2.60E-06 
 
serpin 3a  2 1509.71 1510.1294 0.4195 356 369 EAFEDTASFPGIAR 39.93 0.00093 
   
2375.2332 2376.0562 0.8229 386 408 TGIEVNELGSVAFSAT 64.18 4.30E-06 
        
QIGIQNK 
  
           12 proPO-p2 16 687.4319 687.6714 0.2395 509 514 IFIAPK 28.97 0.016 
   
797.4647 797.7554 0.2908 171 178 EAAAVIPK 34.49 0.0039 
   
808.5171 808.7054 0.1884 183 189 TPIIIPR 39.05 0.0015 
   
1086.5305 1086.7054 0.1749 567 576 DLSIQGSDPR 33.45 0.0066 
   
1126.5618 1126.7474 0.1856 682 691 LSDVTEPNPR 51.93 8.60E-05 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
12 proPO-p2 
 
1205.5968 1206.6574 1.0606 272 281 EPIPEAYYPK 25.03 0.054 
   
1278.6608 1278.8354 0.1746 149 159 VQNYAEIFPAK 53.15 5.10E-05 
   
1310.6619 1311.1894 0.5275 160 170 FLDSQVFTQAR 74.58 3.60E-07 
   
1326.7044 1326.9854 0.281 519 529 NLPWALSDQRK 54.54 4.00E-05 
   
1451.7157 1452.3832 0.6674 469 481 GLDFSDRGPVYAR 43.73 0.00036 
   
1477.6321 1477.8614 0.2294 190 201 DYTATDLEEEHR 80.85 8.30E-08 
   
1502.8093 1503.6894 0.8802 537 550 FVVPLSAGENTITR 96.98 1.80E-09 
   
1695.9043 1696.2614 0.3572 323 338 NIEEAIATGNVILPDK 67.85 1.90E-06 
   
1728.8465 1729.0534 0.207 305 319 RPVDGLNVTIDDMER 73.95 4.60E-07 
   
1744.8414 1745.7952 0.9538 305 319 RPVDGLNVTIDDMER 68.6 1.20E-06 
   
1869.9109 1870.9054 0.9946 551 566 QSTESSLTIPFEQTFR 79.8 1.50E-07 
           13 serpin 3a  10 895.5742 895.7774 0.2032 329 336 LVDVILPK 43.54 0.00044 
   
1148.5648 1148.7374 0.1726 163 172 IYMGEGVQPR 89.67 1.70E-08 
   
1181.575 1181.7834 0.2084 320 328 TEMIYLQER 54.74 3.70E-05 
   
1186.6022 1186.7474 0.1452 175 184 FAAIAQEFYK 49.37 0.00015 
   
1192.6815 1193.7982 1.1166 141 150 FSTIIESLKR 33.79 0.0032 
   
1288.6663 1288.9674 0.3011 443 455 VSDPALVDGAFKA 43.33 0.00064 
   
1334.683 1335.1154 0.4324 122 134 SELASALGFGLDR 83.42 3.80E-08 
   
1362.6779 1362.9694 0.2915 151 162 ESPDYILNLGSR 77.52 1.60E-07 
   
1459.7055 1459.8594 0.1539 201 213 EINNWVSNATQGK 69.14 1.40E-06 
   
1509.71 1509.9174 0.2075 356 369 EAFEDTASFPGIAR 64.42 3.30E-06 
 
proPO-p2 5 1126.5618 1126.7374 0.1756 682 691 LSDVTEPNPR 47.82 0.00023 
   
1278.6608 1278.7834 0.1226 149 159 VQNYAEIFPAK 56.86 2.40E-05 
   
1310.6619 1311.0794 0.4175 160 170 FLDSQVFTQAR 70.9 8.00E-07 
   
1477.6321 1478.4772 0.8451 190 201 DYTATDLEEEHR 27.95 0.021 
   
1502.8093 1502.9974 0.1882 537 550 FVVPLSAGENTITR 35.9 0.0028 
           14 serpin 3a  14 876.4817 876.6334 0.1517 370 376 GQLLYQR 47.09 0.00021 
   
895.5742 895.8374 0.2632 329 336 LVDVILPK 60.21 9.30E-06 
   
1056.5927 1056.7834 0.1907 311 319 VLNNLSELR 63.15 5.70E-06 
   
1164.5597 1164.7034 0.1437 163 172 IYMGEGVQPR 80.73 9.00E-08 
   
1181.575 1181.7794 0.2044 320 328 TEMIYLQER 49.88 0.00011 
   
1186.6022 1186.7854 0.1832 175 184 FAAIAQEFYK 48.34 0.00018 
   
1192.6815 1193.2372 0.5556 141 150 FSTIIESLKR 26.44 0.016 
   
1334.683 1335.0034 0.3204 122 134 SELASALGFGLDR 83.62 3.90E-08 
   
1362.6779 1363.0054 0.3275 151 162 ESPDYILNLGSR 73.94 3.60E-07 
   
1459.7055 1459.9114 0.2059 201 213 EINNWVSNATQGK 82.62 6.20E-08 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
14 serpin 3a 
 
1486.8355 1487.8394 1.004 107 121 LALAILTEAATGSTR 76.92 2.60E-07 
   
1509.71 1509.8974 0.1875 356 369 EAFEDTASFPGIAR 59.66 9.90E-06 
   
1730.9567 1731.1114 0.1548 90 106 VASTSNANFLLSPLGLK 84.15 4.00E-08 
   
2375.2332 2376.1672 0.9339 386 408 TGIEVNELGSVAFSAT 36.7 0.0024 
        
QIGIQNK 
  
 
proPO-p2 5 808.5171 808.6554 0.1384 183 189 TPIIIPR 39.85 0.0013 
   
1126.5618 1126.7114 0.1496 682 691 LSDVTEPNPR 46.02 0.00012 
   
1278.6608 1278.8934 0.2326 149 159 VQNYAEIFPAK 69.52 1.10E-06 
   
1310.6619 1311.1454 0.4835 160 170 FLDSQVFTQAR 82.27 6.10E-08 
   
1477.6321 1477.7752 0.1431 190 201 DYTATDLEEEHR 24.22 0.048 
           15 serpin 3a  12 876.4817 876.6954 0.2137 370 376 GQLLYQR 29.62 0.01 
   
895.5742 895.7474 0.1732 329 336 LVDVILPK 51.98 6.20E-05 
   
1056.5927 1056.8234 0.2307 311 319 VLNNLSELR 69.34 1.30E-06 
   
1148.5648 1149.3234 0.7586 163 172 IYMGEGVQPR 55.04 3.80E-05 
   
1181.575 1181.8094 0.2344 320 328 TEMIYLQER 26.06 0.026 
   
1186.6022 1186.8754 0.2732 175 184 FAAIAQEFYK 51.04 9.20E-05 
   
1192.6815 1193.1772 0.4956 141 150 FSTIIESLKR 25.69 0.019 
   
1334.683 1335.0514 0.3684 122 134 SELASALGFGLDR 85.72 2.30E-08 
   
1362.6779 1362.9214 0.2435 151 162 ESPDYILNLGSR 77.5 1.70E-07 
   
1459.7055 1459.9034 0.1979 201 213 EINNWVSNATQGK 78.78 1.50E-07 
   
1509.71 1509.9054 0.1955 356 369 EAFEDTASFPGIAR 50.17 8.90E-05 
   
1730.9567 1731.7234 0.7668 90 106 VASTSNANFLLSPLGLK 71.92 6.20E-07 
           16 serpin 3a  22 685.4123 685.6214 0.2092 345 350 LEGVLR 33.58 0.0037 
   
876.4817 876.6514 0.1697 370 376 GQLLYQR 47.35 0.00019 
   
895.5742 895.7754 0.2012 329 336 LVDVILPK 47.08 0.00019 
   
1036.5804 1036.7494 0.169 141 149 FSTIIESLK 39.76 0.0015 
   
1056.5927 1056.7614 0.1687 311 319 VLNNLSELR 70.34 1.10E-06 
   
1122.4804 1122.6514 0.171 337 344 FQFEYMSR 27.76 0.022 
   
1164.5597 1164.7394 0.1797 163 172 IYMGEGVQPR 87.75 1.70E-08 
   
1186.6022 1186.9474 0.3452 175 184 FAAIAQEFYK 58.42 1.60E-05 
   
1192.6815 1192.9094 0.2279 141 150 FSTIIESLKR 50.67 7.60E-05 
   
1197.5699 1197.7434 0.1735 320 328 TEMIYLQER 65.59 3.80E-06 
   
1217.6292 1217.8334 0.2042 443 454 VSDPALVDGAFK 94.12 4.20E-09 
   
1264.536 1264.7834 0.2474 271 280 DNFYYVDSSR 71.41 1.10E-06 
   
1288.6663 1289.0734 0.4071 443 455 VSDPALVDGAFKA 79.15 1.60E-07 
   
1320.7765 1321.4872 0.7107 140 150 KFSTIIESLKR 49.83 0.00011 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
16 serpin 3a 
 
1334.683 1335.0434 0.3604 122 134 SELASALGFGLDR 83.83 3.60E-08 
   
1362.6779 1363.0514 0.3735 151 162 ESPDYILNLGSR 77.5 1.50E-07 
   
1379.7197 1380.5254 0.8057 189 200 TTNFFKPEVAAR 47.85 0.00022 
   
1459.7055 1460.2534 0.5479 201 213 EINNWVSNATQGK 82.95 5.10E-08 
   
1486.8355 1487.1094 0.274 107 121 LALAILTEAATGSTR 103.31 6.00E-10 
   
1509.71 1510.7274 1.0175 356 369 EAFEDTASFPGIAR 77.24 2.30E-07 
   
1730.9567 1731.8614 0.9048 90 106 VASTSNANFLLSPLGLK 93.49 4.30E-09 
   
1819.9428 1820.7382 0.7954 122 138 SELASALGFGLDRTEVR 62.39 8.10E-06 
           17 serpin 3a  23 685.4123 685.5714 0.1592 345 350 LEGVLR 35.6 0.0022 
   
876.4817 876.6434 0.1617 370 376 GQLLYQR 44.37 0.00037 
   
895.5742 895.7474 0.1732 329 336 LVDVILPK 60.34 9.10E-06 
   
950.4895 950.6654 0.1759 263 270 TVPFMNVK 26.45 0.036 
   
1056.5927 1056.7554 0.1627 311 319 VLNNLSELR 70.39 1.10E-06 
   
1106.4855 1106.6954 0.2099 337 344 FQFEYMSR 33.24 0.0024 
   
1164.5597 1164.7294 0.1697 163 172 IYMGEGVQPR 87.87 1.60E-08 
   
1181.575 1181.8434 0.2684 320 328 TEMIYLQER 62.22 6.10E-06 
   
1186.6022 1186.7574 0.1552 175 184 FAAIAQEFYK 53.58 5.70E-05 
   
1192.6815 1193.0254 0.3439 141 150 FSTIIESLKR 54.95 2.70E-05 
   
1264.536 1264.7534 0.2174 271 280 DNFYYVDSSR 79.43 1.80E-07 
   
1288.6663 1288.9214 0.2551 443 455 VSDPALVDGAFKA 76.09 3.40E-07 
   
1320.7765 1321.5082 0.7317 140 150 KFSTIIESLKR 48.82 0.00013 
   
1334.683 1335.6054 0.9224 122 134 SELASALGFGLDR 80 9.70E-08 
   
1362.6779 1362.9814 0.3035 151 162 ESPDYILNLGSR 77.54 1.60E-07 
   
1379.7197 1380.5314 0.8117 189 200 TTNFFKPEVAAR 46.32 0.00032 
   
1459.7055 1459.9694 0.2639 201 213 EINNWVSNATQGK 69.81 1.20E-06 
   
1486.8355 1487.1174 0.282 107 121 LALAILTEAATGSTR 94.44 4.70E-09 
   
1509.71 1510.2254 0.5155 356 369 EAFEDTASFPGIAR 62.89 4.30E-06 
   
1730.9567 1731.8714 0.9148 90 106 VASTSNANFLLSPLGLK 68.19 1.50E-06 
   
1808.9495 1809.1374 0.188 295 310 YAMYIVVPNSLTGLPR 65.32 3.10E-06 
   
1819.9428 1820.8882 0.9454 122 138 SELASALGFGLDRTEVR 60.07 1.30E-05 
   
2010.0058 2010.9454 0.9396 30 49 AVFGYSALDQAALV 118.8 2.00E-11 
        
GAESNK 
  
 
GNBP-like  7 864.4593 864.5834 0.1242 472 478 LEVDYVK 29.25 0.018 
 
protein 
 
928.4978 928.6194 0.1217 381 389 VEPTASGLR 34.03 0.0049 
   
1013.5692 1013.7734 0.2043 398 405 QLPQMLLR 39.24 0.0016 
   
1023.5237 1023.5794 0.0558 109 117 DNLSFTVTK 43.71 0.00042 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
17 GNBP-like 
 
1214.6507 1215.5934 0.9428 61 72 NDVGTIAGEVLK 50.86 9.30E-05 
 
protein 
 
1460.6572 1460.7254 0.0683 314 325 QLYYGPNDYSNK 51.22 0.00011 
   
1626.8941 1627.1154 0.2214 57 72 GINKNDVGTIAGEVLK 78.15 1.70E-07 
           18 serpin 3a  4 1148.5648 1148.7174 0.1526 163 172 IYMGEGVQPR 75.72 4.20E-07 
   
1362.6779 1362.9714 0.2935 151 162 ESPDYILNLGSR 47.3 0.00017 
   
1486.8355 1487.0234 0.188 107 121 LALAILTEAATGSTR 52.98 6.60E-05 
   
2375.2332 2376.2302 0.9969 386 408 TGIEVNELGSVAFSAT 52.65 6.00E-05 
        
QIGIQNK 
  
           19 serpin 3a  4 876.4817 876.7074 0.2257 370 376 GQLLYQR 33.47 0.0043 
   
895.5742 895.8274 0.2532 329 336 LVDVILPK 35.39 0.0028 
   
1056.5927 1056.6994 0.1067 311 319 VLNNLSELR 42.81 0.00066 
   
1148.5648 1148.7794 0.2146 163 172 IYMGEGVQPR 67.81 2.40E-06 
           20 beta-1-tubulin 3 1313.6252 1313.8734 0.2483 47 58 INVYYNEASGGK 69.09 1.60E-06 
   
1334.6904 1334.9454 0.255 163 174 IMNTYSVVPSPK 64.63 3.20E-06 
   
1459.6977 1459.8714 0.1738 325 336 EVDEQMLNIQNK 35.75 0.003 
 
SPH-1b  4 762.464 762.6594 0.1955 303 308 YQVILK 28.01 0.011 
   
1053.6182 1053.7454 0.1272 309 317 KIEVPVVDR 24.4 0.038 
   
1098.6186 1099.0462 0.4276 239 247 IVVHKDFNK 27.72 0.013 
   
1141.5152 1142.0992 0.5839 217 226 AGEWDTQHAK 34.17 0.0038 
           21 SPH-1b 6 762.464 762.6574 0.1935 303 308 YQVILK 29.93 0.0073 
   
890.5589 890.7574 0.1985 303 309 YQVILKK 36.77 0.0027 
   
1053.6182 1053.8194 0.2012 309 317 KIEVPVVDR 47.95 0.00017 
   
1141.5152 1141.7734 0.2582 217 226 AGEWDTQHAK 36.67 0.0026 
   
1467.6841 1467.9254 0.2413 172 184 IEPVNENEPDGQK 46.95 0.00022 
   
1523.7005 1524.5014 0.801 227 238 EPYPYQDRDVSR 33.09 0.0051 
           22 serpin 3a  19 876.4817 876.6834 0.2017 370 376 GQLLYQR 42.26 0.00058 
   
895.5742 895.8194 0.2452 329 336 LVDVILPK 60.44 8.90E-06 
   
950.4895 950.6674 0.1779 263 270 TVPFMNVK 26.77 0.033 
   
1036.5804 1036.8234 0.243 141 149 FSTIIESLK 42.34 0.00078 
   
1056.5927 1056.8754 0.2827 311 319 VLNNLSELR 71.77 7.30E-07 
   
1106.4855 1106.7234 0.2379 337 344 FQFEYMSR 33.27 0.0052 
   
1148.5648 1148.8494 0.2846 163 172 IYMGEGVQPR 92.99 7.00E-09 
   
1186.6022 1187.0194 0.4172 175 184 FAAIAQEFYK 48.58 0.00015 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
22 serpin 3a  
 
1192.6815 1192.9954 0.3139 141 150 FSTIIESLKR 50.56 7.50E-05 
   
1197.5699 1197.8514 0.2815 320 328 TEMIYLQER 76.11 3.10E-07 
   
1217.6292 1217.9254 0.2962 443 454 VSDPALVDGAFK 94.18 4.10E-09 
   
1264.536 1264.8654 0.3294 271 280 DNFYYVDSSR 79.4 1.60E-07 
   
1288.6663 1289.0154 0.3491 443 455 VSDPALVDGAFKA 67.53 2.40E-06 
   
1320.7765 1321.6132 0.8367 140 150 KFSTIIESLKR 39.06 0.0013 
   
1334.683 1334.9774 0.2944 122 134 SELASALGFGLDR 86.97 1.80E-08 
   
1362.6779 1363.0514 0.3735 151 162 ESPDYILNLGSR 77.49 1.50E-07 
   
1379.7197 1379.8914 0.1717 189 200 TTNFFKPEVAAR 67.05 2.30E-06 
   
1459.7055 1459.9694 0.2639 201 213 EINNWVSNATQGK 81.2 8.40E-08 
   
1509.71 1509.8794 0.1695 356 369 EAFEDTASFPGIAR 77.52 1.60E-07 
 
SPH-1b  5 762.464 762.6074 0.1435 303 308 YQVILK 23.82 0.031 
   
925.5233 925.7294 0.2062 310 317 IEVPVVDR 23.4 0.044 
   
1053.6182 1053.8834 0.2652 309 317 KIEVPVVDR 38.18 0.0016 
   
1467.6841 1468.3312 0.647 172 184 IEPVNENEPDGQK 25.17 0.038 
   
1523.7005 1524.5092 0.8087 227 238 EPYPYQDRDVSR 36.22 0.0032 
           23 serpin 3a 21 876.4817 876.6614 0.1797 370 376 GQLLYQR 42.28 0.00059 
   
895.5742 895.8054 0.2312 329 336 LVDVILPK 54.48 3.50E-05 
   
950.4895 950.7054 0.2159 263 270 TVPFMNVK 25.65 0.041 
   
1036.5804 1036.7734 0.193 141 149 FSTIIESLK 40.63 0.0012 
   
1056.5927 1056.8854 0.2927 311 319 VLNNLSELR 71.96 6.80E-07 
   
1122.4804 1122.6594 0.179 337 344 FQFEYMSR 26.65 0.028 
   
1164.5597 1164.7734 0.2137 163 172 IYMGEGVQPR 93.1 4.50E-09 
   
1186.6022 1186.9254 0.3232 175 184 FAAIAQEFYK 50.29 0.00011 
   
1192.6815 1192.9734 0.2919 141 150 FSTIIESLKR 47.32 0.00016 
   
1197.5699 1197.8314 0.2615 320 328 TEMIYLQER 64.16 4.80E-06 
   
1217.6292 1217.9154 0.2862 443 454 VSDPALVDGAFK 94.13 4.20E-09 
   
1264.536 1264.7594 0.2234 271 280 DNFYYVDSSR 76.61 3.40E-07 
   
1288.6663 1289.0294 0.3631 443 455 VSDPALVDGAFKA 73.46 6.10E-07 
   
1320.7765 1321.5622 0.7857 140 150 KFSTIIESLKR 46.2 0.00025 
   
1334.683 1335.0714 0.3884 122 134 SELASALGFGLDR 83.76 3.60E-08 
   
1362.6779 1363.0654 0.3875 151 162 ESPDYILNLGSR 77.52 1.50E-07 
   
1379.7197 1380.4874 0.7677 189 200 TTNFFKPEVAAR 58.2 1.90E-05 
   
1459.7055 1460.4314 0.7259 201 213 EINNWVSNATQGK 78.16 1.80E-07 
   
1486.8355 1487.1714 0.336 107 121 LALAILTEAATGSTR 90.51 1.10E-08 
   
1509.71 1510.8214 1.1115 356 369 EAFEDTASFPGIAR 55.39 3.60E-05 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
23 serpin 3a 
 
1730.9567 1731.9314 0.9748 90 106 VASTSNANFLLSPLGLK 84.02 3.80E-08 
           24 serpin 3a 21 876.4817 876.6374 0.1557 370 376 GQLLYQR 35.07 0.0032 
   
895.5742 895.7974 0.2232 329 336 LVDVILPK 60.29 9.20E-06 
   
1036.5804 1036.7714 0.191 141 149 FSTIIESLK 40.7 0.0012 
   
1056.5927 1056.8714 0.2787 311 319 VLNNLSELR 71.69 7.40E-07 
   
1122.4804 1122.6374 0.157 337 344 FQFEYMSR 27.72 0.022 
   
1164.5597 1164.7154 0.1557 163 172 IYMGEGVQPR 87.91 1.70E-08 
   
1164.6754 1165.0754 0.4 140 149 KFSTIIESLK 38.39 0.0012 
   
1181.575 1181.8394 0.2644 320 328 TEMIYLQER 58.69 1.40E-05 
   
1186.6022 1186.9794 0.3772 175 184 FAAIAQEFYK 53.1 5.40E-05 
   
1192.6815 1192.9754 0.2939 141 150 FSTIIESLKR 63.93 3.50E-06 
   
1217.6292 1217.9094 0.2802 443 454 VSDPALVDGAFK 94.16 4.20E-09 
   
1264.536 1264.7154 0.1794 271 280 DNFYYVDSSR 73.99 6.60E-07 
   
1288.6663 1289.0334 0.3671 443 455 VSDPALVDGAFKA 80.85 1.10E-07 
   
1320.7765 1321.5142 0.7377 140 150 KFSTIIESLKR 62 6.50E-06 
   
1334.683 1335.0454 0.3624 122 134 SELASALGFGLDR 83.73 3.60E-08 
   
1362.6779 1363.0874 0.4095 151 162 ESPDYILNLGSR 77.54 1.50E-07 
   
1379.7197 1379.9794 0.2597 189 200 TTNFFKPEVAAR 58.05 1.80E-05 
   
1459.7055 1460.1954 0.4899 201 213 EINNWVSNATQGK 78.89 1.30E-07 
   
1486.8355 1487.1174 0.282 107 121 LALAILTEAATGSTR 98.35 1.90E-09 
   
1509.71 1510.4914 0.7815 356 369 EAFEDTASFPGIAR 68.1 1.30E-06 
   
1730.9567 1731.3714 0.4148 90 106 VASTSNANFLLSPLGLK 72.21 5.40E-07 
           25 serpin 3a 17 685.4123 685.6594 0.2472 345 350 LEGVLR 29.14 0.0098 
   
876.4817 876.6554 0.1737 370 376 GQLLYQR 35.79 0.0027 
   
895.5742 895.8014 0.2272 329 336 LVDVILPK 55.75 2.60E-05 
   
1036.5804 1036.7414 0.161 141 149 FSTIIESLK 42.27 0.00082 
   
1056.5927 1056.8834 0.2907 311 319 VLNNLSELR 68.21 1.60E-06 
   
1164.5597 1164.7614 0.2017 163 172 IYMGEGVQPR 87.91 1.50E-08 
   
1186.6022 1186.9634 0.3612 175 184 FAAIAQEFYK 50.08 0.00011 
   
1192.6815 1193.5914 0.9099 141 150 FSTIIESLKR 51.87 6.90E-05 
   
1197.5699 1197.8194 0.2495 320 328 TEMIYLQER 76.12 3.10E-07 
   
1217.6292 1217.8954 0.2662 443 454 VSDPALVDGAFK 94.06 4.30E-09 
   
1264.536 1264.7834 0.2474 271 280 DNFYYVDSSR 71.42 1.10E-06 
   
1288.6663 1289.0054 0.3391 443 455 VSDPALVDGAFKA 83.68 5.80E-08 
   
1334.683 1334.9154 0.2324 122 134 SELASALGFGLDR 94.05 3.80E-09 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
25 serpin 3a 
 
1362.6779 1363.0474 0.3695 151 162 ESPDYILNLGSR 77.49 1.50E-07 
   
1379.7197 1380.4534 0.7337 189 200 TTNFFKPEVAAR 47.83 0.0002 
   
1459.7055 1460.4814 0.7759 201 213 EINNWVSNATQGK 80.93 1.00E-07 
   
1509.71 1509.9334 0.2235 356 369 EAFEDTASFPGIAR 67.44 1.70E-06 
           26 serpin 3a 19 876.4817 876.6674 0.1857 370 376 GQLLYQR 44.41 0.00036 
   
895.5742 895.8154 0.2412 329 336 LVDVILPK 52.06 6.10E-05 
   
1036.5804 1036.7934 0.213 141 149 FSTIIESLK 41.82 0.00089 
   
1056.5927 1056.7534 0.1607 311 319 VLNNLSELR 66.42 2.70E-06 
   
1148.5648 1148.7254 0.1606 163 172 IYMGEGVQPR 89.58 1.70E-08 
   
1164.6754 1164.9574 0.282 140 149 KFSTIIESLK 37.18 0.0015 
   
1181.575 1181.8194 0.2444 320 328 TEMIYLQER 62.25 6.10E-06 
   
1186.6022 1186.9654 0.3632 175 184 FAAIAQEFYK 49.89 0.00011 
   
1192.6815 1193.0034 0.3219 141 150 FSTIIESLKR 47.58 0.00015 
   
1217.6292 1217.9134 0.2842 443 454 VSDPALVDGAFK 79.49 1.20E-07 
   
1264.536 1264.8414 0.3054 271 280 DNFYYVDSSR 71.43 1.00E-06 
   
1288.6663 1289.0354 0.3691 443 455 VSDPALVDGAFKA 74.24 5.10E-07 
   
1320.7765 1321.5082 0.7317 140 150 KFSTIIESLKR 48.6 0.00014 
   
1334.683 1335.0414 0.3584 122 134 SELASALGFGLDR 86.97 1.70E-08 
   
1362.6779 1363.0834 0.4055 151 162 ESPDYILNLGSR 77.58 1.50E-07 
   
1379.7197 1379.9014 0.1817 189 200 TTNFFKPEVAAR 62.31 6.80E-06 
   
1459.7055 1460.2174 0.5119 201 213 EINNWVSNATQGK 80.96 8.30E-08 
   
1509.71 1510.5994 0.8895 356 369 EAFEDTASFPGIAR 70.21 1.00E-06 
   
1730.9567 1732.0074 1.0508 90 106 VASTSNANFLLSPLGLK 84.3 3.60E-08 
           27 serpin 3a 17 876.4817 876.6494 0.1677 370 376 GQLLYQR 44.6 0.00035 
   
895.5742 895.7634 0.1892 329 336 LVDVILPK 60.35 9.10E-06 
   
1036.5804 1036.8994 0.319 141 149 FSTIIESLK 42.42 0.00075 
   
1056.5927 1056.7794 0.1867 311 319 VLNNLSELR 66.01 3.00E-06 
   
1164.5597 1164.7174 0.1577 163 172 IYMGEGVQPR 83.03 5.10E-08 
   
1181.575 1181.8494 0.2744 320 328 TEMIYLQER 68.04 1.60E-06 
   
1186.6022 1186.9374 0.3352 175 184 FAAIAQEFYK 53.45 5.10E-05 
   
1192.6815 1193.0094 0.3279 141 150 FSTIIESLKR 47.19 0.00016 
   
1217.6292 1217.8014 0.1722 443 454 VSDPALVDGAFK 74.66 3.60E-07 
   
1264.536 1264.8534 0.3174 271 280 DNFYYVDSSR 71.41 1.00E-06 
   
1288.6663 1288.9654 0.2991 443 455 VSDPALVDGAFKA 64.25 5.20E-06 
   
1334.683 1335.0094 0.3264 122 134 SELASALGFGLDR 89.62 9.70E-09 
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count 
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Start End Peptide sequence Ion 
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E-value 
27 serpin 3a 
 
1362.6779 1363.0114 0.3335 151 162 ESPDYILNLGSR 77.48 1.60E-07 
   
1379.7197 1379.9074 0.1877 189 200 TTNFFKPEVAAR 53.89 4.70E-05 
   
1459.7055 1460.4494 0.7439 201 213 EINNWVSNATQGK 72.4 7.00E-07 
   
1509.71 1509.9474 0.2375 356 369 EAFEDTASFPGIAR 53.83 4.00E-05 
   
1730.9567 1731.0114 0.0548 90 106 VASTSNANFLLSPLGLK 67.87 6.40E-07 
 
SPH-1b  3 762.464 762.6434 0.1795 303 308 YQVILK 26.94 0.015 
   
1053.6182 1053.7994 0.1812 309 317 KIEVPVVDR 27.85 0.017 
   
1467.6841 1467.8794 0.1953 172 184 IEPVNENEPDGQK 49.28 0.00013 
           28 serpin 3a 15 876.4817 876.6254 0.1437 370 376 GQLLYQR 47.36 0.0002 
   
895.5742 895.8174 0.2432 329 336 LVDVILPK 60.2 9.40E-06 
   
1036.5804 1036.8654 0.285 141 149 FSTIIESLK 32.9 0.0068 
   
1056.5927 1056.8494 0.2567 311 319 VLNNLSELR 69.61 1.20E-06 
   
1122.4804 1122.6774 0.197 337 344 FQFEYMSR 30.51 0.011 
   
1164.5597 1164.7114 0.1517 163 172 IYMGEGVQPR 85.25 3.10E-08 
   
1181.575 1181.8034 0.2284 320 328 TEMIYLQER 62.25 6.20E-06 
   
1186.6022 1186.9894 0.3872 175 184 FAAIAQEFYK 51.93 7.10E-05 
   
1192.6815 1192.9834 0.3019 141 150 FSTIIESLKR 58.85 1.10E-05 
   
1264.536 1264.9294 0.3934 271 280 DNFYYVDSSR 79.39 1.50E-07 
   
1334.683 1335.0054 0.3224 122 134 SELASALGFGLDR 80.67 7.70E-08 
   
1362.6779 1363.0754 0.3975 151 162 ESPDYILNLGSR 77.51 1.50E-07 
   
1379.7197 1379.9034 0.1837 189 200 TTNFFKPEVAAR 66.85 2.40E-06 
   
1459.7055 1460.6074 0.9019 201 213 EINNWVSNATQGK 78.12 2.20E-07 
   
1509.71 1509.8974 0.1875 356 369 EAFEDTASFPGIAR 54.37 3.30E-05 
 
SPH-4  5 762.464 762.6454 0.1815 275 280 YQVILK 23.98 0.029 
   
890.5589 890.6754 0.1165 275 281 YQVILKK 34.76 0.0044 
   
925.5233 925.6774 0.1542 282 289 IEVPVVDR 26.56 0.02 
   
1053.6182 1053.7994 0.1812 281 289 KIEVPVVDR 38.17 0.0016 
   
1292.7452 1293.5392 0.794 98 108 RPEVTPKPELK 32.05 0.012 
           29 serpin 3a  19 876.4817 876.6354 0.1537 370 376 GQLLYQR 44.64 0.00036 
   
895.5742 895.8114 0.2372 329 336 LVDVILPK 60.18 9.50E-06 
   
950.4895 950.6694 0.1799 263 270 TVPFMNVK 25.39 0.046 
   
1036.5804 1036.7794 0.199 141 149 FSTIIESLK 42.62 0.00075 
   
1056.5927 1056.8354 0.2427 311 319 VLNNLSELR 70.16 1.10E-06 
   
1106.4855 1106.6254 0.1399 337 344 FQFEYMSR 26.87 0.025 
   
1148.5648 1148.7754 0.2106 163 172 IYMGEGVQPR 81.23 1.10E-07 
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count 
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E-value 
29 serpin 3a 
 
1186.6022 1186.9074 0.3052 175 184 FAAIAQEFYK 50.16 0.00011 
   
1192.6815 1193.2462 0.5646 141 150 FSTIIESLKR 31.25 0.0054 
   
1197.5699 1197.8094 0.2395 320 328 TEMIYLQER 62.56 7.00E-06 
   
1264.536 1264.7454 0.2094 271 280 DNFYYVDSSR 80.04 1.60E-07 
   
1320.7765 1321.6012 0.8247 140 150 KFSTIIESLKR 46.81 0.00022 
   
1334.683 1335.0574 0.3744 122 134 SELASALGFGLDR 83.77 3.60E-08 
   
1362.6779 1362.9794 0.3015 151 162 ESPDYILNLGSR 79.48 1.00E-07 
   
1379.7197 1379.9234 0.2037 189 200 TTNFFKPEVAAR 62.18 6.90E-06 
   
1459.7055 1460.2234 0.5179 201 213 EINNWVSNATQGK 84.07 4.00E-08 
   
1486.8355 1487.0554 0.22 107 121 LALAILTEAATGSTR 95.01 4.10E-09 
   
1509.71 1510.5154 0.8055 356 369 EAFEDTASFPGIAR 67.69 1.60E-06 
   
1730.9567 1731.8794 0.9228 90 106 VASTSNANFLLSPLGLK 84.16 3.70E-08 
 
SPH-4  5 762.464 762.7054 0.2415 275 280 YQVILK 24.44 0.025 
   
890.5589 890.6674 0.1085 275 281 YQVILKK 36.09 0.0033 
   
925.5233 925.6874 0.1642 282 289 IEVPVVDR 29.93 0.0097 
   
1053.6182 1053.8154 0.1972 281 289 KIEVPVVDR 41.65 0.00071 
   
1292.7452 1293.4312 0.686 98 108 RPEVTPKPELK 28.19 0.029 
           30 serpin 3a 15 685.4123 685.6134 0.2012 345 350 LEGVLR 32.02 0.0053 
   
876.4817 876.6834 0.2017 370 376 GQLLYQR 44.46 0.00035 
   
895.5742 895.7934 0.2192 329 336 LVDVILPK 60.33 9.10E-06 
   
1036.5804 1036.7974 0.217 141 149 FSTIIESLK 44.35 0.0005 
   
1056.5927 1056.8374 0.2447 311 319 VLNNLSELR 69.56 1.20E-06 
   
1122.4804 1122.6514 0.171 337 344 FQFEYMSR 27.31 0.024 
   
1148.5648 1148.7754 0.2106 163 172 IYMGEGVQPR 80.1 1.40E-07 
   
1181.575 1181.7874 0.2124 320 328 TEMIYLQER 71.28 8.20E-07 
   
1186.6022 1186.9874 0.3852 175 184 FAAIAQEFYK 53.5 4.90E-05 
   
1192.6815 1192.9354 0.2539 141 150 FSTIIESLKR 65.19 2.60E-06 
   
1264.536 1264.7334 0.1974 271 280 DNFYYVDSSR 71.45 1.20E-06 
   
1362.6779 1363.0294 0.3515 151 162 ESPDYILNLGSR 77.44 1.60E-07 
   
1379.7197 1379.8734 0.1537 189 200 TTNFFKPEVAAR 50.1 0.00011 
   
1459.7055 1459.9354 0.2299 201 213 EINNWVSNATQGK 68.22 1.70E-06 
   
1509.71 1509.9854 0.2755 356 369 EAFEDTASFPGIAR 63.52 4.10E-06 
 
proPO-p2 2 1086.5305 1086.7014 0.1709 567 576 DLSIQGSDPR 67.09 1.20E-06 
   
1126.5618 1126.7214 0.1596 682 691 LSDVTEPNPR 52.6 7.60E-05 
 
serpin-4a  2 1086.6073 1086.9434 0.3361 98 106 EISNWLVVK 27.72 0.021 
   
1241.5533 1241.8494 0.2962 217 226 IGEVNMMYNR 74.38 4.30E-07 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
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score* 
E-value 
30 SPH-1b 2 762.464 762.6154 0.1515 303 308 YQVILK 28.23 0.011 
   
1467.6841 1467.9474 0.2633 172 184 IEPVNENEPDGQK 45.89 0.00028 
 
SPH-4  2 762.464 762.6154 0.1515 275 280 YQVILK 28.23 0.011 
   
1497.696 1498.8262 1.1301 199 210 EPYPHQDRDVSR 27.77 0.017 
           31 serpin 3a  6 895.5742 895.7814 0.2072 329 336 LVDVILPK 51.47 7.00E-05 
   
1056.5927 1056.7334 0.1407 311 319 VLNNLSELR 54.06 4.70E-05 
   
1164.5597 1164.8834 0.3237 163 172 IYMGEGVQPR 63.63 3.60E-06 
   
1186.6022 1186.7074 0.1052 175 184 FAAIAQEFYK 24.5 0.049 
   
1197.5699 1197.0874 -0.4825 320 328 TEMIYLQER 30.72 0.0097 
   
1459.7055 1459.9414 0.2359 201 213 EINNWVSNATQGK 65.93 2.80E-06 
           32 serpin 3a  7 876.4817 876.5934 0.1117 370 376 GQLLYQR 28.71 0.015 
   
895.5742 895.9454 0.3712 329 336 LVDVILPK 43.97 0.00035 
   
1056.5927 1057.7374 1.1447 311 319 VLNNLSELR 26.05 0.03 
   
1148.5648 1148.7094 0.1446 163 172 IYMGEGVQPR 91.14 1.30E-08 
   
1181.575 1181.5794 0.0044 320 328 TEMIYLQER 25.68 0.029 
   
1264.536 1264.8894 0.3534 271 280 DNFYYVDSSR 24.4 0.049 
   
1362.6779 1362.8334 0.1555 151 162 ESPDYILNLGSR 77.3 2.00E-07 
           33 SPH-2  9 813.4708 813.7494 0.2786 235 241 NDIALLR 40.56 0.001 
   
946.5488 947.1652 0.6164 227 234 DFKPLSLK 28.69 0.017 
   
1093.6131 1093.8214 0.2083 218 226 DVQEILIHK 43.54 0.00049 
   
1105.4716 1105.6454 0.1738 389 398 WGYGSSTYSV 41.6 0.00068 
   
1171.508 1171.7494 0.2414 380 388 HWVDENMNK 66.98 8.20E-07 
   
1196.5608 1197.0382 0.4774 293 302 VEQDMVPHSR 29.52 0.01 
   
1324.6558 1324.7514 0.0957 292 302 KVEQDMVPHSR 69.19 1.90E-06 
   
1521.8039 1522.5772 0.7733 114 127 DPSEVVKPKPDPSK 42.58 0.00067 
   
1862.0513 1862.9272 0.8759 111 127 VLKDPSEVVKPKPDPSK 56.21 2.70E-05 
           34 SPH-2  10 813.4708 813.6774 0.2066 235 241 NDIALLR 42.14 0.00072 
   
946.5488 947.0512 0.5024 227 234 DFKPLSLK 26.41 0.029 
   
1093.6131 1093.8534 0.2403 218 226 DVQEILIHK 45.23 0.00033 
   
1105.4716 1105.7794 0.3078 389 398 WGYGSSTYSV 42.24 0.00062 
   
1147.5509 1147.7034 0.1525 200 209 AGEWDTQTIK 41.66 0.00096 
   
1171.508 1171.7934 0.2854 380 388 HWVDENMNK 66.94 2.40E-06 
   
1196.5608 1197.2032 0.6424 293 302 VEQDMVPHSR 44.12 0.00036 
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count 
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Start End Peptide sequence Ion 
score* 
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34 SPH-2  
 
1324.6558 1324.7834 0.1277 292 302 KVEQDMVPHSR 72.36 9.00E-07 
   
1521.8039 1522.5082 0.7043 114 127 DPSEVVKPKPDPSK 26.42 0.026 
   
1862.0513 1862.8942 0.8429 111 127 VLKDPSEVVKPKPDPSK 54.5 4.10E-05 
           35 SPH-4  6 762.464 762.4627 -0.0012 275 280 YQVILK 32.54 0.0064 
   
868.4767 868.6174 0.1408 116 123 NPEGVVVR 61.73 8.60E-06 
   
890.5589 890.6454 0.0865 275 281 YQVILKK 33.49 0.006 
   
925.5233 925.6714 0.1482 282 289 IEVPVVDR 25.63 0.025 
   
1053.6182 1053.8294 0.2112 281 289 KIEVPVVDR 41.69 0.00071 
   
1098.6186 1099.1572 0.5386 211 219 IVVHKDFNK 34.21 0.0028 
           36 serpin 3a  4 895.5742 895.8054 0.2312 329 336 LVDVILPK 36.54 0.0022 
   
1056.5927 1056.6154 0.0227 311 319 VLNNLSELR 36.48 0.0031 
   
1164.5597 1164.7054 0.1457 163 172 IYMGEGVQPR 66.97 2.10E-06 
   
1459.7055 1459.7714 0.0659 201 213 EINNWVSNATQGK 39.64 0.0012 
           37 serpin 3a  16 685.4123 685.6874 0.2752 345 350 LEGVLR 25.98 0.02 
   
876.4817 876.6734 0.1917 370 376 GQLLYQR 55.48 2.80E-05 
   
895.5742 895.8134 0.2392 329 336 LVDVILPK 46.24 0.00023 
   
1036.5804 1036.7334 0.153 141 149 FSTIIESLK 33.62 0.0061 
   
1056.5927 1056.7814 0.1887 311 319 VLNNLSELR 53.36 5.40E-05 
   
1164.5597 1164.7274 0.1677 163 172 IYMGEGVQPR 86.25 2.40E-08 
   
1164.6754 1164.9414 0.266 140 149 KFSTIIESLK 37.29 0.0015 
   
1186.6022 1186.9134 0.3112 175 184 FAAIAQEFYK 51.94 7.30E-05 
   
1192.6815 1192.8854 0.2039 141 150 FSTIIESLKR 40.03 0.0009 
   
1197.5699 1197.7574 0.1875 320 328 TEMIYLQER 65.6 3.80E-06 
   
1264.536 1264.7094 0.1734 271 280 DNFYYVDSSR 71.35 1.20E-06 
   
1334.683 1335.0394 0.3564 122 134 SELASALGFGLDR 89.28 1.00E-08 
   
1362.6779 1362.9714 0.2935 151 162 ESPDYILNLGSR 77.46 1.60E-07 
   
1379.7197 1379.8734 0.1537 189 200 TTNFFKPEVAAR 45.47 0.00033 
   
1459.7055 1459.8574 0.1519 201 213 EINNWVSNATQGK 87.44 2.00E-08 
   
1509.71 1509.8574 0.1475 356 369 EAFEDTASFPGIAR 51.97 5.80E-05 
           38 serpin 3a  21 685.4123 685.7114 0.2992 345 350 LEGVLR 36.26 0.0019 
   
876.4817 876.6754 0.1937 370 376 GQLLYQR 50.71 8.30E-05 
   
895.5742 895.8294 0.2552 329 336 LVDVILPK 60.26 9.20E-06 
   
1036.5804 1036.7374 0.157 141 149 FSTIIESLK 31.06 0.011 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
38 serpin 3a 
 
1056.5927 1056.8374 0.2447 311 319 VLNNLSELR 69.65 1.20E-06 
   
1122.4804 1122.7094 0.229 337 344 FQFEYMSR 25.61 0.033 
   
1164.5597 1164.7414 0.1817 163 172 IYMGEGVQPR 82.24 5.90E-08 
   
1186.6022 1186.9274 0.3252 175 184 FAAIAQEFYK 53.09 5.50E-05 
   
1192.6815 1192.9194 0.2379 141 150 FSTIIESLKR 51.07 6.90E-05 
   
1197.5699 1197.7674 0.1975 320 328 TEMIYLQER 62.49 7.60E-06 
   
1217.6292 1217.7994 0.1702 443 454 VSDPALVDGAFK 71.22 8.00E-07 
   
1264.536 1264.7654 0.2294 271 280 DNFYYVDSSR 79.42 1.80E-07 
   
1288.6663 1288.9154 0.2491 443 455 VSDPALVDGAFKA 70.78 1.20E-06 
   
1320.7765 1321.1542 0.3777 140 150 KFSTIIESLKR 37.95 0.0015 
   
1334.683 1335.6654 0.9824 122 134 SELASALGFGLDR 89.62 1.10E-08 
   
1362.6779 1362.9734 0.2955 151 162 ESPDYILNLGSR 77.56 1.60E-07 
   
1379.7197 1380.5794 0.8597 189 200 TTNFFKPEVAAR 39.12 0.0018 
   
1459.7055 1459.9214 0.2159 201 213 EINNWVSNATQGK 78.01 1.80E-07 
   
1509.71 1509.9174 0.2075 356 369 EAFEDTASFPGIAR 64.76 3.10E-06 
   
1730.9567 1731.7554 0.7988 90 106 VASTSNANFLLSPLGLK 73.45 4.20E-07 
   
2010.0058 2010.8854 0.8797 30 49 AVFGYSALDQAALV 70.16 1.50E-06 
        
GAESNK 
  
           39 serpin 3a  15 685.4123 685.6654 0.2532 345 350 LEGVLR 32.99 0.004 
   
876.4817 876.6654 0.1837 370 376 GQLLYQR 50.71 8.40E-05 
   
895.5742 895.7974 0.2232 329 336 LVDVILPK 60.25 9.30E-06 
   
1036.5804 1036.7494 0.169 141 149 FSTIIESLK 41.78 0.00092 
   
1056.5927 1056.7834 0.1907 311 319 VLNNLSELR 67.7 2.00E-06 
   
1164.5597 1164.7394 0.1797 163 172 IYMGEGVQPR 87.99 1.60E-08 
   
1186.6022 1186.8794 0.2772 175 184 FAAIAQEFYK 50.1 0.00011 
   
1192.6815 1193.6394 0.9579 141 150 FSTIIESLKR 51 8.40E-05 
   
1197.5699 1197.7514 0.1815 320 328 TEMIYLQER 75.99 3.40E-07 
   
1264.536 1264.7674 0.2314 271 280 DNFYYVDSSR 79.41 1.80E-07 
   
1320.7765 1321.7722 0.9957 140 150 KFSTIIESLKR 32.13 0.0064 
   
1362.6779 1363.0494 0.3715 151 162 ESPDYILNLGSR 77.46 1.50E-07 
   
1379.7197 1380.5614 0.8417 189 200 TTNFFKPEVAAR 42.14 0.00087 
   
1459.7055 1459.9114 0.2059 201 213 EINNWVSNATQGK 69.39 1.30E-06 
   
1509.71 1509.9154 0.2055 356 369 EAFEDTASFPGIAR 59.65 1.00E-05 
 
PAP-3 2 799.4552 799.7174 0.2623 276 282 NDIGLIR 41.09 0.0011 
   
1422.7255 1422.8594 0.1339 261 272 TIPHPEYNPISR 37.95 0.0018 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
41 PRSP (HP14) 3 711.3955 711.6474 0.2519 178 183 FIAAYK 28.65 0.011 
   
989.4818 989.6534 0.1717 327 334 EHVSVEYK 28.31 0.013 
   
1404.6674 1404.7514 0.0841 363 373 KPNYYSETTFR 43.47 0.00078 
           43 serpin 3a  8 895.5742 895.8534 0.2792 329 336 LVDVILPK 50.45 8.80E-05 
   
1056.5927 1056.8134 0.2207 311 319 VLNNLSELR 78.22 1.70E-07 
   
1164.5597 1164.8054 0.2457 163 172 IYMGEGVQPR 75.89 2.30E-07 
   
1186.6022 1186.8014 0.1992 175 184 FAAIAQEFYK 42.85 0.00064 
   
1197.5699 1197.8294 0.2595 320 328 TEMIYLQER 62.43 7.20E-06 
   
1264.536 1264.7514 0.2154 271 280 DNFYYVDSSR 36.24 0.0038 
   
1288.6663 1288.8254 0.1591 443 455 VSDPALVDGAFKA 66.14 3.60E-06 
   
1362.6779 1363.0294 0.3515 151 162 ESPDYILNLGSR 44.25 0.00033 
           51 proPO-p2 3 808.5171 808.6834 0.1664 183 189 TPIIIPR 38.36 0.0018 
   
1278.6608 1278.8834 0.2226 149 159 VQNYAEIFPAK 33.77 0.0041 
   
1310.6619 1310.9094 0.2475 160 170 FLDSQVFTQAR 70.25 9.80E-07 
 
serpin 3a  2 1056.5927 1056.7814 0.1887 311 319 VLNNLSELR 60.27 1.10E-05 
   
1362.6779 1362.9614 0.2835 151 162 ESPDYILNLGSR 58.62 1.30E-05 
           52 serpin 3a  10 876.4817 876.6734 0.1917 370 376 GQLLYQR 55.7 2.60E-05 
   
895.5742 895.8134 0.2392 329 336 LVDVILPK 49.93 0.0001 
   
1056.5927 1056.7694 0.1767 311 319 VLNNLSELR 58.14 1.80E-05 
   
1122.4804 1122.6654 0.185 337 344 FQFEYMSR 24.77 0.042 
   
1164.5597 1164.7274 0.1677 163 172 IYMGEGVQPR 87.79 1.70E-08 
   
1186.6022 1186.8714 0.2692 175 184 FAAIAQEFYK 58.47 1.70E-05 
   
1192.6815 1193.0872 0.4056 141 150 FSTIIESLKR 24.39 0.026 
   
1197.5699 1197.8774 0.3075 320 328 TEMIYLQER 60.48 1.10E-05 
   
1264.536 1264.7034 0.1674 271 280 DNFYYVDSSR 68.89 2.10E-06 
   
1362.6779 1362.9574 0.2795 151 162 ESPDYILNLGSR 77.42 1.70E-07 
           54 immulectin-2b  7 1173.5596 1173.5174 -0.0421 71 80 FAMASMMILK 55.77 3.30E-05 
   
1254.5955 1254.6914 0.096 30 39 YLDVIDGWMK 53.93 5.40E-05 
   
1307.6762 1307.6974 0.0213 97 108 GDFFSVEGIPLK 74.04 4.00E-07 
   
1435.7711 1435.8274 0.0563 97 109 GDFFSVEGIPLKK 73.13 5.80E-07 
   
1449.7365 1449.7074 -0.029 84 96 QSVFTGIHATFSR 51.97 3.00E-05 
   
1471.732 1471.7294 -0.0026 40 51 LHEIPANWHEAR 59.63 1.10E-05 
   
1989.9771 1990.7392 0.7621 217 233 EIFAQHLPASMVGNFWK 63.86 4.30E-06 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
54 immulectin-2a  6 1240.5798 1240.5714 -0.0084 30 39 YLDVVDGWMK 54.64 4.10E-05 
   
1307.6762 1307.6974 0.0213 97 108 GDFFSVEGIPLK 74.04 4.00E-07 
   
1435.7711 1435.8274 0.0563 97 109 GDFFSVEGIPLKK 73.13 5.80E-07 
   
1449.7365 1449.7074 -0.029 84 96 QSVFTGIHATFSR 51.97 3.00E-05 
   
1471.732 1471.7294 -0.0026 40 51 LHEIPANWHEAR 59.63 1.10E-05 
   
1989.9771 1990.7392 0.7621 217 233 EIFAQHLPASMVGNFWK 63.86 4.30E-06 
           55 immulectin-2b  7 1157.5647 1157.5334 -0.0312 71 80 FAMASMMILK 72.37 6.90E-07 
   
1254.5955 1254.6414 0.046 30 39 YLDVIDGWMK 57.28 2.50E-05 
   
1307.6762 1307.7654 0.0893 97 108 GDFFSVEGIPLK 64.61 3.50E-06 
   
1435.7711 1435.7594 -0.0117 97 109 GDFFSVEGIPLKK 58.72 1.60E-05 
   
1449.7365 1450.1302 0.3937 84 96 QSVFTGIHATFSR 55.22 2.40E-05 
   
1471.732 1471.7074 -0.0246 40 51 LHEIPANWHEAR 59.7 1.10E-05 
   
1989.9771 1990.7872 0.8101 217 233 EIFAQHLPASMVGNFWK 65.98 2.80E-06 
           56 immulectin-2b  5 1254.5955 1254.5934 -0.002 30 39 YLDVIDGWMK 54.06 5.40E-05 
   
1307.6762 1307.7694 0.0933 97 108 GDFFSVEGIPLK 56.44 2.30E-05 
   
1449.7365 1450.4992 0.7627 84 96 QSVFTGIHATFSR 29.04 0.011 
   
1471.732 1472.0512 0.3192 40 51 LHEIPANWHEAR 25.17 0.031 
   
1989.9771 1990.9852 1.0081 217 233 EIFAQHLPASMVGNFWK 46.39 0.00026 
 
immulectin-2b  5 1240.5798 1240.6314 0.0516 30 39 YLDVVDGWMK 54.02 4.80E-05 
   
1307.6762 1307.7694 0.0933 97 108 GDFFSVEGIPLK 56.44 2.30E-05 
   
1449.7365 1450.4992 0.7627 84 96 QSVFTGIHATFSR 29.04 0.011 
   
1471.732 1472.0512 0.3192 40 51 LHEIPANWHEAR 25.17 0.031 
   
1989.9771 1990.9852 1.0081 217 233 EIFAQHLPASMVGNFWK 46.39 0.00026 
 
SPH-1b  4 925.5233 925.4854 -0.0378 310 317 IEVPVVDR 55.39 2.70E-05 
   
1053.6182 1053.6594 0.0412 309 317 KIEVPVVDR 38.37 0.0014 
   
1066.472 1066.5314 0.0595 227 234 EPYPYQDR 41.32 0.001 
   
1452.7475 1452.6474 -0.1001 160 171 FGEFPWMVAILK 69.22 1.50E-06 
 
immulectin III  2 1419.7511 1419.7834 0.0324 220 232 GSEPVNVIFVGFR 55.46 2.70E-05 
   
1547.846 1547.7532 -0.0929 219 232 KGSEPVNVIFVGFR 24.28 0.052 
           57 immulectin-4 5 1130.5469 1130.5954 0.0486 244 252 DLNQSNVWR 37.43 0.0025 
   
1364.7201 1364.7374 0.0174 38 49 LHLVPATWSDAR 33.91 0.0047 
   
1419.7511 1420.4494 0.6984 231 243 GSEPVNVIFVGFR 73.82 3.80E-07 
   
1547.846 1548.5954 0.7494 230 243 KGSEPVNVIFVGFR 99.56 1.40E-09 
   
1788.8293 1789.4212 0.5918 183 196 FHEYAMSWSLAYLR 34.39 0.0032 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
57 immulectin III 4 1130.5469 1130.5954 0.0486 233 241 DLNQSNVWR 37.43 0.0025 
   
1419.7511 1420.4494 0.6984 220 232 GSEPVNVIFVGFR 73.82 3.80E-07 
   
1427.6245 1428.1754 0.551 112 122 GIYYEQYDYSK 66.29 2.80E-06 
   
1547.846 1548.5954 0.7494 219 232 KGSEPVNVIFVGFR 99.56 1.40E-09 
 
immulectin-2b 3 1254.5955 1254.5734 -0.022 30 39 YLDVIDGWMK 33.43 0.0061 
   
1307.6762 1307.9634 0.2873 97 108 GDFFSVEGIPLK 37.87 0.0015 
   
1471.732 1472.1292 0.3972 40 51 LHEIPANWHEAR 42.97 0.00051 
 
dVA-AP7  2 1083.5349 1083.4414 -0.0934 129 137 VQGLYYADR 39.59 0.0011 
   
1427.6245 1428.1754 0.551 111 121 GIYYEQYDYSK 66.29 2.80E-06 
           58 immulectin-3  3 790.4589 790.5534 0.0946 221 227 YPTGLIK 36.45 0.0028 
   
1360.6558 1361.5074 0.8517 299 310 HPNNIMPVPNNV 45.76 0.00024 
   
1735.8834 1736.9032 1.0197 181 194 FHNYGLPWSLAYLR 56.86 2.60E-05 
           59 immulectin III  4 1130.5469 1130.5834 0.0366 233 241 DLNQSNVWR 39.92 0.0014 
   
1419.7511 1419.9034 0.1524 220 232 GSEPVNVIFVGFR 79.89 9.70E-08 
   
1427.6245 1428.5314 0.907 112 122 GIYYEQYDYSK 57.9 2.30E-05 
   
1547.846 1548.6172 0.7711 219 232 KGSEPVNVIFVGFR 32.73 0.0089 
 
immulectin-2a 3 1240.5798 1240.6434 0.0636 30 39 YLDVVDGWMK 55.46 3.40E-05 
   
1307.6762 1307.7514 0.0753 97 108 GDFFSVEGIPLK 45.9 0.00026 
   
1471.732 1472.1622 0.4302 40 51 LHEIPANWHEAR 39.5 0.0012 
 
immulectin-2b  3 1254.5955 1254.6314 0.036 30 39 YLDVIDGWMK 45.39 0.00039 
   
1307.6762 1307.7514 0.0753 97 108 GDFFSVEGIPLK 45.9 0.00026 
   
1471.732 1472.1622 0.4302 40 51 LHEIPANWHEAR 39.5 0.0012 
           60 immulectin-2b  4 1189.5545 1189.4614 -0.0931 71 80 FAMASMMILK 50.74 9.40E-05 
   
1254.5955 1254.6534 0.058 30 39 YLDVIDGWMK 45.75 0.00036 
   
1449.7365 1449.9772 0.2407 84 96 QSVFTGIHATFSR 31.51 0.0063 
   
1471.732 1472.2492 0.5172 40 51 LHEIPANWHEAR 39.91 0.0011 
           61 PAP-1 2 935.4786 935.4234 -0.0552 289 296 LGMPIFDK 63.13 5.80E-06 
   
1433.7303 1434.4534 0.7231 263 276 LATGNDVFVAGWGK 119.18 1.50E-11 
 
immulectin-3 2 790.4589 790.5154 0.0566 221 227 YPTGLIK 26.82 0.027 
   
1360.6558 1361.4114 0.7557 299 310 HPNNIMPVPNNV 38.33 0.0013 
           66 attacin-1  3 1498.7528 1499.1802 0.4273 162 176 VGASASAAHTPLFDR 45.75 0.00028 
   
1677.8223 1678.0372 0.2149 118 131 LNVFHNDNHNLDVK 25.84 0.042 
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Spot Protein name Peptide 
count 
Calc. mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence Ion 
score* 
E-value 
66 attacin-1  
 
1741.8747 1742.4502 0.5754 160 176 DKVGASASAAHTPLFDR 24.53 0.038 
           67 immulectin-2b  5 1254.5955 1254.6094 0.014 30 39 YLDVIDGWMK 44.78 0.00045 
   
1307.6762 1308.5534 0.8773 97 108 GDFFSVEGIPLK 55.59 3.60E-05 
   
1435.7711 1435.5674 -0.2037 97 109 GDFFSVEGIPLKK 39.69 0.0013 
   
1449.7365 1450.1302 0.3937 84 96 QSVFTGIHATFSR 23.21 0.039 
   
1989.9771 1990.8742 0.8971 217 233 EIFAQHLPASMVGNFWK 51.96 7.10E-05 
 
attacin-1  3 1273.5826 1273.5054 -0.0772 192 202 TTSLDFNADYK 50 0.00012 
   
1498.7528 1499.0872 0.3343 162 176 VGASASAAHTPLFDR 56.7 2.20E-05 
   
1677.8223 1678.1152 0.2929 118 131 LNVFHNDNHNLDVK 40.31 0.0014 
           68 attacin-1  8 1273.5826 1273.5054 -0.0772 192 202 TTSLDFNADYK 60.07 1.20E-05 
   
1347.7034 1347.6914 -0.012 65 77 NVFSAIGGLDLDK 86.47 2.50E-08 
   
1498.7528 1499.0302 0.2773 162 176 VGASASAAHTPLFDR 58.66 1.40E-05 
   
1516.7045 1517.1772 0.4726 190 202 DKTTSLDFNADYK 46.48 0.00023 
   
1644.7995 1645.1392 0.3397 190 203 DKTTSLDFNADYKK 31.48 0.0072 
   
1677.8223 1678.9552 1.1329 118 131 LNVFHNDNHNLDVK 27.35 0.024 
   
1741.8747 1742.3212 0.4464 160 176 DKVGASASAAHTPLFDR 50.83 9.00E-05 
   
1829.8756 1830.6532 0.7776 38 56 DTHGSVTVNSDGTS 44.31 0.00038 
        
GAVVK 
  *Ion scores > 22 indicate significant identity (p < 0.05).
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Table B-3. MS/MS results for plasma proteins that bound to a control column of Protein-A Sepharose CL-4B beads without 
antibody and identified in Table 3-3. 
Spot Protein name Peptide 
count 
Calc.  mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence 
Ion 
score* 
E-value 
1c immulectin-2b  7 1173.5596 1173.7154 0.1559 71 80 FAMASMMILK 66.99 2.50E-06 
   
1254.5955 1254.7454 0.15 30 39 YLDVIDGWMK 45.67 0.00035 
   
1307.6762 1307.8834 0.2073 97 108 GDFFSVEGIPLK 66.17 2.40E-06 
   
1435.7711 1435.9814 0.2103 97 109 GDFFSVEGIPLKK 41.53 0.00089 
   
1449.7365 1450.1314 0.395 84 96 QSVFTGIHATFSR 59.53 1.10E-05 
   
1471.732 1472.2642 0.5322 40 51 LHEIPANWHEAR 40.13 0.001 
   
1989.9771 1990.7542 0.7771 217 233 EIFAQHLPASMVGNFWK 56.98 2.10E-05 
           2c immulectin-2b  5 1173.5596 1173.6574 0.0979 71 80 FAMASMMILK 55.29 3.70E-05 
   
1254.5955 1254.7214 0.126 30 39 YLDVIDGWMK 45.63 0.00036 
   
1435.7711 1435.8954 0.1243 97 109 GDFFSVEGIPLKK 63.84 5.00E-06 
   
1449.7365 1450.6194 0.883 84 96 QSVFTGIHATFSR 47.39 9.00E-05 
           3c immulectin-2b  6 1173.5596 1173.7054 0.1459 71 80 FAMASMMILK 59.99 1.20E-05 
   
1254.5955 1254.6854 0.09 30 39 YLDVIDGWMK 59.8 1.40E-05 
   
1307.6762 1308.6554 0.9793 97 108 GDFFSVEGIPLK 37.47 0.0024 
   
1435.7711 1435.8934 0.1223 97 109 GDFFSVEGIPLKK 62.12 7.50E-06 
   
1471.732 1472.2402 0.5082 40 51 LHEIPANWHEAR 37.9 0.0017 
   
1989.9771 1990.5622 0.5851 217 233 EIFAQHLPASMVGNFWK 38.34 0.0016 
           4c immulectin-2b  2 1189.5545 1189.5454 -0.0091 71 80 FAMASMMILK 50.37 0.0001 
   
1254.5955 1254.5834 -0.012 30 39 YLDVIDGWMK 36.46 0.0031 
           5c immulectin-2b  4 1157.5647 1158.4934 0.9288 71 80 FAMASMMILK 56.32 3.30E-05 
   
1254.5955 1254.8514 0.256 30 39 YLDVIDGWMK 46.37 0.00026 
   
1471.732 1472.2372 0.5052 40 51 LHEIPANWHEAR 44.92 0.00034 
   
1989.9771 1990.2802 0.3031 217 233 EIFAQHLPASMVGNFWK 53.58 5.70E-05 
           6c immulectin-2b  2 1189.5545 1189.7274 0.1729 71 80 FAMASMMILK 50.69 9.60E-05 
   
1471.732 1472.6002 0.8682 40 51 LHEIPANWHEAR 34.28 0.0039 
           7c no match 
         
           8c no match 
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Spot Protein name Peptide 
count 
Calc.  mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence 
Ion 
score* 
E-value 
9c serpin-1 1 1457.6998 1458.0494 0.3496 165 177 NLVDPDALDETTR 49.84 0.00012 
           10c endochitinase 4 1119.6441 1120.5534 0.9094 263 272 LVVGIPFYGR 28.12 0.026 
   
1161.5917 1161.7374 0.1457 42 51 YGIEDIPVEK 51.41 7.50E-05 
   
1306.5942 1306.7534 0.1592 340 350 GTQWVGYEDPR 53.65 5.40E-05 
   
1328.6262 1329.3382 0.712 234 243 RPHDQWAYEK 31.53 0.0093 
           11c proPO-p2 5 808.5171 808.6694 0.1524 183 189 TPIIIPR 39.02 0.0015 
   
1086.5305 1086.6234 0.0929 567 576 DLSIQGSDPR 62.19 9.30E-06 
   
1310.6619 1310.7834 0.1215 160 170 FLDSQVFTQAR 87.48 2.20E-08 
   
1451.7157 1452.8542 1.1384 469 481 GLDFSDRGPVYAR 45.45 0.0003 
   
1477.6321 1477.7454 0.1134 190 201 DYTATDLEEEHR 68.25 1.50E-06 
           12c immulectin-2b  4 1157.5647 1157.8474 0.2828 71 80 FAMASMMILK 59.65 1.30E-05 
   
1449.7365 1450.3492 0.6127 84 96 QSVFTGIHATFSR 48.9 0.0001 
   
1471.732 1471.8954 0.1634 40 51 LHEIPANWHEAR 50.24 3.60E-05 
   
1763.8308 1763.0542 -0.7767 154 169 RIPDMVVTECGTVDSK 22.44 0.082 
           13c immulectin-2b  2 1173.5596 1173.9654 0.4059 71 80 FAMASMMILK 35.08 0.004 
   
1471.732 1472.6932 0.9612 40 51 LHEIPANWHEAR 48.6 0.00014 
 
immulectin III 2 1130.5469 1130.6354 0.0886 233 241 DLNQSNVWR 31.8 0.009 
   
1427.6245 1428.7474 1.123 112 122 GIYYEQYDYSK 33.83 0.0064 
 
immulectin-3  1 1360.6558 1360.9834 0.3277 299 310 HPNNIMPVPNNV 25.33 0.026 
           14c immulectin-3  2 790.4589 790.5634 0.1046 221 227 YPTGLIK 24.17 0.046 
   
1360.6558 1360.7594 0.1037 299 310 HPNNIMPVPNNV 30.51 0.011 
 
immulectin-2b  1 1189.5545 1189.6754 0.1209 71 80 FAMASMMILK 42.04 0.00037 
           15c immulectin-2b  5 1173.5596 1173.7614 0.2019 71 80 FAMASMMILK 64.39 4.50E-06 
   
1254.5955 1254.7394 0.144 30 39 YLDVIDGWMK 44.71 0.00044 
   
1449.7365 1450.7152 0.9787 84 96 QSVFTGIHATFSR 41.56 0.00067 
   
1471.732 1472.3152 0.5832 40 51 LHEIPANWHEAR 46.03 0.00026 
   
1763.8308 1764.1882 0.3573 154 169 RIPDMVVTECGTVDSK 29.21 0.015 
           16c immulectin-2b  2 1173.5596 1174.5834 1.0239 71 80 FAMASMMILK 44.32 0.00065 
   
1471.732 1472.2282 0.4962 40 51 LHEIPANWHEAR 41.73 0.00071 
           17c immulectin-2b  4 1189.5545 1189.6314 0.0769 71 80 FAMASMMILK 20.84 0.093 
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Spot Protein name Peptide 
count 
Calc.  mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence 
Ion 
score* 
E-value 
17c immulectin-2b 
 
1254.5955 1254.7774 0.182 30 39 YLDVIDGWMK 50.43 0.00011 
   
1449.7365 1450.1572 0.4207 84 96 QSVFTGIHATFSR 43.86 0.00032 
   
1471.732 1472.4022 0.6702 40 51 LHEIPANWHEAR 33.34 0.0048 
 
scolexin A  1 976.509 976.6294 0.1204 257 265 NGNLAVFSR 47.3 0.00032 
           18c immulectin-3  1 790.4589 790.5894 0.1306 221 227 YPTGLIK 23.91 0.047 
           19c proPO-p2 1 808.5171 807.6154 -0.9016 183 189 TPIIIPR 40.23 0.00033 
 
immulectin-3  1 790.4589 790.5834 0.1246 221 227 YPTGLIK 30.78 0.0097 
           20c immulectin-3  1 790.4589 790.6174 0.1586 221 227 YPTGLIK 36.24 0.0026 
           21c immulectin-3  1 790.4589 790.5874 0.1286 221 227 YPTGLIK 26.8 0.024 
           22c SPH-2 3 813.4708 813.5674 0.0966 235 241 NDIALLR 30.78 0.0095 
   
946.5488 946.6574 0.1087 227 234 DFKPLSLK 28.11 0.0064 
   
1105.4716 1105.6254 0.1538 389 398 WGYGSSTYSV 26.15 0.024 
           23c immulectin-2b  4 1173.5596 1173.8154 0.2559 71 80 FAMASMMILK 57.71 2.10E-05 
   
1254.5955 1254.6334 0.038 30 39 YLDVIDGWMK 56.85 1.10E-05 
   
1449.7365 1450.4182 0.6817 84 96 QSVFTGIHATFSR 38.05 0.0013 
   
1471.732 1472.2342 0.5022 40 51 LHEIPANWHEAR 37.63 0.0018 
 
immulectin-3  1 1360.6558 1360.9054 0.2497 299 310 HPNNIMPVPNNV 32.25 0.0056 
           24c immulectin-3  1 790.4589 790.6294 0.1706 221 227 YPTGLIK 27.28 0.02 
           25c immulectin-2b  2 1173.5596 1173.8014 0.2419 71 80 FAMASMMILK 53.1 6.10E-05 
   
1254.5955 1254.6614 0.066 30 39 YLDVIDGWMK 45.32 0.00015 
 
immulectin-3  2 790.4589 790.5874 0.1286 221 227 YPTGLIK 32.01 0.0072 
   
1360.6558 1361.6894 1.0337 299 310 HPNNIMPVPNNV 42.6 0.00052 
           26c immulectin-2b  4 1157.5647 1157.7834 0.2188 71 80 FAMASMMILK 60.97 9.80E-06 
   
1254.5955 1255.4734 0.878 30 39 YLDVIDGWMK 45.54 0.00012 
   
1449.7365 1450.7302 0.9937 84 96 QSVFTGIHATFSR 31.48 0.0069 
   
1471.732 1472.3092 0.5772 40 51 LHEIPANWHEAR 34.4 0.0038 
 
immulectin III  2 1130.5469 1130.8494 0.3026 233 241 DLNQSNVWR 36.65 0.0023 
   
1427.6245 1427.8994 0.275 112 122 GIYYEQYDYSK 56.96 2.50E-05 
 
immulectin-3 2 790.4589 790.6314 0.1726 221 227 YPTGLIK 24.34 0.04 
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Spot Protein name Peptide 
count 
Calc.  mass Obsrv. mass Peptide 
delta 
Start End Peptide sequence 
Ion 
score* 
E-value 
26c immulectin-3 
 
1360.6558 1361.1074 0.4517 299 310 HPNNIMPVPNNV 39.97 0.00079 
           27c immulectin-2b  7 1141.5697 1141.8834 0.3137 71 80 FAMASMMILK 73.07 5.90E-07 
   
1254.5955 1254.7374 0.142 30 39 YLDVIDGWMK 57.41 2.40E-05 
   
1307.6762 1307.8734 0.1973 97 108 GDFFSVEGIPLK 62.45 5.70E-06 
   
1435.7711 1436.5414 0.7703 97 109 GDFFSVEGIPLKK 60.58 1.20E-05 
   
1449.7365 1450.4002 0.6637 84 96 QSVFTGIHATFSR 49.9 8.20E-05 
   
1471.732 1472.6154 0.8834 40 51 LHEIPANWHEAR 54.47 4.00E-05 
   
1989.9771 1990.9882 1.0111 217 233 EIFAQHLPASMVGNFWK 47.75 0.00019 
           28c immulectin-2b  5 1157.5647 1157.8374 0.2728 71 80 FAMASMMILK 66.82 2.50E-06 
   
1254.5955 1254.6874 0.092 30 39 YLDVIDGWMK 54.02 5.30E-05 
   
1307.6762 1307.8594 0.1833 97 108 GDFFSVEGIPLK 56.18 2.40E-05 
   
1449.7365 1450.6672 0.9307 84 96 QSVFTGIHATFSR 40.81 0.0008 
   
1471.732 1472.2792 0.5472 40 51 LHEIPANWHEAR 32.34 0.0061 
 
SPH-1b 3 925.5233 925.6154 0.0922 310 317 IEVPVVDR 28.06 0.014 
   
1467.6841 1467.7474 0.0633 172 184 IEPVNENEPDGQK 39.95 0.0011 
   
2647.2051 2647.4902 0.285 217 238 AGEWDTQHAKEPYPY 31 0.0098 
        
QDRDVSR 
  
           29c immulectin III  4 1130.5469 1130.7254 0.1786 233 241 DLNQSNVWR 51.3 9.20E-05 
   
1419.7511 1419.9334 0.1824 220 232 GSEPVNVIFVGFR 73.93 3.90E-07 
   
1427.6245 1427.8494 0.225 112 122 GIYYEQYDYSK 59.45 1.40E-05 
   
1547.846 1548.8932 1.0471 219 232 KGSEPVNVIFVGFR 34 0.0068 
 
immulectin-4  4 1130.5469 1130.7254 0.1786 244 252 DLNQSNVWR 51.3 9.20E-05 
   
1364.7201 1364.9494 0.2294 38 49 LHLVPATWSDAR 41.66 0.00062 
   
1419.7511 1419.9334 0.1824 231 243 GSEPVNVIFVGFR 73.93 3.90E-07 
   
1547.846 1548.8932 1.0471 230 243 KGSEPVNVIFVGFR 34 0.0068 
 
immulectin-3 1 1360.6558 1361.6454 0.9897 299 310 HPNNIMPVPNNV 27.45 0.017 
           30c immulectin-3 2 790.4589 790.6274 0.1686 221 227 YPTGLIK 29.5 0.012 
   
1360.6558 1361.6474 0.9917 299 310 HPNNIMPVPNNV 39.33 0.0011 
*Ion scores > 22 indicate significant identity (p < 0.05).
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Appendix C - Impact of Phospholipids on Prophenoloxidase 
Activation 
Prophenoloxidase Activation by the Addition of Phospholipids 
Bidla et al. (2009) found that the addition of inner membrane phospholipids 
(phosphatidylserine and phosphatidylinositol), but not outer membrane phospholipids 
(phosphatidylcholine and phosphatidylethanolamine) to hemolymph from Drosophila 
melanogaster, but not Galleria mellonella stimulated PO activity. These results suggest that the 
release of phospholipids from damaged cells may stimulate the activation of proPO after an 
insect has been injured. To investigate this idea, I used plasma from Manduca sexta to conduct 
prophenoloxidase assays in the presence or absence of phospholipids. 
Materials and methods 
Pooled aliquots of plasma from naïve day 2 fifth instar larvae were checked for low basal 
levels of PO activity that dramatically increased after incubation with M. luteus as described by 
Tong and Kanost (2005), with modification. Phospholipids used include L-α-phosphatidylserine 
(PS; Sigma P0474), L-α-phosphatidylinositol (PI; Sigma P0639), and L-α-phosphatidylcholine 
(PC; Sigma P3556) and were suspended in 50 mM Tris-HCl, 0.1 M NaCl, pH 7.5. Plasma (3µL) 
was mixed with buffer (50 mM Tris-HCl, 0.1 M NaCl, pH 7.5), M. luteus (2 µg), or different 
amounts of each phospholipid (0.1, 0.5, 1.0, 2.0, 10, or 50 µg). Samples were incubated for 10 
min at room temperature, transferred to a 96-well plate, and PO activity was measured by adding 
200 µL of 2 mM dopamine in 50 mM sodium phosphate buffer, pH 6.5. Absorbance at 470 nm 
was monitored for 30 min in a PowerWave XS plate reader (BioTek). One unit of PO activity 
was defined as a change in A470 of 0.001/min. 
Results and conclusions 
Plasma mixed with M. luteus (a positive control) had high levels of PO activity. 
However, regardless of the amount and type of phospholipid, PO activity did not significantly 
increase in comparison to mixture with buffer (Figure C-1, panels A and B). From these 
experiments, it can be concluded that the addition of phospholipids does not stimulate PO 
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activity in plasma from M. sexta. So the question remains, what stimulates PO activity in insects 
after wounding? 
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Figures 
 
 
 
Figure C-1. Prophenoloxidase activation is not enhanced by the addition of phospholipids 
to plasma. 
(A) Plasma (3µL) was mixed with buffer (50 mM Tris-HCl, 0.1 M NaCl, pH 7.5), M. luteus (2 
µg), or phospholipid (0.1, 0.5, 1.0, 2.0 µg of PS or PI). (B) Plasma (3µL) was mixed with buffer 
(50 mM Tris-HCl, 0.1 M NaCl, pH 7.5), M. luteus (2 µg), or phospholipid (1.0, 10, or 50 µg of 
PS or PC). After incubation for 10 min at room temperature, PO activity was measured by 
adding 200 µL of 2 mM dopamine in 50 mM sodium phosphate buffer, pH 6.5. Absorbance at 
470 nm was monitored for 30 min in a PowerWave XS plate reader (BioTek). One unit of PO 
activity was defined as a change in A470 of 0.001/min. The bars represent mean ± SD (n = 2). 
Bars labeled with different letters are significantly different (Analysis of Variance and Newman-
Keuls test, p < 0.05). PS = phosphatidylserine, PI = phosphatidylinositol, PC = 
phosphatidylcholine 
 
